1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35
row_number,t,OMIM no.,Disease Name,Disease Name comments,Gene Affected,Enzyme/protein Defected,EC number/ Protein Entry,Drug formulation/Dosage,Drug name comments,Drug name,Drug ID,Study Type (Evidence code),Mutations improved by treatment,Mutations improved by treatment comments,Mutation that didn't get benefits out the treatment,Mutation that didn't get benefits out the treatment comments,Treatment mechanism of action,Abbreviation for treatment mechanism,new ontology category,Population information,phenotypes  improved,phenotypes  improved comments,Phenotypes  IDS,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference
1,1,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Hydrocortisone,DB00741,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Abnormal plasma aldosterone,,HP:0040085,https://www.ncbi.nlm.nih.gov/pubmed/26161337,,https://www.ncbi.nlm.nih.gov/pubmed/18458702,,,,,,,,
2,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Hydrocortisone,DB00741,,,,,,,,,,Abnormality of potassium homeostasis,,HP:0011042,https://www.ncbi.nlm.nih.gov/pubmed/26161337,,https://www.ncbi.nlm.nih.gov/pubmed/18458702,,,,,,,,
3,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Hydrocortisone,DB00741,,,,,,,,,,Abnormal circulating renin,,HP:0040084,https://www.ncbi.nlm.nih.gov/pubmed/26161337,,https://www.ncbi.nlm.nih.gov/pubmed/18458702,,,,,,,,
4,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Hydrocortisone,DB00741,,,,,,,,,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/26161337,,https://www.ncbi.nlm.nih.gov/pubmed/18458702,,,,,,,,
5,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Dexamethasone,DB01234,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Abnormal plasma aldosterone,,HP:0040085,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,,
6,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Dexamethasone,DB01234,,,,,,,,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
7,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Dexamethasone,DB01234,,,,,,,,,,Abnormal circulating renin,,HP:0040084,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
8,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Dexamethasone,DB01234,,,,,,,,,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
9,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Dexamethasone,DB01234,,,,,,,,,,Bone mass loss,,NA,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
10,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Testosterone,DB00624,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,,,,,,,,,,
11,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Estrogen replacement (Estradiol),DB00783,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,
12,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Estrogen replacement (Estradiol),DB00783,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,
13,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Estrogen replacement (Estradiol),DB00783,,,,,,,,,,Amenorrhea,,HP:0000141,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,
14,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Pioglitazone,DB01132,ECO:0007121 /ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Insulin resistance,,HP:0000855,,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710,,,,,,,,
15,,#202110,17-alpha-hydroxylase deficiency,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,,Pioglitazone,DB01132,,,,,,,,,,Hypertension,,HP:0000822,,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710,,,,,,,,
16,2,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Riboflavin,DB00140,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,,
17,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Riboflavin,DB00140,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,https://www.ncbi.nlm.nih.gov/pubmed/24321868,,,,,,,,,,
18,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Riboflavin,DB00140,,,,,,,,,,Poor motor coordination,,HP:0002275,https://www.ncbi.nlm.nih.gov/pubmed/24321868,,,,,,,,,,
19,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147 +DB00583,ECO:0000352,,,,,Direct interaction+Functional interaction,A+B,combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,defected  L-2-HGDH enzyme activity (Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
20,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147 +DB00583,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
21,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147 +DB00583,,,,,,,,,,Leukodystrophy,,HP:0002415,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
22,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147 +DB00583,,,,,,,,,,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
23,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147 +DB00583,,,,,,,,,,Neurological impairment,,HP:0000707,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+SUCCESSFULLY+TREATED+ADULT+PATIENT+WITH+l-2-HYDROXYGLUTARIC+ACIDURIA&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
24,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,FAD+Riboflavin,DB03147+DB00140,ECO:0000352,,,,,Direct interaction+Functional interaction,A+B,combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Neurological impairment,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/26208971,https://www.ncbi.nlm.nih.gov/pubmed/18343698,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.ncbi.nlm.nih.gov/pubmed/22840416,,,,,,,
25,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,FAD+Riboflavin,DB03147+DB00140,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26208971,https://www.ncbi.nlm.nih.gov/pubmed/18343698,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.ncbi.nlm.nih.gov/pubmed/22840416,,,,,,,
26,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Magnesium,DB14513,ECO:0000352,,,,,Symptomatic,,symptomatic therapeutic procedure,,Status epilepticus,,HP:0002133,https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,,,,,,,,,,
27,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,"EPI-743 potently protected fibroblasts derived from Leigh syndrome (see Fig 5C for representative dose-response rescue curve for Subject 4), Alpers syndrome, and Rett syndrome patients from ferroptosis induced by GSH depletion and excess iron. EPI-743 treatment also protected additional patient-derived fibroblasts from RSL3-induced lipid oxidation and ferroptosis.","EPI-743, α-tocotrienol quinone",DB11917,ECO:0001565/ECO:0007764,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Sizures,The study was preformed on a cell line and the expected phenotypes to be corrected is frequent seizures.,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/30921410,https://clinicaltrials.gov/ct2/show/NCT01370447,,,,,,,,,
28,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,"EPI-743, α-tocotrienol quinone",DB11917,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30921410,https://clinicaltrials.gov/ct2/show/NCT01370447,,,,,,,,,
29,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,"EPI-743, α-tocotrienol quinone",DB11917,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30921410,https://clinicaltrials.gov/ct2/show/NCT01370447,,,,,,,,,
30,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,"EPI-743, α-tocotrienol quinone",DB11917,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30921410,https://clinicaltrials.gov/ct2/show/NCT01370447,,,,,,,,,
31,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,Citrate treatment,DB09125,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24687295,,,,,,,,,,
32,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,Citrate treatment,DB09125,,,,,,,,,,D-2-hydroxyglutaric aciduria,,HP:0012321,https://www.ncbi.nlm.nih.gov/pubmed/24687295,,,,,,,,,,
33,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,Citrate treatment,DB09125,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,https://www.ncbi.nlm.nih.gov/pubmed/24687295,,,,,,,,,,
34,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,Citrate treatment,DB09125,,,,,,,,,,Elevated circulating succinate,,HP:0020149,https://www.ncbi.nlm.nih.gov/pubmed/24687295,,,,,,,,,,
35,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,Citrate treatment,DB09125,,,,,,,,,,Hypocitraturia,,HP:0012405,https://www.ncbi.nlm.nih.gov/pubmed/24687295,,,,,,,,,,
36,3,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Benzhexol,DB00376,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/12555940,,,,,,,,,,
37,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Benzhexol,DB00376,,,,,,,,,,Dystonia,,HP:0001332,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+case+of+adult-onset+type+II+citrullinemia+in+which+oral+administration+of+L-Arginine+Granules+improved+the+patient%27s+encephalopathy+and+the+increased+level+of+serum+ammonia&btnG=,,,,,,,,,,
38,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Vigabatrin,DB01080,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,http://www.medlink.com/scripts/mpdf/print_friendly.php?title=2-methyl-3-hydroxybutyryl-coa_dehydrogenase_deficiency&action=download&channel=public_content&entryid=19985,https://www.ncbi.nlm.nih.gov/pubmed/11102558,,,,,,,,,
39,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Levodopa,DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/30013934,,,,,,,,,,
40,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Carbidopa,DB00190,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/30013934,,,,,,,,,,
41,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Cefoperazone sodium,DB01329,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal inflammatory response,,HP:0012647,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Clinical+Diagnosis+and+Treatment+of+2-Methyl-3-Hydroxybutyryl-CoA+Dehydrogenase+Deficiency+in+One+Infant%3A+A+Case+Report&btnG=,,,,,,,,,,
42,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Tazobactam sodium,DB01606,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal inflammatory response,,HP:0012647,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,,,,,,,,,,
43,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,B vitamins,A11E,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormality of the nervous system,,HP:0000707,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Clinical+Diagnosis+and+Treatment+of+2-Methyl-3-Hydroxybutyryl-CoA+Dehydrogenase+Deficiency+in+One+Infant%3A+A+Case+Report&btnG=,,,,,,,,,,
44,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Creatine phosphate sodium,DB13191,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormality of cardiovascular system physiology,,HP:0011025,,,,,,,,,,,
45,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Carbamazepine,DB00564,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
46,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day),Carnitine,DB00583,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
47,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Carnitine,DB00583,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
48,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,Carnitine,DB00583,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
49,4,# 610006,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSB,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,1.1.1.178,,,L-Carnitine+ low-protein diet,DB00583+NA,ECO:0000352,,,,,Symptomatic+Functional interaction,C+B,combination therapeutic procedure+symptomatic therapeutic procedure+dietary exclusion,,Abnormality of muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/12837870,,,,,,,,,,
50,,# 610006,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSB,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,1.1.1.178,,,L-Carnitine+ low-protein diet,DB00583+NA,,,,,,,,,,Elevated serum toxic intermediates in isoleucine pathway,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/12837870,,,,,,,,,,
51,5,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",Biotin,DB00121,ECO:0000352,MCCA-R385S(heterozygote mutation),https://www.ncbi.nlm.nih.gov/pubmed/15359379,MCCB-(IVS16þ1G>A)/ MCCB-missense mutation E99Q Homozygous mutation,,Direct interaction,A,activity modification of a genetically defective protein,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,,https://www.ncbi.nlm.nih.gov/pubmed/25732994,https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,,,,
52,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,Biotin,DB00121,,"heterozygote missense mutation, MCCA-R385S",https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,,Organic aciduria,,HP:0001992,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,,https://www.ncbi.nlm.nih.gov/pubmed/25732994,https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,,,,
53,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,Biotin,DB00121,,,,,,,,,,EEG abnormality,,HP:0002353,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,,https://www.ncbi.nlm.nih.gov/pubmed/25732994,https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,,,,
54,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,Biotin,DB00121,,,,,,,,,,Hypsarrhythmia,,HP:0002521,https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,,https://www.ncbi.nlm.nih.gov/pubmed/25732994,https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,,,,
55,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,vigabatrin,DB01080,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
56,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,vigabatrin,DB01080,,,,,,,,,,Increased 3-hydroxyisovaleric acid excretion,,NA,,,,,,,,,,,
57,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,vigabatrin,DB01080,,,,,,,,,,Increased 3-methylcrotonylglycine excretion,,NA,,,,,,,,,,,
58,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,vigabatrin,DB01080,,,,,,,,,,Abnormal Biotinidase activity in plasma,,HP:0012379,,,,,,,,,,,
59,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,vigabatrin,DB01080,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
60,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,L-Carnitine,DB00583,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormality of muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/10485305,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,
61,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,L-Carnitine,DB00583,,,,,,,,,,Secondary carnitine deficiency,,HP:0003234*,https://www.ncbi.nlm.nih.gov/pubmed/8831079,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,
62,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,L-Carnitine,DB00583,,,,,,,,,,Elevated serum toxic intermediates,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/8831079,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,
63,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Glycine,DB00145,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,Drug name: controversial results,Defected excertion of 3- MCG,,NA,https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079,,,,,,,,
64,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,Glycine,DB00145,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level (Metabolism abnormality)*,,HP:0001939 *,https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079,,,,,,,,
65,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,Glycine +L-Carnitine,DB00145 +DB00583,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Acute metabolic crisis (Metabolism abnormality)*,,HP:0001939 *,https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/3956533,,,,,,,,,
66,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,Glycine +L-Carnitine,DB00145 +DB00583,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level (Metabolism abnormality)*,,HP:0001939 *,https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/3956533,https://www.ncbi.nlm.nih.gov/pubmed/11181649,,,,,,,,
67,6,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,low-dose carnitine (25 mg/kg/day),"Low long-chain fats diet +Medium-chain triglycerides (MCT)+ Essential fatty acids,+L-carnitine",NA+ NA+ DB13959,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+dietary regime modification+dietary supplementation+dietary supplementation+functional complementation of a genetically defective protein,Drug name: Use is controverial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/?otool=igbcambulib,Secondary carnitine deficiency(Carnitine deficiency)*,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/27117294,,,,,,,,,,
68,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,"Low long-chain fats diet +Medium-chain triglycerides (MCT)+ Essential fatty acids,+L-carnitine",NA+ NA+ DB13959,,,,,,,,,,Elevated serum creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/27117294,,,,,,,,,,
69,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,"Low long-chain fats diet +Medium-chain triglycerides (MCT)+ Essential fatty acids,+L-carnitine",NA+ NA+ DB13959,,,,,,,,,,Myocardial lipid accumulation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/27117294,,,,,,,,,,
70,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Creatine,DB00148,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Exercise intolerance,,HP:0003546,,,,,,,,,,,
71,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Creatine,DB00148,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/12872842,,,,,,,,,,
72,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Vitamin E supplements,DB00163,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormality of peripheral nerves,,HP:0045010,https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc,,,,,,,,,,
73,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Vitamin E supplements,DB00163,,,,,,,,,,Neuropathy,,HP:0009830,https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc,,,,,,,,,,
74,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Triheptanoin,DB11677,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Myalgia,,HP:0003326,https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pubmed/27117294,,,,,,,,,
75,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Triheptanoin,DB11677,,,,,,,,,,Abnormal cardiac function,,HP:0011025,https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pubmed/27117294,,,,,,,,,
76,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Triheptanoin,DB11677,,,,,,,,,,Fatigue,,HP:0011025,https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pubmed/27117294,,,,,,,,,
77,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Prednisone,DB00635,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Fatigue,,HP:0011025,https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.ncbi.nlm.nih.gov/pubmed/7748366,,,,,,,,,
78,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Prednisone,DB00635,,,,,,,,,,Impaired nerve conduction,,HP:0040129,https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.ncbi.nlm.nih.gov/pubmed/7748366,,,,,,,,,
79,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Prednisone,DB00635,,,,,,,,,,Defected sarcolemma,,NA,https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.ncbi.nlm.nih.gov/pubmed/7748366,,,,,,,,,
80,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,Prednisone,DB00635,,,,,,,,,,Defected neuronal plasma membrane,,NA,https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.ncbi.nlm.nih.gov/pubmed/7748366,,,,,,,,,
81,7,% 236795,3-Hydroxyisobutyric aciduria,,ALDH6A1,3-hydroxyisobutyrate dehydrogenase,1.1.1.31,,,Carnitine,DB00583,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Acidemia,,HP:0001941,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Disorders+of+Valine-Isoleucine+Metabolism+Bruce+Barshop&btnG=,,,,,,,,,,
82,8,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,Methylglutaconyl-CoA hydratase,4.2.1.18,,,L-carnitine,DB00583,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/28348715,https://www.ncbi.nlm.nih.gov/pubmed/20882351,,,,,,,,,
83,,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,Methylglutaconyl-CoA hydratase,4.2.1.18,,,L-carnitine,DB00583,,,,,,,,,,Abnormality of movement,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/28348715,https://www.ncbi.nlm.nih.gov/pubmed/20882351,,,,,,,,,
84,,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,Methylglutaconyl-CoA hydratase,4.2.1.18,,,L-carnitine,DB00583,,,,,,,,,,Metabolic Decompensation,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/11400757/,https://www.ncbi.nlm.nih.gov/pubmed/20882351,,,,,,,,,
85,,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,Methylglutaconyl-CoA hydratase,4.2.1.18,,,L-carnitine,DB00583,,,,,,,,,,Delayed Growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/11400757/,https://www.ncbi.nlm.nih.gov/pubmed/20882351,,,,,,,,,
86,9,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Sapropterin,DB00360,ECO:0007121/ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Behavioral abnormality,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,
87,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Sapropterin,DB00360,,,,,,functional complementation of a genetically defective protein by stimulation,,,,Personality disorder,,HP:0012075,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,
88,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Sapropterin,DB00360,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,
89,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Antisense morpholino oligonucleotides (AMOs),NA,ECO:0001565,"c.84−322A>T, c.163 + 695_163 + 751del57, or c.164−712A>T",,,,Direct interaction,A,direct complementation of a genetically defective protein,,Pseudoexon activation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21542064,,,,,,,,,,
90,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
91,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,,,,,,,,,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
92,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
93,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,,,,,,,,,,Neurodevelopmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
94,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,,,,,,,,,,Intellectual disability,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
95,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,,,,,,,,,,Delayed CNS mylinaton,"The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879",HP:0002188,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
96,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879,Oxitriptan,DB02959,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
97,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Oxitriptan,DB02959,,,,,,,,,,Abnormality in serotonin turnover (Abnormality of circulating hormone level),,HP:0003117,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
98,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",Levodopa (L-dopa),DB01235,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
99,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Levodopa (L-dopa),DB01235,,,,,,,,,,Paroxysmal movements,,HP:0007166,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
100,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Levodopa (L-dopa),DB01235,,,,,,,,,,Movement disorder,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
101,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",Carbidopa,DB00190,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
102,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",Pramipexole + L-dopa,DB00413+DB01235,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by stimulation+metabolite replacement,"Drug name: The addition of  pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy. Similar benefits may be expected in other forms of inherited tetrahydrobiopterin deficiency. https://www.ncbi.nlm.nih.gov/pubmed/19704083",Movement Disability,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/19704083,,,,,,,,,,
103,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Pramipexole + L-dopa,DB00413+DB01235,,,,,,,,,,High prolactin level,,HP:0000870,https://www.ncbi.nlm.nih.gov/pubmed/19704083,,,,,,,,,,
104,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Pramipexole + L-dopa,DB00413+DB01235,,,,,,,,,,Behavioural Disability,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/19704083,,,,,,,,,,
105,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Pramipexole + L-dopa,DB00413+DB01235,,,,,,,,,,Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*,,NA,https://www.ncbi.nlm.nih.gov/pubmed/19704083,,,,,,,,,,
106,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",Selective monoamine oxidase (MAO) B inhibitor,DB01247,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Low dopamine level,,HP:0012656,https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Deprenyl+in+6-Pyruvoyl+Tetrahydropterin+Synthase+Deficiency&btnG=,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,,,,,,,,
107,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase,NA,ECO:0001565,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Low tetrahydrobiopterin level,,HP:0040210,https://www.ncbi.nlm.nih.gov/pubmed/8864759,,,,,,,,,,
108,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase,NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8864759,,,,,,,,,,
109,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,Folinic acid,DB03256,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Abnormal serum folate,,HP:0040087,,,,,,,,,,,
110,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4,DB00360,,,,,,Functional interaction,B,metabolite replacement,,Elevated Phe level in blood,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/8433887/,,,,,,,,,
111,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4,DB00360,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/8433887/,,,,,,,,,
112,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4+L-dopa+5-hydroxytryptophan,DB00360+DB01235+DB02959,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement,,Elevated blood phenylalanine concentration,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,,,,,,,,
113,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4+L-dopa+5-hydroxytryptophan,DB00360+DB01235+DB02959,,,,,,,,,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,,,,,,,,
114,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4+L-dopa+5-hydroxytryptophan,DB00360+DB01235+DB02959,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,,,,,,,,
115,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,,,,,,,,,,
116,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,,,,,,,,,,Delayed receptive language,,HP:0010863,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,,,,,,,,,,
117,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,,,,,,,,,,Neurological impairment,,HP:0000707,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,,,,,,,,,,
118,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,,,,,,,,,,
119,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,Folinic acid,DB03256,ECO:0000352,,,,,Functional interaction,B,compensatory complementation of a genetically defective protein,,Progressive basal ganglia calcification,,HP:0002135,https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
120,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,Folinic acid,DB03256,,,,,,,,,,Subcortical calcification,,HP:0007346,https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
121,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,Folinic acid,DB03256,,,,,,,,,,Seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
122,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,Folinic acid,DB03256,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
123,10,# 200100,Abetalipoproteinemia,"The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038",MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin E therapy,DB00163,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Nervous system abnormalities,,HP:0002011,https://www.ncbi.nlm.nih.gov/pubmed/30358967,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,
124,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin E therapy,DB00163,,,,,,,,,,Neurologic dysfunction,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/30358967,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,
125,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin E therapy,DB00163,,,,,,,,,,Retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/3954973/,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,
126,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Medium-chain fatty acid supplements,DB13959,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Growth impairment,,HP:0008897,,,,,,,,,,,
127,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin K,CHEBI:28384,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/26396722,,,,,,,,,,
128,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin D,DB11094,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,,HP:0002630,,,,,,,,,,,
129,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",Vitamin A+ Vitamin E,DB00162+DB00163,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement,,Retinal degeneration,,HP:0000546,https://www.ncbi.nlm.nih.gov/pubmed/11767031,https://www.ncbi.nlm.nih.gov/pubmed/30731125,,,,,,,,,
130,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin A+ Vitamin E,DB00162+DB00163,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/14749227,https://www.ncbi.nlm.nih.gov/pubmed/30731125,,,,,,,,,
131,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K,DB13959+DB00162+DB11094+DB00163+CHEBI:28384,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement,,Neurological abnormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,,
132,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K,DB13959+DB00162+DB11094+DB00163+CHEBI:28384,,,,,,,,,,Disease progression (Progressive),,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,,
133,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",Progesteron,DB00396,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Female infertility,,HP:0008222,,,,,,,,,,,
134,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin B12+iron,DB00115+DB01592,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Anemia,,HP:0001903,,,,,,,,,,,
135,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Levothyroxine,DB00451,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Subclinical hypothyroidism,,HP:0000821,https://www.ncbi.nlm.nih.gov/pubmed/26396722,https://www.ncbi.nlm.nih.gov/pubmed/17132287/,,,,,,,,,
136,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin E+Vitamin A+Vitamin D+Vitamin K+Omega-3-acid ethyl esters+Low fat diet+high medium-chain TG,DB00163 +DB00162+DB11094+CHEBI:28384+DB09539+NA+DB13959,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B+B+B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+dietary regime modification+metabolite replacement,,Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/30875496,,,,,,,,,,
137,,# 200100,Abetalipoproteinemia,,MTTP,microsomal triglyceride transfer protein,P55157,,,Vitamin E+Vitamin A+Vitamin D+Vitamin K+Omega-3-acid ethyl esters+Low fat diet+high medium-chain TG,DB00163 +DB00162+DB11094+CHEBI:28384+DB09539+NA+DB13959,,,,,,,,,,Impaired growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/30875496,,,,,,,,,,
138,11,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Deferasirox,DB01609,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,High serum ferritin concentration,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/23049345,https://www.ncbi.nlm.nih.gov/pubmed/20301666,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pubmed/23049345,https://www.ncbi.nlm.nih.gov/pubmed/17911185,,,,,,
139,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Deferasirox,DB01609,,,,,,,,,,Elevated hepatic iron concentration,,HP:0012465,https://www.ncbi.nlm.nih.gov/pubmed/20801540,https://www.ncbi.nlm.nih.gov/pubmed/20301666,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pubmed/23049345,https://www.ncbi.nlm.nih.gov/pubmed/17911185,,,,,,
140,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Deferasirox,DB01609,,,,,,,,,,Frequent falls,,HP:0002359,https://www.ncbi.nlm.nih.gov/pubmed/17911185,https://www.ncbi.nlm.nih.gov/pubmed/20301666,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pubmed/23049345,https://www.ncbi.nlm.nih.gov/pubmed/17911185,,,,,,
141,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Deferasirox,DB01609,,,,,,,,,,Gait imbalance,,HP:0002141,https://www.ncbi.nlm.nih.gov/pubmed/17911185,https://www.ncbi.nlm.nih.gov/pubmed/20301666,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pubmed/23049345,https://www.ncbi.nlm.nih.gov/pubmed/17911185,,,,,,
142,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Deferasirox,DB01609,,,,,,,,,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/17911185,https://www.ncbi.nlm.nih.gov/pubmed/20301666,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pubmed/23049345,https://www.ncbi.nlm.nih.gov/pubmed/17911185,,,,,,
143,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Deferasirox,DB01609,,,,,,,,,,Gait disturbance,,HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/17911185,https://www.ncbi.nlm.nih.gov/pubmed/20301666,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pubmed/23049345,https://www.ncbi.nlm.nih.gov/pubmed/17911185,,,,,,
144,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Vitamin E+ Zinc,DB00163 +DB01593,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Tissue damage,,NA,https://www.ncbi.nlm.nih.gov/pubmed/17307325,,,,,,,,,,
145,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Vitamin E+ Zinc,DB00163 +DB01593,,,,,,,,,,Liver dysfunction,,HP:0001410,https://www.ncbi.nlm.nih.gov/pubmed/17307325,,,,,,,,,,
146,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Vitamin E+ Zinc,DB00163 +DB01593,,,,,,,,,,Pancreatic dysfunction,,HP:0001738,https://www.ncbi.nlm.nih.gov/pubmed/17307325,,,,,,,,,,
147,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Desferrioxamine,DB00746,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Increased serum ferritin,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/9066364,,,,,,,,,,
148,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Desferrioxamine,DB00746,,,,,,,,,,Diabetes mellitus,,HP:0000819,https://www.ncbi.nlm.nih.gov/pubmed/9066364,,,,,,,,,,
149,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Desferrioxamine,DB00746,,,,,,,,,,Elevated hepatic iron concentration,,HP:0012465,https://www.ncbi.nlm.nih.gov/pubmed/15082597,https://www.ncbi.nlm.nih.gov/pubmed/9066364,,,,,,,,,
150,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Desferrioxamine,DB00746,,,,,,,,,,Iron accumulation in brain,,HP:0012675,https://www.ncbi.nlm.nih.gov/pubmed/21594898,https://www.ncbi.nlm.nih.gov/pubmed/9066364,,,,,,,,,
151,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,Deferiprone therapy had no beneficial effects in an individual in a previous report.https://www.ncbi.nlm.nih.gov/pubmed/15082597,Deferiprone,DB08826,ECO:0000179/ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Iron accumulation in retina,,HP:0011031,https://www.ncbi.nlm.nih.gov/pubmed/21051716,,,,,,,,,,
152,,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,,Deferiprone,DB08826,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/21051716,,,,,,,,,,
153,12,606175,Acetyl-carnitine deficiency (Carnitine acetyltransferase deficiency),,CRAT,Carnitine acetyltransferase,2.3.1.7,,,Acetylcarnitine,DB08842,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Fasting ketogenesis,,HP:0001946/HP:0025212,https://www.ncbi.nlm.nih.gov/pubmed/30061399,,,,,,,,,,
154,,606175,Acetyl-carnitine deficiency (Carnitine acetyltransferase deficiency),,CRAT,Carnitine acetyltransferase,2.3.1.7,,,Acetylcarnitine,DB08842,,,,,,,,,,Cardiac dysfunction,,HP:0011025,https://www.ncbi.nlm.nih.gov/pubmed/30061399,,,,,,,,,,
155,,606175,Acetyl-carnitine deficiency (Carnitine acetyltransferase deficiency),,CRAT,Carnitine acetyltransferase,2.3.1.7,,,Acetylcarnitine,DB08842,,,,,,,,,,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/30061399,,,,,,,,,,
156,,606175,Acetyl-carnitine deficiency (Carnitine acetyltransferase deficiency),,CRAT,Carnitine acetyltransferase,2.3.1.7,,,Acetylcarnitine,DB08842,,,,,,,,,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/30061399,,,,,,,,,,
157,,606175,Acetyl-carnitine deficiency (Carnitine acetyltransferase deficiency),,CRAT,Carnitine acetyltransferase,2.3.1.7,,"THe hyperlipidemic drug fenofibrate being a more potent one, as a consequence of its pharmacological interaction",L-carnitine + fenofibrate,DB00583+DB01039,ECO:0001565,,,,,Direct interaction+Direct interaction,A+A,combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+activity modification of a genetically defective protein by transcriptional or translational modification,,Abnormal CrAt activity (Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/24962334,,,,,,,,,,
158,13,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zinc,DB01593,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Skin inflammation,,HP:0011123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
159,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zinc,DB01593,,,,,,,,,,Alopecia,,HP:0001596,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
160,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zinc,DB01593,,,,,,,,,,Agitation,,HP:0000713,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
161,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zinc,DB01593,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
162,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zinc,DB01593,,,,,,,,,,Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
163,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zinc,DB01593,,,,,,,,,,Emotional disturbances,,HP:0000712,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
164,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zinc+ linoleic acid,DB01593+DB14104,ECO:0000352,,,,,Functional interaction+Symptomatic,B+C,combination therapeutic procedure+metabolite replacement+symptomatic therapeutic procedure,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16224175,,,,,,,,,,
165,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Diiodoquinoline,DB09115,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Acrodermatitis (Dermatitis)*,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,,,,,,,
166,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Diiodoquinoline,DB09115,,,,,,,,,,Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,,,,,,,
167,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Diiodoquinoline,DB09115,,,,,,,,,,Alopecia,,HP:0001596,https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,,,,,,,
168,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Diiodoquinoline,DB09115,,,,,,,,,,Perioral dermatitis,,HP:0040181,https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,,,,,,,
169,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Clioquinol,DB04815,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Dermatitis,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/375935,,,,,,,,,,
170,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Clioquinol,DB04815,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/375935,,,,,,,,,,
171,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Clioquinol,DB04815,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/375935,,,,,,,,,,
172,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",Zn-DTSM (zinc ionophore),PubChem SID:329770515,ECO:0001565/ ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Generalized abnormality of skin,,HP:0011354,https://www.ncbi.nlm.nih.gov/pubmed/30669644,,,,,,,,,,
173,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zn-DTSM (zinc ionophore),PubChem SID:329770515,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30669644,,,,,,,,,,
174,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zn-DTSM (zinc ionophore),PubChem SID:329770515,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30669644,,,,,,,,,,
175,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,Zn-DTSM (zinc ionophore),PubChem SID:329770515,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30669644,,,,,,,,,,
176,14,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Glucose,DB09341,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Excretion of heme precursors (Abnormality of the heme biosynthetic pathway)*,,HP:0010472,https://clinicaltrials.gov/ct2/show/NCT02180412,,https://www.ncbi.nlm.nih.gov/pubmed/26366103,,,,,,,,
177,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Glucose,DB09341,,,,,,,,,,Abdominal pain,,HP:0002027,https://clinicaltrials.gov/ct2/show/NCT02180412,,https://www.ncbi.nlm.nih.gov/pubmed/26366103,,,,,,,,
178,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Glucose,DB09341,,,,,,,,,,Nausea and Vomiting,,HP:0002017,https://clinicaltrials.gov/ct2/show/NCT02180412,,https://www.ncbi.nlm.nih.gov/pubmed/26366103,,,,,,,,
179,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Glucose,DB09341,,,,,,,,,,Mild attack:mild pain (Mild)*,,HP:0012825,https://www.ncbi.nlm.nih.gov/pubmed/23605132/,,https://www.ncbi.nlm.nih.gov/pubmed/26366103,,,,,,,,
180,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Panhematin,DB03404,ECO:0000352/ECO:0007121,,,,,Functional interaction,B,metabolite replacement,,Pain,,HP:0012531,https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,
181,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Panhematin,DB03404,,,,,,,,,,Hypertension,,HP:0000822,https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,
182,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Panhematin,DB03404,,,,,,,,,,Tachycardia,,HP:0001649,https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,
183,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Panhematin,DB03404,,,,,,,,,,Abnormal mental status,,HP:0100543,https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,
184,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Panhematin,DB03404,,,,,,,,,,Acute attack (Acute)*,,HP:0011009,https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,
185,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",rh-HMBS,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Accumulated  plasma porphobilinogen,,NA,https://www.ncbi.nlm.nih.gov/pubmed/17375984/,,,,,,,,,,
186,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,rh-HMBS,NA,,,,,,,,,,Accumulated  urine porphobilinogen,,HP:0012217,https://www.ncbi.nlm.nih.gov/pubmed/17375984/,,,,,,,,,,
187,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,rhPBGD,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Eevated porphyrin precursors porphobilinogen,,HP:0012217,https://www.ncbi.nlm.nih.gov/pubmed/15208740/,,,,,,,,,,
188,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,rAAV8-mediated gene therapy expressing murine HMB-synthase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Hepatic metabolic abnormalities (Metabolism abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/19861948,,,,,,,,,,
189,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,rAAV8-mediated gene therapy expressing murine HMB-synthase,NA,,,,,,,,,,Abnormal neuromotor function,,HP:0002333,https://www.ncbi.nlm.nih.gov/pubmed/19861948,,,,,,,,,,
190,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",AAV2/5-PBGD,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Low PBGD expression in liver (Abnormality of circulating enzyme level)*,,HP:0011021,https://www.ncbi.nlm.nih.gov/pubmed/24933563,https://www.ncbi.nlm.nih.gov/pubmed/24933563,,,,,,,,,
191,,# 176000,Acute intermittent porphyria,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,,,Givosiran,DB15066,ECO:0007121/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Abnormal circulating porphyrin concentration,,HP:0010472,https://www.ncbi.nlm.nih.gov/pubmed/30766957,https://www.ncbi.nlm.nih.gov/pubmed/30726693,https://www.ncbi.nlm.nih.gov/pubmed/24821812,https://clinicaltrials.gov/ct2/show/NCT02452372,,,,,,,
192,15,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Urolithiasis,,HP:0000787,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
193,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,,,,,,,,,,Crystalline nephropathy,,HP:0000112,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
194,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,,,,,,,,,,Hematuria,,HP:0000790,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
195,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,,,,,,,,,,Dysuria,,HP:0100518,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
196,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,,,,,,,,,,Recurrent urinary tract infections,,HP:0000010,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
197,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,,,,,,,,,,Chronic kidney disease,,HP:0012622,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
198,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,,,,,,,,,,Elevated Urinary DHA excretion,,NA,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
199,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Allopurinol,DB00437,,,,,,,,,,Kidney stones,,HP:0000787,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
200,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Febuxostat,DB04854,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Urolithiasis,,HP:0000787,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
201,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Febuxostat,DB04854,,,,,,,,,,Crystalline nephropathy,,HP:0000112,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
202,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Febuxostat,DB04854,,,,,,,,,,Hematuria,,HP:0000790,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
203,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Febuxostat,DB04854,,,,,,,,,,Dysuria,,HP:0100518,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
204,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Febuxostat,DB04854,,,,,,,,,,Recurrent urinary tract infections,,HP:0000010,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
205,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Febuxostat,DB04854,,,,,,,,,,Chronic kidney disease,,HP:0012622,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
206,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,Febuxostat,DB04854,,,,,,,,,,"Elevated Urinary 2,8-dihydroxyadenine (DHA) excretion",,NA,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
207,16,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,ECO:0000352,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Lymphopenia,,HP:0001888,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT03878069,,,,,,,,
208,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT03878069,,,,,,,,
209,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Elevated liver enzyme levels,,HP:0002910,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT03878069,,,,,,,,
210,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Low weight,,HP:0004325,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT03878069,,,,,,,,
211,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Abnormal eosinophil counts,,HP:0001879,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT03878069,,,,,,,,
212,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Hemolysis,,HP:0001878,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.ncbi.nlm.nih.gov/pubmed/20301530,,,,,,,,
213,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Thyroid antibodies (autoimmunity)*,,HP:0002960,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.ncbi.nlm.nih.gov/pubmed/20301530,,,,,,,,
214,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Abnormal immune function,,HP:0010978,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.ncbi.nlm.nih.gov/pubmed/16002636,,,,,,,,
215,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,,,,,,,,,,Dermatitis,,HP:0011123,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.ncbi.nlm.nih.gov/pubmed/16002636,,,,,,,,
216,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061,ECO:0000352,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Abnormal immune function,,HP:0010978,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
217,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Pegademase bovine ((PEG-ADA)),DB00061,,,,,,,,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
218,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Pegademase bovine ((PEG-ADA)),DB00061,,,,,,,,,,"Frequent, severe infections",,HP:0002719,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
219,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Pegademase bovine ((PEG-ADA)),DB00061,,,,,,,,,,Abnormal lymphocyte counts,,HP:0040088,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
220,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Pegademase bovine ((PEG-ADA)),DB00061,,,,,,,,,,Abnormal number of b cells,,HP:0010975,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
221,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,,Pegademase bovine ((PEG-ADA)),DB00061,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
222,,# 102700,"ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,",,ADA,Adenosine deaminase,3.5.4.4,,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,Immune Globulin Human,DB00028,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,,,,,,,,,,
223,17,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,,,D- Ribose,DB02053,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Exercise-induced muscle fatigue,,HP:0009020,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Genetic+Predictors+of+Adenosine+Monophosphate+Deaminase+Deficiency&btnG=,,,,,,,,,,
224,,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,,,D- Ribose,DB02053,,,,,,,,,,Exercise-induced myalgia,,HP:0003738,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Genetic+Predictors+of+Adenosine+Monophosphate+Deaminase+Deficiency&btnG=,,,,,,,,,,
225,,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,,,D- Ribose,DB02053,,,,,,,,,,Limb muscle weakness,,HP:0003690,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Genetic+Predictors+of+Adenosine+Monophosphate+Deaminase+Deficiency&btnG=,,,,,,,,,,
226,,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,,,D- Ribose,DB02053,,,,,,,,,,Muscle cramps,,HP:0003394,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Genetic+Predictors+of+Adenosine+Monophosphate+Deaminase+Deficiency&btnG=,,,,,,,,,,
227,18,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,"It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732 3:https://www.ncbi.nlm.nih.gov/pubmed/10449548?dopt=Abstract",Lorenzo's oil (Terminated),DB12528,ECO:0007121,,,,,Supportive,C,symptomatic therapeutic procedure,,Disease progression,,HP:0003678,https://clinicaltrials.gov/ct2/show/NCT00545597,https://www.ncbi.nlm.nih.gov/pubmed/16009761,https://www.ncbi.nlm.nih.gov/pubmed/7666063,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,,,,,,,
228,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Lorenzo's oil (Terminated),DB12528,,,,,,,,,,Abnormal elevated level of VLCFA in plasma,,HP:0003455,https://clinicaltrials.gov/ct2/show/NCT00545597,https://www.ncbi.nlm.nih.gov/pubmed/16009761,https://www.ncbi.nlm.nih.gov/pubmed/7666063,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,,,,,,,
229,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Lenti-D gene therapy (advanced self-inactivating lentiviral vector TYF-ABCD1),NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Functional disability (Constitutional symptom)*,,HP:0025142,https://clinicaltrials.gov/ct2/show/NCT03727555?cond=Adrenoleukodystrophy&rank=4,https://clinicaltrials.gov/ct2/show/NCT01896102,https://www.ncbi.nlm.nih.gov/pubmed/28976817,,,,,,,,
230,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/,Sobetirome (NV1205),DB07425,ECO:0007121/ECO:0000179,,,,,Functional interaction,B,functional complementatoin of a genetically defective protein by stimulation,,Elevated long chain fatty acids,,HP:0003455,https://www.ncbi.nlm.nih.gov/pubmed/28200172,https://clinicaltrials.gov/ct2/show/NCT03196765?cond=Adrenoleukodystrophy&rank=3,,,,,,,,,
231,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Bezafibrate,DB01393,ECO:0001565,,,,,Functional interaction,B,functional complementatoin of a genetically defective protein by inhibition,,High very long‐chain fatty acids,,HP:0008167,https://www.ncbi.nlm.nih.gov/pubmed/22447153,,,,,,,,,,
232,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,Contraversial results for this treatment option.,Lovastatin,DB00227,ECO:0000352/ECO:0001565/ECO:0007121,,,,,Symptomatic,C,functional complementatoin of a genetically defective protein,,High plasma level of very-long-chain fatty acids,,HP:0003455,https://www.ncbi.nlm.nih.gov/pubmed/16949688,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/20089986,,,,,,,,
233,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Lovastatin,DB00227,,,,,,,,,,High plasma levels of hexacosanoic acid,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/20089986,,,,,,,,
234,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",Interferon beta + Thalidomide,DB00060+DB01041,ECO:0007121,,,,,Supportive+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,,,,https://clinicaltrials.gov/ct2/show/NCT00004450?cond=Adrenoleukodystrophy&rank=20,,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,,,,,,,,
235,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Temsirolimus,DB06287,ECO:0000179/ECO:0001565,,,,,Functional interaction,B,functional complementatoin of a genetically defective protein by inhibition,,Imparied autophagy,,MP:0030940,https://www.ncbi.nlm.nih.gov/pubmed/25549970,,,,,,,,,,
236,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Temsirolimus,DB06287,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/26073123,https://www.ncbi.nlm.nih.gov/pubmed/26684655,,,,,,,,,
237,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Temsirolimus,DB06287,,,,,,,,,,Axonal degeneration,,MP:0005405,https://www.ncbi.nlm.nih.gov/pubmed/26073123,https://www.ncbi.nlm.nih.gov/pubmed/26684655,,,,,,,,,
238,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Pioglitazone,DB01132,ECO:0000179,,,,,Functional interaction,B,functional complementatoin of a genetically defective protein by stimulation,,Axonal degeneration,,MP:0005405,https://www.ncbi.nlm.nih.gov/pubmed/26684655,,,,,,,,,,
239,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Pioglitazone,DB01132,,,,,,,,,,Locomotor disability,,MP:0001392,https://www.ncbi.nlm.nih.gov/pubmed/26684655,,,,,,,,,,
240,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Pioglitazone,DB01132,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/26684655,,,,,,,,,,
241,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Pioglitazone,DB01132,,,,,,,,,,Low ATP level,,MP:0010106,https://www.ncbi.nlm.nih.gov/pubmed/26684655,,,,,,,,,,
242,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,α-tocopherol+ N-acetyl-cysteine + α-lipoic acid,DB00163+DB06151+DB00166,ECO:0000179,,,,,symptomatic+symptomatic+symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Oxidative damage,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/22353463,https://www.ncbi.nlm.nih.gov/pubmed/21786300,,,,,,,,,
243,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,α-tocopherol+ N-acetyl-cysteine + α-lipoic acid,DB00163+DB06151+DB00166,,,,,,,,,,Energetic failure(Fatigable weakness)*,,HP:0003473,https://www.ncbi.nlm.nih.gov/pubmed/22353463,https://www.ncbi.nlm.nih.gov/pubmed/21786300,,,,,,,,,
244,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,α-tocopherol+ N-acetyl-cysteine + α-lipoic acid,DB00163+DB06151+DB00166,,,,,,,,,,Axonal degeneration,,MP:0005405,https://www.ncbi.nlm.nih.gov/pubmed/22353463,https://www.ncbi.nlm.nih.gov/pubmed/21786300,,,,,,,,,
245,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,α-tocopherol+ N-acetyl-cysteine + α-lipoic acid,DB00163+DB06151+DB00166,,,,,,,,,,Locomotor impairment,,MP:0001392,https://www.ncbi.nlm.nih.gov/pubmed/22353463,https://www.ncbi.nlm.nih.gov/pubmed/21786300,,,,,,,,,
246,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,α-lipoic acid + N-acetyl-cysteine,DB00166+DB06151,ECO:0000179,,,,,Symptomatic+symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Oxidative damage,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/21453200,,,,,,,,,,
247,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Lentiviral-mediated gene therapy of hematopoietic stem cells,NA,ECO:0000179/ECO:0001565,,,,,Direct interacion,A,direct complementation of a genetically defective protein by gene therapy,,Hyperintensity of cerebral white matter on MRI,,HP:0030890,https://www.ncbi.nlm.nih.gov/pubmed/19892975?dopt=Abstract,,,,,,,,,,
248,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Lentiviral-mediated gene therapy of hematopoietic stem cells,NA,,,,,,,,,,CNS demyelination,,HP:0007305,https://www.ncbi.nlm.nih.gov/pubmed/19892975,,,,,,,,,,
249,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Hydrocortisone,DB00741,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Spastic paraparesis,,HP:0002313,https://www.ncbi.nlm.nih.gov/pubmed/19892975,,,,,,,,,,
250,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Hydrocortisone,DB00741,,,,,,,,,,Polyneuropathy,,HP:0001271,https://www.ncbi.nlm.nih.gov/pubmed/19892975,,,,,,,,,,
251,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,Hydrocortisone,DB00741,,,,,,,,,,Adrenal insufficiency,,HP:0008207,https://www.researchgate.net/publication/301352258_Adrenoleukodystrophy_two_case_reports,,,,,,,,,,
252,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,Repeated cyclophosphamide pulse therapy has failed to halt the clinical progression or alter the gadolinium accumulation in two cases of childhood cerebral ALD.,Cyclophosphamide,DB00531,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22430161,,,,,,,,,,
253,19,# 263570,Adult polyglucosan body disease,,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",3.2.1.196,,,Triheptanoin,DB11677,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Muscle pain,,HP:0003326,https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,,,,,,,,,,
254,,# 263570,Adult polyglucosan body disease,,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",3.2.1.196,,,Triheptanoin,DB11677,,,,,,,,,,Defective heart function,,HP:0011025,https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,,,,,,,,,,
255,,# 263570,Adult polyglucosan body disease,,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",3.2.1.196,,,Triheptanoin,DB11677,,,,,,,,,,Lack of energy,,HP:0012378,https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,,,,,,,,,,
256,20,# 603471,adult-onset type II citrullinemia,Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,SLC25A13,citrin ( protein),Q9UJS0,,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction,B,functional complementation of genetically defective protein,,High blood ammonia level,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/29651749,,https://www.ncbi.nlm.nih.gov/pubmed/26427088,,,,,,,,
257,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,Medium-chain triglycerides,DB13959,,,,,,,,,,Relapse of hyperammonemic encephalopathy,,HP:0001298*,https://www.ncbi.nlm.nih.gov/pubmed/29651749,,https://www.ncbi.nlm.nih.gov/pubmed/26427088,,,,,,,,
258,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,Medium-chain triglycerides,DB13959,,,,,,,,,,High plasma citrulline levels,,HP:0011966,https://www.ncbi.nlm.nih.gov/pubmed/29651749,,https://www.ncbi.nlm.nih.gov/pubmed/26427088,,,,,,,,
259,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,Medium-chain triglycerides,DB13959,,,,,,,,,,Low plasma glutamine levels,,HP:0010903,https://www.ncbi.nlm.nih.gov/pubmed/29651749,,https://www.ncbi.nlm.nih.gov/pubmed/26427088,,,,,,,,
260,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine,DB00125,ECO:0000352,,,,,Functional interaction,B,functional complementation of genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,,,,,,,,
261,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine,DB00125,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,,,,,,,,
262,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine,DB00125,,,,,,,,,,Encephalopathy,,HP:0001298,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+case+of+adult-onset+type+II+citrullinemia+in+which+oral+administration+of+L-Arginine+Granules+improved+the+patient%27s+encephalopathy+and+the+increased+level+of+serum+ammonia&btnG=,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,,,,,,,,
263,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,Pyruvic acid,DB00119,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.ncbi.nlm.nih.gov/books/NBK1181/,,,,,,,,,
264,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Anorexia,,HP:0002039,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
265,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine+Pyruvic acid,DB00125+DB00119,,,,,,,,,,Lethargy,,HP:0001254,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
266,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine+Pyruvic acid,DB00125+DB00119,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
267,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine+Pyruvic acid,DB00125+DB00119,,,,,,,,,,Poor growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
268,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine+Pyruvic acid,DB00125+DB00119,,,,,,,,,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
269,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine+Pyruvic acid,DB00125+DB00119,,,,,,,,,,Elevated plasma citrulline level,,HP:0011966,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
270,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine+Pyruvic acid,DB00125+DB00119,,,,,,,,,,Elevated threonine-to-serine ratio (Abnormality of amino acid metabolism)*,,HP:0004337*,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
271,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,L-Arginine+Pyruvic acid,DB00125+DB00119,,,,,,,,,,Elevated serum pancreatic secretory trypsin inhibitor,,NA,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
272,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,"According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956",D-mannitol,DB00742,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Brain oedema,,HP:0002181,https://www.ncbi.nlm.nih.gov/pubmed/16449956,,,,,,,,,,
273,21,# 612953,Adult-onset dystonia-parkinsonism,,PLA2G6,Phospholipase A(2),3.1.1.4,,It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,Pergolide,DB01186,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24613933,,,,,,,,,,
274,,# 612953,Adult-onset dystonia-parkinsonism,,PLA2G6,Phospholipase A(2),3.1.1.4,,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",L- dopa,DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/25660576/,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,,,,,
275,22,# 615395,Combined oxidative phosphorylation deficiency 16,,MRPL44,MITOCHONDRIAL RIBOSOMAL PROTEIN L44,Q9H9J2,,,Creatine,DB00148,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Low physical capacity (Constitutional symptom)*,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/25797485,,,,,,,,,,
276,23,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Cholic acid,DB02659,ECO:0007121,,,,,Functional interaction,B,metabolite replacement,,Hepatic Biochemical abnormalities (Laboratory abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
277,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Cholic acid,DB02659,,,,,,,,,,Histologic abnormalities in liver (Abnormal test result)*,,HP:0500014,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
278,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Cholic acid,DB02659,,,,,,,,,,Progression of the disease (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
279,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Cholic acid,DB02659,,,,,,,,,,Bile flow defect,,HP:0001396,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
280,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Cholic acid,DB02659,,,,,,,,,,Synthesis of atypical bile acids,,NA,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
281,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Cholic acid,DB02659,,,,,,,,,,Production of toxic intermediates (Abnormality of metabolism)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
282,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Cholic acid,DB02659,,,,,,,,,,Fat soluble vitamin malabsorption (Fat malabsorption)*,,HP:0002630*,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
283,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Chenodeoxycholic acid,DB06777,ECO:0007121,,,,,Functional interaction,B,functional complementation of genetically defective protein,,Abnormal liver function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,
284,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,
285,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Abnormal urinary steroids levels (Abnormality of urine hormone level)*,,HP:0012029,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,
286,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Ursodeoxycholic acid,DB01586,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal liver function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/7915305,,,,,,,,,,
287,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Glycocholic Acid,DB02691,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/,,,,,,,,,,
288,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Glycocholic Acid,DB02691,,,,,,,,,,Fat soluble vitamin malabsorption (Fat malabsorption)*,,HP:0002630*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/,,,,,,,,,,
289,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B+B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Fat soluble vitamin malabsorption (Fat malabsorption)*,,HP:0002630*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,,,,,,,,,,
290,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,,,,,,,,,,Abnormal gait,,HP:0001288,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,,,,,,,,,,
291,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,,,,,,,,,,
292,24,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,Treatment with cholic acid (10–20 mg/kg daily) should be titrated to ensure that urinary excretion of Δ4-3-oxo bile acids ceases. https://www.ncbi.nlm.nih.gov/pubmed/18577977,Cholic acid,DB02659,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Biochemical abnormalities,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,,,,,
293,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Histologic abnormalities in liver (Abnormal test result)*,,HP:0500014,https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,,,,,
294,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,,,,,
295,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Bile flow defect,,HP:0001396,https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,,,,,
296,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Synthesis of atypical bile acids,,NA,https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,,,,,
297,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Production of bile acid toxic intermediates,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,,,,,
298,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Fat soluble vitamin malabsorption (Fat malabsorption)*,,HP:0002630*,https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,,,,,
299,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid + cholic acid,DB06777+DB02659,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement,,Abnormal liver function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,,
300,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Chenodeoxycholic acid + cholic acid,DB06777+DB02659,,,,,,,,,,Abnormal bilirubin level,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,,
301,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,There are some studies that have concerns over potential hepatotoxicity in animal models of the disease when treated by bile acid replacement therapy that result in curbing the use of chenodeoxycholic acid.https://www.ncbi.nlm.nih.gov/pubmed/15383928/ https://www.ncbi.nlm.nih.gov/pubmed/7075428/ https://www.ncbi.nlm.nih.gov/pubmed/7409382/,Chenodeoxycholic acid,DB06777,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28697823,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,,,,,,,,,
302,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/28697823,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,,,,,,,,,
303,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Abnormal bilirubin level,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,,,,,,,,,
304,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Poor appetite,,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,,,,,,,,,
305,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,,,,,,,,,
306,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Lethargy,,HP:0001254,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,https://www.ncbi.nlm.nih.gov/pubmed/2248502/,,,,,,,,,
307,25,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864 https://www.ncbi.nlm.nih.gov/pubmed/31037385. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",Nitisinone,DB00348,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT00107783?cond=Alkaptonuria&rank=4,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pubmed/28643719,https://clinicaltrials.gov/ct2/show/NCT01390077?cond=alkaptonuria&draw=2&rank=4,,,,
308,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,Nitisinone,DB00348,,,,,,,,,,Ochronosis progression (progressive)*,,HP:0030764,https://www.ncbi.nlm.nih.gov/pubmed/26891864,https://www.ncbi.nlm.nih.gov/pubmed/23511227,https://www.ncbi.nlm.nih.gov/pubmed/25940034,https://www.ncbi.nlm.nih.gov/pubmed/30055994,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pubmed/28643719,https://clinicaltrials.gov/ct2/show/NCT01390077?cond=alkaptonuria&draw=2&rank=4,,,,
309,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,Nitisinone,DB00348,,,,,,,,,,High circulating HGA (homogentisic acid) level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/26891864,https://www.ncbi.nlm.nih.gov/pubmed/31296884,https://www.ncbi.nlm.nih.gov/pubmed/31235217,https://www.ncbi.nlm.nih.gov/pubmed/23511227,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pubmed/28643719,https://clinicaltrials.gov/ct2/show/NCT01390077?cond=alkaptonuria&draw=2&rank=4,,,,
310,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,Nitisinone,DB00348,,,,,,,,,,Joint disesae,,HP:0001367,https://www.ncbi.nlm.nih.gov/pubmed/26891864,https://www.ncbi.nlm.nih.gov/pubmed/31296884,https://www.ncbi.nlm.nih.gov/pubmed/31235217,https://www.ncbi.nlm.nih.gov/pubmed/23511227,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pubmed/28643719,https://clinicaltrials.gov/ct2/show/NCT01390077?cond=alkaptonuria&draw=2&rank=4,,,,
311,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,N-ACETYL-CYSTEINE,DB06151,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Induced apoptosis in chondrocytes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23704321,https://www.ncbi.nlm.nih.gov/pubmed/20648626,https://www.ncbi.nlm.nih.gov/pubmed/21874298/,,,,,,,,
312,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,"Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",ASCORBIC ACID,DB00126,ECO:0000352,,,,,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864 https://www.ncbi.nlm.nih.gov/pubmed/31037385. Dietary restriction of tyrosine and phenylalanine lowers tyrosinaemia associated with nitisinone therapy of alkaptonuria https://www.ncbi.nlm.nih.gov/pubmed/31503358  #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",C,symptomatic therapeutic procedure,,Abnormal chondrocyte growth,,NA,https://www.ncbi.nlm.nih.gov/pubmed/9718357/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,,,,,
313,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,ASCORBIC ACID,DB00126,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,,,,,
314,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,ASCORBIC ACID,DB00126,,,,,,,,,,Abnormality of proteoglycan metabolism (Abnormality of metabolism)*,,HP:0004355,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,,,,,
315,,# 203500,Alkaptonuria,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,Methotrexate,DB00563,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,HGA-induced A-amyloid aggregates,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22850426,,,,,,,,,,
316,26,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated. Diphenhydramine Terminated Phase 1 Trials for Alpha-1 Antitrypsin Deficiency Treatment.",ARC-AAT,NA,ECO:0007121,,,,,Direct interaction,A,procedure to mitigate dominant effects of a genetically abnormal protein,,,,,https://clinicaltrials.gov/ct2/show/NCT02363946?cond=Alpha-1+antitrypsin+deficiency&rank=2,,https://clinicaltrials.gov/ct2/show/NCT02900183,,,,,,,,
317,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,Recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Reduced serum alpha-1-antitrypsin HP:0032025,,HP:0032025,https://www.ncbi.nlm.nih.gov/pubmed/26067712,https://www.ncbi.nlm.nih.gov/pubmed/30194601,https://www.ncbi.nlm.nih.gov/pubmed/23527792,https://www.ncbi.nlm.nih.gov/pubmed/17115945/,https://www.ncbi.nlm.nih.gov/pubmed/9826709/,https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=101.+Toxicology+and+biodistribution+studies+of+a+recombinant+adeno-associated+virus+2+(rAAV2)+alpha-1+antitrypsin+(AAT)+vector[AST]&author=AE+Poirier&author=LA+Combee&author=AT+Martino&volume=9&publication_year=2004&pages=S40&,https://www.ncbi.nlm.nih.gov/pubmed/12231168/,https://www.ncbi.nlm.nih.gov/pubmed/19706466/,,,
318,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,Recombinant alpha 1-antitrypsin (rAAT),DB05481,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Progressive emphysema,,HP:0002097,https://www.ncbi.nlm.nih.gov/pubmed/30723781,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://www.ncbi.nlm.nih.gov/pubmed/27564673,,,,,,,,
319,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,Recombinant alpha 1-antitrypsin (rAAT),DB05481,,,,,,,,,,Decreased lung function,,HP:0005952,https://www.ncbi.nlm.nih.gov/pubmed/30723781,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://www.ncbi.nlm.nih.gov/pubmed/27564673,,,,,,,,
320,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,Recombinant alpha 1-antitrypsin (rAAT),DB05481,,,,,,,,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/30723781,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://www.ncbi.nlm.nih.gov/pubmed/27564673,,,,,,,,
321,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,"AAT augmentation therapy has the disadvanyages of protein infusion, and risk of viral contamination and allergic reactions, and is costly",AAT Augmentation Therapy(plasma-derived AAT),NA,ECO:0000352,,,,,Direct interaction,,metabolite replacement,,Reduced serum alpha-1-antitrypsin HP:0032025,,HP:0032025,https://www.ncbi.nlm.nih.gov/pubmed/18413692,https://www.ncbi.nlm.nih.gov/pubmed/20812844/,,,,,,,,,
322,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,Retinoic acid,DB00755,ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Alveoli damage (interstitial pulmonary abnormality)*,,HP:0006530,https://www.ncbi.nlm.nih.gov/pubmed/22282548/,,,,,,,,,,
323,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,rAAV-CB-hAAT/rAAV1-AAT,NA,ECO:0000179/ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Reduced serum alpha-1-antitrypsin HP:0032025,,HP:0032025,https://www.ncbi.nlm.nih.gov/pubmed/20812844/,https://clinicaltrials.gov/ct2/show/NCT01054339,https://www.ncbi.nlm.nih.gov/pubmed/21609134/,https://www.ncbi.nlm.nih.gov/pubmed/19706466/,https://www.ncbi.nlm.nih.gov/pubmed/24231351/,,,,,,
324,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,Beta2-agonists +corticosteroids + anti-cholinergics,R03CC+S03BA+S01FA,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Difficulty breathing,,HP:0002098,,,,,,,,,,,
325,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,Beta2-agonists +corticosteroids + anti-cholinergics,R03CC+S03BA+S01FA,,,,,,,,,,Lung inflammation (Abnormality of respiratory system),,HP:0002086,,,,,,,,,,,
326,27,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,Lamazym(rhLAMAN),DB12374,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Reduced pulmonary function,,HP:0005952,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
327,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,Lamazym(rhLAMAN),DB12374,,,,,,,,,,Low FVC%,,HP:0030878*,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
328,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,Lamazym(rhLAMAN),DB12374,,,,,,,,,,High NFL (neurofilament light signature ) in CSF,,NA,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
329,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,Lamazym(rhLAMAN),DB12374,,,,,,,,,,Elevated GFAP (Glial fibrillary acidic protein) level in CSF,,NA,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
330,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,Lamazym(rhLAMAN),DB12374,,,,,,,,,,Elevated Tau-p level in CSF,,NA,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
331,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,Lamazym(rhLAMAN),DB12374,,,,,,,,,,High CSF MAN2-oligosaccharides,,NA,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
332,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,Lamazym(rhLAMAN),DB12374,,,,,,,,,,Cognitive deficits,,HP:0100543,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
333,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,AAV1vector expressing α-Mannosidase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/?term=Effective+gene+therapy+for+an+inherited+CNS+disease+in+a+large+animal+mode,,,,,,,,,,
334,28,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,Glycerol phenylbutyrate,DB08909,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Low quality of life (Constitutional symptom )*,,HP:0025142*,https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,,,,,,,,
335,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Elevated blood arginine levels (Abnorality in arginie metabolism)*,,HP:0010909*,https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,,,,,,,,,
336,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I,NA,,,,,,,,,,Unstable neurological function (Abnormality of the nervous system)*,,HP:0000707*,https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,,,,,,,,,
337,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I,NA,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,,,,,,,,,
338,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Sodium benzoate,DB03793,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/11148549,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,,,,,,,,,
339,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,Sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/11148549,,,,,,,,,,
340,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,AAV-based gene therapy,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Neurotoxicity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25474440,,https://www.ncbi.nlm.nih.gov/pubmed/23388701,,,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,,,,,
341,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,AAV-based gene therapy,NA,,,,,,,,,,Neurological abnormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/25474440,,https://www.ncbi.nlm.nih.gov/pubmed/23388701,,,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,,,,,
342,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,AAV-based gene therapy,NA,,,,,,,,,,Cognitive dysfunction,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/25474440,,https://www.ncbi.nlm.nih.gov/pubmed/23388701,,,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,,,,,
343,29,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Nitric oxide supplement,DB00435,ECO:0000179/ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
344,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Nitric oxide supplement,DB00435,,,,,,,,,,Absence of flow-mediated dilatation of brachial artery,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
345,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Nitric oxide supplement,DB00435,,,,,,,,,,Endothelial dysfunction,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
346,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Nitric oxide supplement,DB00435,,,,,,,,,,Left ventricular hypertrophy,,HP:0001712,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
347,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Nitric oxide supplement,DB00435,,,,,,,,,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
348,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Nitric oxide supplement,DB00435,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
349,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Sodium citrate,DB09154,ECO:0000352,,,,,Symptomatic,C,functional complementation of a genetically defective protein,,Abnormal renal nitrogen elimination,,HP:0004364,https://www.ncbi.nlm.nih.gov/pubmed/8582405,,,,,,,,,,
350,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,keto-analogues of essential amino acids,NA,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/668730,,,,,,,,,,
351,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,keto-analogues of essential amino acids,NA,,,,,,,,,,High blood ammonia levels,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/668730,,,,,,,,,,
352,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,keto-analogues of essential amino acids,NA,,,,,,,,,,Defective argininosuccinic acid excretion,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/668730,,,,,,,,,,
353,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Sodium Phenylbutyrate +Arginin,DB06819+DB00125,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://clinicaltrials.gov/ct2/show/NCT00345605,https://www.ncbi.nlm.nih.gov/pubmed/8582405,,,,,,,,,
354,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Arginine,DB00125,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Abnormal hepatic function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,,,,,,,,
355,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Arginine,DB00125,,,,,,,,,,Low plasma arginine levels,,HP:0005961,https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,,,,,,,,
356,,# 207900,Argininosuccinic aciduria,,ASL,argininosuccinate lyase,4.3.2.1,,,Arginine,DB00125,,,,,,,,,,Acute hyperammonemia,,HP:0008281,https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,,,,,,,,
357,30,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,AAV2-hAADC ( Gene therapy),NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Motor malperformance,,HP:0002275,https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2,,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,,,,,,
358,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,AAV2-hAADC ( Gene therapy),NA,,,,,,,,,,Increased dopamine and serotonin levels (neurotransmitter levels),,HP:0012654,https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2,,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,,,,,,
359,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,hypokinesia,,HP:0002375,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
360,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Axial hypotonia,,HP:0008936,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
361,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Limb hypertonia,,HP:0002509,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
362,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
363,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Choreoathetosis,,HP:0001266,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
364,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Poor head control,,HP:0002421,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
365,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Oculogyric crises,,HP:0010553,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
366,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Abnormalitilty in voluntary movements (Abnormality of movement)*,,HP:0100022*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
367,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Bromocriptine,DB01200,,,,,,,,,,Autonomic dysfunction,,HP:0002459,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
368,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pyridoxine,DB00165,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low residual AADC activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,,,,,,,,,,,
369,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,Pyrodixal 5 phosphate,DB00114,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low residual AADC activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,,,,,,,,,,
370,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pramipexole,DB12890,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,Consider PLP trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
371,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pramipexole,DB12890,,,,,,,,,,Oculogyric crisis,,HP:0010553,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
372,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pramipexole,DB12890,,,,,,,,,,Poor head control,,HP:0002421,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
373,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pramipexole,DB12890,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,,HP:0100022*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
374,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pramipexole,DB12890,,,,,,,,,,Autonomic dysfunction,,HP:0002459,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
375,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Rotigotine,DB05271,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,,,,,,,,,
376,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Rotigotine,DB05271,,,,,,,,,,Oculogyric crisis,,HP:0010553,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,,,,,,,,,
377,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Rotigotine,DB05271,,,,,,,,,,Poor head control,,HP:0002421,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,,,,,,,,,
378,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Rotigotine,DB05271,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,,HP:0100022*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,,,,,,,,,
379,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Rotigotine,DB05271,,,,,,,,,,Autonomic dysfunction,,HP:0002459,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,,,,,,,,,
380,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pergolide,DB01186,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
381,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pergolide,DB01186,,,,,,,,,,Oculogyric crisis,,HP:0010553,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
382,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pergolide,DB01186,,,,,,,,,,Poor head control,,HP:0002421,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
383,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pergolide,DB01186,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,,HP:0100022*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
384,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Pergolide,DB01186,,,,,,,,,,Autonomic dysfunction,,HP:0002459,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
385,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,Folinic acid,DB00650,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Cerebral folate depletion,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,,,,,,,,,,
386,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",Pargyline,DB01626,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
387,31,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,,S-adenosylmethionine,DB00118,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,low levels of purines,,HP:0004369,https://www.sciencedirect.com/science/article/pii/S0002929707613470,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
388,,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,,S-adenosylmethionine,DB00118,,,,,,,,,,Progression of retinal degeneration (Rapidly Progressive)*,,HP:0003678*,https://www.sciencedirect.com/science/article/pii/S0002929707613470,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
389,,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,,S-adenosylmethionine,DB00118,,,,,,,,,,Ataxia Progression (Rapid progression),,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
390,,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,,S-adenosylmethionine,DB00118,,,,,,,,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
391,,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,,S-adenosylmethionine,DB00118,,,,,,,,,,Frequent hospital admission,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
392,,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,,S-adenosylmethionine,DB00118,,,,,,,,,,Hearing impairment progression (Rapid progression)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
393,,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,,S-adenosylmethionine,DB00118,,,,,,,,,,Noctornal difficulty breathing,,HP:0002098,https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
394,32,208400,Aspartylglycosaminuria,"As by 2016 Banning et al. mentioned ""Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years",AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,"Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. ""This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. "" It posses the ability to cross the BBB. ""Our data show for the first time that Amlexanox might provide a valid therapy for AGU."" https://www.ncbi.nlm.nih.gov/pubmed/29247835",Amlexanox,DB01025,ECO:0001565,Ser72Pro/Trp168X,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low AGA activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,,https://www.ncbi.nlm.nih.gov/pubmed/29247835,,,https://www.ncbi.nlm.nih.gov/pubmed/29247835,,,,,,
395,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",betaine,DB06756,ECO:0001565,T122K,"Our data show that both T122K and AGU-Fin AGA enzyme variants most likely exhibit a relatively local folding defect that neither completely impairs the structure, nor results in severe destabilization and degradation of the mutant enzyme. These findings are somewhat contradictory to what has been proposed for the AGU-Fin mutated AGA, which has been suggested to become rapidly degraded after synthesis in the ER19,28. However, these previous studies have been based on overexpression of the mutated enzyme mainly in chinese hamster ovarian cells, which may result in ER overload and unfolded protein response, facilitating the degradation of the AGU-Fin mutant precursors. We here show that endogenous T122K and AGU-Fin AGA in patient fibroblasts do not colocalize with the ER marker calnexin, whereas a high degree of colocalization was observed with lysosomal markers. However, it is likely that the misfolding induced by T122K mutation is milder than that of AGU-Fin which impairs the formation of an intramolecular disulfide bond20. This would also be consistent with the data that the PC-like compounds used here showed a higher increase of enzyme activity in the case of T122K than AGU-Fin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/",,,Direct interaction,A,activity modification of a genetically defective protein,,Low AGA activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,,,,,,,,,
396,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,betaine,DB06756,,,,,,,,,,Unstable AGA enzyme (Abnormal enzyme activity)*,,HP:0012379,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,,,,,,,,,
397,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,betaine,DB06756,,,,,,,,,,Misfolded AGA,,NA,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,,,,,,,,,
398,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,betaine,DB06756,,,,,,,,,,Abnormal AGA processing,,NA,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,,,,,,,,,
399,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,Glycine,DB00145,,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low AGA activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pubmed/23601642,,,,,,,,
400,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",Recombinant human Aspartylglucosamidase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Pathology in many somatic tissues (Somatic nervous system abnormalities)*,,MP:0002752,https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,,https://www.ncbi.nlm.nih.gov/pubmed/27906067,,,,,,
401,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,Recombinant human Aspartylglucosamidase,NA,,,,,,,,,,Glycoasparagines accumulation (Metaboic abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,,https://www.ncbi.nlm.nih.gov/pubmed/27906067,,,,,,
402,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,Recombinant human Aspartylglucosamidase,NA,,,,,,,,,,High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,,https://www.ncbi.nlm.nih.gov/pubmed/27906067,,,,,,
403,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,Recombinant human Aspartylglucosamidase,NA,,,,,,,,,,High amount of aspartylglucosamine in brain tissue ((Metabolism abnormality)*),,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,,https://www.ncbi.nlm.nih.gov/pubmed/27906067,,,,,,
404,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",Gene therapy (wild-type Ad-AGA),NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Low expression of AGA enzyme (Abnormality of circulating enzyme level)*,,HP:0011021,https://www.ncbi.nlm.nih.gov/pubmed/9930336/,,,,,,,,,,
405,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,Gene therapy (wild-type Ad-AGA),NA,,,,,,,,,,Liver lysosomal storage abnormality (Abnormality of lysosomal metabolism)*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/9930336/,,,,,,,,,,
406,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,Gene therapy (wild-type Ad-AGA),NA,,,,,,,,,,Brain lysosomal storage disease (Abnormality of lysosomal metabolism)*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/9930336/,,,,,,,,,,
407,,208400,Aspartylglycosaminuria,,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,Gene therapy (wild-type Ad-AGA),NA,,,,,,,,,,Brain neuronal storage abnormalities -ipsilateral (Abnormality of lysosomal metabolism)*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/16518877/,,,,,,,,,,
408,33,# 277460,Ataxia with vitamin E deficiency,,TTPA,α-tocopherol transfer protein,P49638,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Vitamin E,DB00163,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20301419,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,
409,,# 277460,Ataxia with vitamin E deficiency,,TTPA,α-tocopherol transfer protein,P49638,,,Vitamin E,DB00163,,,,,,,,,,Abnormal vitamin E level (Vitamin E deficiency)*,,HP:0100513*,https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20301419,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,
410,,# 277460,Ataxia with vitamin E deficiency,,TTPA,α-tocopherol transfer protein,P49638,,,Vitamin E,DB00163,,,,,,,,,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/9931538,https://www.ncbi.nlm.nih.gov/pubmed/11554913,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,
411,,# 277460,Ataxia with vitamin E deficiency,,TTPA,α-tocopherol transfer protein,P49638,,,Vitamin E,DB00163,,,,,,,,,,Neurological abnormalitis,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/11554913,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,
412,,# 277460,Ataxia with vitamin E deficiency,,TTPA,α-tocopherol transfer protein,P49638,,,RRR-α-tocopherol,DB14002,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*,,HP:0030390*,https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub,,,,,,,,,,
413,,# 277460,Ataxia with vitamin E deficiency,,TTPA,α-tocopherol transfer protein,P49638,,,RRR-α-tocopherol,DB14002,,,,,,,,,,Abnormal H50 (The erythrocyte resistance to oxidative stress),,NA,https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub,,,,,,,,,,
414,34,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Myo-inositol,DB13178,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,neurological malfunction,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
415,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Myo-inositol,DB13178,,,,,,,,,,immune dysfunctions,,HP:0002715,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
416,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Alpha lipoic acid,DB00166,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Neuronal death,,HP:0002529,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
417,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Alpha lipoic acid,DB00166,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
418,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Nicotinamide,DB02701,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal levels of urine total alkanes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
419,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Nicotinamide,DB02701,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
420,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Alpha-lipoic acid + nicotinamide,DB00166+DB02701,ECO:0007121,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Abnormal serum fast ORAC (oxygen reduced absorbance capacity),,NA,,,,,,,,,,,
421,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Alpha-lipoic acid + nicotinamide,DB00166+DB02701,,,,,,,,,,Abnormal lymphocyte counts,,HP:0040088,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
422,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Immunoglobulin replacement therapy,DB00028,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/28318010,,,,,,,,,,
423,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Amantadine,DB00915,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/22550086/,,,,,,,,,,
424,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Amantadine,DB00915,,,,,,,,,,Involuntary movements,,HP:0004305,https://www.ncbi.nlm.nih.gov/pubmed/22550086/,,,,,,,,,,
425,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Amantadine,DB00915,,,,,,,,,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/22550086/,,,,,,,,,,
426,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Clonazepam,DB01068,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Myoclonuic Jerk,,HP:0001336,https://www.ncbi.nlm.nih.gov/pubmed/26232052/,,,,,,,,,,
427,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Clonazepam,DB01068,,,,,,,,,,Poor fine motor skills,,HP:0007010,https://www.ncbi.nlm.nih.gov/pubmed/26232052/,,,,,,,,,,
428,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Clonazepam,DB01068,,,,,,,,,,Voice tremor,,HP:0012477,https://www.ncbi.nlm.nih.gov/pubmed/26232052/,,,,,,,,,,
429,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Clonazepam,DB01068,,,,,,,,,,Poor intelligibility,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/26232052/,,,,,,,,,,
430,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,Study is not yet recruiting. The drug is ment to correct the ataxi,Acetylleucine,DB13226,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://clinicaltrials.gov/ct2/show/NCT03759678,,,,,,,,,,
431,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,4-aminopyridine,DB06637,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Periodic alternating nystagmus (Horizontal nystagmus)*,,HP:0000666,https://www.ncbi.nlm.nih.gov/pubmed/23884713/,,,,,,,,,,
432,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,4-aminopyridine,DB06637,,,,,,,,,,Abnormal vestibulo-ocular reflex,,HP:0007670,https://www.ncbi.nlm.nih.gov/pubmed/23884713/,,,,,,,,,,
433,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,4-aminopyridine,DB06637,,,,,,,,,,Vertical spontaneous nystagmus (Vertical nystagmus)*,,HP:0010544,https://www.ncbi.nlm.nih.gov/pubmed/23884713/,,,,,,,,,,
434,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,"0.1 mg/kg per 24 hours, divided every 12 hours, for 4 weeks then it",The therapy was started with Betamethasone and followed by Methylprednisolone in an attempt to perform long term therapy.No beneficil effect was obtained when they replaced betamethasone with Methylprednisolone.,Betamethasone,DB00443,ECO:0000352/ECO:0007121/ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Abnormal serine-protein kinase ATM activity(Abnormality of circulating enzyme level)*,,HP:0011021,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000338-36,https://www.ncbi.nlm.nih.gov/pubmed/31107893,https://www.ncbi.nlm.nih.gov/pubmed/23055520/,,,,,,,,
435,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Betamethasone,DB00443,,,,,,,,,,Poor head control,,HP:0002421,https://www.ncbi.nlm.nih.gov/pubmed/17030666,https://www.ncbi.nlm.nih.gov/pubmed/31107893,https://www.ncbi.nlm.nih.gov/pubmed/23055520/,,,,,,,,
436,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Betamethasone,DB00443,,,,,,,,,,Gait ataxia,,HP:0002066,https://www.ncbi.nlm.nih.gov/pubmed/17030666,https://www.ncbi.nlm.nih.gov/pubmed/24405665/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,,,,,,,,
437,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Betamethasone,DB00443,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/19475758/,https://www.ncbi.nlm.nih.gov/pubmed/24405665/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,,,,,,,,
438,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Betamethasone,DB00443,,,,,,,,,,Dysarthria,,HP:0001260,https://www.ncbi.nlm.nih.gov/pubmed/24405665/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,,,,,,,,
439,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Betamethasone,DB00443,,,,,,,,,,Oculomotor impairment (Oculomotor apraxia)*,,HP:0000657,https://www.ncbi.nlm.nih.gov/pubmed/24405665/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,,,,,,,,
440,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Betamethasone,DB00443,,,,,,,,,,Extrapyramidal disorders,,HP:0002071,https://www.ncbi.nlm.nih.gov/pubmed/24405665/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,,,,,,,,
441,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,Betamethasone,DB00443,,,,,,,,,,Abnormal kinetic function (Abnormality of movement)*,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/24405665/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,https://www.ncbi.nlm.nih.gov/pubmed/22927201/,,,,,,,,
442,35,# 208920,Ataxia-oculomotor apraxia type 1,,APTX,Aprataxin,3.1.12.2,,,CoQ10,DB09270,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Lack of strenght,,HP:0003750,https://www.ncbi.nlm.nih.gov/pubmed/28277561,https://www.ncbi.nlm.nih.gov/pubmed/17242337,https://www.ncbi.nlm.nih.gov/pubmed/18403580,,,,,,,,
443,,# 208920,Ataxia-oculomotor apraxia type 1,,APTX,Aprataxin,3.1.12.2,,,CoQ10,DB09270,,,,,,,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/28277561,https://www.ncbi.nlm.nih.gov/pubmed/17242337,https://www.ncbi.nlm.nih.gov/pubmed/18403580,,,,,,,,
444,36,# 209300,Atransferrinemia,,TF,transferrin,P02787,,,Human apotransferrin,CHEBI:2786,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Hypochromic anemia,,HP:0001931,https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,,,,https://www.ncbi.nlm.nih.gov/pubmed/8317485,,,,,,
445,,# 209300,Atransferrinemia,,TF,transferrin,P02787,,,Deferoxamine,DB00746,ECO:0000352,,,,,Supportive,C,functional complementation of a genetically defective protein,,Hypochromic anemia,,HP:0001931,https://www.ncbi.nlm.nih.gov/pubmed/8187613,,,,,,,,,,
446,,# 209300,Atransferrinemia,,TF,transferrin,P02787,,"Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. ""Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280",Ferrous sulfate,DB13257,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Decreased hemoglobin,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/28895280,,,,,,,,,,
447,,# 209300,Atransferrinemia,,TF,transferrin,P02787,,,Ferrous sulfate,DB13257,,,,,,,,,,High ferritin level,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/28895280,,,,,,,,,,
448,37,# 162350,Autosomal dominant neuronal ceroid lipofuscinosis 4B,,DNAJC5,DnaJ homolog subfamily C member 5(cysteine string PROTEIN),Q9H3Z4,,"Symptomatic treatment can be successful in mitigating the manifestations of NCL. Seizures, sleep-related problems, malnutrition, gastroesophageal reflux, pneumonia, sialorrhea, hyperactivity and behavior problems, psychosis, anxiety, spasticity, Parkinsonian symptoms, and dystonia can be palliated. https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management",No treatment is available in DDIEM,,,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,,,,,,,,,,,
449,38,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,Cystagon,DB00847,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Progression of neurodegeneration,,HP:0002344,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13,,,,,,,,
450,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Granular osmiophilic deposits (GROD),,HP:0003657,https://www.ncbi.nlm.nih.gov/pubmed/24997880,,,,,,,,,,
451,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pubmed/24997880,,,,,,,,,,
452,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,,,,,,,,,,Defected alertness,,HP:0004372,https://www.ncbi.nlm.nih.gov/pubmed/24997880,,,,,,,,,,
453,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,,,,,,,,,,Isoelectric electroencephalogram,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/24997880,,,,,,,,,,
454,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,δ-tocopherol (DT),DB11251,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Cognitive deficits,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/29631617,,,,,,,,,,
455,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,Hydroxypropyl-β-cyclodextrin (HPBCD),PubChem CID:14049689,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Brain atrophy,,HP:0012444,,,,,,,,,,,
456,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,δ-tocopherol (DT) + hydroxypropyl-β-cyclodextrin (HPBCD),DB11251+PubChem CID:14049689,ECO:0001565,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Lipid accumulation (Abnorality in lipid meabolism)*,,HP:0003119*,,,,,,,,,,,
457,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,δ-tocopherol (DT) + hydroxypropyl-β-cyclodextrin (HPBCD),DB11251+PubChem CID:14049689,,,,,,,,,,Lysosomal enlargment (Abnormality of lysosomal metabolism)*,,HP:0004356*,,,,,,,,,,,
458,,# 256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,Recombinant human palmitoyl-protein thioesterase 1 ( PPT1),NA,ECO:0001565,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*,,HP:0004356*,,,,,,,,,,,
459,39,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,"The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated https://link.springer.com/chapter/10.1007%2F8904_2018_113. 

However, there were no definite effects on measured autoimmunity or clinical outcomes in the setting of short-term use of CellCept(Mycophenolate mofetil).

The brief exposure to treatment was useful to study short-term safety risks and support future long-term studies, but it “did not allow clinical insights into potential efficacy,” researchers stated in https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/",Mycophenolate mofetil,DB00688,ECO:0007121/ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://clinicaltrials.gov/ct2/show/results/NCT01399047?cond=neuronal+ceroid+lipofuscinosis&rank=1&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/29923092,,,,,,,,
460,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: Study has been conducted invivo and invitro in mice. https://www.ncbi.nlm.nih.gov/pubmed/29660499,Blood-brain barrier (BBB) impairment,,MP:0005167,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
461,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,,,,,,,,,,Increased astrocyte endfeet area(Abnormality of the astrocytes )*,,HP:0100707,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
462,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,,,,,,,,,,Membrane fluidity alterations,,NA,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
463,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,,,,,,,,,,Abnormal endocytosis,,MP:0030951,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
464,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,,,,,,,,,,Disturbed Cdc42 activity(Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
465,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,,,,,,,,,,Excessive autofluorescence (Brain imaging abnormality)*,,HP:0410263,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
466,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,,,,,,,,,,Cav-1 plasma membrane distribution defects (abnormal plasma membrane sphingolipid content)*,,MP:0009587,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
467,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,Carbenoxolone,DB02329,,,,,,,,,,Extended G1 interval(Abnormality of the cell cycle)*,,HP:0011018,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,,,
468,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,AAVrh.10hCLN3,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Neurological lysosomal storage defect (Abnormality of lysosomal metabolism)*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/24372003,,,,,,,,,,
469,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,AAVrh.10hCLN3,NA,,,,,,,,,,Astrocyte defect (Abnormality of the astrocytes)*,,HP:0100707,https://www.ncbi.nlm.nih.gov/pubmed/24372003,,,,,,,,,,
470,40,# 601780,Late infantile neuronal ceroid lipofuscinoses CLN6,,CLN6,"CLN6, transmembrane ER protein",NO Human id,,,scAVV9.CB.CLN6,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,Drug name: under investgation/ aim is to slow the neurodegeneration progression HP:0002344,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31331814,,https://clinicaltrials.gov/ct2/show/NCT02725580?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=14,,,,,,
471,41,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,A research paper on management strategies for CLN2 disease https://www.ncbi.nlm.nih.gov/pubmed/28335910,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Cerliponase alfa,DB13173,ECO:0007121/ECO:0000352/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Neurologic deficits,,HP:0000707,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,
472,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Cerliponase alfa,DB13173,,,,,,,,,,Cognitive dysfunction,,HP:0100543,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,
473,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Cerliponase alfa,DB13173,,,,,,,,,,Brain atrophy,,HP:0012444,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,
474,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Cerliponase alfa,DB13173,,,,,,,,,,Loss of ambulation,,HP:0002540,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,
475,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,AAVrh.10CUhCLN2,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,"The clinical study is still active, not yet recruiting. No results have been added yet. The aim is to slow the neurdegeneration process.",Progressive neurologic deterioration,,HP:0002344,,,https://clinicaltrials.gov/ct2/show/NCT01161576?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=8,https://clinicaltrials.gov/ct2/show/NCT01414985?cond=CLN2&draw=3&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/18473686,,,,,,
476,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,AAVrh.10CUhCLN2,NA,,,,,,,,,,Mortality,,HP:0040006,,,https://www.ncbi.nlm.nih.gov/pubmed/18639872?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT01414985?cond=CLN2&draw=3&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/18473686,,,,,,
477,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,AAVrh.10CUhCLN2,NA,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18639872?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT01414985?cond=CLN2&draw=3&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/18473686,,,,,,
478,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,AAV2CUhCLN2,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,"The clinical study is still active, not yet recruiting. No results have been added yet. The aim is to slow the neurdegeneration process.",Progressive neurologic deterioration,,HP:0002344,,,https://clinicaltrials.gov/ct2/show/NCT00151216?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/18473686,,,,,,,
479,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,δ-tocopherol (DT),DB11251,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Cognitive deficits,,HP:0100543,,,https://www.ncbi.nlm.nih.gov/pubmed/29631617,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/,,,,,,
480,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Hydroxypropyl-β-cyclodextrin (HPBCD),PubChem CID:14049689,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Brain atrophy,,HP:0012444,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977/,,,,,,,,
481,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,BMN 190 (recombinant human tripeptidyl peptidase-1 (rhTPP1)),DB13173,ECO:0001565/ECO:0007121/ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Neurological disease,,HP:0000707,,,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://clinicaltrials.gov/ct2/show/NCT01907087?cond=CLN2&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT02485899?cond=CLN2&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT02678689?cond=CLN2&draw=2&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/25257657?dopt=Abstract,,,
482,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,BMN 190 (recombinant human tripeptidyl peptidase-1 (rhTPP1)),DB13173,,,,,,,,,,Neurologic deficits,,HP:0000707,,,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://clinicaltrials.gov/ct2/show/NCT01907087?cond=CLN2&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT02485899?cond=CLN2&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT02678689?cond=CLN2&draw=2&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/25257657?dopt=Abstract,,,
483,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,BMN 190 (recombinant human tripeptidyl peptidase-1 (rhTPP1)),DB13173,,,,,,,,,,Cognitive dysfunction,,HP:0100543,,,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://clinicaltrials.gov/ct2/show/NCT01907087?cond=CLN2&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT02485899?cond=CLN2&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT02678689?cond=CLN2&draw=2&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/25257657?dopt=Abstract,,,
484,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,BMN 190 (recombinant human tripeptidyl peptidase-1 (rhTPP1)),DB13173,,,,,,,,,,Brain atrophy,,HP:0012444,,,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://clinicaltrials.gov/ct2/show/NCT01907087?cond=CLN2&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT02485899?cond=CLN2&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT02678689?cond=CLN2&draw=2&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/25257657?dopt=Abstract,,,
485,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,BMN 190 (recombinant human tripeptidyl peptidase-1 (rhTPP1)),DB13173,,,,,,,,,,Loss of ambulation,,HP:0002540,,,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://clinicaltrials.gov/ct2/show/NCT01907087?cond=CLN2&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT02485899?cond=CLN2&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT02678689?cond=CLN2&draw=2&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/25257657?dopt=Abstract,,,
486,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,One possible limitation might be weight loss that will need to be monitored since NCL patients have weight gain issues.,Gemfibrozil,DB01241,ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Mortality,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/28199020,,,,,,,,,,
487,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Gemfibrozil,DB01241,,,,,,,,,,Lipid accumulation in the motor cortex (Upper motor neuron dysfunction )*,,HP:0002493,https://www.ncbi.nlm.nih.gov/pubmed/28199020,,,,,,,,,,
488,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Gemfibrozil,DB01241,,,,,,,,,,Low TTP 1 activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/22989886,,,,,,,,,,
489,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,Gemfibrozil+fenofibrate,DB01241+ DB01039,ECO:0000179/ECO:0001565,,,,,Direct interaction+Direct interaction,A+A,combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+activity modification of a genetically defective protein by transcriptional or translational modification,,Low TTP 1 activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/22989886/,,,,,,,,,,
490,42,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,ECO:0007121,comp. htz c.[895C > T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24],,"E551K /Compound heterozygotes for( R213W,  G272V","E551K  in one patient & A compound heterozygotes for( R213W,  G272V) in another.  https://www.ncbi.nlm.nih.gov/pubmed/18319072                                                                                                                                                                                                       Duplication mutation on ADCK3/CABC1 https://www.ncbi.nlm.nih.gov/pubmed/27793482",Functional interaction,B,functional complementation of a genetically defective protein,,Tremor,,HP:0001298,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
491,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,,,,,,,,,Drawing inabiliity,,MP:0004144,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
492,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,,,,,Myoclonus,,HP:0002180,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
493,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
494,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,Hetero c.[1541A→G] + [1750_1752 delACC],,,,,,,,Cerebeller atxia progression (Progressive gait ataxia)*,,HP:0007240,https://www.ncbi.nlm.nih.gov/pubmed/18319074,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
495,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072,,,,,,,,Exercise intolerance,"Although there was a slight improvement of one patient on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/",HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
496,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,,,,,,,,,Hyperlactatemia,"Although there was a slight improvement of patient 4 on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/",HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
497,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,Homozygous deletion (c.504del_CT),,,,,,,,Speech problem,,HP:0002167,https://www.ncbi.nlm.nih.gov/pubmed/26818466,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
498,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,,,,,,,,,Gait abnormality,,HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/26818466,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
499,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,,,,,,,,,Neurological abormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/26818466,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
500,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs),,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
501,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,,,,,,,,,High ataxia score (Ataxia)*,,HP:0001251*,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
502,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A,,,,,,,,Myoclonic abnormalities (Myoclouns)*,,HP:0001336*,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
503,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,,,,,,,,,Ataxic gait,,HP:0002066,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
504,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,CoQ10 (ubiquinone),DB09270,,,,,,,,,,Dysarthric speech,,HP:0001260,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
505,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,"Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873",CoQ10 (ubiquinone),DB09270,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
506,,# 612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4",,ADCK3/CABC1,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,Sodium Valproate,DB00313,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,,,,,,,,,,
507,42,# 607091,B4GALT1-CDG (CDG-IId),,GALT1,"beta-1,4-galactosyl transferase.",2.4.1.274,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT02955264,,,,,,,,
508,43,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,Mannose supply,DB12907,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Metabolism abnormality,,HP:0001939,,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
509,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,Mannose supply,DB12907,,,,,,,,,,Hypoproteinemia,,MP:0005567,,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
510,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,Mannose supply,DB12907,,,,,,,,,,Blood coagulation,,HP:0001928,,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
511,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,Mannose supply,DB12907,,,,,,,,,,Protein-losing enteropathy,,HP:0002243,,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
512,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,Mannose supply,DB12907,,,,,,,,,,Hypoglycaemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/10484808,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
513,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,Mannose supply,DB12907,,,,,,,,,,Hypoglycosylation of serum glycoproteins,,NA,https://www.ncbi.nlm.nih.gov/pubmed/9525984,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
514,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,Mannose supply,DB12907,,,,,,,,,,Urinary tract infection,,HP:0000010,https://www.ncbi.nlm.nih.gov/pubmed/9525984,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
515,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D- Galactose,DB11735,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal aPTT level,,HP:0003645,https://www.ncbi.nlm.nih.gov/pubmed/28617415,,,,,,,,,,
516,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D- Galactose,DB11735,,,,,,,,,,Abnormal AST level (Abnormal liver enzymes)*,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28617415,,,,,,,,,,
517,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D- Galactose,DB11735,,,,,,,,,,Abnormal ALT level (Abnormal liver enzymes)*,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28617415,,,,,,,,,,
518,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D- Galactose,DB11735,,,,,,,,,,Abnormal Antithrombin-III levels,,HP:0001976,https://www.ncbi.nlm.nih.gov/pubmed/28617415,,,,,,,,,,
519,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D- Galactose,DB11735,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28617415,,,,,,,,,,
520,44,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,,Fucose therapy,DB03485,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal Golgi located fucosylation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/17276979,,https://www.ncbi.nlm.nih.gov/pubmed/12409504,,,,,,,,
521,,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,,Fucose therapy,DB03485,,,,,,,,,,Abnormal fucosylation state of glycoconjugates.,,NA,https://www.ncbi.nlm.nih.gov/pubmed/17276979,,https://www.ncbi.nlm.nih.gov/pubmed/12409504,,,,,,,,
522,,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,,Fucose therapy,DB03485,ECO:0000179,,,,,,,,,Abnormal selectin ligand function,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10590041,,https://www.ncbi.nlm.nih.gov/pubmed/12409504,,,,,,,,
523,,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,,Fucose therapy,DB03485,ECO:0000179,,,,,,,,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/12406889,,https://www.ncbi.nlm.nih.gov/pubmed/12409504,,,,,,,,
524,45,# 241510,Childhood hypophosphatasia,,ALPL,Alkaline phosphatase,3.1.3.1,,,Asfotase Alfa,DB09105,ECO:0000352/ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Abnormal developmental milestones,,HP:0012759,,,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,,"ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).",,"Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.",,
525,,# 241510,Childhood hypophosphatasia,,ALPL,Alkaline phosphatase,3.1.3.1,,,Asfotase Alfa,DB09105,,,,,,,,,,Pulmonary function deterioration,,HP:0005952,,,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,,"ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).",,"Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.",,
526,,# 241510,Childhood hypophosphatasia,,ALPL,Alkaline phosphatase,3.1.3.1,,,Asfotase Alfa,DB09105,,,,,,,,,,Decreased physical function,,HP:0025142,,,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,,"ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).",,"Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.",,
527,,# 241510,Childhood hypophosphatasia,,ALPL,Alkaline phosphatase,3.1.3.1,,,Asfotase Alfa,DB09105,,,,,,,,,,Failure-to-thrive,,HP:0001508,,,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,,"ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).",,"Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.",,
528,,# 241510,Childhood hypophosphatasia,,ALPL,Alkaline phosphatase,3.1.3.1,,,Asfotase Alfa,DB09105,,,,,,,,,,Dental Defects,,HP:0000164,,,https://www.ncbi.nlm.nih.gov/pubmed/21212313,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,,"ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).",,"Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.",,
529,,# 241510,Childhood hypophosphatasia,,ALPL,Alkaline phosphatase,3.1.3.1,,,Pyridoxal,DB00147,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Epilepsy,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.ncbi.nlm.nih.gov/pubmed/15033207,,,,,,
530,46,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin,DB00641,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Accumulation of toxic metabolites in cholesterol biosynthetic pathway,,HP:0001939*,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
531,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin,DB00641,,,,,,,,,,Ichthyosiform erythematous plaques,,HP:0008064,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
532,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin,DB00641,,,,,,,,,,Waxy scaling plaques,,HP:0040189*,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
533,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin,DB00641,,,,,,,,,,Inflammation,,MP:0001845,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
534,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin,DB00641,,,,,,,,,,Skin thickening,,HP:0100725,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
535,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Lovastatin+Cholesterol,DB00227+DB04540,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement,,Cutaneous abnormalities,,MP:00011911,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
536,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Lovastatin+Cholesterol,DB00227+DB04540,,,,,,,,,,Ichthyosiform erythroderma,,HP:0007431,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
537,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Ketoconazole,DB01026,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Cutaneous abnormalities,,MP:0001191,,,https://www.ncbi.nlm.nih.gov/pubmed/29687057,,,,,,,,
538,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin+Cholesterol,DB00641+ DB04540,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement,,Ichthyosiform erythroderma,,HP:0007431,,,,,,,,,,,
539,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin+Cholesterol,DB00641+ DB04540,,,,,,,,,,Itchy skin,,HP:0000989,,,,,,,,,,,
540,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin+Cholesterol,DB00641+ DB04540,,,,,,,,,,Scaling Skin,,HP:0040189,,,,,,,,,,,
541,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin+Cholesterol,DB00641+ DB04540,,,,,,,,,,Erythema,,HP:0010783,,,,,,,,,,,
542,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin+Cholesterol,DB00641+ DB04540,,,,,,,,,,Verruciform plaques (verruciform xanthomas)*,,HP:0031517*,,,https://www.ncbi.nlm.nih.gov/pubmed/29341259,,,,,,,,
543,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Simvastatin+Cholesterol,DB00641+ DB04540,,,,,,,,,,VX‐like lesions,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/29341259,,,,,,,,
544,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Retinoids,CHEBI:26537,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Scaling Skin,,HP:0040189,,,https://www.ncbi.nlm.nih.gov/pubmed/29392821,,,,,,,,
545,,# 308050,CHILD syndrome,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,Glycolic acid+lovastatin+cholesterol,DB03085+DB00227+DB04540,ECO:0000352,,,,,Symptomatic+Functional interaction+Functional interaction,C+B+B,combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement,,Verruciform xanthomas,,HP:0031517,,,,,,,,,,,
546,47,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients +acitretin,A06AA+DB00459,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Ichthyosis,,HP:0008064,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Acitretin%E2%80%90Responsive+Ichthyosis+in+Chanarin–Dorfman+Syndrome+with+a+Novel+Mutation+in+the+ABHD5%2FCGI%E2%80%9058+Gene,https://www.ncbi.nlm.nih.gov/pubmed/23756328,,,,,,,
547,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients +acitretin,A06AA+DB00459,,,,,,,,,,Erythroderma,,HP:0001019,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,https://www.ncbi.nlm.nih.gov/pubmed/23756328,,,,,,,
548,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients +acitretin,A06AA+DB00459,,,,,,,,,,Diffuse scaling (Skin Scaling)*,,HP:0040189*,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,https://www.ncbi.nlm.nih.gov/pubmed/23756328,,,,,,,
549,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients +acitretin,A06AA+DB00459,,,,,,,,,,Collodion membrane (Nonbullous congenital ichthyosiform erythroderma)*,,HP:0007479*,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,https://www.ncbi.nlm.nih.gov/pubmed/23756328,,,,,,,
550,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients +acitretin,A06AA+DB00459,,,,,,,,,,Erythema,,HP:0010783,,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,https://www.ncbi.nlm.nih.gov/pubmed/23756328,,,,,,,
551,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients +acitretin,A06AA+DB00459,,,,,,,,,,Scaling,,HP:0040189,,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,https://www.ncbi.nlm.nih.gov/pubmed/23756328,,,,,,,
552,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients,A06AA,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Erythema,,HP:0010783,,,https://www.ncbi.nlm.nih.gov/pubmed/21549082,,,,,,,,
553,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients,A06AA,,,,,,,,,,Ichthyosis,,HP:0008064,,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,,,,,,,,
554,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients,A06AA,,,,,,,,,,Pruritis,,HP:0000989,,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,,,,,,,,
555,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Emollients,A06AA,,,,,,,,,,Scaling,,HP:0040189,,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,,,,,,,,
556,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Ursodeoxycholic acid,DB01586,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Steatohepatitis,,HP:0001397,,,https://www.ncbi.nlm.nih.gov/pubmed/21549082,,,,,,,,
557,,# 275630,Chanarin-Dorfman syndrome,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,,,Vitamin E,DB00163,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Steatohepatitis,,HP:0001397,,,https://www.ncbi.nlm.nih.gov/pubmed/21549082,,,,,,,,
558,49,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Neurological dysfunctions,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/25424010,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
559,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Cataracts,,HP:0000518,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/25424010,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
560,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Chronic diarrhoea,,MP:0001665,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/25424010,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
561,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Elevated serum cholesterol,,HP:0003124,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
562,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,EEG abnormalities,,HP:0002353,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
563,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Abnormal gait,,HP:0001288,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
564,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Xanthoma,,HP:0001114,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
565,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Incoordination,,HP:0002311,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
566,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Movement disorder,,HP:0100022,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
567,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Cognitive impairment,,HP:0100543,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
568,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Abnormal nerve conduction velocity,,HP:0040129,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
569,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Seizure,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
570,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Pravastatin+Chenodeoxycholic acid,DB00175 +DB06777,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement,,Xanthoma,,HP:0001114,,,https://www.ncbi.nlm.nih.gov/pubmed/7964884,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
571,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Pravastatin+Chenodeoxycholic acid,DB00175 +DB06777,,,,,,,,,,Elevated serum cholesterol,,HP:0003124,,,https://www.ncbi.nlm.nih.gov/pubmed/7964884,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
572,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Pravastatin+Chenodeoxycholic acid,DB00175 +DB06777,,,,,,,,,,Disease progression (Progressive)*,,HP:0003676,,,https://www.ncbi.nlm.nih.gov/pubmed/7964884,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
573,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,Coenzyme Q10,DB09270,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,muscle weakness,,HP:0001324,,,https://www.ncbi.nlm.nih.gov/pubmed/20301583,,,,,,,,
574,50,# 613068,Cerebral folate deficiency,,FOLR1,Folate receptor alpha,P15328,,,Folinic acid,DB00650,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Impaired social interaction,,HP:0000735,,,,,,,,,,,
575,,# 613068,Cerebral folate deficiency,,FOLR1,Folate receptor alpha,P15328,,,Folinic acid,DB00650,,,,,,,,,,Movement disorder,,HP:0100022,,,,,,,,,,,
576,,# 613068,Cerebral folate deficiency,,MTHFR,Methylenetetrahydrofolate reductase,1.5.1.20,,,Folinic acid,DB00650,,,,,,,,,,seizure,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671/,,,,,,,,
577,,# 613068,Cerebral folate deficiency,,MTHFR,Methylenetetrahydrofolate reductase,1.5.1.20,,,Folinic acid,DB00650,,,,,,,,,,Myoclonic seizures,,HP:0002123,,,https://www.ncbi.nlm.nih.gov/pubmed/22734130,,,,,,,,
578,,# 613068,Cerebral folate deficiency,,MTHFR,Methylenetetrahydrofolate reductase,1.5.1.20,,,Folinic acid,DB00650,,,,,,,,,,Astatic seizures,,HP:0010819,,,https://www.ncbi.nlm.nih.gov/pubmed/22734130,,,,,,,,
579,51,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Desmopressin,DB00035,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Polyuria,,HP:0000103,,,https://clinicaltrials.gov/ct2/show/NCT01280188?cond=Central+diabetes+insipidus&rank=1,,,,,,,,
580,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Vasopressin,DB00067,,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Polydipsia,,MP:0001426,,,https://www.ncbi.nlm.nih.gov/pubmed/23884783,,,,,,,,
581,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Vasopressin,DB00067,,,,,,,,,,Thirst,,HP:0001959,,,https://www.ncbi.nlm.nih.gov/pubmed/23884783,,,,,,,,
582,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Chlorpropamide,DB00672,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Polyurea,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/5563815,,,,,,,,
583,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,Chlorpropamide + carbamazepine,DB00672+DB00564,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,Drug name: This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,Chlorpropamide-induced hypoglycaemia (Hypoglycemia)*,,HP:0001943*,,,https://www.ncbi.nlm.nih.gov/pubmed/1220254,,,,,,,,
584,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Chlorpropamide + carbamazepine,DB00672+DB00564,,,,,,,,,,Polyuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/1220254,,,,,,,,
585,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Chlorpropamide+Hydrochlorothiazide,DB00672+DB00999,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,Drug name: Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Polyuria,,HP:0000103,,,,,,,,,,,
586,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Chlorpropamide+Hydrochlorothiazide,DB00672+DB00999,,,,,,,,,,,,,,,,,,,,,,,
587,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Chlorpropamide+Hydrochlorothiazide,DB00672+DB00999,,,,,,,,,,,,,,,,,,,,,,,
588,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Pitressin tannate in oil,NA,ECO:0000352,,,,,Direct interaction,A,direct complementation of a genetically defective protein,Drug name: The study was withdrawn.,Polyuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/3940717,,,,,,,,
589,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Clofibrate,DB00636,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Polyuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/23884783,,,,,,,,
590,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Clofibrate,DB00636,,,,,,,,,,Hyposthenuria,,HP:0003158,,,https://www.ncbi.nlm.nih.gov/pubmed/23884783,,,,,,,,
591,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Indapamide,DB00808,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High serum osmolality,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,,,,,,,
592,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Indapamide,DB00808,,,,,,,,,,Polyuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,,,,,,,
593,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,Indapamide,DB00808,,,,,,,,,,Reduced urinary osmolality,,HP:0003158,,,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,,,,,,,
594,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",dDAVP (1-Desamino-8-D Arginine Vasopressin),DB00035,ECO:0000352,,,,,Direct interaction,A,direct complementation of a genetically defective protein,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Increased urine output,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/626447,,,,,,,,
595,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,dDAVP (1-Desamino-8-D Arginine Vasopressin),DB00035,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/626447,,,,,,,,
596,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,dDAVP (1-Desamino-8-D Arginine Vasopressin),DB00035,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/626447,,,,,,,,
597,52,# 212138,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,carnitine-acylcarnitine translocase,1.5.1.20,,,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Developmental delay,,HP:0001263,,,https://www.ncbi.nlm.nih.gov/pubmed/25614308,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,,,,,,,
598,,# 212138,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,carnitine-acylcarnitine translocase,1.5.1.20,,,Carnitine,DB00583,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypocarnitinemia,,HP:0003234,,,https://www.ncbi.nlm.nih.gov/pubmed/25614308,,,,,,,,
599,,# 212138,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,carnitine-acylcarnitine translocase,1.5.1.20,,,Carnitine+Medium-chain triglycerides,DB00583+DB13959,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Developmental delay,,HP:0001263,,,https://www.ncbi.nlm.nih.gov/pubmed/17508264,,,,,,,,
600,,# 212138,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,carnitine-acylcarnitine translocase,1.5.1.20,,,Carnitine+Medium-chain triglycerides,DB00583+DB13959,,,,,,,,,,Hypocarnitinemia,,HP:0003234,,,https://www.ncbi.nlm.nih.gov/pubmed/17508264,,,,,,,,
601,,# 212138,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,carnitine-acylcarnitine translocase,1.5.1.20,,,Carnitine+Medium-chain triglycerides,DB00583+DB13959,,,,,,,,,,High plasma long-chain acylcarnitines,,HP:0045045,,,https://www.ncbi.nlm.nih.gov/pubmed/17508264,,,,,,,,
602,53,* 601987,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1B,"carnitine O-palmitoyltransferase 1, muscle isoform",2.3.1.21,,,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Neurological damage,,HP:0000707,,https://www.ncbi.nlm.nih.gov/pubmed/1922174?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9048718,,,,,,,,
603,,* 601987,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1B,"carnitine O-palmitoyltransferase 1, muscle isoform",2.3.1.21,,,Medium-chain triglycerides,DB13959,,,,,,,,,,Hypoglycemia,,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/1922174?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9048718,,,,,,,,
604,54,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,carnitine palmitoyltransferase 1A,2.3.1.21,,,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/20301700,https://www.ncbi.nlm.nih.gov/pubmed/11350183,https://www.ncbi.nlm.nih.gov/pubmed/6682967,https://www.ncbi.nlm.nih.gov/pubmed/28466427,https://www.ncbi.nlm.nih.gov/pubmed/22301540,,,,,,
605,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,carnitine palmitoyltransferase 1A,2.3.1.21,,,Medium-chain triglycerides,DB13959,,,,,,HP:0002611,,,,Hepatic Dysfunction (Liver disease),,HP:0001392,https://www.ncbi.nlm.nih.gov/pubmed/20301700,https://www.ncbi.nlm.nih.gov/pubmed/11350183,https://www.ncbi.nlm.nih.gov/pubmed/6682967,https://www.ncbi.nlm.nih.gov/pubmed/28466427,https://www.ncbi.nlm.nih.gov/pubmed/22301540,,,,,,
606,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,carnitine palmitoyltransferase 1A,2.3.1.21,,,Medium-chain triglycerides,DB13959,,,,,,,,,,Muscle Weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/20301700,https://www.ncbi.nlm.nih.gov/pubmed/11350183,https://www.ncbi.nlm.nih.gov/pubmed/6682967,https://www.ncbi.nlm.nih.gov/pubmed/28466427,https://www.ncbi.nlm.nih.gov/pubmed/22301540,,,,,,
607,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,carnitine palmitoyltransferase 1A,2.3.1.21,,,Cornstarch+Low‐fat diet,DB11599,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+dietary supplementation+diet regime modification,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15669684,https://www.ncbi.nlm.nih.gov/pubmed/20301700,,,,,,,,,
608,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,carnitine palmitoyltransferase 1A,2.3.1.21,,,Cornstarch+Low‐fat diet,DB11599,,,,,,,,,,Low growth rate (Abnormal growth)*,,HP:0001507*,https://www.ncbi.nlm.nih.gov/pubmed/15669684,https://www.ncbi.nlm.nih.gov/pubmed/20301700,,,,,,,,,
609,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,carnitine palmitoyltransferase 1A,2.3.1.21,,,High carbohydrate and low fat diet +medium chain triglyceride oil,NA+DB13959,ECO:0000352,,,,,Functional interaction,B,dietary regime modification+dietary supplementation,,Cholestatic hepatitis,,HP:0002611,https://www.ncbi.nlm.nih.gov/pubmed/23969540,,,,,,,,,,
610,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,,Triheptanoin,DB11677,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/14615409,https://www.ncbi.nlm.nih.gov/pubmed/18645163,,,,,,,,,
611,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,,Triheptanoin,DB11677,,,,,,,,,,Muscle pain,,HP:0003326,https://www.ncbi.nlm.nih.gov/pubmed/14615409,https://www.ncbi.nlm.nih.gov/pubmed/18645163,,,,,,,,,
612,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,,Triheptanoin,DB11677,,,,,,,,,,Rhabdomyolysis,,HP:0003201,https://www.ncbi.nlm.nih.gov/pubmed/14615409,https://www.ncbi.nlm.nih.gov/pubmed/18645163,,,,,,,,,
613,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,,Triheptanoin,DB11677,,,,,,,,,,Abnormal SF-36 physical composite scores,,NA,https://www.ncbi.nlm.nih.gov/pubmed/14615409,https://www.ncbi.nlm.nih.gov/pubmed/18645163,,,,,,,,,
614,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,,Glucose,DB01914,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/14615409,https://www.ncbi.nlm.nih.gov/pubmed/12370460?dopt=Abstract,,,,,,,,,
615,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,,Glucose,DB01914,,,,,,,,,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/14615409,https://www.ncbi.nlm.nih.gov/pubmed/12370460?dopt=Abstract,,,,,,,,,
616,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,"The long-term effects of MCT were not elucidated. Other authors have recommended avoidance of C12-fatty acids in the medium-chain triglycerides preparations in addition to tightly regulated doses. https://www.ncbi.nlm.nih.gov/pubmed/9048718?dopt=Abstract

In some other cases, treatment with medium-chain triglycerides has not altered the symptoms. https://www.ncbi.nlm.nih.gov/pubmed/750917?dopt=Abstract",Medium chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/1922174?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14615409,,,,,,,,,
617,,# 600649,Carnitine palmitoyl transferase 2 deficiency,,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial",2.3.1.21/P23786,,,Theophylline,DB00277,ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Reduced carnitine O-palmitoyltransferase activity,,HP:0012380,https://www.ncbi.nlm.nih.gov/pubmed/11578754?dopt=Abstract,,,,,,,,,,
618,55,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,The drug works on certain CPS1D mutations.,N-Carbamylglutamate,DB06775,ECO:0001565/ECO:0000352,p.T471N and p.Y1491H/P1439L/ T1443A and Y1491H/R1371L and T1391M/p.Thr1443Ala,"These mutations might benefit from specific treatment with NAG analogues because they exhibit reduced affinity for NAG.https://www.ncbi.nlm.nih.gov/pubmed/20578160
https://www.ncbi.nlm.nih.gov/pubmed/23649895
https://www.ncbi.nlm.nih.gov/pubmed/26059772
https://www.ncbi.nlm.nih.gov/pubmed/15876373",,,Direct interaction,A,activity modification of a genetically defective protein,Active,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28281899,https://www.ncbi.nlm.nih.gov/pubmed/16126063/,https://www.ncbi.nlm.nih.gov/pubmed/20578160,https://www.ncbi.nlm.nih.gov/pubmed/31392111,https://www.ncbi.nlm.nih.gov/pubmed/23649895/,https://www.ncbi.nlm.nih.gov/pubmed/14213380/,https://www.ncbi.nlm.nih.gov/pubmed/13992367/,https://www.ncbi.nlm.nih.gov/pubmed/30034506,https://www.ncbi.nlm.nih.gov/pubmed/26059772,,
619,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,N-acetyl-l-glutamate,DB04075,ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Acidemia,,HP:0001941,,,https://www.ncbi.nlm.nih.gov/pubmed/23649895,,,,,,,,
620,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,HDAd CPS1,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,Under trial,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/29801986/,,https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Cell+and+Gene+Therapy+for+Carbamoyl+Phosphate+Synthetase+1+Deficiency&btnG=,,,,,,,
621,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,HDAd CPS1,NA,,,,,,,,,,Elevated plasma glutamine,,HP:0003217,https://www.ncbi.nlm.nih.gov/pubmed/29801986/,,https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Cell+and+Gene+Therapy+for+Carbamoyl+Phosphate+Synthetase+1+Deficiency&btnG=,,,,,,,
622,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,HDAd CPS1,NA,,,,,,,,,,Low carbamoyl phosphate synthetase 1 expression(Abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/29801986/,,https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Cell+and+Gene+Therapy+for+Carbamoyl+Phosphate+Synthetase+1+Deficiency&btnG=,,,,,,,
623,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,Glycerol phenylbutyrate(HPN-100),DB08909,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://clinicaltrials.gov/ct2/show/NCT00992459,https://www.ncbi.nlm.nih.gov/pubmed/20382058/,https://www.ncbi.nlm.nih.gov/pubmed/22961727,https://www.ncbi.nlm.nih.gov/pubmed/21612962/,https://www.ncbi.nlm.nih.gov/pubmed/23324524,https://clinicaltrials.gov/ct2/show/NCT01347073,,,,,
624,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,Sodium phenylbutyrate,DB06819,ECO:0000352/ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/20382058/,https://www.ncbi.nlm.nih.gov/pubmed/22961727,https://clinicaltrials.gov/ct2/show/NCT00992459,https://www.ncbi.nlm.nih.gov/pubmed/21612962/,https://www.ncbi.nlm.nih.gov/pubmed/23324524,https://clinicaltrials.gov/ct2/show/NCT01347073,,,,,
625,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,Sodium benzoate,DB03793,ECO:0007121/ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27663197,,,,,,,,,,
626,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,This treatment regimen was introduced to those patient whose ammonia level wasnot reduced by sodium benzote alone. and Regimen was accomapnied by haemofiltration as well. https://www.ncbi.nlm.nih.gov/pubmed/27663197,Sodium phenylacetate + sodium benzoate,DB09269+ DB03793,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27663197,,,,,,,,,,
627,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,Sodium phenylacetate + sodium benzoate+arginine,DB09269+ DB03793+DB00125,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+dietary supplementation,,Hyperammonemia,,HP:0001987,,https://www.ncbi.nlm.nih.gov/pubmed/17538087/,https://www.ncbi.nlm.nih.gov/pubmed/6427608,,,,,,,,
628,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,,Sodium benzoate + Arginine,DB03793+DB00125,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+dietary supplementation,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/7078580,,,,,,,,,,
629,56,# 253260,Biotinidase deficiency,,BTD,biotinidase,3.5.1.12,,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin,DB00121,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Active,Seizure,,HP:0001250,,,https://clinicaltrials.gov/ct2/show/NCT03269045,https://www.ncbi.nlm.nih.gov/pubmed/28649539,https://www.ncbi.nlm.nih.gov/pubmed/26577040,https://www.ncbi.nlm.nih.gov/pubmed/25638506/,https://www.ncbi.nlm.nih.gov/pubmed/28220409,,,,
630,,# 253260,Biotinidase deficiency,,BTD,biotinidase,3.5.1.12,,,Baclofen,DB00181,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Active,Dystonia,,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/9285607,https://www.ncbi.nlm.nih.gov/pubmed/28220409,,,,,,,,
631,,# 253260,Biotinidase deficiency,,BTD,biotinidase,3.5.1.12,,,Baclofen,DB00181,,,,,,,,,,Spasticity,,HP:0001257,,https://www.ncbi.nlm.nih.gov/pubmed/9285607,https://www.ncbi.nlm.nih.gov/pubmed/28220409,,,,,,,,
632,57,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,thiamine transporter,not available,,,Biotin+thiamine,DB00121+DB00152,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,Active,Seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
633,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,thiamine transporter,not available,,,Biotin+thiamine,DB00121+DB00152,,,,,,Symptomatic,C,,,Encephalopathy,,HP:0001298,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
634,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,thiamine transporter,not available,,,Biotin+thiamine,DB00121+DB00152,,,,,,,,,,Signal abnormality of the cortex,,HP:0030178,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
635,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,thiamine transporter,not available,,,Biotin+thiamine,DB00121+DB00152,,,,,,,,,,Abnormal movement,,HP:0100022,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
636,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,thiamine transporter,not available,,,Biotin+thiamine,DB00121+DB00152,,,,,,,,,,Dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
637,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,thiamine transporter,not available,,,Biotin+thiamine,DB00121+DB00152,,,,,,,,,,Abnormal reflexes,,HP:0001347,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
638,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,thiamine transporter,not available,,,L-dopa,DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/24260777,,,,,,,,
639,58,# 203750,Beta ketothiolase deficiency,,ACAT1,Acetyl-CoA C-acetyltransferase.,2.3.1.9,,,Glucose,DB09341,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Active,Ketosis,,HP:0001946,,,https://www.ncbi.nlm.nih.gov/pubmed/23163837,,,,,,,,
640,,# 203750,Beta ketothiolase deficiency,,ACAT1,Acetyl-CoA C-acetyltransferase.,2.3.1.9,,,Carnitine,DB00583,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Organic aciduria,,HP:0001992,,,https://www.sciencedirect.com/science/article/pii/S1110863016300763,https://scholar.google.com/scholar_lookup?journal=+EJMHG&title=Two+Libyan+siblings+with+beta-ketothiolase+deficiency:+A+case+report+and+review+of+literature&author=E+Abdelkreem&author=H+Alobaidy&author=Y+Aoyama&author=S+Mahmoud&author=Aal+MA+El&volume=18&issue=2&publication_year=2017&pages=199-203&,,,,,,,
641,,# 203750,Beta ketothiolase deficiency,,ACAT1,Acetyl-CoA C-acetyltransferase.,2.3.1.9,,,Bicitra,DB09154,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Acidosis,,HP:0001941,,,http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency,,,,,,,,
642,,# 203750,Beta ketothiolase deficiency,,ACAT1,Acetyl-CoA C-acetyltransferase.,2.3.1.9,,,Levertriacetam,DB01202,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Generalized tonic clonic seizures,,HP:0002069,https://www.ncbi.nlm.nih.gov/pubmed/23958592,,,,,,,,,,
643,59,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,,,Spironolactone+potassium+ACE-inhibitor,DB00421+DB14500+C09A,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,Active,Electrolyte disturbances,,HP:0003111,https://www.ncbi.nlm.nih.gov/pubmed/30519073,,,https://www.ncbi.nlm.nih.gov/pubmed/2646391,,,,,,,
644,,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,,,Acetazolamide,DB00819,EC:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Metabolic alkalosis,,HP:0200114,https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22,,,,,,,,,,
645,,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,,,Acetazolamide,DB00819,,,,,,,,,,Hypokalemia Metabolic Alkalosis,,HP:0002900,https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22,,,,,,,,,,
646,,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,,,Acetazolamide,DB00819,,,,,,,,,,Hypomagnesemia,,HP:0002917,https://www.ncbi.nlm.nih.gov/pubmed/2646391,,,,,,,,,,
647,60,# 241200,Bartter Syndrome 2,,KCNJ1,ATP-sensitive inward rectifier potassium channel 1,P48048,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
648,61,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Tanespimycin,DB05134,ECO:0001565/ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low plasma membrane expression of R8Lin kidney(Abnormality of circulating enzyme level HP:0011021,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
649,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Tanespimycin,DB05134,,,,,,,,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
650,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Tanespimycin,DB05134,,,,,,,,,,Metabolic alkalosis,,HP:0200114,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
651,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Tanespimycin,DB05134,,,,,,,,,,Sensorineural hearing impairment,,HP:0000407,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
652,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Tanespimycin,DB05134,,,,,,,,,,ER-associated degradation of R8L,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
653,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Tanespimycin,DB05134,,,,,,,,,,Mislocalization of R8L,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
654,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Potassium Chloride,DB00761,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/books/NBK442019/,,,,,,,,,,
655,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Naproxen,DB00788,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypokalemia,,HP:0002900,https://www.nejm.org/doi/full/10.1056/NEJM197807132990214,,,,,,,,,,
656,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Niflumic acid,DB04552,ECO:0001565,"L155/ G345/ A349/L155A, G345S and A349E","Those three mutants are localized in two different protein regions that, based on the crystal structure of bacterial CLC homologs, are expected to be exposed to the extracellular side of the channel, relatively close to each other, and are thus good candidates for being part of the potentiating NFA binding site",G167A / F213A,These two. mutations drastically altered general gating properties and are unlikely to be involved in NFA binding,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal ClC-Ka function,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20649569/,,,,,,,,,,
657,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,Niflumic acid,DB04552,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20649569/,,,,,,,,,,
658,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Potassium sparing agents,C03D,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Deleterious prognosis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30387909,,,,,,,,,,
659,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Potassium sparing agents,C03D,,,,,,,,,,Decreased life expectancy (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/30387909,,,,,,,,,,
660,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Potassium sparing agents,C03D,,,,,,,,,,Salt wasting,,HP:0000127,https://www.ncbi.nlm.nih.gov/pubmed/30387909,,,,,,,,,,
661,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Potassium sparing agents,C03D,,,,,,,,,,Growth retardation,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/30387909,,,,,,,,,,
662,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Indomethacin,DB00328,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Deleterious prognosis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,
663,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Indomethacin,DB00328,,,,,,,,,,Decreased life expectancy (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,
664,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Indomethacin,DB00328,,,,,,,,,,Salt wasting,,HP:0000127,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,
665,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Growth hormone,DB00052,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,,,,,,,,,
666,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Growth hormone,DB00052,,,,,,,,,,Decreased serum IGF‐1,,HP:0030353,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,,,,,,,,,
667,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Growth hormone,DB00052,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,,,,,,,,,
668,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Potassium,DB14500,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,,
669,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Magnesium,DB14513,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypomagnesemia,,HP:0002917,https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895?via%3Dihub,,,,,,,,,,
670,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Sodium,DB09395,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hyponatremia,,HP:0002902,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,,
671,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Aminoglycoside (Geneticin),DB04263,ECO:0001565,W610X,,,,Direct Interaction,A,direct complementation of a genetically defective protein by transcriptional or translational modification,,Defected ClC-Kb expression,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23772144?dopt=Abstract,,,,,,,,,,
672,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Potassium+Indomethacin±Spironolactone,DB14500+DB00328+ DB00421,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/28288174,,,,,,,,,,
673,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Nonsteroidal anti-inflammatory drugs,M01AX,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Elevated prostaglandin E2,,HP:0003566,https://www.ncbi.nlm.nih.gov/pubmed/24189473/,,,,,,,,,,
674,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Nonsteroidal anti-inflammatory drugs,M01AX,,,,,,,,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/24189473/,,,,,,,,,,
675,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,Nonsteroidal anti-inflammatory drugs,M01AX,,,,,,,,,,High calcium excretion in urine,,HP:0002150,https://www.ncbi.nlm.nih.gov/pubmed/24189473/,,,,,,,,,,
676,,# 300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5","Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084",MAGED2,Melanoma-associated antigen D2,Q9UNF1,,,Electrolytes,B05BB01,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Renal salt wasting,,HP:0000127,https://www.ncbi.nlm.nih.gov/pubmed/27120771,,,,,,,,,,
677,,# 300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,MAGED2,Melanoma-associated antigen D2,Q9UNF1,,,Indomethacin,DB00328,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,,,,,,,,,,,
678,62,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Elamipretide,DB11981,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT03098797,,,,,,,,,,
679,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Elamipretide,DB11981,,,,,,,,,,Abnormal energy production in damaged mitochondria,,HP:0003287,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1,,,,,,,,,,
680,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Elamipretide,DB11981,,,,,,,,,,Fatigue,,HP:0012378,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1,,,,,,,,,,
681,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Granulocyte colony stimulating factor (G‐CSF),DB00020,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/15098233/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,,,,,
682,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Granulocyte colony stimulating factor (G‐CSF),DB00020,,,,,,,,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,,,,,
683,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin,DB00390,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: Temporary improvemnet,Low ejection fraction,,HP:0012664,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,,,,,,,,,,
684,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin,DB00390,,,,,,,,,,Tricusped incompetence,,HP:0005180,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,,,,,,,,,,
685,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin,DB00390,,,,,,,,,,Mitral incomptence,,HP:0001653,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,,,,,,,,,,
686,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Pantothenic acid,DB01783,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Low myocardial function,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
687,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Pantothenic acid,DB01783,,,,,,,,,,T wave abnormalities,,HP:0005135,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
688,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Pantothenic acid,DB01783,,,,,,,,,,Delayed Growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
689,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Pantothenic acid,DB01783,,,,,,,,,,Hypocholesterolaemia,,HP:0003146,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
690,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Pantothenic acid,DB01783,,,,,,,,,,Hyperuricaemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
691,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Pantothenic acid,DB01783,,,,,,,,,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
692,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics,C09A/C09CA/C07/C03,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Heart failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/31239752,,,,,,,,,,
693,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics + anticoagulate,C09A/C09CA/C07/C04+B01A,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Atrial fibrillation,,HP:0005110,https://www.ncbi.nlm.nih.gov/pubmed/31239752,,,,,,,,,,
694,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Bezafibrate,DB01393,ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Cardiac dysfunction,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/29695963/,https://www.ncbi.nlm.nih.gov/pubmed/28279226/,,,,,,,,,
695,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Bezafibrate,DB01393,,,,,,,,,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/29695963/,https://www.ncbi.nlm.nih.gov/pubmed/28279226/,,,,,,,,,
696,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,AAV9-TAZ,NA,ECO:0000179,,,,,Direct interaction,A,direct complementatoin of a genetically defective protein by gene therapy,,Abnormal cardiac protein (TAZ) expression (Abnormal circulating protein level )*,,HP:0010876,https://www.ncbi.nlm.nih.gov/pubmed/30788385/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,
697,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,AAV9-TAZ,NA,,,,,,,,,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,
698,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,AAV9-TAZ,NA,,,,,,,,,,Mueculoskeletal dysfunction,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,
699,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Cardiomegaly,,HP:0001640,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
700,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,,,,,,,,,,Reduced ejection fraction,,HP:0012664,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
701,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,,,,,,,,,,Developmetal delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
702,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,,,,,,,,,,Abormal liver size,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
703,,302060,Barth syndrome,,TAZ,tafazzin ( Protein),Not available,,,Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
704,63,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Sebelipase alfa,DB11563,ECO:0000352/ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,High plasma cholesterol level*,,HP:0003107,https://www.ncbi.nlm.nih.gov/pubmed/29773783,https://www.ncbi.nlm.nih.gov/pubmed/27878737,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,,,,,,,
705,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Sebelipase alfa,DB11563,,,,,,,,,,hypertriglycemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,,,,,,,
706,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Sebelipase alfa,DB11563,,,,,,,,,,Abnormal liver function,,HP:0002910,https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,,,,,,,
707,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Sebelipase alfa,DB11563,,,,,,,,,,Dyslipidemia,,HP:0003119,https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,,,,,,,
708,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Sebelipase alfa,DB11563,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,,,,,,,
709,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Fenofibrate,DB01039,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Increased plasma triglycerides,,HP:0002155,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475/,,,,,,,,,,
710,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Simvastatin,DB00641,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperlipidemia,,HP:0003077,https://www.ncbi.nlm.nih.gov/pubmed/16848116,,,,,,,,,,
711,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,Treatment success with statins has been mixed.,Lovastatin,DB00227,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Increased LDL cholesterol,,HP:0003141,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,,,,,,,,,,
712,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Lovastatin,DB00227,,,,,,,,,,Increased plasma triglycerides,,HP:0002155,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,,,,,,,,,,
713,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Lovastatin,DB00227,,,,,,,,,,Increased total cholesterol,,HP:0003124,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,,,,,,,,,,
714,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Lovastatin,DB00227,,,,,,,,,,Elevated urine mevalonate levels,,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,,,,,,,,,,
715,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Colestyramine+Simivastatin,DB01432+DB00641,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Dyslipidemia,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/1801793,https://www.sciencedirect.com/science/article/pii/S1521691810001101,,,,,,,,,
716,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Colestyramine+Simivastatin,DB01432+DB00641,,,,,,,,,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/1801793,https://www.sciencedirect.com/science/article/pii/S1521691810001101,,,,,,,,,
717,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Ezetimibe,DB00973,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Dyslipidemia,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/29374495,,,,,,,,,,
718,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase,P38571,,,Ezetimibe,DB00973,,,,,,,,,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/29374495,,,,,,,,,,
719,64,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,"Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.",Colchicine(COL),DB01394,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Arthritis,,HP:0001369,https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,,,,,,,,,
720,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Colchicine(COL),DB01394,,,,,,,,,,Arthralgia,,HP:0002829,https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,,,,,,,,,
721,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,Prednisone,DB00635,ECO:0000352/ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Arthritis,,HP:0001369,https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/27790033/,https://www.ncbi.nlm.nih.gov/pubmed/30891381,,https://www.ncbi.nlm.nih.gov/pubmed/21257614/,https://www.ncbi.nlm.nih.gov/pubmed/27586801,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Anakinra+Compared+to+Prednisone+on+the+Treatment+of+Acute+CPPD+Crystal+Arthritis%2C+a+Randomized%2C+Controlled%2C+Double-Blind+Study&btnG=,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,,
722,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Naproxen sodium,DB00788,,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,,,,,,,,,
723,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Naproxen sodium,DB00788,,,,,,,,,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,,,,,,,,,
724,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",Anakinra/canakinuma,DB00026/DB06168,ECO:0007121/ ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pubmed/19289295,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Anakinra+Compared+to+Prednisone+on+the+Treatment+of+Acute+CPPD+Crystal+Arthritis%2C+a+Randomized%2C+Controlled%2C+Double-Blind+Study&btnG=,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,
725,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Anakinra/canakinuma,DB00026/DB06168,,,,,,,,,,Arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/23022422,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Anakinra+Compared+to+Prednisone+on+the+Treatment+of+Acute+CPPD+Crystal+Arthritis%2C+a+Randomized%2C+Controlled%2C+Double-Blind+Study&btnG=,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,
726,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Anakinra/canakinuma,DB00026/DB06168,,,,,,,,,,Refractory Arthritis,,HP:0031375,https://www.ncbi.nlm.nih.gov/pubmed/22658375,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Anakinra+Compared+to+Prednisone+on+the+Treatment+of+Acute+CPPD+Crystal+Arthritis%2C+a+Randomized%2C+Controlled%2C+Double-Blind+Study&btnG=,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,
727,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Anakinra/canakinuma,DB00026/DB06168,,,,,,,,,,Synovitis,,HP:0100769,https://www.ncbi.nlm.nih.gov/pubmed/22341584?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Anakinra+Compared+to+Prednisone+on+the+Treatment+of+Acute+CPPD+Crystal+Arthritis%2C+a+Randomized%2C+Controlled%2C+Double-Blind+Study&btnG=,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,
728,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Rilonacept,DB06372,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,,,,,,,,,,
729,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Methotrexate,DB00563,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Swollen joint,,HP:0001386,https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/,https://www.ncbi.nlm.nih.gov/pubmed/25315665,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,
730,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Methotrexate,DB00563,,,,,,,,,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/,https://www.ncbi.nlm.nih.gov/pubmed/25315665,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,
731,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Hydroxychloroquine,DB01611,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Swollen joint,,HP:0001386,https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,,,
732,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Hydroxychloroquine,DB01611,,,,,,,,,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,,,
733,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Hydroxychloroquine,DB01611,,,,,,,,,,Arthropathy,,HP:0003040,https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,,,,,,,,
734,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Probenecid,DB01032,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormality of phosphate homeostasis,,HP:0100529,https://www.ncbi.nlm.nih.gov/pubmed/7520501,,,,,,,,,,
735,,# 118600,Chondrocalcinosis 2,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,Probenecid,DB01032,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/7520501,,,,,,,,,,
736,65,118610,Chondrocalcinosis due to apatite crystal deposition,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,,,NSAIDs,DB00788,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Acute arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/17541659,,,,,,,,,,
737,67,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin E,DB00163,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Neurological abnormalities,,HP:0012638,https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,,,,,,,,
738,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Alpha-tocopherol,DB11251,,,,,,Functional interaction,B,metabolite replacement,,Neurological abnormalities,,HP:0012638,,,,,,,,,,,
739,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Alpha-tocopherol,DB11251,,,,,,,,,,Abnormal Adipose tissue tocopherol level.,,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212/,,,,,,,,,,
740,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Tocofersolan,DB11635,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Disease progression(Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/27520363,https://www.ncbi.nlm.nih.gov/pubmed/20920215,https://www.ncbi.nlm.nih.gov/pubmed/30021760,,,,,,,,
741,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin A+ Vitamin E,DB00162+DB00163,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement,,Minor visual abnormalities,,HP:0000505,https://www.ncbi.nlm.nih.gov/pubmed/19285442/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
742,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin A+ Vitamin E,DB00162+DB00163,,,,,,,,,,Neurological abnormality,,HP:0012638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
743,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin A+ Vitamin E,DB00162+DB00163,,,,,,,,,,Muscular abnormality,,HP:0012638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
744,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin D,DB11094,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,osteopenia,,HP:0000938,,,,,,,,,,,
745,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin D,DB11094,,,,,,,,,,Vitamin D insufficiency,,HP:0100512,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
746,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin K,DB01022,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Bleeding tendency,,HP:0001892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
747,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Vitamin K,DB01022,,,,,,,,,,Vitamin K insufficiency,,HP:0011892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
748,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction,B,dietary regime modification,,Low weight/growth,,HP:0004325,https://www.ncbi.nlm.nih.gov/pubmed/27266643,,,,,,,,,,
749,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Medium-chain triglycerides,DB13959,,,,,,,,,,Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/20920215,,,,,,,,,,
750,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Medium-chain triglycerides,DB13959,,,,,,,,,,Malnutrition,,HP:0004395,https://www.ncbi.nlm.nih.gov/pubmed/20920215,,,,,,,,,,
751,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,Fat emulsion,DB09422,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Fat malabsorption,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/2596948/,https://www.ncbi.nlm.nih.gov/pubmed/20920215,,,,,,,,,
752,68,#215720,Citrulline transport defect,,SAR1B,Sar1b protein,Q9HCJ1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
753,69,# 611209,COG1-CDG (CDG-IIg),,COG1,component of oligomeric golgi complex 1,Q9HCJ1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21175687,,,,,,,,,,
754,70,# 615395,Combined oxidative phosphorylation deficiency 16,,MRPL44,mitochondrial ribosomal protein L44,Q9H9J2,,,L-carnitine +Propranolol,DB00583+DB00571,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,low physical capacity,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/25797485,,,,,,,,,,
755,71,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,Cholic acid,DB02659,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Atypical bile acids,,NA,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,
756,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,Cholic acid,DB02659,,,,,,,,,,Defected bile flow,,HP:0001396,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,
757,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,Cholic acid,DB02659,,,,,,,,,,Cirrhosis,,HP:0001394,https://www.ncbi.nlm.nih.gov/pubmed/30373615,https://www.ncbi.nlm.nih.gov/pubmed/30373615,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,
758,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,Chenodeoxycholic acid,DB06777,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/2072042,,,,,,,,,,
759,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Abnormal urinary steroid level,,HP:0012030,https://www.ncbi.nlm.nih.gov/pubmed/2072042,,,,,,,,,,
760,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Ill-being (Constitutional symptoms)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/2072042,,,,,,,,,,
761,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,Ursodeoxycholic acid,DB01586,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,,,,,,,,,,,,,,
762,72,# 235555,"Congenital bile acid synthesis defect, type 2",UDCA is not recommended for long-term management.,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,Therapeutic dose requires individualized optimization. UDCA is not recommended for long-term management.,Cholic acid,DB02659,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Liver biochemical abnormalities (Laboratory abnormalities)*,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/30809085,https://www.ncbi.nlm.nih.gov/pubmed/28727657,https://www.ncbi.nlm.nih.gov/pubmed/31337596,https://www.ncbi.nlm.nih.gov/pubmed/15030995/,https://www.ncbi.nlm.nih.gov/pubmed/20522910,,,,,,
763,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Histological abnormalities (Abnormal test result)*,,HP:0500014,https://www.ncbi.nlm.nih.gov/pubmed/30809085,https://www.ncbi.nlm.nih.gov/pubmed/28727657,https://www.ncbi.nlm.nih.gov/pubmed/31337596,https://www.ncbi.nlm.nih.gov/pubmed/15030995/,https://www.ncbi.nlm.nih.gov/pubmed/20522910,,,,,,
764,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pubmed/30809085,https://www.ncbi.nlm.nih.gov/pubmed/28727657,https://www.ncbi.nlm.nih.gov/pubmed/31337596,https://www.ncbi.nlm.nih.gov/pubmed/15030995/,https://www.ncbi.nlm.nih.gov/pubmed/20522910,,,,,,
765,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Defected bile flow (Cholestasis)*,,HP:0001396,https://www.ncbi.nlm.nih.gov/pubmed/30809085,https://www.ncbi.nlm.nih.gov/pubmed/28727657,https://www.ncbi.nlm.nih.gov/pubmed/31337596,https://www.ncbi.nlm.nih.gov/pubmed/15030995/,https://www.ncbi.nlm.nih.gov/pubmed/20522910,,,,,,
766,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Fat soluble vitamin malabsorption*,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/30809085,https://www.ncbi.nlm.nih.gov/pubmed/28727657,https://www.ncbi.nlm.nih.gov/pubmed/31337596,https://www.ncbi.nlm.nih.gov/pubmed/15030995/,https://www.ncbi.nlm.nih.gov/pubmed/20522910,,,,,,
767,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Atypical bile acid synthesis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30809085,https://www.ncbi.nlm.nih.gov/pubmed/28727657,https://www.ncbi.nlm.nih.gov/pubmed/31337596,https://www.ncbi.nlm.nih.gov/pubmed/15030995/,https://www.ncbi.nlm.nih.gov/pubmed/20522910,,,,,,
768,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid,DB02659,,,,,,,,,,Production of toxic bile acid metabolic intermediates,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30809085,https://www.ncbi.nlm.nih.gov/pubmed/28727657,https://www.ncbi.nlm.nih.gov/pubmed/31337596,https://www.ncbi.nlm.nih.gov/pubmed/15030995/,https://www.ncbi.nlm.nih.gov/pubmed/20522910,,,,,,
769,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Chenodeoxycholic acid,DB06777,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28697823,,,,,,,,,,
770,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Chenodeoxycholic acid,DB06777,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/28697823,,,,,,,,,,
771,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,Patients with genetic 5beta-reductase deficiency may respond well to treatment with chenodeoxycholic acid and cholic acid if liver disease is not too advanced.,Cholic acid +chenodeoxycholic acid,DB02659+DB06777,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+metabolite replacement+metabolite replacement,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/12970144,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,
772,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid +chenodeoxycholic acid,DB02659+DB06777,,,,,,,,,,Elevated hepatic transaminase,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/12970144,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,
773,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid +chenodeoxycholic acid,DB02659+DB06777,,,,,,,,,,Cholestasis,,HP:0001396,https://www.ncbi.nlm.nih.gov/pubmed/12970144,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,
774,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid +chenodeoxycholic acid,DB02659+DB06777,,,,,,,,,,Steatorrhea,,HP:0002570,https://www.ncbi.nlm.nih.gov/pubmed/12970144,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,
775,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid +chenodeoxycholic acid,DB02659+DB06777,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/12970144,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,
776,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,Cholic acid +chenodeoxycholic acid,DB02659+DB06777,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12970144,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,
777,73,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,,,Interferon α-2a,DB00034,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,controversial,Low hemoglobin concentration,,HP:0001931,https://www.ncbi.nlm.nih.gov/pubmed/16141353,https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,,,,,,,,
778,,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,,,Interferon α-2a,DB00034,,,,,,,,,,Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*,,HP:0011031*,https://www.ncbi.nlm.nih.gov/pubmed/16141353,https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,,,,,,,,
779,,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,,,Deferoxamine,DB00746,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,high plasma ferritin,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,,,,,,,,,
780,,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,,,Deferiprone,DB08826,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Elevated serum ferritin concentrations,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pubmed/16141353,,,,,,,,,
781,74,# 220120,D-glycericacidemia,,GLYCTK,d-glycerate kinase,2.7.1.31,,,Sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Active,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/26247153,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=D-glyceric+aciduria+NÁDIA+W.+DIMER.+PATRÍCIA+F.+SCHUCK.&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,,,,,,,,
782,75,# 261515,D-bifunctional protein deficiency,"No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/",HSD17B4,17β-hydroxysteroid dehydrogenase type 4,2.7.1.31,,The study was terminated,Chenodeoxycholic acid+Cholic acid,DB06777+DB02659,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,,,,https://clinicaltrials.gov/ct2/show/NCT00004442?cond=D-bifunctional+protein+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,,,,,,,,,
783,,# 261515,D-bifunctional protein deficiency,,HSD17B4,17β-hydroxysteroid dehydrogenase type 4,2.7.1.31,,The study was terminated,Cholic acid+Ursodiol,DB02659 +DB14555,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,,,,https://clinicaltrials.gov/ct2/show/study/NCT00004442,,,,,,,,,,
784,76,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,,,L- carnitine,DB00583,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,DNA damage (Abnormality of DNA repair)*,,HP:0003254*,https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,,,,,,,,,,
785,,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,,,L- carnitine,DB00583,,,,,,,,,,oxidative injury*,,HP:0025463,https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,,,,,,,,,,
786,,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,,,L- carnitine,DB00583,,,,,,,,,,Protein oxidation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,,,,,,,,,,
787,,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,,,L- carnitine,DB00583,,,,,,,,,,lipid peroxidation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,,,,,,,,,,
788,77,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Valproic acid,DB00313,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,better to be avoided,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22149023,,,,,,,,,,
789,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Carbamazepine,DB00593,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
790,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Phenobarbital,DB01174,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
791,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Phenytoin,DB00252,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
792,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Oxcarbazepine,DB00776,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
793,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Vigabatrin,DB01080,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
794,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Gabapentin,DB00996,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
795,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Topiramate,DB00273,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
796,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Zonisamide,DB00909,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
797,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,,,Ethosuximide,DB00593,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
798,78,# 219750,"Cystinosis, ocular nonnephropathic",,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,ECO:0000179/ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Corneal crystals,,HP:0000531,https://www.ncbi.nlm.nih.gov/pubmed/12370309/,,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12488257/,https://www.ncbi.nlm.nih.gov/pubmed/1929112/,,,,,,
799,79,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",Cysteamine,DB00847,ECO:0000352/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,"Drug name: Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients.    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/                                                                                                                                                                                                                                                                                                                                          Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",Corneal crystals,,HP:0000531,https://www.ncbi.nlm.nih.gov/pubmed/11001803,https://www.ncbi.nlm.nih.gov/pubmed/9758713,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
800,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,,Photophobia,,HP:0000613,https://www.ncbi.nlm.nih.gov/pubmed/22903658,https://www.ncbi.nlm.nih.gov/pubmed/9758713,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
801,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,,Kidney disease progression (Progressive disorder)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/25165189,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
802,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications",development of extra-renal pathologies (Progressive disorder)*,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/22903658,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
803,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",hypothyroidism,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0000821,https://www.ncbi.nlm.nih.gov/pubmed/22903658,https://www.ncbi.nlm.nih.gov/pubmed/22903658,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
804,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications",Delayed growth,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
805,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications",cystine accumulation in muscle parenchyma,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0003358,https://www.ncbi.nlm.nih.gov/pubmed/22903658,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
806,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,,Shorter life expectancy (Mortality)*,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/22903658,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
807,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,,Reduction of WBC cystine levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22903658,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
808,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,,Renal function declines,,HP:0012622,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
809,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,,Elevated intralysosomal cystine accumulation (abnormality of cysteine metabolism),,HP:0010918*,https://www.ncbi.nlm.nih.gov/pubmed/23416144,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
810,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Cysteamine,DB00847,,,,,,,,,,Glomerular damage,,HP:0000095*,https://www.ncbi.nlm.nih.gov/pubmed/23416144,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
811,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,Indomethacin,DB00328,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,Polyuria,,HP:0000103,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
812,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Indomethacin,DB00328,,,,,,,,,,Weight gain,,HP:0004324,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
813,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Indomethacin,DB00328,,,,,,,,,,Proximal tubule salt losses (Proximal tubular defect),,HP:0000114,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
814,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Indomethacin,DB00328,,,,,,,,,,Renal salt wasting,,HP:0000127,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
815,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Bicarbonate+potassium supplements,DB01390+DB01345,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Acidosis,,HP:0001941,,,,,,,,,,,
816,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Neutral phosphate+Vitamin D,DB14502 orDB09449 +DB11094,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,Drug name: Substitution with sodium or potassium phosphate and 1–25-(OH)2 cholecalciferol should be initiated from early childhood to compensate for the phosphate imbal- ance and to prevent rickets in patients with preserved GFR https://www.ncbi.nlm.nih.gov/pubmed/27102039,Phosphate imbalance (Abnormality of phosphate homeostasis)*,,HP:0100529,https://www.ncbi.nlm.nih.gov/pubmed/27102039,,,,,,,,,,
817,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Thiazide,DB01324,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,"Drug name: Usage of Diutics like thiazide to avoid volume expansion, could aggrevate Potassium loss and augments the need for potassium supplements https://emedicine.medscape.com/article/981774-treatment not benefical",Low proximal tubular reabsorption of bicarbonates,,HP:0004910*,,,,,,,,,,,
818,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Growth hormone,DB00052,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Retarded growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,,,,,,,,,
819,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Growth hormone,DB00052,,,,,,,,,,Low phosphate reabsorption,,HP:0000117,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,,,,,,,,,
820,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Thyroxine,DB00451,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypothyroidism,,HP:0000821,,,,,,,,,,,
821,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,ACE inhibitors,DB01348,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: Effectivness of the drug is controversial.                                                                                                                                                                                                                     ACE inhibitors must be used with caution in patients with extracellular volume and sodium depletion https://www.ncbi.nlm.nih.gov/pubmed/14690254/,Glomerular proteinuria,,HP:0000100,,,,,,,,,,,
822,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,ACE inhibitors,DB01348,,,,,,,,,,Albuminuria,,HP:0012592,https://www.ncbi.nlm.nih.gov/pubmed/14690254/,,,,,,,,,,
823,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,Testosterone,DB00624,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,"Drug name:  Currently, insufficient data is available on the pathophysiology of the azoospermia observed in male cystinosis patients. Testosterone supplementation is indicated in patients with a primary testicular failure and low plasma testosterone levels https://www.ncbi.nlm.nih.gov/pubmed/19217094/",Low serum testosterone levels,,HP:004017,https://www.ncbi.nlm.nih.gov/pubmed/19217094/,,,,,,,,,,
824,80,# 606785,"Crigler Najjar syndrome, type 2","Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,"""Effectiveness of the drug is controversial, the risk of hypotension and consequent renal function decline, ACE 
ACE inhibitors must be used with caution in patients with extracellular 
volume and sodium depletion https://www.ncbi.nlm.nih.gov/pubmed/14690254/""",Phenobarbital,DB01174,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,High serum bilirubin level,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/23162302/,https://www.ncbi.nlm.nih.gov/pubmed/1899849,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=27264814&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,,,
825,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,Orlistat,DB01083,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,High plasma level of unconjugated bilirubin concentration,,HP:0008282,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,,,,,,,,
826,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,Orlistat,DB01083,,,,,,,,,,Increased fecal fat excretion (Steatorrhea),,HP:0002570,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,,,,,,,,
827,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,Orlistat,DB01083,,,,,,,,,,Low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*,,HP:0008282*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,,,,,,,,
828,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,AT342,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,High serum  bilirubin concentration,,HP:0002904,,,https://clinicaltrials.gov/ct2/show/NCT03223194?cond=Crigler+Najjar+syndrome&rank=3,,,,,,,,
829,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,GNT0003,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,High serum  bilirubin concentration,,HP:0002904,,,https://clinicaltrials.gov/ct2/show/NCT03466463?cond=Crigler+Najjar+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,,,,,,,
830,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,Hypericum extract,DB01323,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Hyperbilirubinemia,,HP:0002904,,,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,,,,,,,,
831,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,AAV-mediated gene therapy,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,
832,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,AAV-mediated gene therapy,NA,,,,,,,,,,High serum  bilirubin concentration,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,
833,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,AAV-mediated gene therapy,NA,,,,,,,,,,Increased inflammatory response,,HP:0012649,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,
834,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,AAV-mediated gene therapy,NA,,,,,,,,,,Abnormality of metabolism,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,
835,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,Chlofibrate,DB00636,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,High serum  bilirubin concentration,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/7483726,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,,,,,,,,,
836,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,Drug showed an insignificant effect,Fenofibrate,DB01039,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16830281,,,,,,,,,,
837,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,Calcium makes phototherapy more efficient,Calcium,DB01373,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,,
838,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,Calcium,DB01373,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,,
839,81,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,The drug is effective in conjuction with phototherapy,Tin-protoporphyrin,DB02285,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,High serum bilirubin level,,HP:0002904,https://www.nature.com/articles/pr1989488,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=TIN-PROTOPORPHYRIN+%28Sn-pP%29+EFFECT+ON+HYPER-+BILIRUBINEMIA+DUE+TO+CRIGLER-NAJJAR+DISEASE+%28CND%29+TYPE+1&btnG=,,,,,,,,,
840,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,"Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.",orlistat,DB01083,ECO:0007121/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,High plasma level of unconjugated bilirubin concentration,,HP:0008282,https://www.ncbi.nlm.nih.gov/pubmed/17957158,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662,,,,,,,
841,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,Study was suspended based on Sponsor Decision.,AT342,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,,,,https://clinicaltrials.gov/ct2/show/NCT03223194,,,,,,,,,,
842,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,"Information about the Study can be found in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,However study is still recruiting.",GNT0003,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,,,,https://clinicaltrials.gov/ct2/show/NCT03466463,,,,,,,,,,
843,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,Ad5/CMV/hUG-Br1,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/9525311/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292,,,,,,,,
844,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,Chimeric oligonucleotide (oligonucleotide-based gene therapy),NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,UDP-glucuronosyltransferase gene defect,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10468611/,,,,,,,,,,
845,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,Retrovirus,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/9457971/,,,,,,,,,,
846,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,Ad-hBUGT1,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/8900123/,,,,,,,,,,
847,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,Zinc protoporphyrin,CHEBI:28783,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Increased total bilirubin,,HP:0003573,https://www.ncbi.nlm.nih.gov/pubmed/29399656,,,,,,,,,,
848,82,% 608158,CoQ-responsive OXPHOS deficiency,,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Sodium benzoate,DB03793,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Not Active,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,,,,,,,,
849,,% 608158,CoQ-responsive OXPHOS deficiency,,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Sodium phenylacetate,DB09269,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Not Active,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,,,,,,,,,
850,,% 608158,CoQ-responsive OXPHOS deficiency,,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,CoQ,DB09270,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,,,,,,,,,
851,83,121270,"Copper deficiency, familial benign",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,Copper,DB09130,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypocupraemia,,HP:0010836,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/,,,,,,,,,,
852,,121270,"Copper deficiency, familial benign",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,Copper,DB09130,,,,,,,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/,,,,,,,,,,
853,84,# 263700,Congenital erythropoietic porphyria,,UROS,uroporphyrinogen III synthase,4.2.1.75,,,Bortezomib,DB00188,ECO:0000179/ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High porphyrin accumulation in circulating RBCs,,HP:0012187,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/,https://www.ncbi.nlm.nih.gov/pubmed/24145442,,,,,,,,,
854,,# 263700,Congenital erythropoietic porphyria,,UROS,uroporphyrinogen III synthase,4.2.1.75,,,Bortezomib,DB00188,,,,,,,,,,Skin photosensitivity,,HP:0000992,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/,https://www.ncbi.nlm.nih.gov/pubmed/24145442,,,,,,,,,
855,,# 263700,Congenital erythropoietic porphyria,,UROS,uroporphyrinogen III synthase,4.2.1.75,,,Bortezomib,DB00188,,,,,,,,,,Premature degradation of misfolded UROS mutants,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28334762,https://www.ncbi.nlm.nih.gov/pubmed/24145442,,,,,,,,,
856,,# 263700,Congenital erythropoietic porphyria,,UROS,uroporphyrinogen III synthase,4.2.1.75,,,Bortezomib,DB00188,,,,,,,,,,Abnormal porphyrin accumulation in urine,,HP:0010473,https://www.ncbi.nlm.nih.gov/pubmed/28334762,https://www.ncbi.nlm.nih.gov/pubmed/24145442,,,,,,,,,
857,85,# 610198,"DCMA syndrome (3-methylglutaconic aciduria, type V)",,DNAJC19,DnaJ heat shock protein family (Hsp40) member C19,Q96DA6,,,Angiotensin-converting enzyme (ACE) inhibitors+digoxin+furosemide,C09C+DB00390+DB00695,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Reduced ejection fraction,,HP:0012664,https://www.ncbi.nlm.nih.gov/pubmed/27928778,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,,,,,,,,
858,86,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,Dextrothyroxine,DB00509,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
859,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,Dextrothyroxine,DB00509,,,,,,,,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
860,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,Dextrothyroxine,DB00509,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
861,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,Dextrothyroxine,DB00509,,,,,,,,,,Mild asymptomatic hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
862,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,Complex Carbohydrates,NA,ECO:0000352,,,,,Functional interaction,B,dietary regime modification,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
863,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,Complex Carbohydrates,NA,,,,,,,,,,Short Stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
864,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,Complex carbohydrates+Beneprotein+Low fats,NA+NA+NA,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+dietary regime modification+dietary supplementation+dietary regime modification,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
865,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,Uncooked cornstarch+ Beneprotein+Low fats diet,DB11599+NA,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+dietary supplementation+dietary supplementation+dietary regime modification,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
866,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,Uncooked cornstarch+ Beneprotein,DB11599+NA,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+dietary supplementation+dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
867,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,Uncooked cornstarch+ Beneprotein,DB11599+NA,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
868,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,Uncooked cornstarch,DB11599,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
869,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,Uncooked cornstarch,DB11599,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
870,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,Uncooked cornstarch+ Beneprotein+CoCarbs(Complex carbohydrate),DB11599+NA+NA,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+dietary supplementation+dietary supplementation+dietary regime modification,,Elevated hepatic transaminases,"On this regimen, one patient had the enlevated liver enxymes stabilized while the other had mild improvement.",HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
871,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,CoCarbs + HPro,NA+NA,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+dietary regime modification+dietary regime modification,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
872,,# 613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",P15735,,,Uncooked cornstarch+ Beneprotein,DB11599+NA,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+dietary supplementation+dietary supplementation,,Elevated hepatic transaminases,Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/12930917,,,,,,,,,
873,,# 613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",P15735,,,Uncooked cornstarch+ Beneprotein,DB11599+NA,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pubmed/12930917,,,,,,,,,
874,87,# 240600,"Glycogen storage disease type 0, liver","GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",GYS2,glycogen synthase 2,2.4.1.11,,,Glycosade,NA,ECO:0007121,,,,,Functional interaction,B,dietary supplementation,,Nocturnal Hypoglycemia (Hypoglycemia)*,,HP:0001943*,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=Glycogen+Storage+Disease+Type+0&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,
875,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,,,Glycosade,NA,,,,,,,,,,Poor sleep quality (Sleep disturbance)*,,HP:0002360*,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,
876,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Cornstarch,DB11599,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,,MorningHypoglycemia (Hypoglycemia)*,,HP:0012051,https://www.ncbi.nlm.nih.gov/pubmed/12794686,,,,,,,,,,
877,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,,,Cornstarch,DB11599,,,,,,,,,,Ketosis,,HP:0001946,https://www.ncbi.nlm.nih.gov/pubmed/12794686,,,,,,,,,,
878,88,#611881,Glycogen storage disease type 12,,ALDOA,"aldolase, fructose-bisphosphate A",4.1.2.13,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28932990,,,,,,,,,,
879,89,#612932,Glycogen storage disease type 13,,ENO3,enolase 3,4.2.1.11,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28932990,,,,,,,,,,
880,90,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level.",DTX401,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,,,,https://clinicaltrials.gov/ct2/show/NCT03517085?cond=von+Gierke&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20163245,,,,,,,,,
881,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,FIV-hAAT-G6Pase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,,,,,,,,,,
882,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Ad-mG6Pase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Growth retardation,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
883,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Ad-mG6Pase,NA,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
884,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Ad-mG6Pase,NA,,,,,,,,,,Hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
885,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Ad-mG6Pase,NA,,,,,,,,,,Hyperlipidemia,,HP:0003077,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
886,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Ad-mG6Pase,NA,,,,,,,,,,Enlarged kidney,,HP:0000105,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
887,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Ad-mG6Pase,NA,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
888,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,AAV-cG6PGH,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Growth Failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/16672983,,,,,,,,,,
889,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,AAV-cG6PGH,NA,,,,,,,,,,Hyperlipidemia,,HP:0003077,https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128,,,,,,,,,
890,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,AAV-cG6PGH,NA,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128,,,,,,,,,
891,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",HDAd-G6Pase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/17505475,,,,,,,,,,
892,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Glycosade,NA,ECO:0007121,,,,,Functional interaction,B,dietary supplementation,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
893,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Glycosade,NA,,,,,,,,,,Sleep disturbance/Poor sleep quality,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
894,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Glycosade,NA,,,,,,,,,,Low quality of life (Constitutional symptoms)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
895,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,L-carnitine,DB00583,ECO:0007764,,,,,Symptomatic,C,symptomatic therapeutic procedure,,mitochondrial dysfunction,,HP:0003287,http://www.ncbi.nlm.nih.gov/pubmed/28317891?dopt=Abstract,https://www.nature.com/articles/srep44408,,,,,,,,,
896,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Tempol,DB12449,ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
897,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Tempol,DB12449,,,,,,,,,,Renal disease progression (Progressive disorder)*,,HP:0003676*,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
898,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Tempol,DB12449,,,,,,,,,,Nephropathy,,HP:0000112,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
899,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,ACE‐inhibitors,C09C,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Glomerular hyperfilteration (Abnormal glomerular filtration rate),,HP:0012212,https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,,,,,,,,,
900,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Antioxidant + ACE inhibitors,DB12449+C09C,ECO:0007764,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Nephropathy,,HP:0000112,,,,,,,,,,,
901,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Glucose,DB01914,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,,,,,,,,,
902,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Uncooked cornstarch,DB11599+NA,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,,Hypoglycemia,,HP:0001943,https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,,,,,,,,
903,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Allopurinol,DB00437,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High plasma uric acid levels,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/26835382,,,,,,,,,,
904,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,Calcium+ vitamin D3,DB01373+DB00169,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Osteoporosis,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,HP:0000939,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,,,,,,,,,,
905,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Medium chain triglycerides,DB13959,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
906,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Medium chain triglycerides,DB13959,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
907,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Medium chain triglycerides,DB13959,,,,,,,,,,Growth failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
908,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,Medium chain triglycerides,DB13959,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
909,91,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382,Human granulocyte-colony-stimulating-factor,DB00099,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,
910,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Human granulocyte-colony-stimulating-factor,DB00099,,,,,,,,,,Recurrent bacterial infection,,HP:0002718,https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.ncbi.nlm.nih.gov/pubmed/1719175,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,
911,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Human granulocyte-colony-stimulating-factor,DB00099,,,,,,,,,,"Frequent, severe infections",,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.ncbi.nlm.nih.gov/pubmed/1719175,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,
912,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",G‐CSF + 5‐aminosalicylic acid,DB00099+DB00244,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Neutropenia with IBD,,HP:0001875+HP:0002037,https://www.ncbi.nlm.nih.gov/pubmed/12373585,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/19541498,,,,,,,,
913,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Adalimumab,DB00051,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,GSD-associated enterocolitis (enterocolitis),,HP:0004387,https://www.ncbi.nlm.nih.gov/pubmed/18172743,,,,,,,,,,
914,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Glycosade,NA,ECO:0007121,,,,,Functional interaction,B,dietary supplementation,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
915,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Glycosade,NA,,,,,,,,,,Sleep disturbance/Poor sleep qaulity,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
916,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Glycosade,NA,,,,,,,,,,Low quality of life (Constitutional symptoms)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
917,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,rAAV-GPE-G6PT,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Hyperlipidemia,,HP:0003077,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
918,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,rAAV-GPE-G6PT,NA,,,,,,,,,,Hypoglycemia,,HP:0001943,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
919,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,rAAV-GPE-G6PT,NA,,,,,,,,,,Hyperuricemia,,HP:0002149,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
920,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,rAAV-GPE-G6PT,NA,,,,,,,,,,Lactic acidemia,,HP:0003128,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
921,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,rAAV-GPE-G6PT,NA,,,,,,,,,,Age-related insulin resistance (Insulin resistance)*,,HP:0000855*,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
922,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,rAAV-GPE-G6PT,NA,,,,,,,,,,Obesity,,HP:0001513,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
923,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.",Galactose+Uridine,DB11735+DB02745,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Partial correction of neutrophil dysfunction,"In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract",HP:0011990,http://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract,,,,,,,,,,
924,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Vitamin E,DB00163,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,,,,
925,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Vitamin E,DB00163,,,,,,,,,,"Frequent, severe infections",,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,,,,
926,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.",Testosterone,DB00624,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Decreased male libido,,HP:0040306,https://www.ncbi.nlm.nih.gov/pubmed/28160246,,,,,,,,,,
927,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Testosterone,DB00624,,,,,,,,,,Low physical activity,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/28160246,,,,,,,,,,
928,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Testosterone,DB00624,,,,,,,,,,decrease muscle strenght,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/28160246,,,,,,,,,,
929,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Medium chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,,Hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
930,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Medium chain triglycerides,DB13959,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
931,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,Medium chain triglycerides,DB13959,,,,,,,,,,Growth failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
932,92,# 232400,Glycogen storage disease type 3,Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Cornstarch,DB11599,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,,Linear growth velocity (Abnormality of body height)*,,HP:0000002*,,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482,,,,,,,
933,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Cornstarch,DB11599,,,,,,,,,,Hypoglycemic seizures,,HP:0002173,,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482,,,,,,,
934,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Cornstarch,DB11599,,,,,,,,,,Enlarged size of the liver,,HP:0002240,,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482,,,,,,,
935,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Calcium+Vitamin D,DB01373 + DB11094,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Osteoporosis,,HP:0000939,,,,,,,,,,,
936,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Glycosade,NA,ECO:0007121,,,,,Functional interaction,B,dietary supplementation,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,,
937,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Glycosade,NA,,,,,,,,,,Sleep disturbance,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,,
938,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Rapamycin,DB00877,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,Drug name:   Study was done in a canine model.,High glycogen levels in muscles,,HP:0009051,https://www.ncbi.nlm.nih.gov/pubmed/24509886,,,,,,,,,,
939,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Rapamycin,DB00877,,,,,,,,,,Liver fibrosis progression,,HP:0001395,https://www.ncbi.nlm.nih.gov/pubmed/24509886,,,,,,,,,,
940,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Fructose,DB04173,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/25832663,,,,,,,,,,
941,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,High protein diet,NA,,,,,,Functional interaction,B,dietary regime modification,Drug name: A dietary tretament,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,,,,,,,,,
942,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,High protein diet,NA,,,,,,,,,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,,,,,,,,,
943,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,High protein diet,NA,,,,,,,,,,Cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,,,,,,,,,
944,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Modified Atkins diet,NA,ECO:0000352,,,,,Functional interaction,B,dietary regime modification,Drug name: A dietary tretament,Abnormal blood levels of ketone bodies,,HP:0001939,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
945,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Modified Atkins diet,NA,,,,,,,,,,Abnormal blood levels of  fatty acids,,HP:0004359,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
946,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Modified Atkins diet,NA,,,,,,,,,,High creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
947,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Modified Atkins diet,NA,,,,,,,,,,Cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
948,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Modified Atkins diet,NA,,,,,,,,,,Low energetic state of heart (Abnormality of cardiovascular system physiology)*,,HP:0011025*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
949,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Modified Atkins diet,NA,,,,,,,,,,Low energetic state of skeletal muscle,,HP:0011804,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
950,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,Modified Atkins diet,NA,,,,,,,,,,Increased creatine kinase activity,,HP:0003236,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
951,93,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Sodium Valproate,DB00313,ECO:0007121/ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,Drug name:,Difficulty walking,,HP:0002355,,https://clinicaltrials.gov/ct2/show/NCT03112889?cond=McArdle+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25762569,,,,,,,
952,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Triheptanoin,DB11677,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal fat metabolism,,HP:0004359,https://www.ncbi.nlm.nih.gov/pubmed/28932990,https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1,,,,,,,,,
953,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Triheptanoin,DB11677,,,,,,,,,,Abnormal carbohydrate metabolism*,,HP:0011013,https://www.ncbi.nlm.nih.gov/pubmed/28932990,https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1,,,,,,,,,
954,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Creatine,DB00148,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/25391139,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,,,,,,
955,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Sucrose,DB02772,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Exercise intolerance,,HP:0003547,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25391139,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,,,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract,,,
956,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Vitamin B6,DB00165,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Insufficient anaerobic glycolysis of skeletal muscle,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22334182,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,,,,,,,
957,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Vitamin B6,DB00165,,,,,,,,,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/22334182,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,,,,,,,
958,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Vitamin B6,DB00165,,,,,,,,,,Abnormal muscle phosphorylase activity(Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/22334182,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,,,,,,,
959,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Ramipril,DB00178,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Disability (Functional motor problems)*,,HP:0004302*,https://www.ncbi.nlm.nih.gov/pubmed/18098237,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,,,,,,,,
960,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,Ramipril,DB00178,,,,,,,,,,Abnormal exercise physiology,,HP:0009020,https://www.ncbi.nlm.nih.gov/pubmed/18098237,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,,,,,,,,
961,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,Drug has been proven to be unsuccessful,GENTAMICIN,DB04729,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,Drug name: ineffective/ further study is needed,,,,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,,,,,,,,,
962,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,PTC124,DB05016,ECO:0007764,,,,,,,activity modification of a genetically defective protein,,Exercise intolerance,,HP:0003546,,,,,,,,,,,
963,94,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,Cornstarch (Uncooked),DB11599,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,"Drug name: Uncooked cornstarch administartion can result in avoidance of ketosis, hypoglycemia and hepatomegaly. https://www.ncbi.nlm.nih.gov/pubmed/20301760",Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,
964,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,Cornstarch (Uncooked),DB11599,,,,,,,,,,Abnormal blood glucose concentration,,HP:0011015,https://www.ncbi.nlm.nih.gov/pubmed/20301760,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,
965,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,Cornstarch (Uncooked),DB11599,,,,,,,,,,Low energy level (Tiredness)*,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/20301760,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,
966,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,Cornstarch (Uncooked),DB11599,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,
967,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,Cornstarch (Uncooked),DB11599,,,,,,,,,,Elevated Hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,
968,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,Beneprotein,NA,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,,Short stature,,HP:0004322,,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,
969,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,Uncooked cornstarch+Beneprotein,DB11599+NA,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+dietary supplementation+dietary supplementation,,Elevated Hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
970,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,D-Thyroxine,DB00509,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hepatomeglay,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/3483883,,,,,,,,,,
971,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,D-Thyroxine,DB00509,,,,,,,,,,Elevated Hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/3483883,,,,,,,,,,
972,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,D-Thyroxine,DB00509,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/3483883,,,,,,,,,,
973,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,D-Thyroxine,DB00509,,,,,,,,,,Increased erythrocyte glycogen content,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/3483883,,,,,,,,,,
974,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,D-Thyroxine,DB00509,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/3483883,,,,,,,,,,
975,95,# 232800,Glycogen storage disease type 7,"The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272",PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",2.7.1.11,,"A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process(in the Recruiting stage. ). https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1",Triheptanoin,DB11677,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1,,,,,,,,,,
976,,# 232800,Glycogen storage disease type 7,,PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",2.7.1.11,,,Triheptanoin,DB11677,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1,,,,,,,,,,
977,96,# 606664,Glycine N-methyltransferase deficiency,"Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.",GNMT,glycine N-methyltransferase,2.1.1.20,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Nicotinamide,DB02701,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,"Disease name: Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high.

https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.  Drug name: An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/",Liver steatosis,,HP:0001397,https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,,,,,,,,
978,,# 606664,Glycine N-methyltransferase deficiency,,GNMT,glycine N-methyltransferase,2.1.1.20,,,Nicotinamide,DB02701,,,,,,,,,,Fatty liver,,HP:0001397,https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,,,,,,,,
979,,# 606664,Glycine N-methyltransferase deficiency,,GNMT,glycine N-methyltransferase,2.1.1.20,,,Nicotinamide,DB02701,,,,,,,,,,Liver fibrosis,,HP:0001395,https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,,,,,,,,
980,,# 606664,Glycine N-methyltransferase deficiency,,GNMT,glycine N-methyltransferase,2.1.1.20,,,Nicotinamide,DB02701,,,,,,,,,,DNA hypermethylation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,,,,,,,,
981,96,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,OTZ (L-2-oxothiazoline-4-carboxylic acid),NA,ECO:0000179,,,,,Functional interaction,B,metabolite replacement,Disease name : In 2007 Ristoff et al.   mentioned in their paper  that there is no treatment that has been recommended. https://www.ncbi.nlm.nih.gov/pubmed/17397529?dopt=Abstract. Drug name: These drugs have been tested on mice.,Low intracellular cysteine(Abnormal cysteine level)*,,MP:0030621,,,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,,,,,,,,
982,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,OTZ (L-2-oxothiazoline-4-carboxylic acid),NA,,,,,,,,,,Behavioral abnormalities,,HP:0000708,,,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,,,,,,,,
983,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,OTZ (L-2-oxothiazoline-4-carboxylic acid),NA,,,,,,,,,,GSH deficiency,,HP:0003343,,,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,,,,,,,,
984,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,N-acetylcysteine,DB06151,ECO:0000179,,,,,Functional interaction,B,metabolite replacement,Drug name: These drugs have been tested on mice.,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850/,,https://www.ncbi.nlm.nih.gov/pubmed/20868666,,,,,,,,
985,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,N-acetylcysteine,DB06151,,,,,,,,,,Cataract,,HP:0000518,https://www.ncbi.nlm.nih.gov/pubmed/11095909,,https://www.ncbi.nlm.nih.gov/pubmed/20868666,,,,,,,,
986,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,N-acetylcysteine,DB06151,,,,,,,,,,Low reproductive capacity (infertility),,HP:0000144,https://www.ncbi.nlm.nih.gov/pubmed/11089562,,https://www.ncbi.nlm.nih.gov/pubmed/20868666,,,,,,,,
987,97,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Ascorbic acid,DB00126,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/8301428/,,https://www.ncbi.nlm.nih.gov/pubmed/17397529,,,,,,,,
988,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Ascorbate + N-acetylcysteine,DB00126+DB06151,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High erythrocyte turnover (Abnormality of erythrocytes)*,,HP:0001877*,https://www.ncbi.nlm.nih.gov/pubmed/8301428/,,,,,,,,,,
989,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Polycitra (Citric acid +Potassium citrate + Sodium citrate)+vitamin C+vitamin E+selenium,(DB04272+DB09125+DB09154)+DB00126+DB00163+DB11135,ECO:0000352,,,,,Symptomatic+Functional interaction+Functional interaction+Functional interaction,C+B+B+B,combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Oxidative stress,,HP:0025464,http://www.ncbi.nlm.nih.gov/pubmed/26984560?dopt=Abstract,,,,,,,,,,
990,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Alpha-tocopherol,DB00163,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal microtubule assembly,,NA,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
991,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Alpha-tocopherol,DB00163,,,,,,,,,,Short erythrocyte survival (Abnormality of erythrocytes)*,,HP:0001877*,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
992,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Alpha-tocopherol,DB00163,,,,,,,,,,Abnormal polymorphonuclear leukocyte function,,HP:0001874,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
993,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Alpha-tocopherol,DB00163,,,,,,,,,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
994,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Alpha-tocopherol,DB00163,,,,,,,,,,Susceptibility to Bacterial infection,,HP:0002718,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
995,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Alpha-tocopherol,DB00163,,,,,,,,,,Retinal dystrophy,,HP:0000556,https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
996,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Alpha-tocopherol,DB00163,,,,,,,,,,CNS damage progression,,HP:0007367,https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
997,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+Vitamin E+Vitamin B1+Cobalamin,DB00583+DB00163+DB00152+DB14098,ECO:0000352,,,,,Symptomatic+Functional interaction+Symptomatic+Symptomatic,C+B+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Hypersomnia,,HP:0100786,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
998,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+Vitamin E+Vitamin B1+Cobalamin,DB00583+DB00163+DB00152+DB14098,,,,,,,,,,Jaundice,,HP:0000952,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
999,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+Vitamin E+Vitamin B1+Cobalamin,DB00583+DB00163+DB00152+DB14098,,,,,,,,,,Carnitine deficiency,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1000,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+Vitamin E+Vitamin B1+Cobalamin,DB00583+DB00163+DB00152+DB14098,,,,,,,,,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1001,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+vitamin B1+B2+ B12+ C+E + Sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic+Symptomatic+Functional interaction+Functional interaction+Symptomatic,C+C+C+C+B+B+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1002,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+vitamin B1+B2+ B12+ C+E + Sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1003,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+vitamin B1+B2+ B12+ C+E + Sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,,,,,,,,,,Elevated urine 5-oxoproline,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1004,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+vitamin B1+B2+ B12+ C+E + Sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,,,,,,,,,,Decreased blood free carnitine,,HP:0008315,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1005,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+ Vitamin B1+B12+C+E,DB00583+DB00152+DB00115+DB00126+DB00163,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic+Functional interaction+Functional interaction,C+C+C+B+B,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Elevated urine 5-oxoproline,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1006,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,L-carnitine+ Vitamin B1+B12+C+E,DB00583+DB00152+DB00115+DB00126+DB00163,,,,,,,,,,Decreased blood free carnitine,,HP:0008315,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
1007,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Sodium Bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/26669244/,,,,,,,,,
1008,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Coenzyme Q10,DB09270,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High-anion gap acidosis,,HP:0001941*,http://www.ncbi.nlm.nih.gov/pubmed/26669244?dopt=Abstract,,,,,,,,,,
1009,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Dorzolamide+acetazolamide,DB00869+DB00819,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Cystoid macular edema,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/29395598?dopt=Abstract,,,,,,,,,,
1010,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,Erythropoietin + iron+folic acid + vitamin B12,DB00016+DB01592+DB00158+DB00165,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic+Symptomatic,C+C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Anaemia,,HP:0001903,http://www.ncbi.nlm.nih.gov/pubmed/16435214?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16435214,,,,,,,,,
1011,98,# 231670,Glutaric acidemia type I,"It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622",GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",Carnitine +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,DB00583+DB00130+DB09393,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+dietary supplementation,,Brain damage,Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622,HP:0001298,https://www.ncbi.nlm.nih.gov/pubmed/23326493,,,,,,,,,,
1012,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,Carnitine +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,DB00583+DB00130+DB09393,,,,,,,,,,Cerebral palsy,"Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918",HP:0100021,https://www.ncbi.nlm.nih.gov/pubmed/10630918,,,,,,,,,,
1013,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,Carnitine +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,DB00583+DB00130+DB09393,,,,,,,,,,Secondary Carnitine deficiency (Carnitine deficiency)*,,HP:0003234*,https://www.ncbi.nlm.nih.gov/pubmed/10630918,,,,,,,,,,
1014,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,Carnitine+ Riboflavin+baclofen,DB00583+DB00130+DB00181,ECO:0000352,,,,,Functional interaction+Direct interaction+Functional interaction,B+A+B,combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Disease progression,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
1015,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,Carnitine+ Riboflavin+baclofen,DB00583+DB00130+DB00181,,,,,,Symptomatic,C,,,Secondary Carnitine deficiency (Carnitine deficiency)*,,HP:0003234*,https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/16368216,,,,,,,
1016,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,Carnitine+ Riboflavin+baclofen,DB00583+DB00130+DB00181,,,,,,,,,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/16368216,,,,,,,
1017,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,Carnitine+Thioridazine Hcl+Chloral hydrate+Baclofen,DB00583+DB00679+DB01563+DB00181,ECO:0000352,,,,,Functional interaction+Symptomatic+Symptomatic+Functional interaction,B+C+C+B,combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein,,Dystonia,The phenotype has been reported in association to treatment with baclofen as,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/8881997,,,,,,,,,,
1018,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,Chlorpromazine,DB00477,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hyperpyrexia in case of acute encephalopathic crises (Fever)*,,HP:0001945*,https://www.ncbi.nlm.nih.gov/pubmed/10222465,,,,,,,,,,
1019,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,The combination was accompanied by Low L-lysine diet,Carnitine+Riboflavin+L-Arginine+clofibrate,DB00583+DB00130+DB00125+DB00636,ECO:0000179,,,,,Functional interaction+Direct interaction+Functional interaction+Symptomatic,B+A+B+C,combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure,,Glutaric acidemia,Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787,HP:0003530,https://www.ncbi.nlm.nih.gov/pubmed/20923787,,,,,,,,,,
1020,99,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,Synergism inmproves results,Carnitine+ riboflavin,DB00583+DB00140,ECO:0000352,,,,,Functional interaction+Direct interaction,B+A,combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein,,High serum creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,
1021,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Carnitine+ riboflavin,DB00583+DB00140,,,,,,,,,synergism inmproves results,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,
1022,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Carnitine+ riboflavin,DB00583+DB00140,,,,,,,,,,Secondary Carnitine deficiency (Carnitine deficiency)*,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,
1023,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Carnitine+ riboflavin+Coenzyme Q,DB00583+DB00140+DB09270,ECO:0000352,,,,,Functional interaction+Direct interaction+Functional interaction,B+A+B,combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Dysphagia,,HP:0002015,https://www.ncbi.nlm.nih.gov/pubmed/26236614,,,,,,,,,,
1024,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Carnitine+ riboflavin+Coenzyme Q,DB00583+DB00140+DB09270,,,,,,,,,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pubmed/26236614,,,,,,,,,,
1025,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Carnitine+ riboflavin+Coenzyme Q,DB00583+DB00140+DB09270,,,,,,,,,,Secondary Carnitine deficiency (Carnitine deficiency)*,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/10723193,,,,,,,,,,
1026,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Glycine+Riboflavin+Carnitine,DB00145+DB00140+DB00583,ECO:0000352,,,,,Functional interaction+Direct interaction+Functional interaction,B+A+B,combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/3229565,,,,,,,,,,
1027,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,"Sodium-d,l-3-hydroxybutyrate",CHEBI:113373,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Progressive leukodystrophy,,HP:0002415,https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
1028,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,"Sodium-d,l-3-hydroxybutyrate",CHEBI:113373,,,,,,,,,,Paralysis,,HP:0003470,https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
1029,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,"Sodium-d,l-3-hydroxybutyrate",CHEBI:113373,,,,,,,,,,Cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
1030,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,"Sodium-d,l-3-hydroxybutyrate",CHEBI:113373,,,,,,,,,,Impaired myocardial contractility,,HP:0006670,https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
1031,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Riboflavin+Carnitine+Corticosteroid,DB00140+DB00583+S03BA,ECO:0000352,,,,,Direct interaction*+Functional interaction+Symptomatic,A,combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/10581232,,,,,,,,,,
1032,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Riboflavin+Carnitine+Corticosteroid,DB00140+DB00583+S03BA,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/10581232,,,,,,,,,,
1033,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Riboflavin+Carnitine+Corticosteroid,DB00140+DB00583+S03BA,,,,,,,,,,Elevated serum creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/10581232,,,,,,,,,,
1034,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,Riboflavin+Carnitine+Corticosteroid,DB00140+DB00583+S03BA,,,,,,,,,,Ketonuria,,HP:0002919,https://www.ncbi.nlm.nih.gov/pubmed/10581232,,,,,,,,,,
1035,100,# 231690,Glutaric acidemia type III,,SUGCT,succinate-hydroxymethylglutarate coA-transferase,2.8.3.13,,,Metronidazole,DB00140,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Cyclic vomiting (Vomiting)*,,HP:0002013,https://www.ncbi.nlm.nih.gov/pubmed/28766179,,,,,,,,,,
1036,,# 231690,Glutaric acidemia type III,,SUGCT,succinate-hydroxymethylglutarate coA-transferase,2.8.3.13,,,Metronidazole,DB00140,,,,,,,,,,Bacterial glutric acid production,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28766179,,,,,,,,,,
1037,101,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,L-glutamine,DB00130,ECO:0007121,,,,,Functional interaction,B,metabolite replacement,,Abnormal plasma glutamine levels,,HP:0010903,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
1038,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,L-glutamine,DB00130,,,,,,,,,,Low CSF glutamine level,,HP:0030980*,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
1039,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,L-glutamine,DB00130,,,,,,,,,,Unalertness,,HP:0002329,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
1040,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,L-glutamine,DB00130,,,,,,,,,,Lack of emotional expressions,,HP:0030213,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
1041,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,L-glutamine,DB00130,,,,,,,,,,Abnormal EEG results,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
1042,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,L-glutamine,DB00130,,,,,,,,,,Low brain glutamine concentration,,HP:0030980,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
1043,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,L-glutamine,DB00130,,,,,,Symptomatic,,,,Secondary NAD+ deficiency in leucocytes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
1044,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,Nicotinamide,DB02701,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Secondary NAD+ deficiency in leucocytes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,,,,,,,,,,
1045,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,Vitamin C+Vitamin E+Selenium,DB00126+DB00163+DB11135,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/26984560,,,,,,,,,,
1046,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,Citric acid+Sodium citrate+ Potassium citrate,DB04272+DB09154+DB09125,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/26984560,,,,,,,,,,
1047,102,# 229100,Glutamate formiminotransferase deficiency,The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726,FTCD,formiminotransferase cyclodeaminase,6.3.1.2,,,Pyridoxine +Folic acid,DB00165+DB00158,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/5301410,,,,,,,,,,
1048,103,# 606824,Glucose-galactose malabsorption,Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187,SLC5A1,sodium/glucose cotransporter protein called SGLT1,6.3.1.2,,The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,Fructose +Carbohydrate free formula,DB04173+NA,ECO:0000352,,,,,Symptomatic+Functional interaction,C+B,combination therapeutic procedure+symptomatic therapeutic procedure+dietary regime modification,,Watery Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/10404446,https://www.ncbi.nlm.nih.gov/pubmed/20486940,,https://www.ncbi.nlm.nih.gov/pubmed/28283348,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/,,,,,,
1049,,# 606824,Glucose-galactose malabsorption,,SLC5A1,sodium/glucose cotransporter protein called SGLT1,6.3.1.2,,,Fructose +Carbohydrate free formula,DB04173+NA,,,,,,,,,,Dehydration,,HP:0001944,https://www.ncbi.nlm.nih.gov/pubmed/10404446,https://www.ncbi.nlm.nih.gov/pubmed/20486940,,https://www.ncbi.nlm.nih.gov/pubmed/28283348,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/,,,,,,
1050,104,# 606777,Glucose transporter type 1 deficiency syndrome,"The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract",SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,UX007 (triheptanoin),DB11677,ECO:0007121/ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,,,,
1051,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,UX007 (triheptanoin),DB11677,,,,,,,,,,EEG with focal spike waves,,HP:0011197,https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,,,,
1052,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,UX007 (triheptanoin),DB11677,,,,,,,,,,Nonepileptic paroxysmal abnormalities,,NA,https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,,,,
1053,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,UX007 (triheptanoin),DB11677,,,,,,,C,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,,,,
1054,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,UX007 (triheptanoin),DB11677,,,,,,,C,,,Movement disorders,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,,,,
1055,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,UX007 (triheptanoin),DB11677,,,,,,,,,,Dyskinesia,,HP:0100660,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/26982753,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,,,,
1056,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,AAV-GLUT1,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Abnormal CSF glucose levels,,HP:0031884,,,https://www.ncbi.nlm.nih.gov/pubmed/29624790,,,,,,,,
1057,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,AAV-GLUT1,NA,,,,,,,,,,Abnormal motor function,,HP:0004302,,,https://www.ncbi.nlm.nih.gov/pubmed/29624790,,,,,,,,
1058,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,AAV-GLUT1,NA,,,,,,,,,,Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia),,HP:0007166,,,https://www.ncbi.nlm.nih.gov/pubmed/29624790,,,,,,,,
1059,105,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,Rofecoxib,DB00533,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Refractory hypokalemia,,HP:0002900*,https://www.ncbi.nlm.nih.gov/pubmed/12141411,,,,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,,,,,,
1060,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Rofecoxib,DB00533,,,,,,,,,,Abnormally reduced levels of aldosterone,,HP:0004319,https://www.ncbi.nlm.nih.gov/pubmed/12141411,,,,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,,,,,,
1061,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Rofecoxib,DB00533,,,,,,,,,,Abnormal serum renin level,,HP:0040084,https://www.ncbi.nlm.nih.gov/pubmed/12141411,,,,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,,,,,,
1062,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Indometacin/Amiloride/Eplerenone+Potassium,(DB00328/DB00594/DB00700)+DB00761,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Refractory hypokalemia,,HP:0002900*,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,https://clinicaltrials.gov/ct2/show/NCT01146197?cond=Gitelman+syndrome&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,,,,
1063,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Indometacin,DB00328,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/25852896/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,,,,,,,,
1064,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Indometacin,DB00328,,,,,,,,,,High plasma RAAS activity,,HP:0000847*,https://www.ncbi.nlm.nih.gov/pubmed/25852896/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,,,,,,,,
1065,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Indometacin,DB00328,,,,,,Symptomatic,C,,,Abnormally reduced levels of aldosterone,,HP:0004319,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,,,,,,,,
1066,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Indometacin,DB00328,,,,,,Symptomatic,C,,,Abnormal serum renin level,,HP:0040084,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,,,,,,,,
1067,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Magnesium,DB14513,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Hypomagnesemia,"In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications",HP:0002917,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,,,,,,,,,,
1068,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Magnesium,DB14513,,,,,,,,,,Chondrocalcinosis,,HP:0000934,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,,,,,,,,,,
1069,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,Potassium chloride,DB00761,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Hypokalemia,,HP:0002900,,,,,,,,,,,
1070,106,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Taliglucerase alfa,DB08876,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Hepatomegaly,,HP:0002240,https://clinicaltrials.gov/ct2/show/results/NCT01422187?cond=Gaucher+disease&draw=3&rank=23&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27839981,,,,,,,
1071,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Taliglucerase alfa,DB08876,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,,,,,,
1072,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Taliglucerase alfa,DB08876,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,,,,,,
1073,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Taliglucerase alfa,DB08876,,,,,,,,,,Low mean hemoglobin concentration,,HP:0025547,https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,,,,,,
1074,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Taliglucerase alfa,DB08876,,,,,,,,,,Low bone marrow fat fraction value,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,,,,,,
1075,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Imiglucérase (ISU302),DB00053,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Primary low heamoglobin level,,HP:0001903*,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1076,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Imiglucérase (ISU302),DB00053,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1077,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Imiglucérase (ISU302),DB00053,,,,,,,,,,Splenomegaly,,HP:0001744,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1078,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Imiglucérase (ISU302),DB00053,,,,,,,,,,Hepatomegaly,,HP:0002240,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1079,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Imiglucérase (ISU302),DB00053,,,,,,,,,,High angiotensin- converting enzyme,,HP:0000841,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1080,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Imiglucérase (ISU302),DB00053,,,,,,,,,,High  Chitotriosidase Level (Abnormality of lysosomal metabolism)*,,HP:0004356,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1081,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Imiglucérase (ISU302),DB00053,,,,,,,,,,Elevated Chemokine Ligand (CCL-18) Level [ng/mL],,NA,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1082,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,Trial is no longer available,prGCD,DB06667,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,Study is no longer available,,,,https://clinicaltrials.gov/ct2/show/NCT00705939,https://www.ncbi.nlm.nih.gov/pubmed/19277123,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/NCT00376168?cond=NCT00376168&draw=2&rank=1,,,,,,,
1083,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,prGCD,DB06667,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT00705939,https://www.ncbi.nlm.nih.gov/pubmed/19277123,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/NCT00376168?cond=NCT00376168&draw=2&rank=1,,,,,,,
1084,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat tartrate,DB09039,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Low mean hemoglobin level,,HP:0001903,https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,,,,,,,,,
1085,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat tartrate,DB09039,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,,,,,,,,,
1086,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat tartrate,DB09039,,,,,,,,,,Hepatomegaly,,HP:0002240,https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,,,,,,,,,
1087,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat tartrate,DB09039,,,,,,,,,,Splenomegaly,,HP:0001744,https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,,,,,,,,,
1088,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat tartrate,DB09039,,,,,,,,,,Low lumbar spine bone mineral density (abnormality of bone mineral density)*,,HP:0004348,https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,,,,,,,,,
1089,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,N-acetylcysteine,DB06151,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT01427517,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,
1090,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,N-acetylcysteine,DB06151,,,,,,,,,,Low blood glutathione redox ratios,,MP:0012604*,https://clinicaltrials.gov/ct2/show/NCT01427517,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,
1091,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,N-acetylcysteine,DB06151,,,,,,,,,,Inflammation,,HP:0012649,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,
1092,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,N-acetylcysteine,DB06151,,,,,,,,,,Concentration of myo-inositol in brain,,HP:0025460,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,
1093,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,N-acetylcysteine,DB06151,,,,,,,,,,Concentration of TNF-alpha in plasma,,HP:0011118*,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,
1094,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Elelyso,DB08876,ECO:0000352/ ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,,,,,,,,
1095,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Elelyso,DB08876,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,,,,,,,,
1096,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Elelyso,DB08876,,,,,,,,,,thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,,,,,,,,
1097,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Elelyso,DB08876,,,,,,,,,,Anaemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,,,,,,,,
1098,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Changes in lumbar spine (LS),,HP:0100712,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1099,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Abnormality in bone mineral density,,HP:0004348,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1100,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Anaemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1101,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1102,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1103,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Growth faliure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1104,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Avascular osteonecrosis,,HP:0010885,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1105,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Bone pain,,HP:0002653,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17,,,,,
1106,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,The drug was used in a pilot study.,Ambroxol,DB06742,ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Anemia,,HP:0001903,https://clinicaltrials.gov/ct2/show/NCT01463215?cond=Gaucher+disease&draw=2&rank=17,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT03950050,,,,,,,,
1107,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Ambroxol,DB06742,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT03950050,,,,,,,,
1108,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Ambroxol,DB06742,,,,,,,,,,Thrombocytpenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT03950050,,,,,,,,
1109,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Ambroxol,DB06742,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT03950050,,,,,,,,
1110,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Miglustat (NB-DNJ)(OGT 918),DB00419,ECO:0007121/ECO:0000179/ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Splenomegly,,HP:0001744,,,https://www.ncbi.nlm.nih.gov/pubmed/11227045,https://www.ncbi.nlm.nih.gov/pubmed/12064906,,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,,,,
1111,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Miglustat (NB-DNJ)(OGT 918),DB00419,,,,,,,,,,Hepatomegly,,HP:0002240,,,https://www.ncbi.nlm.nih.gov/pubmed/16199246,https://www.ncbi.nlm.nih.gov/pubmed/16285070,,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,,,,
1112,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Miglustat (NB-DNJ)(OGT 918),DB00419,,,,,,,,,,High chitotriosidase level,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/16199246,https://www.ncbi.nlm.nih.gov/pubmed/16285070,,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,,,,
1113,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,PEG-Glucocerebrosidase(Lysodase),NA,ECO:0007121,,,,,Direct interaction (ERT),A,direct complementation of a genetically defective protein,,Fatigue,,HP:0012378,https://clinicaltrials.gov/ct2/show/NCT00001410?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,,,,,
1114,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,PEG-Glucocerebrosidase(Lysodase),NA,,,,,,,,,,Asthenia,,HP:0025406,https://clinicaltrials.gov/ct2/show/NCT00001410?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,,,,,
1115,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,PEG-Glucocerebrosidase(Lysodase),NA,,,,,,,,,,Pancytopenia,,HP:0001876,https://clinicaltrials.gov/ct2/show/NCT00001410?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,,,,,
1116,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,PEG-Glucocerebrosidase(Lysodase),NA,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,https://clinicaltrials.gov/ct2/show/NCT00001410?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,,,,,
1117,109,# 230900,Gaucher disease type 2,"By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.",GBA,beta-glucocerebrosidase,3.2.1.45,,"The treatment was done via convection-enhanced delivery, however, no results were added to the result section.",Glucocerebrosidase,DB06667,ECO:0007121/ ECO:0000352,,,,,Direct interaction (ERT),A,direct complementation of a genetically defective protein,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/17065591,https://clinicaltrials.gov/ct2/show/NCT00244582?cond=Gaucher+disease+type+II&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24441827,,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,
1118,,# 230900,Gaucher disease type 2,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Glucocerebrosidase,DB06667,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/17065591,https://clinicaltrials.gov/ct2/show/NCT00244582?cond=Gaucher+disease+type+II&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24441827,,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,
1119,110,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Miglustat (Substrate reduction therapy)+imiglucerase,DB00419+DB00053,ECO:0007121,,,,,Functional interaction+Direct interaction,B+A,combination therapeutic procedure+functional complementation of a genetically defective protein+direct complementation of a genetically defective protein,,Neuropathy,,HP:0009830,https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,,,,,,,,,
1120,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Miglustat (Substrate reduction therapy)+imiglucerase,DB00419+DB00053,,,,,,,,,,Generalized tonic-clonic seizures,,HP:0002069,https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,,,,,,,,,
1121,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Miglustat (Substrate reduction therapy)+imiglucerase,DB00419+DB00053,,,,,,,,,,Speech impairment,,HP:0002167,https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,,,,,,,,,
1122,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat(Substrate reduction therapy),DB09039,ECO:0007121,CYP2D6,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal glucocerebroside level,,HP:0003656,https://www.ncbi.nlm.nih.gov/pubmed/29680197,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/29326879,,,,,
1123,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat(Substrate reduction therapy),DB09039,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/28935503,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/29326879,,,,,
1124,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat(Substrate reduction therapy),DB09039,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28935503,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/29326879,,,,,
1125,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Eliglustat(Substrate reduction therapy),DB09039,,,,,,,,,,Low mean hemoglobin concentration,,HP:0025547,https://www.ncbi.nlm.nih.gov/pubmed/28935503,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/29326879,,,,,
1126,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Decreased hemoglobin,,HP:0001903,https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,,,,,,,,,
1127,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,,,,,,,,,
1128,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,High spleen volume,,HP:0001744,https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,,,,,,,,,
1129,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,Velaglucerase alfa,DB06720,,,,,,,,,,High liver volume,,HP:0002240,https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,,,,,,,,,
1130,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,PEG-Glucocerebrosidase(Lysodase),NA,ECO:0007121,,,,,Direct interaction (ERT),A,direct complementation of a genetically defective protein,,Glucocerebroside accumulation in blood stream (Abnormal circulating lipid concentration)*,,HP:0003119,https://clinicaltrials.gov/ct2/show/NCT00001410?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=9,,,,,,,,,,
1131,107,# 608013,Gaucher disease perinatal lethal,,GBA,beta-glucocerebrosidase,3.2.1.45,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1132,111,# 219500,Gamma-cystathionase deficiency,Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897,CTH,cystathionine gamma-lyase,4.4.1.1,,,Pyridoxine,DB00165,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Cystathioninuria,,HP:0003153,http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,,,,,,,
1133,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,Pyridoxine,DB00165,,,,,,,,,,Tremor,,HP:0001337,http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,,,,,,,
1134,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,Pyridoxine,DB00165,,,,,,,,,,Impaired fine motor skillls,,HP:0007010,http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,,,,,,,
1135,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,Pyridoxine,DB00165,,,,,,,,,,EEG abnormality,,HP:0002353,http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,,,,,,,
1136,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,Pyridoxine,DB00165,,,,,,,,,,High total homocysteine level,,HP:0010919,http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,,,,,,,
1137,112,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Flumazenil,DB01205,ECO:0007121/ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Unalertness,,HP:0002329,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1138,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Flumazenil,DB01205,,,,,,,,,,EEG abnormality,,HP:0002353,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1139,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Flumazenil,DB01205,,,,,,,,,,Functional motor deficit,,HP:0004302,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1140,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Flumazenil,DB01205,,,,,,,,,,Excessive adventitious movements,,HP:0100022*,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1141,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Flumazenil,DB01205,,,,,,,,,,Hypersomnolence,,HP:0100786,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1142,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Flumazenil,DB01205,,,,,,,,,,Oculomotor apraxia,,HP:0000657,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1143,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Flumazenil,DB01205,,,,,,,,,,Developmental delay,,HP:0012758,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1144,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",Phenobarbital/clonazepam/valproate/ midazolam,DB01174/DB01068/DB00313/DB00683,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
1145,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Rapamycin,DB00877,ECO:0007764/ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Elevated CSF GHB levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/24578415/,,,,,,,,,
1146,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,Rapamycin,DB00877,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/24578415/,,,,,,,,,
1147,113,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,rAAV-PPCR,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Edematous,,HP:0000969,,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,,,,,,,
1148,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,rAAV-PPCR,NA,,,,,,,,,,Infertility,,HP:0000789,,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,,,,,,,
1149,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,rAAV-PPCR,NA,,,,,,,,,,Incoordination,,HP:0002311,,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,,,,,,,
1150,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,rAAV-PPCR,NA,,,,,,,,,,Gait abnormality,,HP:0001288,,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,,,,,,,
1151,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,rAAV-PPCR,NA,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,,,,,,,
1152,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,N-octyl-4-epi-β-valienamine (NOEV),NA,ECO:0001565,SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Low β-gal activity (Abnormal enzyme/coenzyme activity )*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/21520340,https://www.ncbi.nlm.nih.gov/pubmed/20826101,https://www.ncbi.nlm.nih.gov/pubmed/26259553,,,,,,,,
1153,114,# 230200,Galactokinase deficiency,,GALK1,galactokinase 1,2.7.1.6,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1154,115,# 606812,Fumarase deficiency,"The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812",FH,"Fumarate hydratase, mitochondrial",4.2.1.2,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1155,116,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,Antisense oligonucleotide (VMO AED cocktail),NA,ECO:0000179/ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Abnormal fukutin mRNA expression,,HP:0030098,https://www.nature.com/articles/nature10456,https://www.ncbi.nlm.nih.gov/pubmed/27421908,,,,,,,,,
1156,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,Antisense oligonucleotide (VMO AED cocktail),NA,,,,,,,,,,Pathogenic exon trapping,,NA,https://www.nature.com/articles/nature10456,https://www.ncbi.nlm.nih.gov/pubmed/27421908,,,,,,,,,
1157,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,AAV9-MCK-fukutin,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Imapired muscle function,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,,,,,
1158,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,Corticosteroid,DB00288,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21726969,,,,,,,,,,
1159,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,Corticosteroid,DB00288,,,,,,,,,,Muscle necrosis,,HP:0003713,https://www.ncbi.nlm.nih.gov/pubmed/21726969,,,,,,,,,,
1160,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,Corticosteroid,DB00288,,,,,,,,,,Muscle inflammation,,HP:0100614,https://www.ncbi.nlm.nih.gov/pubmed/21726969,,,,,,,,,,
1161,117,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,High level of fucosyl-oligosaccharide accumulation (Increased urinary fucosylated oligosaccharide)*,,HP:0410350,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1162,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Neuronal vacuolation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1163,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Pyramidal neuron loss,,HP:0002062*,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1164,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Astrocytosis,,MP:0003354,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1165,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Microgliosis,,HP:0100708,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1166,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Purkinje cells apoptosis,,MP:0000880,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1167,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Oligodendrocyte loss,,HP:0100709,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1168,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Hypomyelination,,MP:0013438,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1169,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Lysosomal expansion in neurons of deep cortex,,HP:0004356*,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1170,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Astrocytosis in cerebral cortex,,HP:0002446,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1171,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression (Abnormality of lysosomal metabolism )*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1172,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Recombinant canine α-l-fucosidase enzyme,NA,,,,,,,,,,Abnormal neurololgical function,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1173,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,Tocilizumab,DB06273,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943/,,,,,,,,,,
1174,118,# 229700,"Fructose-1,6-bisphosphatase deficiency","The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9",FBP1,"Fructose-1,6-bisphosphatase 1",3.1.3.11,,"Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains <7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193",Glucose,DB01914,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/29203193,,https://www.ncbi.nlm.nih.gov/pubmed/29390242,,,,,,,,
1175,119,# 136120,Fish-eye disease,"Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146",LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Statin,DB00175,ECO:0000352,,,,,Functional interaction,B,functional complementation of a defective protein,,Decreased cholesterol absorption,,MP:0002647,https://www.ncbi.nlm.nih.gov/pubmed/24636183,,,,,,,,,,
1176,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,The drug was accomapined with fat-restricted diet,Angiotensin II receptor blockers (ARBs),C09C,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal lipoprotein profile,,HP:0010979,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1177,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Angiotensin II receptor blockers (ARBs),C09C,,,,,,,,,,Abnormal renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1178,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Angiotensin II receptor blockers (ARBs),C09C,,,,,,,,,,Proteinuria,,HP:0000093,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1179,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Angiotensin II receptor blockers (ARBs),C09C,,,,,,,,,,Low serum HDL-cholesterol,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1180,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,r LCAT,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Abnormal lipoprotein profile,,HP:0010979,https://www.ncbi.nlm.nih.gov/pubmed/20605907,,,,,,,,,,
1181,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,r LCAT,NA,,,,,,,,,,Low HDL-C  level,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/20605907,,,,,,,,,,
1182,120,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,,,Baclofen/Tizanidine/Trihexyphenidyl/Benzodiazepine/Dantrolene,DB00182/DB00697/DB00376/DB12537/DB01219,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1183,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,,,Baclofen/Tizanidine/Trihexyphenidyl/Benzodiazepine/Dantrolene,DB00182/DB00697/DB00376/DB12537/DB01219,,,,,,,,,,Spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1184,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,,,Botulinum toxin,DB00083,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal muscular co-contraction,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1185,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,,,Nimodipine,DB00393,ECO:0000305/ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Abnormality of circulating enzyme level,,HP:0011021,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/,,,,,,,,,,
1186,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,,Iron Chelation is one of the therapies under investigation.,Deferiprone,DB08826,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1187,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,,,Deferiprone,DB08826,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1188,121,# 616896,Fatal infantile encephalomyopathy,,OPA1,mitochondrial dynamin like GTPase,2.3.1.43,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1189,122,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,ECO:0000179/ECO:0001565,,,,,Direct interaction (ERT),A,direct complementation of a genetically defective protein,,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1190,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,High cermaide level,,MP:0020582,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1191,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,High intracellular cermaid level,,MP:0020582*,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1192,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,Abnormal spleen size,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1193,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,Abnormal sphingosine level (Abnormality of lipid metabolism)*,,MP:0009587,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1194,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,high plasma MCP-1,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1195,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,High macrophage infiltration into tissues (Abnormal inflammatory response)*,,HP:0012647*,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1196,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,Abnormal tissue lipid profiles (Abnormality of lipid metabolism)*,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1197,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,Joint inflammation,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1198,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,"The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.",Amitriptyline,DB00321,ECO:0000305/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Abnormal pulmonary ceramide level(Abnormal circulating lipid concentration )*,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/18376404,,,,,,,,,,
1199,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,Amitriptyline,DB00321,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18376404,,,,,,,,,,
1200,123,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Uncooked Cornstarch,DB11599,ECO:0000352,,,,,Functional interaction,B,Dietary supplementation,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/24912437,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,,,,,,,,,
1201,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,,,Uncooked Cornstarch,DB11599,,,,,,,,,,Fasting hypoglycemia,,HP:0003162,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Late+Diagnosis+of+Fanconi-Bickel+Syndrome%3A+Challenges+With+the+Diagnosis+and+Literature+Review&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,,,,,,,,,
1202,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,,,Vitamin D,DB11094,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/24912437,,,,,,,,,,
1203,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,,,Phosphorus,DB14151,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Rickets,,HP:0002748,https://www.ncbi.nlm.nih.gov/pubmed/24912437,,,,,,,,,,
1204,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,,,Bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Renal tubular acidosis,,HP:0001947,https://www.ncbi.nlm.nih.gov/pubmed/24912437,,,,,,,,,,
1205,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,,,Insulin,DB00030,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Diabetes mellitus,,HP:0000819,http://www.ncbi.nlm.nih.gov/pubmed/29116606?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/23456528,,,,,,,,,
1206,124,151660,Familial partial lipodystrophy type 2,Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/,LMNA,lamins ( Lamins A and C),P02545,,,ISIS 703802 (AKCEA-ANGPTL3-LRx),PubChem SID: 384573165,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High fasting triglycerides,,HP:0002155*,https://clinicaltrials.gov/ct2/show/NCT03514420?cond=Familial+partial+lipodystrophy+type+2&rank=1,,,,,,,,,,
1207,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Metreleptin (A-100),DB09046,ECO:0007121/ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal free fatty acid levels,,HP:0040300,https://clinicaltrials.gov/ct2/show/NCT00025883?cond=Familial+partial+lipodystrophy+type+2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25734254,,,,,,,,,
1208,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Metreleptin (A-100),DB09046,,,,,,,,,,High facial soft tissue volume,,HP:0000287,https://www.ncbi.nlm.nih.gov/pubmed/28993984,https://www.ncbi.nlm.nih.gov/pubmed/25734254,,,,,,,,,
1209,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Metreleptin (A-100),DB09046,,,,,,,,,,Abnormal fasting glucose,,MP:0013277,https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,,,,,,,,,
1210,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Metreleptin (A-100),DB09046,,,,,,,,,,High  HbA1c levels,,HP:0040217,https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,,,,,,,,,
1211,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Albiglutide (glucagon-like peptide-1 receptor agonist),DB09043,,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal fasting glucose,,MP:0013277,,,,,,,,,,,
1212,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Albiglutide (glucagon-like peptide-1 receptor agonist),DB09043,,,,,,,,,,High HbA1c levels,,HP:0040217,,,,,,,,,,,
1213,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Volanesorsen (IONIS-APOCIIIRx),NA,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal fasting triglycerides,,HP:0002155*,https://clinicaltrials.gov/ct2/show/NCT02300233,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,,,,,,,,
1214,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Obeticholic Acid,DB05990,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hepatic steatosis,,HP:0001397,https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3,,,,,,,,,,
1215,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Obeticholic Acid,DB05990,,,,,,,,,,High liver triglyceride level (hyperlipidemia)*,,HP:0003077*,https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3,,,,,,,,,,
1216,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Gemcabene,DB05123,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypertriglyceridemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6,,,,,,,,,,
1217,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Gemcabene,DB05123,,,,,,,,,,Hepatic steatosis,,HP:0001397,https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6,,,,,,,,,,
1218,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,Fibrates + Omega-3 fatty acids (OMG-3),DB00636 +DB11133,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/27710244,,,,,,,,,,
1219,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,Fibrates + Omega-3 fatty acids (OMG-3),DB00636 +DB11133,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27710244,,,,,,,,,,
1220,125,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Anemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1221,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Abnormal lecithin:cholesterol acyltransferase activity,,MP:0011598,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1222,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Abnormal plasma lipids levels,,HP:0003119,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1223,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Low HDL level,,HP:0003233,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1224,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Low HDL-C level,,HP:0003233,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1225,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Abnormal cholesterol efflux from cells,,MP:0003193,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1226,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Dyslipidemia,,MP:0003949,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1227,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Low APO A level,,HP:0025201*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1228,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Low Apo B protein level,,HP:0025201*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1229,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Recombinant human LCAT (ACP-501),NA,,,,,,,,,,Proteinuria,,HP:0000093,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1230,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Captopril,DB01197,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/23391322,,,,,,,,,,
1231,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,Thiazide,DB01324,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Oedema,,HP:0000969,,,,,,,,,,,
1232,126,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,,Probenecid,DB01032,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/20301530,https://www.ncbi.nlm.nih.gov/pubmed/8842764,,,,,,,,,
1233,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,,Probenecid+Allopurinol,DB01032+DB00437,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/8842764,,,,,,,,,,
1234,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Allopurinol,DB00437,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/12205338,https://www.ncbi.nlm.nih.gov/pubmed/11068651,,,,,,,,,
1235,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,,Allopurinol,DB00437,,,,,,,,,,Mortality,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/12205338,https://www.ncbi.nlm.nih.gov/pubmed/11068651,,,,,,,,,
1236,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,,Allopurinol,DB00437,,,,,,,,,,Disease progression (Progressive)*,,HP:0003676,https://clinicaltrials.gov/ct2/show/NCT03098797,https://www.ncbi.nlm.nih.gov/pubmed/11068651,,,,,,,,,
1237,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,,Allopurinol+Benzbromarone,DB00437+DB12319,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/9678437,,,,,,,,,,
1238,127,# 145980,Familial hypocalciuric hypercalcemia type 1,"In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511",CASR,calcium-sensing receptor,P41180,,,Cinacalcet,DB01012,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Hypercalcemia,,HP:0003072,https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/16882283/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,,,,,
1239,,# 145980,Familial hypocalciuric hypercalcemia type 1,,CASR,calcium-sensing receptor,P41180,,,Cinacalcet,DB01012,,,,,,,,,,Elevated circulating parathyroid hormone level,,HP:0003165,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,,,,,
1240,,# 145980,Familial hypocalciuric hypercalcemia type 1,,CASR,calcium-sensing receptor,P41180,,,Cinacalcet,DB01012,,,,,,,,,,Impaired renal uric acid clearance,,HP:0004732,https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,,,,,
1241,,# 145980,Familial hypocalciuric hypercalcemia type 1,,CASR,calcium-sensing receptor,P41180,,,Cinacalcet,DB01012,,,,,,,,,,Polydipsia,,HP:0001959,https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,,,,,
1242,128,# 145981,Familial hypocalciuric hypercalcemia type 2,,GNA11,guanine nucleotide-binding protein (Gα11),P21278,,,Cinacalcet,DB01012,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High serum ionized calcium concentrations,,HP:0003072*,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,,https://www.ncbi.nlm.nih.gov/pubmed/28833550,,,,,,,,
1243,,# 145981,Familial hypocalciuric hypercalcemia type 2,,GNA11,guanine nucleotide-binding protein (Gα11),P21278,,,Cinacalcet,DB01012,,,,,,,,,,Abnormal parathyroid hormone level,,HP:0003165,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,,https://www.ncbi.nlm.nih.gov/pubmed/28833550,,,,,,,,
1244,129,# 600740,Familial hypocalciuric hypercalcemia type 3,,AP2S1,adaptor protein-2 σ-subunit,P53680,,,Cinacalcet,DB01012,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High serum ionized calcium concentrations,,HP:0003072*,https://www.ncbi.nlm.nih.gov/pubmed/27050234/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,,,,,,,,
1245,,# 600740,Familial hypocalciuric hypercalcemia type 3,,AP2S1,adaptor protein-2 σ-subunit,P53680,,,Cinacalcet,DB01012,,,,,,,,,,Abnormal parathyroid hormone level,,HP:0003165,https://www.ncbi.nlm.nih.gov/pubmed/27050234/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,,,,,,,,
1246,,# 600740,Familial hypocalciuric hypercalcemia type 3,,AP2S1,adaptor protein-2 σ-subunit,P53680,,,Cinacalcet,DB01012,,,,,,,,,,Low calcium urine excretion,,HP:0003127,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,,,,,,,,
1247,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Gemfibrozil+Dietary fat restriction,DB01241+NA,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+dietary exclusion,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/15251700/,,,,,,,,,,
1248,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Gemfibrozil+Dietary fat restriction,DB01241+NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15251700/,,,,,,,,,,
1249,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Fenofibrate +niacin+omega‐3 fatty acids,DB01039+DB00627 +DB11133,ECO:0000352,,,,,Direct interaction+Functional interaction+Functional interaction,A+B+B,combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/24524914,,,,,,,,,,
1250,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Omega 3 FA,DB11133,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/10925336?dopt=Abstract,,,,,,,,,,
1251,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Omega-3-acid ethyl esters,DB09539,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/16390715?dopt=Abstract,,,,,,,,,,
1252,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Insulin,DB01306,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,,,,,,,,,
1253,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Heparin,DB01109,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/1800965,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,,,,,,,
1254,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Heparin,DB01109,,,,,,,,,,Acute pancreatitis,,HP:0001735,https://www.ncbi.nlm.nih.gov/pubmed/1800965,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,,,,,,,
1255,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Chenodeoxycholic acid,DB06777,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Hypertriglyceridemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00465751?cond=Familial+hypertriglyceridemia&draw=3&rank=2,,,,,,,,,,
1256,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Rosuvastatin,DB01098,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/23323877,,,,,,,,,,
1257,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Rosuvastatin,DB01098,,,,,,,,,,High LDL level,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/23323877,,,,,,,,,,
1258,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,Rosuvastatin,DB01098,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23323877,,,,,,,,,,
1259,130,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,Niacin,DB00627,ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Hypoalphalipoproteinemia,,HP:0003233,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622/,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,,,,,,,,,
1260,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,Niacin,DB00627,,,,,,,,,,Low HDL cholesterol concentration,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,,,,,,,,,
1261,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,Gemfibrozil,DB01241,ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low HDL cholesterol concentration,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/9493705,,,,,,,,,,
1262,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,Pravastatin,DB00175,ECO:0007121,R219K,,,,Direct interaction,A,activity modification of a genetically defective protein,,Increased low-density lipoprotein cholesterol concentration,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/24854628/,,,,,,,,,,
1263,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",Atorvastatin/ Fenofibrate/ Niacin,DB01076/DB01039/DB00627,ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Hypoalphalipoproteinemia,,HP:0003233,https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/18993152,,,,,,,,,
1264,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,Atorvastatin/ Fenofibrate/ Niacin,DB01076/DB01039/DB00627,,,,,,,A,,,Low HDL cholesterol concentration,Niacin was the only effective drug to increase HDL cholesterol.,HP:0003233,https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/18993152,,,,,,,,,
1265,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,"CER 001, a recombinant high-density lipoprotein (HDL)",NA,ECO:0007121/ECO:0000179/ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Decreased apolipoprotein AI level,,HP:0031799,https://www.ncbi.nlm.nih.gov/pubmed/25561459/,,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,,,,,,,
1266,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,"CER 001, a recombinant high-density lipoprotein (HDL)",NA,,,,,,,,,,Vasculitis,,HP:0002633,https://www.ncbi.nlm.nih.gov/pubmed/25561459/,,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,,,,,,,
1267,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,"CER 001, a recombinant high-density lipoprotein (HDL)",NA,,,,,,,,,,Decreased plasma HDL-c levels,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/25561459/,,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,,,,,,,
1268,,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,"CER 001, a recombinant high-density lipoprotein (HDL)",NA,,,,,,,,,,Arterial pluque,,HP:0002621,https://www.ncbi.nlm.nih.gov/pubmed/25561459/,,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,,,,,,,
1269,131,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,Fabrazyme ( agalsidase beta) + pegunigalsidase alfa ( PRX-102),DB00103+DB14992,ECO:0007121,,,,,Direct interaction+Direct interaction,A+A,combination therapeutic procedure+direct complementation of a genetically defective protein+direct complementation of a genetically defective protein,,Abnormal kidney function,,HP:0012211,,https://clinicaltrials.gov/ct2/show/study/NCT02795676?term=PRX-102&cond=Fabry+Disease&show_locs=Y#locn,https://www.ncbi.nlm.nih.gov/pubmed/25885911,,,,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8,,,,
1270,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,REPLAGAL (Agalsidase Alfa),DB00103,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Cardiomegaly,,HP:0001640,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/25885911,,,,,,,,,
1271,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,REPLAGAL (Agalsidase Alfa),DB00103,,,,,,,,,,Low renal glomerular filtration rate,,HP:0012213,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/25885911,,,,,,,,,
1272,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,REPLAGAL (Agalsidase Alfa),DB00103,,,,,,,,,,Pain,,HP:0012531,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/25885911,,,,,,,,,
1273,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,"Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy",Pegunigalsidase alfa ( PRX-102),DB14992,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Abnormal kidney function,,HP:0012211,https://clinicaltrials.gov/ct2/show/NCT03180840?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01678898?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01769001?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01981720?term=PRX-102&cond=Fabry+Disease,,,,,,,
1274,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,Lucerastat,DB14872,ECO:0007121/ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,High Gb3 (globotriaosylceramide) accumulation.,,NA,https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2,https://clinicaltrials.gov/ct2/show/NCT03425539,https://clinicaltrials.gov/ct2/show/NCT03737214,https://www.ncbi.nlm.nih.gov/pubmed/28088251,https://www.ncbi.nlm.nih.gov/pubmed/29982630,,,,,,
1275,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/",Migalastat hydrochloride (AT1001),DB05018,ECO:0007121/ECO:0001565,"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W",,"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S",,Direct interaction,A,activity modification of a genetically defective protein,,High plasma lyso-globotriaosylsphingosine level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30875019,https://www.ncbi.nlm.nih.gov/pubmed/30765910,https://www.ncbi.nlm.nih.gov/pubmed/27509102/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,,,,,
1276,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,Migalastat hydrochloride (AT1001),DB05018,,,,,,,,,,High mean number of GL-3 inclusions/kidney interstitial capillary(KIC),,NA,https://www.ncbi.nlm.nih.gov/pubmed/30875019,https://www.ncbi.nlm.nih.gov/pubmed/30765910,https://www.ncbi.nlm.nih.gov/pubmed/27509102/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,,,,,
1277,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,Migalastat hydrochloride (AT1001),DB05018,,,,,,,,,,Left ventricular hypertrophy,,HP:0001712,https://www.ncbi.nlm.nih.gov/pubmed/27834756/,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://www.ncbi.nlm.nih.gov/pubmed/27509102/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,,,,,
1278,132,# 612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,Succinyl-CoA synthetase ( beta subunit),7.6.2.1,,,Carbamazepine,DB00564,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/books/NBK6803/,,,,,,,,
1279,,# 612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,Succinyl-CoA synthetase ( beta subunit),7.6.2.1,,,Riboflavin+thiamine,DB00140+DB00152,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/19666145,,,,,,,,,,
1280,,# 612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,Succinyl-CoA synthetase ( beta subunit),7.6.2.1,,"The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.",L-DOPA,DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal facial expression,,HP:0005346,https://www.ncbi.nlm.nih.gov/pubmed/19666145,,,,,,,,,,
1281,,# 612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,Succinyl-CoA synthetase ( beta subunit),7.6.2.1,,,L-DOPA,DB01235,,,,,,,,,,Functional motor deficit,,HP:0004302,https://www.ncbi.nlm.nih.gov/pubmed/19666145,,,,,,,,,,
1282,,# 612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,Succinyl-CoA synthetase ( beta subunit),7.6.2.1,,,L-DOPA,DB01235,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19666145,,,,,,,,,,
1283,133,# 249900,Encephalopathy due to prosaposin deficiency,,PSAP,prosaposin,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1284,134,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Vitamin D,DB11094,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Concommitant low vit D level(Low levels of vitamin D)*,,HP:0100512*,,,https://www.ncbi.nlm.nih.gov/pubmed/24137761,,,,,,,,
1285,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Afamelanotide (Scenesse),DB04931,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Erythema,,HP:0010783,https://www.ncbi.nlm.nih.gov/pubmed/28003770,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/,,,,,
1286,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Afamelanotide (Scenesse),DB04931,,,,,,,,,,Cutaneous photosensitivity,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/28003770,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/,,,,,
1287,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Corticosteroids,DB00288,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Pain,,HP:0012531,https://www.ncbi.nlm.nih.gov/pubmed/27139922,https://www.ncbi.nlm.nih.gov/pubmed/19744342,,,,,,,,,
1288,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Corticosteroids,DB00288,,,,,,,,,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/27139922,https://www.ncbi.nlm.nih.gov/pubmed/19744342,,,,,,,,,
1289,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Zinc,DB01593,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Increased ROS formation,,HP:0025464,http://www.ncbi.nlm.nih.gov/pubmed/22092997?dopt=Abstract,,,https://www.ncbi.nlm.nih.gov/pubmed/22092997,,,,,,,
1290,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,"Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/",β-carotene,DB06755,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,No significant difference was found in the controlled trial. https://www.ncbi.nlm.nih.gov/pubmed/341955/,intolerance to sunlight,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/341955/,https://www.ncbi.nlm.nih.gov/pubmed/22791288,,,,,,,,,
1291,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,β-carotene,DB06755,,,,,,,,,,Pain in the skin,,HP:0025280*,https://www.ncbi.nlm.nih.gov/pubmed/341955/,https://www.ncbi.nlm.nih.gov/pubmed/22791288,,,,,,,,,
1292,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Cholestyramine,DB01432,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal  protoporphyrin enterhepatic circulation,,HP:0012187,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,,,,,,,,,
1293,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,Activated charcoal,DB09278,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal liver function test,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,,,,,,,,,
1294,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Activated charcoal,DB09278,,,,,,,,,,Abdominal pain,,HP:0002027,https://www.ncbi.nlm.nih.gov/pubmed/20375647,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,,,,,,,,,
1295,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Activated charcoal,DB09278,,,,,,,,,,Photosenstivity,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/20375647,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,,,,,,,,
1296,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Activated charcoal,DB09278,,,,,,,,,,Pruritis,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,,,,,,,,
1297,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Activated charcoal,DB09278,,,,,,,,,,Hepatotoxicity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,,,,,,,,
1298,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Activated charcoal,DB09278,,,,,,,,,,Fluid retention,,HP:0000969,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,,,,,,,,
1299,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Hemin,DB03404,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Hepatic prophyria (Abnormality of the heme biosynthetic pathway)*,,HP:0010472*,https://www.ncbi.nlm.nih.gov/pubmed/23016163,,,,,,,,,,
1300,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Cysteine hydrochloride,DB00151,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,photosensitivity,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/12535027,https://clinicaltrials.gov/ct2/show/NCT00004940,https://clinicaltrials.gov/ct2/show/NCT00004831,,,,,,,,
1301,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,"The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal، model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332
Study was Terminated (Interim analysis demonstrated the treatment was not effective)",Isoniazid,DB00951,ECO:0000179/ECO:0007121,,,,,Symptomatic,C,functional complementation of a genetically defective protein by inhibition,Terminated,,,,https://www.ncbi.nlm.nih.gov/pubmed/31395332,,https://clinicaltrials.gov/ct2/show/NCT01550705,,,,,,,,
1302,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,Iron,DB01592,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High erythrocyte protoporphyrin levels,,HP:0012187,,,https://clinicaltrials.gov/ct2/show/NCT02979249?cond=Erythropoietic+protoporphyria&draw=1&rank=10,,,,,,,,
1303,135,# 177000,Erythropoietic uroporphyria associated with myeloid malignancy,,FECH,ferrochelatase,7.6.2.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,,,,,,,,
1304,136,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Acetylcysteine,DB06151,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein/functional complementation of a genetically defective protein by inhibition,,High Lactic acid,,HP:0003648,https://www.ncbi.nlm.nih.gov/pubmed/16376514,https://www.ncbi.nlm.nih.gov/pubmed/27830356,,https://www.ncbi.nlm.nih.gov/pubmed/29526615,,,,,,,
1305,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,Drug used as an aternate therapy with (Metronidazole+Acetylcysteine),Neomycin+Acetylcysteine,DB00994+DB06151,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition,,Abnormal thiosulfates level,,HP:0011943,https://www.ncbi.nlm.nih.gov/pubmed/29526615,,,,,,,,,,
1306,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,(Metronidazole+Acetylcysteine)+Dietary restricting sulfur containing amino acids treatment,(DB00916+DB06151)+NA,ECO:0000352,,,,,(Functional interaction+Functional interaction)+Functional interaction,(B+B)+B,combination therapeutic procedure+(functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition)+dietary exclusion,,Hypotonia,,MP:0004144,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,,,,,,,,,
1307,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,(Metronidazole+Acetylcysteine)+Dietary restricting sulfur containing amino acids treatment,(DB00916+DB06151)+NA,,,,,,,,,,Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,,,,,,,,,
1308,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,(Metronidazole+Acetylcysteine)+Dietary restricting sulfur containing amino acids treatment,(DB00916+DB06151)+NA,,,,,,,,,,High EMA levels,,HP:0003219,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,,,,,,,,,
1309,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Ascorbic acid,DB00126,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Decreased activity of cytochrome C oxidase in muscle tissue,,HP:0003688,https://www.ncbi.nlm.nih.gov/pubmed/29526615,,,,,,,,,,
1310,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,A drug regimen that was used as a postoperative therapy after liver transplataion surgery to maintain the achieved metabolic results.,Carnitine+metronidazole,DB00583+DB00916,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Disease progression (Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/26917598,,,,,,,,,,
1311,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Riboflavin and/orCoenzyme Q10,DB00140+DB09270,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Functional motor deficit,,HP:0004302,https://www.ncbi.nlm.nih.gov/pubmed/11916321,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1312,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Riboflavin and/orCoenzyme Q10,DB00140+DB09270,,,,,,,,,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1313,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Riboflavin and/orCoenzyme Q10,DB00140+DB09270,,,,,,,,,,Elevated plasma acylcarnitine levels,,HP:0045045,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1314,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Riboflavin and/orCoenzyme Q10,DB00140+DB09270,,,,,,,,,,Chronic mucoid diarrhea,,HP:0002028,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1315,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Riboflavin and/orCoenzyme Q10,DB00140+DB09270,,,,,,,,,,Petechiae,,HP:0000967,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1316,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,Riboflavin and/orCoenzyme Q10,DB00140+DB09270,,,,,,,,,,Psychomotor retardation,,HP:0025356,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1317,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,"It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.",Dehydroascorbic acid,DB08830,ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Sulfide toxicity,,NA,https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230,,,,,,,,,,
1318,137,# 237500,Dubin-Johnson syndrome,DJS is a benign disease that does not require treatment.https://www.ncbi.nlm.nih.gov/pubmed/20955959 https://www.ncbi.nlm.nih.gov/pubmed/28923092,ABCC2,Multidrug resistance protein-2,7.6.2.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1319,138,# 608799,DPM1-CDG (CDG-Ie),,DPM1,dolichol-P-mannose synthase 1,7.6.2.1,,https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1320,139,# 615042,DPM2-CDG,,DPM2,dolichyl-phosphate mannosyltransferase subunit 2,7.6.2.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1321,140,# 612937,DPM3-CDG (CDG-Io),,DPM3,dolichyl-phosphate mannosyltransferase subunit 3,7.6.2.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1322,141,# 179850,Dowling-Degos disease,,KRT5/POGLUT1,keratin 5/protein O-glucosyltransferase,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1323,142,# 223360,Dopamine beta hydroxylase deficiency,,DBH,dopamine beta (β)-hydroxylase,7.6.2.1,,,Droxidopa,DB06262,ECO:0007121,,,,,Functional interaction,B,metabolite replacement,,Orthostatic hypotension,,HP:0001278,https://www.ncbi.nlm.nih.gov/pubmed/20301647,https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency,https://clinicaltrials.gov/ct2/show/NCT00889135?cond=Dopamine+beta+hydroxylase+deficiency&rank=10,,,,,,,,
1324,143,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,Levedopa/carbidopa,DB01235/DB00190,ECO:0007121,,,,,Functional interaction,B,metabolite replacement,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/9886460/,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887,,,
1325,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,Levedopa/carbidopa,DB01235/DB00190,,,,,,,,,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/9886460/,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887,,,
1326,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,Levedopa/carbidopa,DB01235/DB00190,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/9886460/,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887,,,
1327,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,Levedopa/carbidopa,DB01235/DB00190,,,,,,,,,,Cerebellar dysfunction,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16908750,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887,,,
1328,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,Serotonin reuptake inhibitors,N06AB,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Depression,,HP:0000716,https://www.ncbi.nlm.nih.gov/pubmed/16361586,,,,,,,,,,
1329,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,Serotonin reuptake inhibitors,N06AB,,,,,,,,,,Obsessive-compulsive behavior,,HP:0000722,https://www.ncbi.nlm.nih.gov/pubmed/16361586,,,,,,,,,,
1330,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,5‐hydroxytryptophan,DB02959,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Depression,,HP:0000716,https://www.ncbi.nlm.nih.gov/pubmed/16361586,,,,,,,,,,
1331,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,5‐hydroxytryptophan,DB02959,,,,,,,,,,Serotonin deficiency,,HP:0003117*,https://www.ncbi.nlm.nih.gov/pubmed/16361586,,,,,,,,,,
1332,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,Selegiline+L-dopa,DB01037+DB01235,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein+metabolite replacement,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,,,,,,,,
1333,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,Selegiline+L-dopa,DB01037+DB01235,,,,,,,,,,lack of eye contact,,HP:0000817,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,,,,,,,,
1334,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,Selegiline+L-dopa,DB01037+DB01235,,,,,,,,,,Delayed motor skills,,HP:0002194,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,,,,,,,,
1335,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,Selegiline+L-dopa,DB01037+DB01235,,,,,,,,,,Poor head control,,HP:0002421,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,,,,,,,,
1336,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,Selegiline+L-dopa,DB01037+DB01235,,,,,,,,,,Delayed mental development,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,,,,,,,,
1337,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,Selegiline+L-dopa,DB01037+DB01235,,,,,,,,,,lack of gross motor function,,HP:0002194,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,,,,,,,,
1338,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,DB01235,ECO:0000352,,,(926T>C,,Functional interaction,B,metabolite replacement,,Decreased CSF homovanillic acid,,HP:0003785,https://www.ncbi.nlm.nih.gov/pubmed/8817341,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,,,,,,,
1339,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,L- dopa,DB01235,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/22815559,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,,,,,,,
1340,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,L- dopa,DB01235,,,,,,,,,,Myoclonus jerk,,HP:0001336,https://www.ncbi.nlm.nih.gov/pubmed/22815559,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,,,,,,,
1341,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,L- dopa,DB01235,,,,,,,,,,Abnormal epinephrine/norepinephrin ratio,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,,,,,,,
1342,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,L- dopa,DB01235,,,,,,,,,,Hypokinesia,,HP:0002375,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,,,,,,,
1343,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,,L- dopa,DB01235,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,,,,,,,
1344,144,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D-galactose,DB11735,ECO:0007121/ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal alanine transaminase,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,,,,,,,,
1345,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D-galactose,DB11735,,,,,,,,,,Abnormal aspartate transaminase,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,,,,,,,,
1346,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D-galactose,DB11735,,,,,,,,,,Abnormal activated partial thromboplastin time,,HP:0003645,https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,,,,,,,,
1347,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D-galactose,DB11735,,,,,,,,,,Abnormal Antithrombin-III levels,,HP:0001976,https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,,,,,,,,
1348,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,D-galactose,DB11735,,,,,,,,,,Abnormal nucleotide sugars,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,,,,,,,,
1349,145,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,Fucose,DB03485,ECO:0001565/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Defected phagocytic function,,HP:0010977,https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,,,,,,,,
1350,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,Fucose,DB03485,,,,,,,,,,low neutrophil count,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,,,,,,,,
1351,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,Fucose,DB03485,,,,,,,,,,recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,,,,,,,,
1352,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,Fucose,DB03485,,,,,,,,,,abnormal expression of E- and P-selectin ligands,,NA,https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,,,,,,,,
1353,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,Fucose,DB03485,,,,,,,,,,Atypical psychomotor development,,HP:0001263*,https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,,,,,,,,
1354,146,# 610768,DOLK-CDG,,DOLK,dolichol kinase,2.7.1.108,,,Vigabatrin,DB01080,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/23890587,,,,,,,,,
1355,,# 610768,DOLK-CDG,,DOLK,dolichol kinase,2.7.1.108,,,Carbamazepine,DB00564,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Generalized tonic–clonic seizure,,HP:0002069,,,,,,,,,,,
1356,,# 610768,DOLK-CDG,,DOLK,dolichol kinase,2.7.1.108,,,Carbamazepine,DB00564,,,,,,,,,,Focal seizures,,HP:0007359,,,,,,,,,,,
1357,,# 610768,DOLK-CDG,,DOLK,dolichol kinase,2.7.1.108,,,Clonazepam+Vigabatrin,DB01068+DB01080,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
1358,147,# 610768,Dipsogenic diabetes insipidus,Behavioural therapy was a successful treatmemnt for primary polydipsia.https://www.ncbi.nlm.nih.gov/pubmed/2373769?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/12102585?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/3392224?dopt=Abstract,DOLK,dolichol kinase,2.7.1.108,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Desmopressin,DB00035,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Polyuria,,HP:0000103,https://www.ncbi.nlm.nih.gov/pubmed/16544179,,https://www.ncbi.nlm.nih.gov/pubmed/16544179,,,,,,,,
1359,,# 610768,Dipsogenic diabetes insipidus,,DOLK,dolichol kinase,2.7.1.108,,,Desmopressin,DB00035,,,,,,,,,,Affected functional activity (Constitutional symptom)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/16544179,,https://www.ncbi.nlm.nih.gov/pubmed/16544179,,,,,,,,
1360,148,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,1.3.1.2,,,Uridine triacetate,DB09144,ECO:0000179/ECO:0000305,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Mortality,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/29908244,https://www.ncbi.nlm.nih.gov/pubmed/27622829,,,,,,,,,
1361,,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,1.3.1.2,,,Uridine triacetate,DB09144,,,,,,,,,,Weight loss,,HP:0001824,https://www.ncbi.nlm.nih.gov/pubmed/29908244,https://www.ncbi.nlm.nih.gov/pubmed/27622829,,https://www.ncbi.nlm.nih.gov/pubmed/28275972,,,,,,,
1362,,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,1.3.1.2,,,Valproic acid,DB00313,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Generalized muscular hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/28275972,,,,,,,,,,
1363,,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,1.3.1.2,,,Valproic acid,DB00313,,,,,,,,,,EEG with parito-occipital spike waves,,HP:0012011,https://www.ncbi.nlm.nih.gov/pubmed/28275972,,,,,,,,,,
1364,,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,1.3.1.2,,,Valproic acid,DB00313,,,,,,,,,,Developmental impairment,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/28275972,,,,,,,,,,
1365,,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,1.3.1.2,,,Valproic acid,DB00313,,,,,,,,,,Speech and languague delay,,HP:0000750,https://www.ncbi.nlm.nih.gov/pubmed/28275972,,,,,,,,,,
1366,,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,1.3.1.2,,,Valproic acid+Carbamazepine,DB00313+DB00564,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/30349988,,,,,,,,,,
1367,149,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,L-dopa/carbidopa+BH4+5-hydroxytryptophan+ Folinic acid,DB01235/DB00190+DB00360+DB02959+DB00650,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High plasma phenylalanine level,,HP:0004923,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1368,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,L-dopa/carbidopa+BH4+5-hydroxytryptophan+ Folinic acid,DB01235/DB00190+DB00360+DB02959+DB00650,,,,,,,,,,Developmental delay,,HP:0001263,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1369,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,L-dopa/carbidopa+BH4+5-hydroxytryptophan+ Folinic acid,DB01235/DB00190+DB00360+DB02959+DB00650,,,,,,,,,,Unalertencess,,HP:0002329*,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1370,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,L-dopa/carbidopa+BH4+5-hydroxytryptophan+ Folinic acid,DB01235/DB00190+DB00360+DB02959+DB00650,,,,,,,,,,Receptive language delay,,HP:0010863,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1371,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phe-restricted diet +Folinic acid+L-dopa+5-hydroxytryptophan,NA+DB00650 +DB01235+DB02959,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+dietary exclusion+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High plasma phenylalanine level,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,,,,,,,,
1372,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phe-restricted diet +Folinic acid+L-dopa+5-hydroxytryptophan,NA+DB00650 +DB01235+DB02959,,,,,,,,,,High serum  prolactin,,HP:0040086,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,,,,,,,,
1373,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phe-restricted diet +Folinic acid+L-dopa+5-hydroxytryptophan,NA+DB00650 +DB01235+DB02959,,,,,,,,,,Neurological abnormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,,,,,,,,
1374,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phe-restricted diet +Folinic acid+L-dopa+5-hydroxytryptophan,NA+DB00650 +DB01235+DB02959,,,,,,,,,,Abnormal blood Phe levels,,HP:0010893,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,,,,,,,,
1375,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,L‐dopa+5-hydroxytryptophan+BH4+Entacapone,DB01235+DB02959+DB00360+DB00494,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Supportive,B+B+B+C,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+metabolite replacement+symptomatic therapeutic procedure,,high plasma phenylalanine level,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/25667865,,,,,,,,,,
1376,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Levetiracetam,DB01202,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/25667865,,,,,,,,,,
1377,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phenobarbital + Valproate,DB01174+DB00313,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Spastic tetraparesis,,HP:0001285,https://www.ncbi.nlm.nih.gov/pubmed/18060820,,,,,,,,,,
1378,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phenobarbital + Valproate,DB01174+DB00313,,,,,,,,,,Epilepsy,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/18060820,,,,,,,,,,
1379,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phenobarbital + Valproate,DB01174+DB00313,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18060820,,,,,,,,,,
1380,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Phenobarbital + Valproate,DB01174+DB00313,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18060820,,,,,,,,,,
1381,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,L‐dopa+carbidopa+5-hydroxytryptophan+selegiline,DB01235+DB00190+DB02959+DB01037,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Supportive,B+B+B+C,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/18425437,,,,,,,,,,
1382,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Pramipexole,DB00413,ECO:0000352,,,,,Supportive,C,symptomatic therapeutic procedure,,Dopamine deficiency,,HP:0012656,https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,
1383,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Pramipexole,DB00413,,,,,,,,,,Movement disability,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,
1384,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Pramipexole,DB00413,,,,,,,,,,Behavioral disability,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,
1385,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Pramipexole,DB00413,,,,,,,,,,Hyperprolactinemia,,HP:0000870,https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,
1386,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by stimulation+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Parkinsonian symptoms,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,,,
1387,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,,,,,,,,,,Postural tremor,,HP:0002174,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,,,
1388,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,,,,,,,,,,Kinetic tremor,,HP:0030186,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,,,
1389,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,,,,,,,,,,Bradykinesia,,HP:0002067,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,,,
1390,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,,Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,,,
1391,150,# 222748,Dihydropyrimidinase deficiency,,DPYS,dihydropyrimidinase,3.5.2.2,,,No treatment is available in DDIEM,,,,,,,,,,,Dyskinesias,,HP:0100660,,,,,,,,,,,
1392,151,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Riboflavin,DB00140,ECO:0000352/ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Exercise intolerance,,HP:0003546,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889,,,,,,
1393,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Riboflavin,DB00140,,,,,,,,,,Myopathy,,HP:0003198,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889,,,,,,
1394,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Riboflavin,DB00140,,,,,,,,,,Fatiguability,,HP:0003750,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889,,,,,,
1395,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Biotin+Coenzyme Q+Carnitine+Riboflavin,DB00121+DB09270+DB00148+DB00140,ECO:0000352,,,,,Supportive+Supportive+Supportive+Direct interaction,C+C+C+A,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+activity modification of a genetically defective protein,,Repeated vomiting,,HP:0002572,https://www.ncbi.nlm.nih.gov/pubmed/14765544,,,,,,,,,,
1396,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Biotin+Coenzyme Q+Carnitine+Riboflavin,DB00121+DB09270+DB00148+DB00140,,,,,,Supportive,C,,,Encephalopathy,,HP:0001298,https://www.ncbi.nlm.nih.gov/pubmed/14765544,,,,,,,,,,
1397,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Biotin+Coenzyme Q+Carnitine+Riboflavin,DB00121+DB09270+DB00148+DB00140,,,,,,Supportive,C,,,Lactic acidosis,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/14765544,,,,,,,,,,
1398,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Sodium bicarbonate+Dichloroacetate+Carnitine+Thiamine+Coenzyme Q+Riboflavin,DB01390+DB08809+DB00583+ DB00152+DB09270+DB00140,ECO:0000352,,,,,Supportive+Functional interaction+Supportive+Direct interaction+Direct interaction,C+B+C+A+A,combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein by inhibition+symptomatic therapeutic procedure+activity modification of a genetically defective protein+activity modification of a genetically defective protein,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/10448086,,,,,,,,,,
1399,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Thiamine,DB00152,ECO:0000352,p.I480M,,,,Direct interaction,A,activity modification of a genetically defective protein,,Recurrent vomiting,,HP:0002572,,,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10448086,,,,,,,
1400,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Thiamine,DB00152,,,,,,,,,,Ptosis,,HP:0000508,https://www.ncbi.nlm.nih.gov/pubmed/20652410,,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10448086,,,,,,,
1401,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Thiamine,DB00152,,,,,,,,,,Increased muscle fatiguability,,HP:0003750,https://www.ncbi.nlm.nih.gov/pubmed/20652410,,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10448086,,,,,,,
1402,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",Sodium dichloroacetate,DB08809,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Lactic acidemia,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/8652022,https://www.ncbi.nlm.nih.gov/pubmed/11687750,https://www.ncbi.nlm.nih.gov/pubmed/23478190,https://www.ncbi.nlm.nih.gov/pubmed/25032271,,,,,,,
1403,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Lipoic acid,DB00166,ECO:0000352,,,,,Functional interaction,B,functional complementation of a defective protein,,Lactic acidemia,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/6418873,,,,,,,,,,
1404,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,,Lipoic acid,DB00166,,,,,,,,,,Pyruvic acidemia,,HP:0001941,https://www.ncbi.nlm.nih.gov/pubmed/6418873,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1405,152,# 222730,Dicarboxylic aminoaciduria,,SLC1A1,Excitatory amino acid transporter 3,P43005,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1406,154,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Levetiracetam,DB01202,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Tonic-clonic seizures,,HP:0002069,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,,,,,,,
1407,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Levetiracetam,DB01202,,,,,,,,,,Myoclonus,,HP:0001336,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,,,,,,,
1408,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Levetiracetam,DB01202,,,,,,,,,,EEG abnormality,,HP:0002353,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,,,,,,,
1409,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Levetiracetam,DB01202,,,,,,,,,,Poor appetite,,HP:0004396,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,,,,,,,
1410,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Levetiracetam,DB01202,,,,,,,,,,Low quality of life (Constitutional symptom)*,,HP:0025142,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,,,,,,,
1411,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Levetiracetam,DB01202,,,,,,,,,The drug reduces the frequency of the epileptic seizures.,Epileptic seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,,,,,,,
1412,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,"""A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA."" https://www.ncbi.nlm.nih.gov/pubmed/29739138",Olanzapine,DB00334,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Psychosis,,HP:0000709,,,https://www.ncbi.nlm.nih.gov/pubmed/29739138,,,,,,,,
1413,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Olanzapine,DB00334,,,,,,,,,,Hallucinatory-paranoid state,,HP:0011999*,,,https://www.ncbi.nlm.nih.gov/pubmed/29739138,,,,,,,,
1414,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Olanzapine,DB00334,,,,,,,,,,Auditory hallucinations,,HP:0008765,,,https://www.ncbi.nlm.nih.gov/pubmed/29739138,,,,,,,,
1415,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,The treatment regimen resulted in neuroleptic malignant syndrome.,Haloperidol +Levomepromazine,DB00502+DB01403,ECO:0000352,,,,,Symptomatic+Functional interaction,C+B,combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein by inhibition,,Psychosis,,HP:0000709,https://www.ncbi.nlm.nih.gov/pubmed/11449034/,,,,,,,,,,
1416,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Perampanel,DB08883,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Diminished intellectual abilities,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/28856097,,,,,,,,,,
1417,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Perampanel,DB08883,,,,,,,,,,Myoclonic seizures,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/28856097,,,,,,,,,,
1418,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,P54259,,,Perampanel,DB08883,,,,,,,,,,Inability to walk,,HP:0002540,https://www.ncbi.nlm.nih.gov/pubmed/28856097,,,,,,,,,,
1419,155,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,1.3.1.72,,,Riboflavin+Nicotinamide+Thiamine,DB00140+DB02701+DB00152,ECO:0007764/ECO:0007121,,,,,Direct interaction+Direct interaction+Direct interaction,A+A+A,combination therapeutic procedure+activity modification of a genetically defective protein+activity modification of a genetically defective protein+activity modification of a genetically defective protein,,High desmosterol levels (Abnormality of cholesterol metabolism)*,The change was not statistically significant.,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,,,,,,,,
1420,,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,1.3.1.72,,,Riboflavin+Nicotinamide+Thiamine,DB00140+DB02701+DB00152,,,,,,,,,,High desmosterol/cholesterol ratio,The change was not statistically significant.,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,,,,,,,,
1421,,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,1.3.1.72,,,Riboflavin+Nicotinamide+Thiamine,DB00140+DB02701+DB00152,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,,,,,,,,
1422,,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,1.3.1.72,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Cholesterol,DB04540,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,High desmosterol levels (Abnormality of cholesterol metabolism)*,,HP:0003107*,https://www.ncbi.nlm.nih.gov/pubmed/10959439,,,,,,,,,,
1423,156,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,L-leucine,DB00149,ECO:0007121/ECO:0000179/ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,low heamoglobin level,,HP:0001903,,,https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294,,,,
1424,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,L-leucine,DB00149,,,,,,,,,,Defect in protein synthesis (Abnormality of circulating protein level)*,,HP:0010876*,,,https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294,,,,
1425,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,L-leucine,DB00149,,,,,,,,,,Decreased red blood cell production,,HP:0012133*,,,https://clinicaltrials.gov/ct2/show/NCT01362595?cond=Diamond-Blackfan+anemia&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294,,,,
1426,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Antithymocyte globulin+Cyclosporine,DB00098+DB00091,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+functional complementation of a genetically defective protein by inhibition,In other blood/bone marrow disorders of immune etiology these drugs have synergistic effects. We propose a Phase II study to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of Diamond Blackfan anemia. No results were posted in the website to tell what was the actual responce to the treatment. https://clinicaltrials.gov/ct2/show/NCT00001749,Pure red blood cell aplasia,,HP:0012410,https://www.ncbi.nlm.nih.gov/pubmed/15813920,,https://clinicaltrials.gov/ct2/show/NCT00001749,,,,,,,,
1427,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Rituximab,DB00073,ECO:0007121/ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Low RBC count,,HP:0001877,,,https://clinicaltrials.gov/ct2/show/study/NCT00229619?cond=Diamond-Blackfan+anemia&rank=7&sect=X70156,,,,,,,,
1428,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Daclizumab,DB00111,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Low RBC count,,HP:0001877,,,https://clinicaltrials.gov/ct2/show/results/NCT00001962?cond=Diamond-Blackfan+anemia&rank=8&sect=X70156#outcome1,,,,,,,,
1429,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Lenalidomide,DB00480,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Low RBC count,,HP:0001877,,,https://clinicaltrials.gov/ct2/show/NCT01034592?cond=Diamond-Blackfan+anemia&rank=9,,,,,,,,
1430,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Prednisolone,DB00635,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,,,,,
1431,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Prednisolone,DB00635,,,,,,,,,,Low quality of life,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,,,,,
1432,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Prednisolone,DB00635,,,,,,,,,,Abnormal apoptosis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,,,,,
1433,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Prednisolone,DB00635,,,,,,,,,,Erythroid progenitor depletion,,HP:0025034*,https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,,,,,
1434,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Prednisolone,DB00635,,,,,,,,,,Premature differentiation of erythroid cells,,HP:0012130*,https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,,,,,
1435,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Prednisone+Cyclosporine,DB00635+DB00091,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition,,Low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/27329125,https://www.ncbi.nlm.nih.gov/pubmed/3389144?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2503027?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/1546717?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,,,,,,
1436,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Prednisone+Cyclosporine,DB00635+DB00091,,,,,,,,,,Reticulocytopenia,,HP:0001896,https://www.ncbi.nlm.nih.gov/pubmed/27329125,https://www.ncbi.nlm.nih.gov/pubmed/3389144?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2503027?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/1546717?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,,,,,,
1437,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Metoclopramide,DB01233,ECO:0000352,,,,,Functional interaction,,functional complementation of a genetically defective protein by stimulation,,Low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/15795909,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655,,,,,,,
1438,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Metoclopramide,DB01233,,,,,,,,,,Reduced hematocrit,,HP:0031851,https://www.ncbi.nlm.nih.gov/pubmed/15795909,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655,,,,,,,
1439,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Metoclopramide+prednisolone,DB01233+DB00635,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by stimulation+functional complementation of a genetically defective protein,,Low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/24744655,,,,,,,,,,
1440,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Eltrombopag,DB06210,ECO:0007121/ECO:0000352,(c.356+3>C),,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Low Hb level,,HP:0001903,http://www.bloodjournal.org/content/128/22/2682,https://clinicaltrials.gov/ct2/show/NCT01328587,https://www.ncbi.nlm.nih.gov/pubmed/29684566,,,,,,,,
1441,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,Eltrombopag,DB06210,,,,,,,,,,Thrombocytopenia,,HP:0001873,http://www.bloodjournal.org/content/128/22/2682,https://clinicaltrials.gov/ct2/show/NCT01328587,https://www.ncbi.nlm.nih.gov/pubmed/29684566,,,,,,,,
1442,157,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Vitamin B6,DB00165,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High ornithine level,,HP:0012026,https://www.ncbi.nlm.nih.gov/pubmed/29757052,https://www.ncbi.nlm.nih.gov/pubmed/17565677/,https://www.ncbi.nlm.nih.gov/pubmed/7028650/,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911,,,,,,
1443,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Lysine supplementation,DB00123,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High ornithine level,,HP:0012026,https://www.ncbi.nlm.nih.gov/pubmed/11486915,https://www.ncbi.nlm.nih.gov/pubmed/11486915,https://www.ncbi.nlm.nih.gov/pubmed/10896280,,,,,,,,
1444,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Low protein intake(arginine-restricted diet)+pyridoxine,NA+DB00165,ECO:0000352,,,,,Functional interaction+Direct interaction,B+A,combination therapeutic procedure+dietary exclusion+activity modification of a genetically defective protein,,Cystoid macular edema,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract,,,,,,,,,,
1445,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Low protein intake(arginine-restricted diet)+pyridoxine,NA+DB00165,,,,,,,,,,Low visual acuity,,HP:0007663,https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract,,,,,,,,,,
1446,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Arginine-restricted diet,NA,ECO:0000352,,,,,Functional interaction,B,dietary exclusion,,Disease progresssion,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/16601905,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,,,,,,
1447,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Arginine-restricted diet,NA,,,,,,,,,,High ornithine plasma level,,HP:0012026,https://www.ncbi.nlm.nih.gov/pubmed/16601905,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,,,,,,
1448,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Arginine-restricted diet,NA,,,,,,,,,,Low visual acuity,,HP:0007663,https://www.ncbi.nlm.nih.gov/pubmed/16601905,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,,,,,,
1449,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Topical NSAIDs +Systemic CAI,DB00586+DB00311,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Cystoid macular edema,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/28708224?dopt=Abstract,,,,,,,,,,
1450,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Intravitreal bevacizumab,DB00112,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Choroidal neovascularization,,HP:0011506,https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,,,,,,,,,,
1451,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Intravitreal bevacizumab,DB00112,,,,,,,,,,Decreased visual acuity,,HP:0007663,https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,,,,,,,,,,
1452,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Intravitreal bevacizumab,DB00112,,,,,,,,,,Abnormal central vision,,HP:0000504,https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,,,,,,,,,,
1453,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Alpha-aminoisobutyric acid,DB02952,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High ornithine plasma level,,HP:0012026,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,,,,,,,,,
1454,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,Gene therapy *,NA,ECO:0007121/ECO:0001565,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Abnormal enzyme/coenzyme activity,,HP:0012379,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/9414260,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,,,,,,,,
1455,158,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Creatine-monohydrate,DB00148,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Extrapyramidal movement disorders,,HP:0002071,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/18652077,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986,,,,
1456,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation,L-ornithine+Arginine restriction,DB00129+NA,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+dietary exclusion,,Epileptic seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/11749046,https://www.ncbi.nlm.nih.gov/pubmed/9686828,,,,,,,,,
1457,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,L-ornithine+Arginine restriction,DB00129+NA,,,,,,,,,,Slow background activity in the EEG (EEG abnormality)*,,HP:0002353*,https://www.ncbi.nlm.nih.gov/pubmed/11749046,https://www.ncbi.nlm.nih.gov/pubmed/9686828,,,,,,,,,
1458,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,L-ornithine+Arginine restriction,DB00129+NA,,,,,,,,,,Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*,,HP:0002453*,https://www.ncbi.nlm.nih.gov/pubmed/11749046,https://www.ncbi.nlm.nih.gov/pubmed/9686828,,,,,,,,,
1459,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,"The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys",Sodium benzoate+ornithine+creatine,DB03793+DB00129+DB00148,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition+metabolite replacement,,High CSF guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24071436,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1460,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Sodium benzoate+ornithine+creatine,DB03793+DB00129+DB00148,,,,,,,,,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24071436,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1461,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129+NA,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+metabolite replacement+functional complementation of a genetically defective protein by inhibition+dietary exclusion,,Epilepsy,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1462,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129+NA,,,,,,,,,,Low urinary creatine excretion,,HP:0012113,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1463,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129+NA,,,,,,,,,,Low brain creatine phosphate,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1464,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129+NA,,,,,,,,,,Low cerebral creatine,,HP:0025051,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1465,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129+NA,,,,,,,,,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1466,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129+NA,,,,,,,,,,Abnormal coordination of movements,,HP:0011443,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency,,,,,,,,
1467,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129+NA,,,,,,,,,,Behavioral abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency,,,,,,,,
1468,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,2.1.1.2,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,Sodium phenylbutyrate+L-ornithine+Arginine restriction,DB06819+DB00129+NA,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition+dietary exclusion,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24268530,,,,,,,,,,
1469,159,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,Tetrahydrobiopterin,DB00360,ECO:0007121/ECO:0000352,,,,,Functional interaction,B,metabolite replacement,Mechanistic (A),High serum phenylalanine,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/9667588,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES,https://www.ncbi.nlm.nih.gov/pubmed/16275037,,,,,,,
1470,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,L-dopa,DB01235,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,Symptomatic ©,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/12391354,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179,,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/21937252,,,
1471,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,benserazide,DB12783,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Oromandibular dystonia,,HP:0012048,https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
1472,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,5-hydroxytryptophane,DB04159,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Spasticity,,HP:0001257,,,,,,,,,,,
1473,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,5-hydroxytryptophane,DB04159,,,,,,,,,,Abnormal motor development,,HP:0001270,,,,,,,,,,,
1474,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,5-hydroxytryptophane,DB04159,,,,,,,,,,Sleep disturbance,,HP:0002360,,,,,,,,,,,
1475,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,5-hydroxytryptophane,DB04159,,,,,,,,,,Defected neurotransmitter homeostasis in the CNS,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/22729819,,,,,,,,,,
1476,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,Folinic acid,DB00650,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Depletion of cerebral folate,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179,,,,,,,,,
1477,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,Folinic acid,DB00650,,,,,,,,,,Abnormal folate homeostasis in the CNS,,HP:0012335,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179,,,,,,,,,
1478,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Amantadine,DB00915,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Levodopa‐induced choreic dyskinesia (Dyskinesia)*,,HP:0100660*,https://www.ncbi.nlm.nih.gov/pubmed/15389992,,,,,,,,,,
1479,169,# 215140,Greenberg dysplasia,,LBR,lamin B receptor,Q14739,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1480,170,# 603358,GRACILE syndrome,,BCS1L,ubiquinol-cytochrome c reductase complex chaperone,Q9Y276,,,Sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Symptomatic ©,Lactic acidosis,,HP:0003128,,,https://www.ncbi.nlm.nih.gov/pubmed/22970607,https://www.ncbi.nlm.nih.gov/pubmed/24655110,,,,,,,
1481,171,# 609056,GM3 synthase deficiency,,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",2.4.99.9,,,Gangliosides,DB12351,ECO:0007121,,,,,Functional interaction,B,metabolite replacement,Mechanistic (A),Delayed Develoment,,HP:0001263,,,https://clinicaltrials.gov/ct2/show/NCT02234024?cond=GM3+synthase+deficiency&rank=1,,,,,,,,
1482,,# 609056,GM3 synthase deficiency,,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",2.4.99.9,,,CoQ10,DB09270,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Poor eye contect,,HP:0000817,,,https://www.ncbi.nlm.nih.gov/pubmed/22990144,,,,,,,,
1483,,# 609056,GM3 synthase deficiency,,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",2.4.99.9,,,CoQ10,DB09270,,,,,,,,,,Abnormal interactivity,,HP:0012433,,,https://www.ncbi.nlm.nih.gov/pubmed/22990144,,,,,,,,
1484,172,# 230500,GM1 gangliosidosis type 1,,GLB1,beta-galactosidase,3.2.1.23,,,(5aR)-5a-C-Pentyl-4-epi-isofagomine,NA,ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,Mechanistic (B),Neurologic abnormalities,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/27750150,,,,,,,,
1485,,# 230500,GM1 gangliosidosis type 1,,GLB1,beta-galactosidase,3.2.1.23,,,β-galactosidase:RTB lectin fusion,NA,ECO:0001565,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Decreased beta-galactosidase activity,,HP:0008166,https://www.ncbi.nlm.nih.gov/pubmed/26766614,,,,,,,,,,
1486,,# 230500,GM1 gangliosidosis type 1,,GLB1,beta-galactosidase,3.2.1.23,,,N-octyl 4-epi-β-valienamine,NA,ECO:0000179,,,,,,,functional complementation of a defective protein,,Intracellular ganglioside accumulation,,NA,,,,,,,,,,,
1487,,# 230500,GM1 gangliosidosis type 1,,GLB1,beta-galactosidase,3.2.1.23,,,N-octyl 4-epi-β-valienamine,NA,,,,,,,,,,Short survival time (Mortality)*,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/22436580,,,,,,,,,,
1488,173,# 230600,GM1 gangliosidosis type 2,,GLB1,beta-galactosidase,3.2.1.23,,,6S-NBI-DGJ,PubChem CID:76070514,ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,Mechanisitic (B),Brain pathology,,HP:0001298,,,https://www.ncbi.nlm.nih.gov/pubmed/23337983?dopt=Abstract,,,,,,,,
1489,174,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,3.2.1.23,,,Cyclodextrin,CHEBI:23456,ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,Mechanistic (,CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,,,,,,,
1490,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,3.2.1.23,,,Cyclodextrin,CHEBI:23456,,,,,,,,,,Elevated intraneuronal cholesterol,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,,,,,,,
1491,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,3.2.1.23,,,AAV-treated βgal,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,Mechanisitic(A),Abnormally decreased rate of beta-galactosidase activity,,HP:0008166,,,https://www.ncbi.nlm.nih.gov/pubmed/17164772?dopt=Abstract,,,,,,,,
1492,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,3.2.1.23,,,Miglustat,DB00419,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,Mechanisitic (B),High ganglioside accumulation,,NA,,,https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1,,,,,,,,
1493,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,3.2.1.23,,,Miglustat,DB00419,,,,,,,,,,Ataxic gait,,HP:0002066,,,https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1,,,,,,,,
1494,175,# 607625,Niemann-Pick disease type C2,,NPC2,NPC intracellular cholesterol transporter 2,P61916,,,2-hydroxypropyl-beta-cyclodextrin,DB15146,ECO:0000352,,,,,Functional interaction,B,functional complementation of a defective protein,Mechanistic (B),Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*,,HP:0003107*,,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Use+of+2-Hydroxypropyl-Beta-Cyclodextrin+for+Niemann-Pick+Type+C+Disease&btnG=,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,,,,,,,,
1495,,# 607625,Niemann-Pick disease type C2,,NPC2,NPC intracellular cholesterol transporter 2,P61916,,,2-hydroxypropyl-beta-cyclodextrin,DB15146,,,,,,,,,,High intraneuronal GSL storage,,NA,,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Use+of+2-Hydroxypropyl-Beta-Cyclodextrin+for+Niemann-Pick+Type+C+Disease&btnG=,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,,,,,,,,
1496,,# 607625,Niemann-Pick disease type C2,,NPC2,NPC intracellular cholesterol transporter 2,P61916,,,2-hydroxypropyl-beta-cyclodextrin,DB15146,,,,,,,,,,Increased free sphingosine accumulation (Abnormality of lipid metabolism)*,,HP:0003119*,,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Use+of+2-Hydroxypropyl-Beta-Cyclodextrin+for+Niemann-Pick+Type+C+Disease&btnG=,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,,,,,,,,
1497,176,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,N-butyldeoxynojirimycin+allopregnanolone,DB00419 +DB11859,ECO:0000179,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement,Mechanistic (B),elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*,,HP:0003107*,https://www.ncbi.nlm.nih.gov/pubmed/11227045/,,,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,,,,,,
1498,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,ECO:0007121/ECO:0000352/ECO:0000179,,,,,Functional interaction,B,functional complementation of a defective protein,,High intraneuronal GSL storage,,NA,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1499,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Increased free sphingosine accumulation (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1500,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Neurodegeneration,,HP:0002180,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1501,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Poor swallowing,,HP:0002015,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1502,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1503,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Fine motor impairment,,HP:0007010,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1504,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Liver injury,,HP:0001392,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1505,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Cholesterol sequestration (Abnormality of cholesterol metabolism)*,,HP:0003107*,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1506,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Reduced life span (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1507,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,,,,,,,,,,Rapid progression,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1508,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Miglustat+Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,ECO:0000179,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement+functional complementation of a genetically defective protein,,Motor function impairment,,HP:0002275,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/23948640,,,,,,,,
1509,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Miglustat+Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,,,,,,,,,,Cerebeller neurodegeneration (neurodegeneration)*,,HP:0002180*,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/25400034,,,,,,,,
1510,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Miglustat+Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,,,,,,,,,,Abnormality of lipid metabolism,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1511,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Miglustat+Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1512,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Miglustat+Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,,,,,,,,,,Increased number of splenic myeloid cells,,NA,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1513,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,ECO:0000179,,,,,Functional interaction,B,metabolite replacement,,Mortality,,HP:0040006,,,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,,,,,,,,
1514,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,Disease progression,,HP:0003678,,,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,,,,,,,,
1515,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,cortical GM2 ganglioside accumulation,,HP:0003495,,,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,,,,,,,,
1516,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,GM3 ganglioside accumulation (Ganglioside accumulation)*,,HP:0004345,,,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,,,,,,,,
1517,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/,,,,,,,,
1518,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/,,,,,,,,
1519,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/,,,,,,,,
1520,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/,,,,,,,,
1521,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/,,,,,,,,
1522,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/,,,,,,,,
1523,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,,Allopregnanolone,DB11859,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/,,,,,,,,
1524,177,# 245010,Haim-Munk syndrome,,CTSC,Dipeptidyl peptidase 1,3.4.14.1,,,(Trimethoprim+Sulfamethoxazole)+Acitretin,(DB00440+DB01015)+DB00459,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,Symptomatic ©,Palmoplantar keratoderma,,HP:0000982,,,https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract,,,,,,,,
1525,,# 245010,Haim-Munk syndrome,,CTSC,Dipeptidyl peptidase 1,3.4.14.1,,,(Trimethoprim+Sulfamethoxazole)+Acitretin,(DB00440+DB01015)+DB00459,,,,,,,,,,Periodontitis,,HP:0000704,,,https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract,,,,,,,,
1526,,# 245010,Haim-Munk syndrome,,CTSC,Dipeptidyl peptidase 1,3.4.14.1,,,Acitretin,DB00459,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Periodontitis,,HP:0000704,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,,,,,,,,
1527,,# 245010,Haim-Munk syndrome,,CTSC,Dipeptidyl peptidase 1,3.4.14.1,,,Etretinate,DB00926,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Keratoderma,,HP:0000982,,,https://www.ncbi.nlm.nih.gov/pubmed/10738634/,,,,,,,,
1528,,# 245010,Haim-Munk syndrome,,CTSC,Dipeptidyl peptidase 1,3.4.14.1,,,Etretinate,DB00926,,,,,,,,,,Aggressive periodontitis (Sever periodontitis),,HP:0000166,,,https://www.ncbi.nlm.nih.gov/pubmed/10738634/,,,,,,,,
1529,,# 245010,Haim-Munk syndrome,,CTSC,Dipeptidyl peptidase 1,3.4.14.1,,,Salicylic acid+Urea,DB00936+DB03904,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Palmoplantar hyperkeratosis,,HP:0000972,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,,,,,,,,
1530,178,# 234500,Hartnup disease,,SLC6A19,Sodium-dependent neutral amino acid transporter B(0)AT1,Q695T7,,,Niacin,DB00627,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,Mechanistic (A),Chronic diarrhea,,HP:0002028,,https://www.ncbi.nlm.nih.gov/pubmed/6236384,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,,,,,,,,
1531,,# 234500,Hartnup disease,,SLC6A19,Sodium-dependent neutral amino acid transporter B(0)AT1,Q695T7,,,Niacin,DB00627,,,,,,,,,,Hypoalbuminemia,,HP:0003073,,https://www.ncbi.nlm.nih.gov/pubmed/6236384,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,,,,,,,,
1532,,# 234500,Hartnup disease,,SLC6A19,Sodium-dependent neutral amino acid transporter B(0)AT1,Q695T7,,,Niacin,DB00627,,,,,,,,,,Exfoliative erythema,,HP:0001019,,https://www.ncbi.nlm.nih.gov/pubmed/6236384,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,,,,,,,,
1533,179,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Ascorbic acid,DB00126,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low activity of the immature 4-HPPD enzyme (Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/26226126,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=The+Incidence+of+Transient+Neonatal+Tyrosinemia+Within+a+Mexican+Population&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/14206878,,,,,,,,
1534,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,N-acetyl-L-cysteine,DB06151,ECO:0000352,,,,,Symptomatic (Functional),C (B),functional complementation of a genetically defective protein,,Secondary glutathione deficiency (Abnormality of metabolism/homeostasis)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1535,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,N-acetyl-L-cysteine,DB06151,,,,,,,,,,Pyroglutamic aciduria (Organic aciduria)*,,HP:0001992*,https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1536,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,N-acetyl-L-cysteine,DB06151,,,,,,,,,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1537,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,N-acetyl-L-cysteine,DB06151,,,,,,,,,,Decreased appetite,,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1538,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Medium-chain triglyceride oil,DB13959,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Symptomatic ©,Failure to thrive,,HP:0001508,,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1539,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Medium-chain triglyceride oil,DB13959,,,,,,,,,,Growth delay,,HP:0001510,,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1540,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Medium-chain triglyceride oil,DB13959,,,,,,,,,,Hemolytic anemia,,HP:0001878,,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1541,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Medium-chain triglyceride oil,DB13959,,,,,,,,,,Low β2 microglobulin/creatinine ratio,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1542,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Phosphate,DB14573,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypophosphatemia,,HP:0002148,,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1543,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Metabolic acidosis,,HP:0001942,,,,,,,,,,,
1544,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,,Nitisinone (NTBC),DB00348,ECO:0000179,,,,,Direct interaction,A,procedure to mitigate dominant effects of a genetically abnormal protein,,Extreme frailty (Fatigue)*,,HP:0012378*,,,https://www.ncbi.nlm.nih.gov/pubmed/20677779,,,,,,,,
1545,,# 235200,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,Hereditary hemochromatosis protein,Q30201,,,Pantoprazole,DB00213,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High serum ferritin,,HP:0003281,,,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,,,,,,,
1546,,# 235200,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,Hereditary hemochromatosis protein,Q30201,,,Pantoprazole,DB00213,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,,,,,,,
1547,,# 235200,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,Hereditary hemochromatosis protein,Q30201,,,Pantoprazole,DB00213,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,,,,,,,
1548,180,# 602390,Hemochromatosis type 2,,HJV/HAMP,hemojuvelin/hepcidin,Q30201,,,Deferoxamine,DB00746,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Iron overload (Abnormality of iron homeostasis)*,,HP:0011031*,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,https://www.ncbi.nlm.nih.gov/pubmed/17124037,,,,,,,,
1549,,# 602390,Hemochromatosis type 2,,HJV/HAMP,hemojuvelin/hepcidin,Q30201,,,hepcidin,NA,ECO:0007764,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Increased plasma iron concentration (Increased serum iron),,HP:0003452,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives,http://www.bloodjournal.org/content/107/7/2952.abstract?ijkey=8710a861648a7799043d81f5a481aa922c2bd6df&keytype2=tf_ipsecsha&sso-checked=true,,,,,,
1550,181,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,,,Deferoxamine,DB00746,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,Symptomatic ©,Iron overload (Abnormality of iron homeostasis)*,,HP:0011031*,,,https://www.ncbi.nlm.nih.gov/pubmed/29134618,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,,,,,
1551,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,,,hepcidin,NA,ECO:0007764,,,,,Functional interaction,B,metabolite replacement,,Increased plasma iron concentration (Increased serum iron),,HP:0003452,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,,,,,,,,
1552,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,,,LJPC-401(Synthetic human hepcidin),NA,ECO:0007121,,,,,Functional interaction,B,metabolite replacement,,High serum iron,,HP:0003452,,,https://clinicaltrials.gov/ct2/show/NCT03395704?cond=Hemochromatosis+type+3&draw=2&rank=13,,,,,,,,
1553,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,,,Deferiprone (L1),DB08826,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Elevated liver iron concentration,,HP:0040134,,,https://clinicaltrials.gov/ct2/show/NCT00350662?cond=Hemochromatosis+type+3&draw=4&rank=23,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,,,,,,,
1554,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,,,Nifedipine,DB01115,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Iron overload (Abnormality of iron homeostasis)*,,HP:0011031*,,,https://clinicaltrials.gov/ct2/show/NCT00712738?cond=Hemochromatosis+type+3&draw=4&rank=30,,,,,,,,
1555,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,,"Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927",flavanols,NA,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Iron overload (Abnormality of iron homeostasis)*,,HP:0011031*,,,https://clinicaltrials.gov/ct2/show/NCT03453918?cond=Hemochromatosis+type+3&draw=5&rank=34,,,,,,,,
1556,183,* 151670,Hepatic lipase deficiency,,LIPC,hepatic lipase,3.1.1.3,,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Rosuvastatin,DB01098,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Symptomatic ©,High atherogenic lipoprotein (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/22798447,https://www.ncbi.nlm.nih.gov/pubmed/26194979,https://www.ncbi.nlm.nih.gov/pubmed/12547874,,,,,,,,
1557,,* 151670,Hepatic lipase deficiency,,LIPC,hepatic lipase,3.1.1.3,,,Rosuvastatin,DB01098,,,,,,,,,,High low-density lipoprotein (LDL)-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/22798447,https://www.ncbi.nlm.nih.gov/pubmed/26194979,https://www.ncbi.nlm.nih.gov/pubmed/12547874,,,,,,,,
1558,,* 151670,Hepatic lipase deficiency,,LIPC,hepatic lipase,3.1.1.3,,,Rosuvastatin,DB01098,,,,,,,,,,High Apolipoprotein B (ApoB) (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/22798447,https://www.ncbi.nlm.nih.gov/pubmed/26194979,https://www.ncbi.nlm.nih.gov/pubmed/12547874,,,,,,,,
1559,184,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Hemin,DB03404,ECO:0000179/ECO:0001565,,,,,Functional interaction,B,metabolite replacement,,Acute episodic abdominal pain,,HP:0002574,https://www.ncbi.nlm.nih.gov/pubmed/24652768,https://www.ncbi.nlm.nih.gov/pubmed/24175354,,,,,,,,,
1560,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Hemin,DB03404,,,,,,,,,,Low pancreatic zymogens,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24652768,https://www.ncbi.nlm.nih.gov/pubmed/24175354,,,,,,,,,
1561,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,ECO:0000352,,,C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation),https://www.ncbi.nlm.nih.gov/pubmed/12622622. https://www.ncbi.nlm.nih.gov/pubmed/4739135,Symptomatic,C,symptomatic therapeutic procedure,,Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*,,HP:0010472*,https://www.ncbi.nlm.nih.gov/pubmed/12622622,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.ncbi.nlm.nih.gov/pubmed/7324107,https://www.ncbi.nlm.nih.gov/pubmed/22985607,,,,,,,
1562,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Chloroquine,DB00608,,,,,,,,,,Increased liver iron level,,HP:0012465,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.ncbi.nlm.nih.gov/pubmed/4744026,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/6173993/,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,,,,,,
1563,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Chloroquine,DB00608,,,,,,,,,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.ncbi.nlm.nih.gov/pubmed/4744026,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,,,,,,
1564,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Chloroquine,DB00608,,,,,,,,,,Increased serum ferritin,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.ncbi.nlm.nih.gov/pubmed/4744026,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,,,,,,
1565,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Chloroquine,DB00608,,,,,,,,,,Elevated transferrin saturation,,HP:0012463,https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.ncbi.nlm.nih.gov/pubmed/4744026,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,,,,,,
1566,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Chloroquine,DB00608,,,,,,,,,,Increased serum iron,,HP:0003452,https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.ncbi.nlm.nih.gov/pubmed/4744026,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,,,,,,
1567,,# 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,,Chloroquine,,,,,,,,,,,,,,,,,,,,,,,,
1568,185,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Defect of bone mineralisation,,HP:0004348,https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1569,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Growth delay,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1570,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Poor skeletal mineralization,,HP:0006462,https://www.ncbi.nlm.nih.gov/pubmed/30083035,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1571,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Respiratory insufficiency,,HP:0002093,https://www.ncbi.nlm.nih.gov/pubmed/30083035,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1572,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Rickets,,HP:0002748,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Caused+by+Alkaline+Phosphatase+Deficiency+Hypophosphatasia%3A+A+Systemic+Skeletal+Disorder+Caused+by+Alkaline+Phosphatase+Deficiency&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1573,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Gross motor dysfunction,,HP:0007015,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1574,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Fine motor dysfunction,,HP:0007010,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1575,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1576,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1577,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1578,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Asfotase alfa,DB09105,,,,,,,,,,Delayed growth (stature),,HP:0000002,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29405935,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/30288020,https://www.ncbi.nlm.nih.gov/pubmed/30576866,,,,,,
1579,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,Vitamin D,DB11094,,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Secondary hyperparathyrodism,,HP:0000867,,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Caused+by+Alkaline+Phosphatase+Deficiency+Hypophosphatasia%3A+A+Systemic+Skeletal+Disorder+Caused+by+Alkaline+Phosphatase+Deficiency&btnG=,,,,,,,,,
1580,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,NSAID,S01BC,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Lower limb pain,,HP:0012514,https://www.ncbi.nlm.nih.gov/pubmed/16803637,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1581,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,NSAID,S01BC,,,,,,,,,,Abnormal prostaglandin level,,HP:0011023,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1582,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,NSAID,S01BC,,,,,,,,,,Low quality of life (Constitutional symptoms)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1583,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,NSAID,S01BC,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1584,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,NSAID,S01BC,,,,,,,,,,Abnormal walking distance (low or weak muscle tone)*,,HP:0001252,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1585,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,NSAID,S01BC,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1586,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,,D378V /G339R/E191K/A176T/V423A,,N461L,,Functional interaction,B,activity modification of a genetically defective protein,,Stress fractures (Pathologic fracture)*,,HP:0002756*,https://www.ncbi.nlm.nih.gov/pubmed/26245849,https://www.ncbi.nlm.nih.gov/pubmed/27042741,https://www.ncbi.nlm.nih.gov/pubmed/22218563,,,,,,,,
1587,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,Ala176Thr/Val423Ala/Val522Ala,,,,,,,,Metatarsal stress fractures,,HP:0001832,https://www.ncbi.nlm.nih.gov/pubmed/20089612,https://www.ncbi.nlm.nih.gov/pubmed/17213282?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1588,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,compound heterozygotes for a p.G339R and p.E191K ALPL mutation,,,,,,,,Proximal femur pseudofractures,,HP:0100036,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1589,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,,,,,,,,,High bone turnover markers,,HP:0003260*,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1590,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,,,,,,,,,Defect in skeletal mineralization,,HP:0006462,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1591,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,,,,,,,,,Pain,,HP:0012531,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1592,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,,,,,,,,,Mobility problems,,HP:0001376,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1593,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,,,,,,,,,High urine phosphoethanolamine,,HP:0003239,https://www.ncbi.nlm.nih.gov/pubmed/20089612,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1594,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Teriparatide,DB06285,,,,,,,,,,High serum pyridoxal 5'-phosphate,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20089612,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1595,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,Vitamin B6,DB00165,,,,,,,,,,Seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/17395561?dopt=Abstract,,,,,,,,,,
1596,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,BPS804 (setrusumab),DB14778,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Bone weakness (Osteomalacia)*,,HP:0002749,https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,
1597,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,BPS804 (setrusumab),DB14778,,,,,,,,,,Bone fructure,,HP:0002757,https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,
1598,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,BPS804 (setrusumab),DB14778,,,,,,,,,,Low bone formation biomarkers,,HP:0031429,https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,
1599,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,BPS804 (setrusumab),DB14778,,,,,,,,,,Low bone mineral density,,HP:0004349,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,
1600,186,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin A,DB00162,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Fat soluble vitamin  Malabsorption,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1601,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin A,DB00162,,,,,,,,,,Progressive ataxic retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1602,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Central nervous degeneration,,HP:0007009,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1603,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Retinal degeneration,,HP:0000546,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1604,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Neuromuscular degeneration,,HP:0002180,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1605,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1606,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Progressive ataxic neuropathy,,HP:0003434,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1607,187,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin A,DB00162,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Fat soluble vitamin  Malabsorption (Fat malabsorption)*,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1608,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin A,DB00162,,,,,,,,,,Progressive ataxic retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1609,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Central nervous degeneration,,HP:0007009,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1610,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Retinal degeneration,,HP:0000546,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1611,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Neuromuscular degeneration,,HP:0002180,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1612,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1613,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,Vitamin E,DB00163,,,,,,,,,,Progressive ataxic neuropathy,,HP:0003434,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1614,188,# 600627,Hypertryptophanemia,Hypertryptophanemia should be regarded as a benign condition,TDO2,"tryptophan 2,3-dioxygenase",1.13.11.11,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22081291,https://www.ncbi.nlm.nih.gov/pubmed/28285122,,,,,,,,,
1615,,# 600627,Hypertryptophanemia,,TDO2,"tryptophan 2,3-dioxygenase",1.13.11.11,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12822831,https://www.ncbi.nlm.nih.gov/pubmed/28285122,,,,,,,,,
1616,,# 600627,Hypertryptophanemia,,TDO2,"tryptophan 2,3-dioxygenase",1.13.11.11,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15036384,https://www.ncbi.nlm.nih.gov/pubmed/28285122,,,,,,,,,
1617,,# 600627,Hypertryptophanemia,,TDO2,"tryptophan 2,3-dioxygenase",1.13.11.11,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15036384,https://www.ncbi.nlm.nih.gov/pubmed/28285122,,,,,,,,,
1618,189,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,Vitamen B6,DB00165,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,"However vitamin B6 and/or PP supplementation was not clinically effective in our patient group. In one patient it seemed to give a temporary improvement, in another patient however, it even seemed to result in a deterioration of the epilepsy",Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24173411,,,,,,,,,,
1619,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,Pyridoxine phosphate,DB02209,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24173411,,,,,,,,,,
1620,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,Olanzapine,DB00334,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Behavioural disturbance,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/28202261,,,,,,,,,,
1621,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,Lithium,DB14507,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Psychotic  disorder,,HP:0000725,,,,,,,,,,,
1622,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,Green tea extract,DB14307,ECO:0000179,,,,,Supportive,C,symptomatic therapeutic procedure,,Oxidative Stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/27589827,https://www.ncbi.nlm.nih.gov/pubmed/24980685,,,,,,,,,
1623,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,Vitamin D,DB11094,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Schizophrenia,"The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.",HP:0100753,https://www.ncbi.nlm.nih.gov/pubmed/24787057,,,,,,,,,,
1624,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,α-Tocopherol+ascorbic acid,DB14476+DB00126,ECO:0000179,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Impairment of spatial memory (Memory impairment)*,,HP:0002354,https://www.ncbi.nlm.nih.gov/pubmed/16214240,,,,,,,,,,
1625,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,α-Tocopherol+ascorbic acid,DB14476+DB00126,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/16214240,,,,,,,,,,
1626,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,α-Tocopherol+ascorbic acid,DB14476+DB00126,,,,,,,,,,Cerebral cortex acetylcholinesterase inhibition,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16214240,,,,,,,,,,
1627,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,1.5.5.2,,,α-Tocopherol+ascorbic acid,DB14476+DB00126,,,,,,,,,,"Hippocampal Na+, K+-ATPase reduced activity(Abnormal enzyme activity)*",,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/16214240,,,,,,,,,,
1628,190,# 239510,Hyperprolinemia type 2,,ALDH4A1,Δ1-pyrroline 5-carboxylate dehydrogenase,1.2.1.88,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1629,191,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,Protein and phenylalanine restriction should be maintained in order to avoid disease progression.,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Tetrahydrobiopterin,DB00360,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Muscular hypotonia,,HP:0001252,https://www.ncbi.nlm.nih.gov/pubmed/22729819,,,,,,,,,,
1630,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Tetrahydrobiopterin,DB00360,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/22729819,,,,,,,,,,
1631,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Tetrahydrobiopterin,DB00360,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/9585615,https://www.ncbi.nlm.nih.gov/pubmed/24204001,,,,,,,,,
1632,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Tetrahydrobiopterin,DB00360,,,,,,,,,,Growth failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/9760199,https://www.ncbi.nlm.nih.gov/pubmed/24204001,,,,,,,,,
1633,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Tetrahydrobiopterin,DB00360,,,,,,,,,,High urinary levels of primapterin (7-biopterin),,NA,https://www.ncbi.nlm.nih.gov/pubmed/24204001,https://www.ncbi.nlm.nih.gov/pubmed/24204001,,,,,,,,,
1634,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Sulfonylureas,DB01124,ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,PCBD1-diabetes (Noninsulin-dependent diabetes)*,,HP:0005978*,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1635,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Sulfonylureas,DB01124,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1636,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Sulfonylureas,DB01124,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1637,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Sulfonylureas,DB01124,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1638,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Sulfonylureas,DB01124,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1639,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Sulfonylureas,DB01124,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1640,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,,Sulfonylureas,DB01124,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1641,192,# 238700,Hyperlysinemia,Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,,,Botulinum toxin,DB00083,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Delayed motor development,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1642,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,,,Valproate+Carbamazepine,DB00313+DB00564,,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1643,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,,,Valproate+Carbamazepine,DB00313+DB00564,,,,,,Symptomatic,C,,,Generalized tonic convulsions,,HP:0010818,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1644,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,,The drug was accompanied with lysin restricted diet,Valproic acid+Lysin restricted diet,DB00313+NA,ECO:0000352,,,,,Symptomatic+Functional interaction,C+B,combination therapeutic procedure+symptomatic therapeutic procedure+dietary exclusion,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1645,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,,"No remarkable clinical improvement was observed and therefore, treatment was discontinued",pyridoxine,DB00165,ECO:0000352,,,,,Functional interaction,B,dietary supplementation,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23890588,,,,,,,,,,
1646,193,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Rosuvastatin,DB01098,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,,,,,,,,,,
1647,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Rosuvastatin,DB01098,,,,,,,,,,High LDL level,,HP:0003141,https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,,,,,,,,,,
1648,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Rosuvastatin,DB01098,,,,,,,,,,High total cholesterol,,HP:0003124,https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,,,,,,,,,,
1649,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Rosuvastatin,DB01098,,,,,,,,,,High Apoliporprotein B level (Abnormal abpolipoprotein level)*,,HP:0025201*,https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,,,,,,,,,,
1650,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Fenofibrates,DB13873,ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496,,,,,,,
1651,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Fenofibrates,DB13873,,,,,,,,,,High level of very low-density lipoprotein,,HP:0003362,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496,,,,,,,
1652,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Fenofibrates,DB13873,,,,,,,,,,High total cholesterol,,HP:0003124,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496,,,,,,,
1653,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Fenofibrates,DB13873,,,,,,,,,,Low HDL-cholesterol,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496,,,,,,,
1654,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",Nicotinic acid,DB00627,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477,,,,,,,
1655,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Nicotinic acid,DB00627,,,,,,,,,,High total plasma cholesterol,,HP:0003124,https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477,,,,,,,
1656,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Nicotinic acid,DB00627,,,,,,,,,,Elevated LDL-C level,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477,,,,,,,
1657,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Nicotinic acid,DB00627,,,,,,,,,,High VLDL-triglycerides,,HP:0003362,https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477,,,,,,,
1658,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Nicotinic acid,DB00627,,,,,,,,,,Low HDL-C,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477,,,,,,,
1659,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,"Strong statins (atorvastatin, pitavastatin, and rosuvastatin)",DB01076 or DB08860 or DB01098,ECO:0000352,TT-1131,,C-1131,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/19530961/,https://www.ncbi.nlm.nih.gov/pubmed/29695967,,,,,,,,
1660,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Gemfibrozil,DB01241,ECO:0000352/ ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Tuberoeruptive xanthomas,"The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860",HP:0001013*,https://www.ncbi.nlm.nih.gov/pubmed/2702860,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1661,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Gemfibrozil,DB01241,,,,,,,,,,Hyperchylomicronemia,,HP:0012238,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1662,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Gemfibrozil,DB01241,,,,,,,,,,High total plasma cholesterol leve,,HP:0003124,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1663,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Gemfibrozil,DB01241,,,,,,,,,,Elevated LDL-C level,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1664,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Gemfibrozil,DB01241,,,,,,,,,,High VLDL-triglycerides,,HP:0003362,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1665,,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,Gemfibrozil,DB01241,,,,,,,,,,Low HDL-C,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1666,194,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Rosuvastatin+Pravastatin,DB01098 +DB00175,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Hypertriglycernemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00214604?cond=Hyperlipidemia+type+3&rank=2,,,,,,,,,,
1667,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,Study was terminated due to safety issues.,Torcetrapib/atorvastatin,DB06281/DB01076,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,,,,https://clinicaltrials.gov/ct2/show/NCT00145431?cond=Hyperlipidemia+type+3&rank=3,,,,,,,,,,
1668,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",Simvastatin,DB00641,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,High non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1669,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Simvastatin,DB00641,,,,,,,,,,High VLDL triglycerides (Increased VLDL cholesterol concentration)*,,HP:0003362,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1670,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",Gemfibrozil,DB01241,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1671,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Gemfibrozil,DB01241,,,,,,,,,,High VLDL triglycerides,,NA,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1672,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Lovastatin,DB00227,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,High non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract,,,,,,,
1673,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Clofibrate,DB00636,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,,,,,,,,
1674,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Lovastatin+Clofibrate,DB00227+DB00636,ECO:0000352,,,,,Functional interaction+Direct interaction,B+A,combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein,,Hypercholesterolemia,,HP:0003124,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,,,,,,,,
1675,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Fenofibrate,DB13873,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1676,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Niacin,DB00627,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002156,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1677,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Fish oil,DB13961,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypertriglyceridemia,,HP:0002157,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,,,,,,,,
1678,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Fenofibrate + Atorvastatin,DB13873+ DB01076,ECO:0000352,,,,,Direct interaction+Functional interaction,A+B,combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Xanthomas,,HP:0000991,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1679,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Fenofibrate + Atorvastatin,DB13873+ DB01076,,,,,,,,,,Stenotic coronary atherosclerosis,,HP:0001677,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1680,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Fenofibrate + Atorvastatin,DB13873+ DB01076,,,,,,,,,,Angina pectoris,,HP:0001681,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1681,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Atrovastatin,DB01076,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,High serum total cholesterol,,HP:0003124,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1682,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Atrovastatin,DB01076,,,,,,,,,,High serum triglyceride,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1683,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Atrovastatin,DB01076,,,,,,,,,,High remnant-like particle (RLP)-cholesterol,,NA,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1684,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Atrovastatin,DB01076,,,,,,,,,,High remnant-like particle (RLP)-TG,,NA,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1685,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Atrovastatin,DB01076,,,,,,,,,,Elevated VLDL-cholesterol/serum TG ratio,,HP:0003362,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1686,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Atrovastatin,DB01076,,,,,,,,,,Elevated apolipoprotein B level,,HP:0031798,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1687,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,"Although  probucol effectively lowers the total plasma cholesterol levels in the apoE /  mice, but unexpectedly it accelerates the development of their aortic atherosclerotic plaquesis. 
Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703",Probucol,DB01599,ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High total plasma cholesterol,,HP:0003124,https://www.ncbi.nlm.nih.gov/pubmed/9185508,,,,,,,,,,
1688,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Probucol,DB01599,,,,,,,,,,Increased LDL cholesterol concentration,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/9185508,,,,,,,,,,
1689,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Probucol,DB01599,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9185508,,,,,,,,,,
1690,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Probucol,DB01599,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9185508,,,,,,,,,,
1691,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",Bezafibrate/ atorvastatin,DB01393/DB01076,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Atherogenic dyslipidemia (Dyslipidemia)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract,,,,,,,,,,
1692,,617347,"HYPERLIPOPROTEINEMIA, TYPE III",,APOE,apolipoprotein E,P02649,,,Recombinant apolipoprotein A-I,NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Atherosclerosis,,HP:0002621,https://www.ncbi.nlm.nih.gov/pubmed/11425766/,,,,,,,,,,
1693,195,606762,Hyperinsulinism-hyperammonemia syndrome,"Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/",GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,Diazoxide,DB01119,ECO:0000352,,,,,Functional interaction,B,procedure to mitigate dominant effects of a genetically abnormal protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/23295286,https://www.ncbi.nlm.nih.gov/pubmed/20936362,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,
1694,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,Diazoxide,DB01119,,,,,,,,,,Epileptic seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481/,https://www.ncbi.nlm.nih.gov/pubmed/28621098,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,
1695,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,Diazoxide,DB01119,,,,,,,,,,Hyperinsulinism,,HP:0000842,https://www.ncbi.nlm.nih.gov/pubmed/10969108,https://www.ncbi.nlm.nih.gov/pubmed/10453735/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,
1696,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,Carglumic acid + diazoxide+ Glucose,DB06775+DB01119+DB01914,ECO:0000352,,,,,Symptomatic+Functional interaction+Functional interaction,C+B+B,combination therapeutic procedure+symptomatic therapeutic procedure+procedure to mitigate dominant effects of a genetically abnormal protein+functional complementation of a genetically defective protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,,,,
1697,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,Levetiracetam,DB01202,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,,,,
1698,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,Levetiracetam,DB01202,,,,,,,,,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/10969108,,,,,,,,,,
1699,196,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,ECO:0000352,T65I,,GK-Y214C(De novo muttation),,Functional interaction,B,procedure to mitigate dominant effects of a genetically abnormal protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15277402,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1700,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,,(Val455Met) at codon 455,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1701,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,,M197I,,Y214C,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1702,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,,A456V,,ins454A,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1703,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,,W99R,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1704,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,,S64Y,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1705,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,,V452L,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1706,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Diazoxide,DB01119,,"M197I/G68V
W99L",W99Lwas partially responsive to diazoxide.https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://www.ncbi.nlm.nih.gov/pubmed/9435328,,,,,,,,
1707,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Octreotide,DB00104,ECO:0007121,,,,,Functional interaction,B,procedure to mitigate dominant effects of a genetically abnormal protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/8410522/,,,,,,,,,,
1708,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,Dextrose +Diazoxide,DB09341+DB01119,ECO:0000352,,,,,Symptomatic+Functional interaction,C+B,combination therapeutic procedure+symptomatic therapeutic procedure+procedure to mitigate dominant effects of a genetically abnormal protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/30026763,,,,,,,,,,
1709,197,307030,Hyperglycerolemia (Isolated glycerol kinase deficiency),,GK,Glycerol kinase,2.7.1.30,,,Rosuvastatin,DB01098,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,,,,,,,,,
1710,198,307030,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,GPI mannosyltransferase 1,2.4.1.-,,,Antithrombotic agents,B01,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Thrombosis,,HP:0001977,https://www.ncbi.nlm.nih.gov/pubmed/16767100,,,,,,,,,,
1711,,307030,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,GPI mannosyltransferase 1,2.4.1.-,,,Sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/17442906,,,,,,,,,,
1712,199,237400,HYPER-BETA-ALANINEMIA,,PIGM,beta-alanine-alpha-ketoglutarate transaminase.,2.4.1.-,,,Taurine,DB01956,ECO:0001565,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Mitochondrial toxicity (Mitochondrial abnormalities)*,,HP:0012103,https://www.ncbi.nlm.nih.gov/pubmed/27023909,https://www.ncbi.nlm.nih.gov/pubmed/28718066,https://www.ncbi.nlm.nih.gov/pubmed/7936305,,,,,,,,
1713,,237400,HYPER-BETA-ALANINEMIA,,PIGM,beta-alanine-alpha-ketoglutarate transaminase.,2.4.1.-,,,Pyridoxine,DB00165,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,??,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/6198500,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=β-Alanine-α-Ketoglutarate+Aminotransferase+Deficiency&btnG=,,,,,,,,
1714,,237400,HYPER-BETA-ALANINEMIA,,PIGM,beta-alanine-alpha-ketoglutarate transaminase.,2.4.1.-,,,Pyridoxine,DB00165,,,,,,,,,,somnolence,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/6198500,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=β-Alanine-α-Ketoglutarate+Aminotransferase+Deficiency&btnG=,,,,,,,,
1715,200,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Anti-TNF-alpha (Adalimumab)+Etanercept,DB00051+DB00005,ECO:0000352,,,,,Symptomatic,C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/24935455,,,,,,,,,,
1716,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Anti-TNF-alpha (Adalimumab)+Etanercept,DB00051+DB00005,,,,,,Symptomatic,C,,,Abnormality of immune system physiology,,HP:0010978,https://www.ncbi.nlm.nih.gov/pubmed/24935455,,,,,,,,,,
1717,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Anakinra,DB00026,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pubmed/20712835,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,,,,,,,,,
1718,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Anakinra,DB00026,,,,,,,,,,joint swelling,,HP:0001386,https://www.ncbi.nlm.nih.gov/pubmed/20712835,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,,,,,,,,,
1719,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Canakinumab,DB06168,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Fever,,HP:0001945,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,
1720,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Canakinumab,DB06168,,,,,,,,,,High serum amyloid A protein (Abnormal circulating protein level)*,,HP:0010876,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,
1721,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Canakinumab,DB06168,,,,,,,,,,Elevated C-reactive protein,,HP:0011227,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,
1722,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,prednisolone + azathioprine + immunoglobulins,DB00860+DB00993+DB00028,ECO:0000352,compound V377I and I126T mutations,,,,Symptomatic,C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/18839211?dopt=Abstract,,,,,,,,,,
1723,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,"Limited Efficacy of the drug. Drug has been withdrawn , it resulted in negative effects.",Thalidomide,DB01041,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11504824?dopt=Abstract,,,,,,,,,,
1724,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Steroids + Simvastatin,DB00641+S02BA,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/19011501?dopt=Abstract,,,,,,,,,,
1725,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Infliximab,DB00065,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Nummular keratitis (keratitis)*,,HP:0000491,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,,,,,,,,,,
1726,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Infliximab,DB00065,,,,,,,,,,Corneal scar,,HP:0000559,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,,,,,,,,,,
1727,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Infliximab,DB00065,,,,,,,,,,Decreased visual acuity,,HP:0007663,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,,,,,,,,,,
1728,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Tocilizumab,DB06273,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Fever,,HP:0001945,https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,,,,,,,,
1729,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Tocilizumab,DB06273,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,,,,,,,,
1730,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Tocilizumab,DB06273,,,,,,,,,,Pain,,HP:0012531,https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,,,,,,,,
1731,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Tocilizumab,DB06273,,,,,,,,,,Oral ulceration,,HP:0000155,https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,,,,,,,,
1732,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,Anakinra+ tocilizumab,DB00026+DB06273,ECO:0001565/ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Abnormal inflammatory response,,HP:0012647,https://www.ncbi.nlm.nih.gov/pubmed/25173351,,,,,,,,,,
1733,201,236800,hydroxykynureninuria,,KYNU,kynureninase,3.7.1.3,,,Niacin,DB00627,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Dermatitis,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/14169454,,,,,,,,,,
1734,,236800,hydroxykynureninuria,,KYNU,kynureninase,3.7.1.3,,,Niacin,DB00627,,,,,,,,,,Diarrhoea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/14169454,,,,,,,,,,
1735,,236800,hydroxykynureninuria,,KYNU,kynureninase,3.7.1.3,,,Niacin,DB00627,,,,,,,,,,Dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/17334708,,,,,,,,,,
1736,,236800,hydroxykynureninuria,,KYNU,kynureninase,3.7.1.3,,,Niacin,DB00627,,,,,,,,,,Sensitivity to sunlight,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/10540864,,,,,,,,,,
1737,,236800,hydroxykynureninuria,,KYNU,kynureninase,3.7.1.3,,,Pyridoxal phosphate,DB00114,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Low enzyme activity,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/5586569,,,,,,,,,,
1738,202,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Laronidase,DB00090,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Low Forced Vital Capacity,,HP:0002111,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,,,,,,
1739,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Laronidase,DB00090,,,,,,,,,,High Apnea/Hypopnea Index (sleep apnea)*,,HP:0010535*,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,,,,,,
1740,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Laronidase,DB00090,,,,,,,,,,Decreased pulmonary function,,HP:0005952,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,,,,,,
1741,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Laronidase,DB00090,,,,,,,,,,Hepatomegaly,,HP:0002240,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,,,,,,
1742,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Laronidase,DB00090,,,,,,,,,,Limitation of the Joint range of motion,,HP:0001376,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,,,,,,
1743,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Laronidase,DB00090,,,,,,,,,,Six Minute Walk Test,,NA,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,,,,,,
1744,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Nanotechnology-based gene therapy (Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene),NA,ECO:0001565,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Low IDUA activity (Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/29122734,,,,,,,,,,
1745,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,Nanotechnology-based gene therapy (Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene),NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29122734,,,,,,,,,,
1746,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",GNeo-IDUA,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Neurodegenerative astrogliosis (Neurodegeneration)*,in the olfactory bulb and primary somatosensory cortex,HP:0002180*,https://www.ncbi.nlm.nih.gov/pubmed/28958576,,,,,,,,,,
1747,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,3.7.1.3,,,GNeo-IDUA,NA,,,,,,,,,,Glycosaminoglycan accumulation (Abnormality of glycosaminoglycan metabolism)*,,HP:0004371,https://www.ncbi.nlm.nih.gov/pubmed/28958576,,,,,,,,,,
1748,203,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,ECO:0000352,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Hepatosplenomegaly,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1749,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Abnormality of joint mobility,,HP:0011729,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1750,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Sleep apnea,,HP:0010535,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1751,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Nocturnal hypopnea,,HP:0002877,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1752,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Abnormal apnea–hypopnea index,,NA,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1753,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Urinary glycosaminoglycan excretion,,HP:0003541,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1754,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Photophobia,,HP:0000613,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1755,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Conjunctival irritation,,HP:0030953,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1756,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Impaired Visual acuity,,HP:0007663,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1757,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Low exercise endurance,,NA,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1758,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Tricuspid regurgitation,,HP:0005180,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1759,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Pulmonary regurgitation,,HP:0010444,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1760,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Dyspnea at rest,,HP:0012763,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1761,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Pitting edema,,HP:0000969,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1762,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Low quality of sleep,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1763,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Daytime somnolence,,HP:0002189,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1764,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,White matter abnormalities,,HP:0002500,https://www.ncbi.nlm.nih.gov/pubmed/19748810,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1765,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Brain ventricular dilatation,,HP:0002119,https://www.ncbi.nlm.nih.gov/pubmed/19748810,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1766,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Laronidase (IRT),DB00090,,,,,,,,,,Brain MRI abnormalities,,HP:0002500,https://www.ncbi.nlm.nih.gov/pubmed/19748810,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1767,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,NA,ECO:0001565,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,In Vitro Experiment,Lysosomal storage abnormalities (Abnormality of lysosomal metabolism)*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/8700879,,,,,,,,,,
1768,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Neonatal retroviral vector (RV)-mediated gene therapy+immunmodulator(CTLA4-Ig or (CTLA4-Ig + anti-CD40 ligand antibody or anti-CD4 antibody),NA+NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy+symptomatic therapeutic procedure,,Abnormal serum IDUA activity (Abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/17311010,,,,,,,,,,
1769,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Neonatal retroviral vector (RV)-mediated gene therapy+immunmodulator(CTLA4-Ig or (CTLA4-Ig + anti-CD40 ligand antibody or anti-CD4 antibody),NA+NA,,,,,,,,,,Increased bone mineral density,,HP:0011001,https://www.ncbi.nlm.nih.gov/pubmed/17311010,,,,,,,,,,
1770,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Neonatal retroviral vector (RV)-mediated gene therapy+immunmodulator(CTLA4-Ig or (CTLA4-Ig + anti-CD40 ligand antibody or anti-CD4 antibody),NA+NA,,,,,,,,,,Hearing impairment,,HP:0000365,https://www.ncbi.nlm.nih.gov/pubmed/17311010,,,,,,,,,,
1771,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,CRISPR-Cas9-mediated gene editing,NA,ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein by genome editing,,Low IDUA level (Abnormality of circulating enzyme level)*,,HP:0011021,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://www.ncbi.nlm.nih.gov/pubmed/29122734,,,,,,,,,
1772,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,CRISPR-Cas9-mediated gene editing,NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://www.ncbi.nlm.nih.gov/pubmed/29122734,,,,,,,,,
1773,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Cationic liposomes carrying the CRISPR/Cas9 plasmid  MPS I gene,NA,ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein by genome editing,in vivo (mice),Ventricular hypertrophy,,HP:0001714,https://www.ncbi.nlm.nih.gov/pubmed/30170069,,,,,,,,,,
1774,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Cationic liposomes carrying the CRISPR/Cas9 plasmid  MPS I gene,NA,,,,,,,,,,Cardiac dilation/ Heart enlargment/cardiomegaly,,HP:0001640,https://www.ncbi.nlm.nih.gov/pubmed/30170069,,,,,,,,,,
1775,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Cationic liposomes carrying the CRISPR/Cas9 plasmid  MPS I gene,NA,,,,,,,,,,Left ventricularc contractility abnormalities,,HP:0006670*,https://www.ncbi.nlm.nih.gov/pubmed/30170069,,,,,,,,,,
1776,,607014,Hurler syndrome,,IDUA,"iduronidase, alpha-L",3.7.1.3,,,Cationic liposomes carrying the CRISPR/Cas9 plasmid  MPS I gene,NA,,,,,,,,,,Left ventricle dysfunction,,HP:0030872,https://www.ncbi.nlm.nih.gov/pubmed/30170069,,,,,,,,,,
1777,204,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,,Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine,DB04789 + DB00200 +DB00165+ DB06756,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Abnormal Folate level,,HP:0040087,https://www.ncbi.nlm.nih.gov/pubmed/11916316,,,,,,,,,,
1778,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,,Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine,DB04789 + DB00200 +DB00165+ DB06756,,,,,,,,,,Abnormal serum Methylfolate Level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/11916316,,,,,,,,,,
1779,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract",Betaine+Folinic acid,DB06756+DB00650,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Abnormality of homocysteine metabolism,,HP:0010919,https://www.ncbi.nlm.nih.gov/pubmed/25024447,,,,,,,,,,
1780,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,,Betaine+Folinic acid,DB06756+DB00650,,,,,,,,,,Low muscle tone,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/25024447,,,,,,,,,,
1781,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,,Topiramate,DB00273,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Symptomatic © + Mechanistic (B),Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/25024447,,,,,,,,,,
1782,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,,Betaine+Folic acid+Vitamin B6+Vitamin B12,DB06756+DB00158+DB00165+DB00115,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High plasma homocysteine level (Abnormal homocysteine level)*,,HP:0010919,https://www.ncbi.nlm.nih.gov/pubmed/29246599,,,,,,,,,,
1783,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,"Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773",Vitamin B+Betaine,DB00165+DB6756,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Developmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/20356773,,,,,,,,,,
1784,205,236200,Homocystinuria due to CBS deficiency,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",CBS,cystathionine beta-synthase,4.2.1.22,,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).,Pyridoxine,DB00165,ECO:0000352/ECO:0000179,"P49L, A114V, I278T, R266K, or R336H",,"R125Q, E176K, T191M, T262M, or G307S",,Direct interaction,A,activity modification of a genetically defective protein,Mehanistic(B),Misfolding of cystathionine β-synthase (Abnormal enzyme activity)*,,HP:0012379*,https://www.ncbi.nlm.nih.gov/pubmed/29119254,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,
1785,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,δ-aminolevulinate,DB00855,ECO:0001565,R125Q,"One of the mutations (R125Q) exhibited an outstanding heme sensitivity, and addition of heme arginate to a fibroblast culture obtained from a patient homozygous for this mutation rescued also the activity in these human cells and increased production of cystathionine",,,Direct interaction,A,activity modification of a genetically defective protein,,Misfolding of cystathionine β-synthase (Abnormal enzyme activity)*,,HP:0012379*,https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,,,,,,,,,,
1786,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,δ-aminolevulinate,DB00855,,R266K,,,,,,,,Homocystinuria,,HP:0002156,https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,,,,,,,,,,
1787,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,δ-aminolevulinate,DB00855,,,,H65R,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,,,,,,,,,,
1788,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM.",S-Adenosylmethionine,DB00118,ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20506325?dopt=Abstract,,,,,,,,,,
1789,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,"These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU",Bortezomib,DB00188,ECO:0000179,I278T,,,,Direct interaction,A,activity modification of a genetically defective protein,Tried on Mice not human,Misfolding of cystathionine β-synthase (Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,,,,,,,,,,
1790,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,ONX-0912,DB11991,ECO:0000179,S466L /I278T,"However, response rates varied, with 100% (8/8) of the p.S466L animals showing correction, but only 38% (10/26) of the p.I278T animals.https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract",,,Direct interaction,A,activity modification of a genetically defective protein,Tried on Mice not human,Abnormal Hcy level,,HP:0010919*,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,,,,,,,,,,
1791,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,ONX-0912,DB11991,,,,,,,,,,Homocystinuria,,HP:0002156,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,,,,,,,,,,
1792,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",Pyridoxine/Betaine,DB00165/DB06756,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High total homocysteine levels,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,,,,
1793,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,Pyridoxine/Betaine,DB00165/DB06756,,,,,,,,,,High total cysteine levels,,HP:0010918,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,,,,
1794,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,Pyridoxine/Betaine,DB00165/DB06756,,,,,,,,,,Low plasma serine levels,,HP:0012279,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,,,,
1795,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,Pyridoxine/Betaine,DB00165/DB06756,,,,,,,,,,High blood S -adenosylhomocysteine level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,,,,
1796,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",Serine,DB00133,ECO:0007764,,,,,Symptomatic,C,symptomatic therapeutic procedure,No trials / speculation,Low plasma serine,The phenotype represents an expected correction based on a common finding in perople with homocystinuria.,HP:0012279,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,,,,
1797,206,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1798,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Low cerebral creatine content,,HP:0012113*,https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1799,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Low developmental score,,HP:0012759*,https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1800,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Neurodevelopmental delay,,HP:0012758,https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1801,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Cognitive dysfunction,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/20682460,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1802,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Low IQ score,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/20682460,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1803,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Language impairment,,HP:0002463,https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1804,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Behavioral abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1805,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Communicative skills abnormalities,,HP:0002474*,https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1806,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Psychomotor retardation,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1807,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,Creatine/Creatine phosphate,DB00148/DB13191,,,,,,,,,,Metabolic encephalomyopathy,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1808,207,# 612933,Lactate dehydrogenase A deficiency,,LDHA,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1.1.1.27,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1809,208,# 614128,Lactate dehydrogenase B deficiency,,LDHB,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1.1.1.27,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1810,209,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,,,Cholesterol+Simvastatin,DB04540+DB00641,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+metabolite replacement+functional complementation of a genetically defective protein by inhibition,,Abnormal blood lathosterol level,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/30097991,,,,,,,,,,
1811,,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,,The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991,Simvastatin,DB00641,ECO:0000352,p.K148E and p.D210E,A compound heterozygous missense mutation,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Abnormal neurodevelopmental profile,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/24142275,,,,,,,,,,
1812,,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,,,Simvastatin,DB00641,,,,,,,,,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/24142275,,,,,,,,,,
1813,,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,,,Simvastatin,DB00641,,,,c.479C>G p.(Pro160Arg) and c.630C>A p.(Asp210Glu),,,,,,Abnormal blood lathosterol level,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/24142275,,,,,,,,,,
1814,210,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,heptanoate,CHEBI:32362,ECO:0000352,,,,,Symptomatic,C,dietary supplementation,,Elevation of creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/24997711/,,,,,,,,,,
1815,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,heptanoate,CHEBI:32362,,,,,,,,,,Exercise-induced muscle cramps,,HP:0003710,https://www.ncbi.nlm.nih.gov/pubmed/24997711/,,,,,,,,,,
1816,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,Dietry treatment supplementation,Docosahexaenoic acid (DHA),DB03756,ECO:0007121,,,,,Symptomatic,C,dietary supplementation,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,,,,,,,,,,
1817,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Docosahexaenoic acid (DHA),DB03756,,,,,,,,,,Retinopathy progression (Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,,,,,,,,,,
1818,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Docosahexaenoic acid (DHA),DB03756,,,,,,,,,,Reduced visual acuity,,HP:0007663,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,,,,,,,,,,
1819,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Triheptanoin,DB11677,ECO:0000352,,,,,Symptomatic,C,dietary supplementation,,Cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/12122118/,,,,,,,,,,
1820,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Triheptanoin,DB11677,,,,,,,,,,Rhabdomyolysis,,HP:0003201,https://www.ncbi.nlm.nih.gov/pubmed/12122118/,,,,,,,,,,
1821,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Triheptanoin,DB11677,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/12122118/,,,,,,,,,,
1822,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Triheptanoin,DB11677,,,,,,,,,,Low quality of life (constitutional symptom)*,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/16763896/,,,,,,,,,,
1823,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Bezafibrate,DB01393,ECO:0001565,c.1528G > C,,c.1528G > C,,Direct interaction,A,activity modification of a genetically defective protein,,Abnormal Fatty acid oxidation,,HP:0004359*,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1824,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Bezafibrate,DB01393,,C2129-2A > C,,,,,,,,Low long chain 3-Hydroxyacyl-CoA dehydrogenase activity(abnormal enzyme/coenzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1825,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Bezafibrate,DB01393,,c. 1393_1479del-Del exon,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1826,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Bezafibrate,DB01393,,c.180 + 3A > G,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1827,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Bezafibrate,DB01393,,c.914 T > A,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1828,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,Bezafibrate,DB01393,,c.982G > A and c.1072C > A,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1829,211,535000,Leber hereditary optic neuropathy,,MT-ND1/MT-ND4L/MT-ND6,mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6,1.1.1.211/4.2.1.17,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1830,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene),NA,ECO:0001565,G11778A,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Optic nerve damage,,HP:0001138,https://www.ncbi.nlm.nih.gov/pubmed/17296905,,,https://www.ncbi.nlm.nih.gov/pubmed/30107658,,,,,,,
1831,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene),NA,,,,,,,,,,Mitochondrial oxidative stress,,HP:0012103,https://www.ncbi.nlm.nih.gov/pubmed/17296905,,,https://www.ncbi.nlm.nih.gov/pubmed/30107658,,,,,,,
1832,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,"rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))",NA,ECO:0007121,G11778A,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Abnormal visual acuity,,HP:0030532,https://clinicaltrials.gov/ct2/show/results/NCT01267422?cond=Leber+Hereditary+Optic+Neuropathy&rank=2&sect=X970156#outcome3,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,,,,,,,,,
1833,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,ECO:0007121,G11778A,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Low ATP synthesis,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/30208599,,,,,,,,,,
1834,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,,,,,,,,,,Optic atrophy,,HP:0000648,https://www.ncbi.nlm.nih.gov/pubmed/30208599,,,,,,,,,,
1835,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,,,,,,,,,,Abnormal visual acuity,,HP:0030534,https://www.ncbi.nlm.nih.gov/pubmed/30208599,,,,,,,,,,
1836,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30208599,,,,,,,,,,
1837,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,ECO:0000352/ECO:0007121/ECO:0000179,"m.3460G>A, m.11778G>A, and m.14484T>C",,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal visual acuity,,HP:0030532,https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://www.ncbi.nlm.nih.gov/pubmed/11001192,https://www.ncbi.nlm.nih.gov/pubmed/17573650,https://www.ncbi.nlm.nih.gov/pubmed/21788663,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,https://www.ncbi.nlm.nih.gov/pubmed/27071925,https://www.ncbi.nlm.nih.gov/pubmed/28093355,https://www.ncbi.nlm.nih.gov/pubmed/23028832/
1838,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Idebenone,DB09081,,,,,,,,,,Abnormal retinal ganglion cell function,,HP:0001112,https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,https://www.ncbi.nlm.nih.gov/pubmed/27071925,,
1839,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Idebenone,DB09081,,,,,,,,,,Retinal thickness,,HP:0000630,https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,https://www.ncbi.nlm.nih.gov/pubmed/27071925,,
1840,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Idebenone,DB09081,,,,,,,,,,Gliosis,,HP:0002171,https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,https://www.ncbi.nlm.nih.gov/pubmed/27071925,,
1841,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Idebenone,DB09081,,,,,,,,,,Functional loss of vision,,HP:0000572,https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,https://www.ncbi.nlm.nih.gov/pubmed/27071925,,
1842,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Idebenone,DB09081,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,https://www.ncbi.nlm.nih.gov/pubmed/27071925,,
1843,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Idebenone+Vitamin C+Vitamin B12,DB09081+DB00126+DB00115,ECO:0000352,,,,,Functional interaction+Symptomatic+Symptomatic,B+C+C,combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Slow recovery,,HP:0012823*,https://www.ncbi.nlm.nih.gov/pubmed/11001192/,,,,,,,,,,
1844,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,EPI-743(Vatiquinone),DB11917,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,,,,,,
1845,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,EPI-743(Vatiquinone),DB11917,,,,,,,,,,Abnormal visual acuity,,HP:0030534,https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,,,,,,
1846,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,EPI-743(Vatiquinone),DB11917,,,,,,,,,,Visual loss,,HP:0000572,https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,,,,,,
1847,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,EPI-743(Vatiquinone),DB11917,,,,,,,,,,Retinal ganglion loss,,HP:0000479,https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,,,,,,
1848,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Estrogens,DB00783,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/20943885,,,,,,,,,,
1849,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Elamipretide (MTP-131),DB11981,ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Increased reactive oxygen species production,,HP:0025464,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790,,,,,,,,
1850,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Elamipretide (MTP-131),DB11981,,,,,,,,,,Low ATP synthesis,,HP:0025464,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790,,,,,,,,
1851,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Curcumin,DB11672,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT00528151,,,,,,,,,,
1852,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Cyclosporine,DB00091,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Disease progression,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pubmed/24161764,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,,,,,,,,,
1853,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,Corticosteroid+Antiaggregates,H02+B01A,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Large central visual field defect,,HP:0001129,https://www.ncbi.nlm.nih.gov/pubmed/11723211,,,,,,,,,,
1854,212,220111,"Leigh syndrome, French Canadian type","Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/",LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,Methylene blue,DB09241,ECO:0001565,A354V,,,,Functional interaction,B,metabolite replacement,,Low COX content and activity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22202226,,,,,,,,,,
1855,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,Methylene blue,DB09241,,A354V and C12775STOP,,,,,,,,Acidotic crises,,HP:0001941*,https://www.ncbi.nlm.nih.gov/pubmed/22202226,,,,,,,,,,
1856,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,Propionate,DB03766,ECO:0001565,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Palmitate plus lactate-induced cell death(abnormal cell death)*,,MP:0000313,https://www.ncbi.nlm.nih.gov/pubmed/25835550,,,,,,,,,,
1857,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,L-carnitine,DB00583,ECO:0001565,,,,,Symptomatic,C,symptomatic therapeutic procedure,,PL-induced cytotoxicity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25835550,,,,,,,,,,
1858,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,Trolox ornithylamide hydrochloride,NA,ECO:0001565,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Increased ROS production,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/25620325/,,,,,,,,,,
1859,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,Trolox ornithylamide hydrochloride,NA,,,,,,,,,,Decreased activity of mitochondrial complex I,,HP:0011923,https://www.ncbi.nlm.nih.gov/pubmed/25620325/,,,,,,,,,,
1860,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,Trolox ornithylamide hydrochloride,NA,,,,,,,,,,Decreased activity of mitochondrial complex IV,,HP:0008347,https://www.ncbi.nlm.nih.gov/pubmed/25620325/,,,,,,,,,,
1861,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,Trolox ornithylamide hydrochloride,NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25620325/,,,,,,,,,,
1862,213,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Ecopipam ((PSYRX 101),DB12273,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Self-injurious Behavior,,HP:0100716,https://clinicaltrials.gov/ct2/show/results/NCT01751802?cond=Lesch-Nyhan+Disease&rank=3&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,,,,,,,
1863,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Sapropterin,DB00360,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Behaviour abnormalities,,HP:0100851,https://clinicaltrials.gov/ct2/show/NCT00935753,,,,,,,,,,
1864,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,No result was added to the study.,Aminomidazole carboxamide riboside,NA,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,,,,https://clinicaltrials.gov/ct2/show/NCT00004314?cond=Lesch-Nyhan+Disease&rank=4,,,,,,,,,,
1865,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,Treatment with tetrahydrobiopterin had no effect on the neurological symptoms although his urinary dopamine excretion increased significantly.https://www.nature.com/articles/pr19852350,Hypoxanthine+ tetrahydrobiopterin,DB04076+DB00360,ECO:0000352,,,,,Functional interaction+Symptomatic,B+C,combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure,,,,,https://www.ncbi.nlm.nih.gov/pubmed/3728152,,,,,,,,,,
1866,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,SAM (S-adenosyl methionine ),DB00118,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Self-injurious behaviour,,HP:0100716,https://www.ncbi.nlm.nih.gov/pubmed/16906475/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,,,,,,,,
1867,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,SAM (S-adenosyl methionine ),DB00118,,,,,,,,,,Aggressive behavior,,HP:0000718,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,,,,,,,,
1868,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,SAM (S-adenosyl methionine ),DB00118,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,,,,,,,,
1869,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,The therapy had to be interrupted because of renal colics,Hypoxanthine+Allopurinol,DB04076+DB00437,ECO:0000352,,,,,Functional interaction+Symptomatic,,combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure,,Disturbances of equilibrium,,HP:0002141,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=HYPOXANTHINE+AND+TETRAHYDROBIOPTERIN+TREATMENT+OF+A+PATIENT+WITH+FEATURES+OF+THE+LESCH-NYHAN+SYNDROME%3A+118&btnG=,,,,,,,,,,
1870,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Hypoxanthine+Allopurinol,DB04076+DB00437,,,,,,,,,,Aggressive behavior,,HP:0000718,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=HYPOXANTHINE+AND+TETRAHYDROBIOPTERIN+TREATMENT+OF+A+PATIENT+WITH+FEATURES+OF+THE+LESCH-NYHAN+SYNDROME%3A+118&btnG=,,,,,,,,,,
1871,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Allopurinol,DB00437,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,,,,,,,,
1872,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Allopurinol,DB00437,,,,,,,,,,Gouty arthritis,,HP:0001997,https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,,,,,,,,
1873,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Allopurinol,DB00437,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,,,,,,,,
1874,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Baclofen,DB00181,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/16549399,,,,,,,,,,
1875,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Diazepam/Alprazolam,DB00829 or DB00404,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Anxiety,,HP:0000739,https://www.ncbi.nlm.nih.gov/pubmed/21126241,,,,,,,,,,
1876,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Diazepam/Alprazolam,DB00829 or DB00404,,,,,,,,,,Abnormal muscle tone,,HP:0003808,https://www.ncbi.nlm.nih.gov/pubmed/21126241,,,,,,,,,,
1877,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Risperidone,DB00734,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Self-mutilation,,HP:0000742,https://www.ncbi.nlm.nih.gov/pubmed/8870064/,,,,,,,,,,
1878,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Tetrabenazin,DB04844,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Chorea,,HP:0002072,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,,,,,,,,,
1879,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Tetrabenazin,DB04844,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,,,,,,,,,
1880,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Carbidopa‐levodopa,DB00190+DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1881,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Carbidopa‐levodopa,DB00190+DB01235,,,,,,,,,,Chorea,,HP:0002072,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1882,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,Carbidopa‐levodopa,DB00190+DB01235,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1883,214,240800,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ATP binding cassette subfamily C member 8,1.1.1.211/4.2.1.17,,,Diazoxide,DB01119,ECO:0000352,E1506K,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15356046,,,,,,,,,,
1884,,240800,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ATP binding cassette subfamily C member 8,1.1.1.211/4.2.1.17,,,Diazoxide,DB01119,,R1353H,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15356046,,,,,,,,,,
1885,,240800,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ATP binding cassette subfamily C member 8,1.1.1.211/4.2.1.17,,,Diazoxide,DB01119,,delSer1387,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15356046,,,,,,,,,,
1886,215,613724,Leukoencephalopathy-dystonia-motor neuropathy syndrome(STEROL CARRIER PROTEIN 2 DEFICIENCY),,SCP2,sterol carrier protein 2,1.1.1.211/4.2.1.17,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16685654,,,,,,,,,,
1887,216,611105,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,mitochondrial aspartyl-tRNA synthetase,1.1.1.211/4.2.1.17,,,acetazolamide,DB00819,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Paroxysmal exercise-induced gait ataxia (exercise-induced episodic ataxia ),,HP:0002066*,https://www.ncbi.nlm.nih.gov/pubmed/21749991,,,,,,,,,,
1888,,611105,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,mitochondrial aspartyl-tRNA synthetase,1.1.1.211/4.2.1.17,,,acetazolamide,DB00819,,,,,,,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/21749991,,,,,,,,,,
1889,,611105,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,mitochondrial aspartyl-tRNA synthetase,1.1.1.211/4.2.1.17,,,glucocorticosteroid,DB00288,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Spastic bladder,,HP:0005340,https://www.ncbi.nlm.nih.gov/pubmed/23644316,,,,,,,,,,
1890,217,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,Prednisolone,DB00860,ECO:0000352/ECO:0007764,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: It has been mentioned that it might be beneficial in compound heterozygous mutations as patients have a milder phenotypes. https://www.ncbi.nlm.nih.gov/pubmed/28931339#,Myositis,,HP:0100614,https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099,,,,,,,,,
1891,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,Prednisolone,DB00860,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099,,,,,,,,,
1892,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,Prednisolone,DB00860,,,,,,,,,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099,,,,,,,,,
1893,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,Prednisolone,DB00860,,,,,,,,,,Rapid progression,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099,,,,,,,,,
1894,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,rAAV-Fkrp,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Abnormal serum creatine kinase,,HP:0040081,https://www.ncbi.nlm.nih.gov/pubmed/25048216,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302,,,,,,,
1895,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,rAAV-Fkrp,NA,,,,,,,,,,Muscle dystrophy,,HP:0006785,https://www.ncbi.nlm.nih.gov/pubmed/28107841,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302,,,,,,,
1896,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,rAAV-Fkrp,NA,,,,,,,,,,Abnormal muscle function,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/28107841,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302,,,,,,,
1897,218,609308,LGMD2K,,POMT1,protein O-mannosyltransferase 1,2.4.1.109,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,,
1898,219,611307,Limb-girdle muscular dystrophy type 2I (LGMD2I),,ANO5,anoctamin 5,Q75V66,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1899,220,253601,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B",,DYSF,dysferlin,O75923,,,Resolaris (ATYR1940),NA,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal muscle function,,HP:0011804,https://clinicaltrials.gov/ct2/show/NCT02579239,https://musculardystrophynews.com/resolaris-atyr1940/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,
1900,221,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,calpain 3,3.4.22.17,,,AAV2 /1-mSeAP-propmyoD76A,NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Muscle atrophy,,HP:0003797,https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,
1901,,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,calpain 3,3.4.22.17,,,AAV2 /1-mSeAP-propmyoD76A,NA,,,,,,,,,,Abnormal muscle strenght,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A,,,,,,,
1902,,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,calpain 3,3.4.22.17,,,(r) AAV2/1-mediated calpain 3,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Low muscle mass,,HP:0003199,https://www.ncbi.nlm.nih.gov/pubmed/17330087,,,,,,,,,,
1903,222,608099,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D",,SGCA,sarcoglycan alpha,Q16586,,,AAV2/1-MCK-Sgca,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,Drug name: Tried in mice not human,Decreased muscle mass,,HP:0003199,https://www.ncbi.nlm.nih.gov/pubmed/?term=AAV-mediated+delivery+of+a+mutated+myostatin+propeptide+ameliorates+calpain+3+but+not+α-sarcoglycan+deficiency,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/15252120,,,,,,,,
1904,223,608896,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C",,SGCG,sarcoglycan gamma,Q16586,,,AAV1-gamma-sarcoglycan,NA,ECO:0007121,,,,,,,,,Reduced muscle fiber gamma sarcoglycan,,HP:0030108,https://clinicaltrials.gov/ct2/show/NCT01344798?cond=MUSCULAR+DYSTROPHY%2C+LIMB-GIRDLE%2C+TYPE+2C%3B+LGMD2C&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22240777,https://www.ncbi.nlm.nih.gov/pubmed/16635485,,,,,,,,
1905,224,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,,Poor compliance to the treatment was noticed,Fenofibrate+ω-3 fatty acids+EPA+DHA,DB01039+DB11133+DB00159 +DB03756,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,Drug name: Poor compliance to the treatment was noticed,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1906,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,,"Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil",gemfibrozil+ω-3 fatty acids,DB01241+DB11133,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,"Drug name: Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil (600 mg twice a day",Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1907,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,,,Insulin aspart+Fibrate(gemfibrozil)+ ω-3 fatty acids,DB01306+DB01241+DB11133,ECO:0000352,W464X,,,,Symptomatic+Functional interaction+Functional interaction,C+B+B,combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,Drug name: Improvement in the triglycride level startrd Under insulin therapy with a good blood glucose control (glycosylated hemoglobin 5.6%) and an improved lipid profile with TG plasma levels as low as 195 mg/dl (2.2 mmol/liter),Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1908,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,,,Insulin aspart+Fibrate(gemfibrozil)+ ω-3 fatty acids,DB01306+DB01241+DB11133,,,,,,,,,,Hyperglycemia,,HP:0003074,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1909,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,,A low fat regimen was added to metformin while treating the patient.,Metformin,DB00331,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/17994020/,,,,,,,,,,
1910,225,614462,Lipoic acid synthetase deficiency,,LIAS,lipoic acid synthetase,2.8.1.8,,,Topiramate+lamotrigine,DB00273+DB00555,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24777537,,,,,,,,,,
1911,226,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,Acitretin,DB00459,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Skin lesion,,HP:0011122,https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,,,,,,,,,
1912,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,Acitretin,DB00459,,,,,,,,,,Skin papules,,HP:0200034,https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,,,,,,,,,
1913,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,Acitretin,DB00459,,,,,,,,,,Mucosal lesions (Abnormal oral mucosa morphology)*,,HP:0011830,https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,,,,,,,,,
1914,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,Acitretin,DB00459,,,,,,,,,,Hoarseness,,HP:0001609,https://www.ncbi.nlm.nih.gov/pubmed/23259080/,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,,,,,,,,,
1915,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,Acitretin,DB00459,,,,,,,,,,Elbow skin thickening,,HP:0001072,https://www.ncbi.nlm.nih.gov/pubmed/28681064,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,,,,,,,,,
1916,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,Acitretin,DB00459,,,,,,,,,,Hyperkeratosis,,HP:0000962,https://www.ncbi.nlm.nih.gov/pubmed/28681064,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,,,,,,,,,
1917,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,Acitretin,DB00459,,,,,,,,,,Verrucous lesions,,HP:0012500,https://www.ncbi.nlm.nih.gov/pubmed/28681064,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,,,,,,,,,
1918,227,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",Sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Proximal tubular dysfunction,,HP:0000114,https://www.ncbi.nlm.nih.gov/pubmed/12937245,https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.ncbi.nlm.nih.gov/pubmed/27708066,,,,,,,,
1919,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,Potassium bicarbonate,DB11098,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.ncbi.nlm.nih.gov/pubmed/27708066,,,,,,,,,
1920,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",Potassium citrate,DB09125,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Metabolic acidosis (Hyperchloremic metabolic acidosis),,HP:0004918,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1921,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,Potassium citrate,DB09125,,,,,,,,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1922,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",Phosphate+Calcitriol,DB14573+DB00136,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Renal rickets,,HP:0002748,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1923,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,Phosphate+Calcitriol,DB14573+DB00136,,,,,,Symptomatic,C,,,Hypophosphatemia,,HP:0002148,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1924,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",1-OH vitamin D,DB11094,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Hyperparathyrodism,,HP:0000867,https://www.ncbi.nlm.nih.gov/pubmed/2017228,https://www.ncbi.nlm.nih.gov/pubmed/27708066,https://www.ncbi.nlm.nih.gov/pubmed/18480301/,,,,,,,,
1925,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,Pamidronate +Growth hormone,DB00282+DB00052,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Hypophosphatasia,,HP:0002148,https://www.ncbi.nlm.nih.gov/pubmed/19773212/,,,,,,,,,,
1926,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,Pamidronate +Growth hormone,DB00282+DB00052,,,,,,,,,,Osteoporosis,,HP:0000939,https://www.ncbi.nlm.nih.gov/pubmed/19773212/,,,,,,,,,,
1927,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,Thiazide,DB01325,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High calcium excretion,,HP:0002150,https://www.ncbi.nlm.nih.gov/pubmed/26251718,,,,,,,,,,
1928,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,L-carnitine,DB00583,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Secondary carnitine deficiency (Carnitine deficiency)*,,HP:0003234,https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf,https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+First+Reported+Case+of+Oculocerebrorenal+Syndrome+of+Lowe+in+Hong+Kong+and+Review+of+Literature&btnG=,,,,,,,,
1929,228,222700,Lysinuric protein intolerance,"General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/",SLC7A7,Y+L amino acid transporter 1,Q9UM01,,"Citrulline should be given in ""Low-dose"" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650",Citrulline,DB00155,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,"Drug name: in ""Low-dose""",Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380,,,,,,
1930,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,"The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",corticosteroids (Amcinonide)+cyclosporin,DB00288+DB00091,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,"Drug namre: The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",Hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*,Only one patient improved using this regimen in this study. The other two patients required platelets transfusion.,HP:0010978,https://www.ncbi.nlm.nih.gov/pubmed/28057010,,,,,,,,,,
1931,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",Alendronate,DB00630,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Osteopenia,,HP:0000938,https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,,,,,,,,,,
1932,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,ACEI (Benazepril),DB00542,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Kidney failure,,HP:0000083,,,,,,,,,,,
1933,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,ACEI (Benazepril),DB00542,,,,,,,,,,Proteinuria,,HP:0000093,,,,,,,,,,,
1934,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,ACEI (Benazepril),DB00542,,,,,,,,,,Hypertension,,HP:0000822,,,,,,,,,,,
1935,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,Drug has no difference in terms of prognosis.,Sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,Drug has no difference in terms of prognosis.,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/26865117,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,
1936,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,Drug has no difference in terms of prognosis.,Sodium benzoate,DB03793,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,Drug has no difference in terms of prognosis.,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1937,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Lysine,DB00123,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Hypolysinemia,,HP:0500142,,,,,,,,,,,
1938,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583/DB00155,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,"No obvious benefit from oral supplementation with citrulline, lysine or arginine.",Orotic aciduria,The drug works through preventing the aciduria and the hyperammonemia rather than treating it.,HP:0003218,https://www.ncbi.nlm.nih.gov/pubmed/25614305,,,,,,,,,,
1939,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583/DB00155,,,,,,Symptomatic,C,,"No obvious benefit from oral supplementation with citrulline, lysine or arginine.",Hypolysinemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1940,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583/DB00155,,,,,,,,,,Intracellular defect of arginine,,HP:0005961,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1941,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583/DB00155,,,,,,,,,The dosage of L-citrulline dosage was a subject of controversy because of the possibility that it could increase inflammatory damages through its conversion to arginine and NO. L-Citrulline supplementation is thus usually limited to 100 mg/kg/d,Hyperproteinemia,,HP:0002152,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1942,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Growth hormone,DB00052,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,"In order to get a favorable outcome in GH-treated children, Treatment with rhGH should be started early.",Growth impairment,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/16775724/,https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,,,,,,,,
1943,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Growth hormone,DB00052,,,,,,,,,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/16775724/,https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,,,,,,,,
1944,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Carnitine,DB00583,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/28057010,,,,,,,,,
1945,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Episodic behavioral abnormalities (Behavioral abnormality)*,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27567650,,,,,,,,,,
1946,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,,,,,,,,,,Social interaction defect,,HP:0000735,https://www.ncbi.nlm.nih.gov/pubmed/27567650,,,,,,,,,,
1947,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,,,,,,,,,,Lack eye-eye contact,,HP:0000817,https://www.ncbi.nlm.nih.gov/pubmed/27567650,,,,,,,,,,
1948,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/27567650,,,,,,,,,,
1949,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Sargramostim,DB00020,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,symptomatic therapeutic procedure,Pulmonary Alveolar Proteinosis,,HP:0006517,https://www.ncbi.nlm.nih.gov/pubmed/27783330,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,,,,,,,
1950,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Sargramostim,DB00020,,,,,,,,,,Low pulmonary function,,HP:0005952,https://www.ncbi.nlm.nih.gov/pubmed/27783330,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,,,,,,,
1951,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Regramostim,DB05386,ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Pulmonary Alveolar Proteinosis,,HP:0006517,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527,,https://www.ncbi.nlm.nih.gov/pubmed/24886114,,,,,
1952,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Regramostim,DB05386,,,,,,,,,,Low pulmonary function,,HP:0005952,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527,,https://www.ncbi.nlm.nih.gov/pubmed/24886114,,,,,
1953,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,Prednisolone+mycophenolate mofetil,DB00860+DB00688,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Membranoproliferative glomerulonephritis,,HP:0000793,https://www.ncbi.nlm.nih.gov/pubmed/28087478,,,,,,,,,,
1954,229,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,"The diet regime consists of 30% long‐chain triglycerides – LCTs; 70% MCTs in this study https://www.ncbi.nlm.nih.gov/pubmed/28781843 
In another study the diset regime consisited of  (Long chain triglyceride-restricted/medium-chain triglyceride-supplemented diet with the composition of  1.9% energy from LCT, 25% from MCT and the remainder carbohydrate. https://www.ncbi.nlm.nih.gov/pubmed/20549361
While in two other studies the diet regime didn't improve the case. https://www.ncbi.nlm.nih.gov/pubmed/9177981?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/17535268?dopt=Abstract",Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+dietary regime modification+dietary regime modification+dietary regime modification,,High urinary malonic acid,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/24613099,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1955,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,,,,,,,,,,High blood malonylcarnitine level,,HP:0031544,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1956,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,,,,,,,,,,Low endurance,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1957,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,,,,,,,,,,Failurre to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/24613099,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1958,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,,,,,,,,,,Cardiomyopathy progrssion (Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/16078122,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1959,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,,,,,,,,,,Muscular hypotonia,,HP:0001252,https://www.ncbi.nlm.nih.gov/pubmed/16078122,https://www.ncbi.nlm.nih.gov/pubmed/16078122,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1960,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,,,,,,,,,,Delayed ability to sit,,HP:0025336,https://www.ncbi.nlm.nih.gov/pubmed/16078122,https://www.ncbi.nlm.nih.gov/pubmed/16078122,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1961,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil,DB00583+NA+NA+DB13961,,,,,,,,,,Abnormal cardiac ventricular function,,HP:0030872,https://www.ncbi.nlm.nih.gov/pubmed/20549361,https://www.ncbi.nlm.nih.gov/pubmed/16078122,,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract,,,,,,
1962,230,614202,MAN1B1-CDG,,MAN1B1,mannosidase alpha class 1B member 1,4.1.1.9,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29908352,,,,,,,,,,
1963,231,611722,Krabbe disease atypical due to Saposin A deficiency,,PSAP,prosaposin,4.1.1.9,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1964,232,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Folinic acid,DB00650,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,Drug has a controversial study regarding patients reponce to treatment. https://www.ncbi.nlm.nih.gov/pubmed/28318733,Low 5‐MTHF level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733,,,,,,,,,
1965,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Folinic acid,DB00650,,,,,,,,,,White matter alteration,,HP:0002500,https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733,,,,,,,,,
1966,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Folinic acid,DB00650,,,,,,,,,,Deambulation,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733,,,,,,,,,
1967,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Growth Hormone,DB00052,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Short Stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/27718492,,,,,,,,,,
1968,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Coenzyme Q10,DB09270,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Corneal Oedema,,HP:0012040,https://www.ncbi.nlm.nih.gov/pubmed/27442316,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,
1969,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Coenzyme Q10,DB09270,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/26118651,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,
1970,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,L-carnitine,DB00583,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Mitochondrial respiratory chain defects,,HP:0200125,https://www.ncbi.nlm.nih.gov/pubmed/19891905,,,,,,,,,,
1971,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,L-carnitine,DB00583,,,,,,,,,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,,,
1972,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Dopamine+Dobutamine+Thiazide+Milrinone,DB00988+DB0084+DB00232+DB00235,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic+Symptomatic,C+C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Acute congestive heart failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,,,
1973,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Mitochonic acid 5,NA,ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1974,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Mitochonic acid 5,NA,,,,,,,,,,Decreased cellular ATP level,,HP:0011925*,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1975,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Mitochonic acid 5,NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1976,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Insulin,DB00030,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Diabetes mellitus,,HP:0000819,https://www.ncbi.nlm.nih.gov/pubmed/25092642,,,,,,,,,,
1977,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001,Cysteamine bitartrate,DB00847,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,,,,https://clinicaltrials.gov/ct2/show/NCT02023866?cond=Kearns-Sayre+Syndrome&rank=4,https://clinicaltrials.gov/ct2/show/NCT02473445,,,,,,,,,
1978,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Sodium Pyruvate,DB00119,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Elevated serum lactate level,,HP:0002151,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
1979,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Sodium Pyruvate,DB00119,,,,,,,,,,High lactate/pyruvate ratio (Mitochondrial respiratory chain defects)*,,HP:0200125,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
1980,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Sodium Pyruvate,DB00119,,,,,,,,,,Increased lateral ventricular lactate level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
1981,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Sodium Pyruvate,DB00119,,,,,,,,,,High serum GDF15 level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
1982,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Phenobarbital+phenytoin,DB01174 +DB00252,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Generalized tonic-clonic seizures,,HP:0002069,,,,,,,,,,,
1983,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,Phenobarbital+phenytoin,DB01174 +DB00252,,,,,,,,,,,,,,,,,,,,,,,
1984,233,609242,Kanzaki disease/schindler Disease type 2,,NAGA,alpha-N-acetylgalactosaminidase,4.1.1.9,,"A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.","Iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)",NA,ECO:0000179/ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,"clinical candidate , tested invitro and in cellular experiments",Abnormal alpha-N-acetylgalactosaminidase (Abnormal enzyme/coenzyme activity),,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/23045655,,,,,,,,,,
1985,,609242,Kanzaki disease/schindler Disease type 2,,NAGA,alpha-N-acetylgalactosaminidase,4.1.1.9,,,L-deoxygalactonojirimycin (DGJ),DB05018,ECO:0000179/ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein,,,,,,,,,,,,,,,
1986,234,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,Carglumic acid,DB06775,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Acute hyperammonemia,,HP:0008281,https://www.ncbi.nlm.nih.gov/pubmed/21207059,https://www.ncbi.nlm.nih.gov/pubmed/21403788,,,,,,,,,
1987,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High toxic acyl-CoA level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21290185,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1988,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,L-carnitine +L- glycine,DB00583+DB00145,,,,,,,,,,"Abnormal Na+,K+-ATPase activity(Abnormal enzyme activity)*",,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/15624372,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1989,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,L-carnitine +L- glycine,DB00583+DB00145,,,,,,,,,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/16602101,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1990,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,L-carnitine +L- glycine,DB00583+DB00145,,,,,,,,,,High 3-hydroxyisovaleric acid level (C5),,NA,https://www.ncbi.nlm.nih.gov/pubmed/17299485,https://www.ncbi.nlm.nih.gov/pubmed/16602101/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1991,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,L-carnitine +L- glycine,DB00583+DB00145,,,,,,,,,,Metabolic stress,The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/8804338,https://www.ncbi.nlm.nih.gov/pubmed/16602101/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1992,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,L-carnitine +L- glycine,DB00583+DB00145,,,,,,,,,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/8804338,https://www.ncbi.nlm.nih.gov/pubmed/16602101/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1993,235,611283,Isobutyryl-CoA dehydrogenase deficiency,"It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379",ACAD8,isobutyryl-CoA dehydrogenase,4.1.1.9,,,L-carnitine,DB00583,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Carnitine deficiency,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/28053874,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/9889013/,,,,,,,,
1994,,611283,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,isobutyryl-CoA dehydrogenase,4.1.1.9,,,L-carnitine,DB00583,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/9889013/,,,,,,,,
1995,,611283,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,isobutyryl-CoA dehydrogenase,4.1.1.9,,,L- carnitine+valine-restricted diet+riboflavin,DB00583+NA+DB00140,ECO:0000352,,,,,Functional interaction+Functional interaction+Symptomatic,B+B+C,combination therapeutic procedure+metabolite replacement+dietary exclusion+symptomatic therapeutic procedure,,Growth abnormality,,HP:0001507,https://www.ncbi.nlm.nih.gov/pubmed/16857760?dopt=Abstract&holding=npg,,,,,,,,,,
1996,236,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/",Vitamin B12,DB00115,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Low levels of serum vitamin B12,,HP:0100502,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707,,,,,,,
1997,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,,Vitamin B12,DB00115,,,,,,,,,,High RBC's mean corpuscular volume,,HP:0025548,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707,,,,,,,
1998,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,,Vitamin B12,DB00115,,,,,,,,,,Low Hemoglobin concentration,,HP:0020062,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707,,,,,,,
1999,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,,Vitamin B12,DB00115,,,,,,,,,,Abnormal reticulocyte count,,HP:0004312,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707,,,,,,,
2000,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,,Corticosteroid,DB00860,,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Gastric mucosal atrophy (Abnormality of gastric mucosa)*,,HP:0004295,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/921733,,,,,,,,,
2001,237,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,ECO:0007121/ECO:0000352,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Low height velocity,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,https://clinicaltrials.gov/ct2/show/NCT00125164?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=7,https://clinicaltrials.gov/ct2/show/NCT00330668?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=6
2002,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Low lean body mass,,HP:0045082,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2003,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Abnormal linear growth (Decreased linear growth/Abnormal body height)*,,HP:0000002,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2004,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Low insulin senstivity,,HP:0008189,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2005,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Abnormal circulating GH level,,HP:0032367,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2006,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Abnormal circulating IGFBP level,,HP:0031034,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2007,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Abnormal circulating insulin level,,HP:0040215,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2008,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Decreased body mass index,,HP:0045082,https://www.ncbi.nlm.nih.gov/pubmed/10770174,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2009,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Abnormal Body fat composition,,HP:0025521,https://www.ncbi.nlm.nih.gov/pubmed/10770174,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2010,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Recombinant human IGF1(Mecasermin),DB01277,,,,,,,,,,Insulin resistance,,HP:0000855,https://www.ncbi.nlm.nih.gov/pubmed/10770174,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,,
2011,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,The study is terminated (The study was prematurely terminated due to strategic reasons.),NutropinAq® (Somatropin [rDNA origin],DB00052,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Short stature,,HP:0004322,https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4,,,,,,,,,,
2012,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,The study is terminated (The study was prematurely terminated due to strategic reasons.),Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]),DB01277+DB00052,ECO:0007121,,,,,Direct interaction+Functional interaction,A+B,combination therapeutic procedure+direct complementation of a genetically defective protein+Functional complementation of a genetically defective protein,,Short stature,,HP:0004322,https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4,,,,,,,,,,
2013,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,"Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement",Mecasermin rinfabate,DB14751,ECO:0000352,,,,,Direct interaction,A,direct complementation of a genetically defective protein,"Drug name: Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement",hypoglycemia,"The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.",HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/19627167,,,,,,,,,,
2014,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,,,Mecasermin rinfabate,DB14751,,,,,,,,,,Low serum ICFBP level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/19627167,,,,,,,,,,
2015,238,271245,Infantile-onset spinocerebellar ataxia,Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.,TWNK,twinkle mtDNA helicase,Q96RR1,,The drug is occasionally effective especially when started early in status epilepticus.,Benzodiazepines,DB00252,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,"Drug nmae:However, phenytoin and phenobarbitates are ineffective in most affected individuals",Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/20301746,,,,,,,,,,
2016,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,The drug has some effects but hyponatremia is a troublesome side effect.,Oxcarbazepine,DB00776,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Short nocturnal tonic seizures,,HP:0031951,https://www.ncbi.nlm.nih.gov/pubmed/19304794,https://www.ncbi.nlm.nih.gov/pubmed/20301746,,,,,,,,,
2017,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",Valproate,DB00313,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: Should be avoided as it results in elevated liver enzymes only when treated with valproate,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/27551684,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
2018,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,,Selective serotonin reuptake inhibitors+Antipsychotics,N06AB +N05A,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Agitation,,HP:0000713,https://www.ncbi.nlm.nih.gov/pubmed/19304794,,,,,,,,,,
2019,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,,Selective serotonin reuptake inhibitors+Antipsychotics,N06AB +N05A,,,,,,,,,,Aggressive behavior,,HP:0000718,https://www.ncbi.nlm.nih.gov/pubmed/19304794,,,,,,,,,,
2020,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,,Carbamazepine,DB00564,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Complex partial seizure,,HP:0002384,,,,,,,,,,,
2021,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,,Carbamazepine,DB00564,,,,,,,,,,Generalized convulsion,,HP:0002197,,,,,,,,,,,
2022,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,,Topiramate + pyridoxine,DB00273+DB00165,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/27551684,,,,,,,,,,
2023,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,"The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890",Creatine,DB00583,ECO:0007764,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Abnormal circulating creatinine level,,HP:0012100,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
2024,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,"Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891",Glutathione [N‐acetyl‐cysteine],DB00143,ECO:0007764,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
2025,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,,Glutathione [N‐acetyl‐cysteine],DB00143,,,,,,,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
2026,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,Q96RR1,,A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892,NAD+ [nicotinamide riboside],DB14933,ECO:0007764,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Niacinamide depletion,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
2027,239,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,ECO:0007121/ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Chronic constipation,,HP:0012450,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,,,,,,,,,
2028,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,"RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,Bulbar dysfunction,,HP:0001283,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,,,,,,,,,
2029,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,"RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,Functional motoe deficit,,HP:0004302,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,,,,,,,,,
2030,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,"RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,Defective eye motor function,,HP:0000496,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,,,,,,,,,
2031,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,"RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,Poor head control,,HP:0002421,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,,,,,,,,,
2032,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,"RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,,,,,,,,,
2033,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Desipramine,DB01151,ECO:0007121/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Lysosomal stress (Abnormality of lysosomal metabolism)*,In the mouse model syudy,HP:0004356,https://clinicaltrials.gov/ct2/show/NCT03726996,https://www.ncbi.nlm.nih.gov/pubmed/29909971,,,,,,,,,
2034,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,Desipramine,DB01151,,,,,,,,,,Neurodegeneration,In the mouse model syudy,HP:0002180,https://clinicaltrials.gov/ct2/show/NCT03726996,https://www.ncbi.nlm.nih.gov/pubmed/29909971,,,,,,,,,
2035,240,269920,Free sialic acid storage disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,,Treatment of manifestations:Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions. https://www.ncbi.nlm.nih.gov/pubmed/20301643,No treatment is available in DDIEM,,,,,,,,C,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20301643,,,,,,,,,
2036,241,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,,,Levetiracetam,DB01202,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Generalized tonic-clonic seizure,,HP:0002069,https://www.ncbi.nlm.nih.gov/pubmed/28662915,,,,,,,,,,
2037,,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,,,Phenobarbital,DB01174,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/12794688,,,,,,,,,,
2038,,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,,,Phenobarbital,DB01174,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12794688,,,,,,,,,,
2039,,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,,,Phenobarbital,DB01174,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12794688,,,,,,,,,,
2040,242,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,ManNac (N-acetylmannosamine),DB12536,ECO:0007121,,,,,Functional interaction,B,metabolite replacement,,Decreased sialylation of muscle glycans,,HP:0012350,https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,,,,,,,,
2041,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,ManNac (N-acetylmannosamine),DB12536,,,,,,,,,,Low circulating levels of free sialic acids,,HP:0012363,https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,,,,,,,,
2042,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,ManNac (N-acetylmannosamine),DB12536,,,,,,,,,,Rimmed vacuoles,,HP:0003805,https://www.ncbi.nlm.nih.gov/pubmed/21517694,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,,,,,,,,
2043,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,ManNac (N-acetylmannosamine),DB12536,,,,,,,,,,Amyloid deposition,,HP:0003216*,https://www.ncbi.nlm.nih.gov/pubmed/21517694,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,,,,,,,,
2044,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine),CHEBI:17012+DB12536,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+metabolite replacement+metabolite replacment,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,,,,,,,
2045,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine),CHEBI:17012+DB12536,,,,,,,,,,Decreased sialylation of muscle glycans,,HP:0012350,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,,,,,,,
2046,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,GNE gene lipoplex,NA,ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Decline of muscle strength (Muscle weakness),,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
2047,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,,Sialic acid,CHEBI:17012,,,,,,Functional interaction,B,metabolite replacement,,Muscle weakness,,HP:0001324,,,,,,,,,,,
2048,243,252500,I cell disease,,GNPTAB,(α) &(β)GlcNAc-1-phosphotransferas,"3.2.1.183, 2.7.1.60",,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2049,244,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,Drug name :This study has been conducted in puppies but the treatment's results are the same for humans based on this sudy https://www.ncbi.nlm.nih.gov/pubmed/18768530,Megalobalstic anaemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2050,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,,,,,,,,,,Low level of serum B12,,HP:0040126,https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2051,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,,,,,,,,,,Neurological abnormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2052,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,,,,,,,,,,Normocytic anemia,,HP:0001897,https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2053,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,,,,,,,,,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2054,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,,,,,,,,,,Increased liver enzyme activities,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2055,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,,,,,,,,,,Abnormal methylmalonic acid level.,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2056,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"3.2.1.183, 2.7.1.60",,,Methylcobalamin,DB03614,,,,,,,,,,Hyperpigmentation,,HP:0000953,https://www.ncbi.nlm.nih.gov/pubmed/24222293,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
2057,245,242600,Iminoglycinuria,,SLC36A2 /SLC6A20/SLC6A19,solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19,"3.2.1.183, 2.7.1.60",,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2058,246,605637,Inclusion body myopathy type 3,,MYH2,myosin heavy chain 2,"3.2.1.183, 2.7.1.60",,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2059,247,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,"3.2.1.183, 2.7.1.60",,,Carnitine+high-carbohydrate+low-protein and low-fat diet,DB00583+NA+NA+NA,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+dietary regime modification+dietary regime modification,,Disease progression,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/29565174,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407,,,,,
2060,,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,"3.2.1.183, 2.7.1.60",,,Carnitine+high-carbohydrate+low-protein and low-fat diet,DB00583+NA+NA+NA,,,,,,,,,,Decreased plasma carnitine,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/29565174,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407,,,,,
2061,,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,"3.2.1.183, 2.7.1.60",,,Leucine-restricted diet,NA,ECO:0000352,,,,,Symptomatic,C,dietary exclusion,,White matter changes,,HP:0007103,https://www.ncbi.nlm.nih.gov/pubmed/17628222/,,,,,,,,,,
2062,,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,"3.2.1.183, 2.7.1.60",,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Glucose+leucine-restricted diet,DB01914+NA,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+dietary exclusion,,Nonketotic hypoglycemia,,HP:0001958,https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/28220407,,,,,,,,,
2063,,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,"3.2.1.183, 2.7.1.60",,,Glucose+leucine-restricted diet,DB01914+NA,,,,,,,,,,Acute metabolic decompensation (Metabolic acidosis)*,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/28220407,,,,,,,,,
2064,,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,"3.2.1.183, 2.7.1.60",,,Glucose+leucine-restricted diet,DB01914+NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/28220407,,,,,,,,,
2065,1,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Tauroursodeoxycholic acid,DB08834,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,Drug name: Study was done on preclinical model of the disease.,ER (endoplasmic reticulum) stress,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2066,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Tauroursodeoxycholic acid,DB08834,,,,,,,,,,High triglyceride levels,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2067,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Tauroursodeoxycholic acid,DB08834,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2068,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Bezafibrate,DB01393,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Increased muscle lipid droplets,,HP:0012240,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2069,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Bezafibrate,DB01393,,,,,,,,,,ER (endoplasmic reticulum) stress,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2070,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Bezafibrate,DB01393,,,,,,,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2071,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Bezafibrate,DB01393,,,,,,,,,,Fiber necrosis,,HP:0003713,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2072,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,Bezafibrate,DB01393,,,,,,,,,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
2073,2,# 550500,Myoglobinuria recurrent,,MT-CO1/MT-CYB/MT-CO3,Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3,1.9.3.1/P00403/P00414,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2074,3,# 545000,Myoclonic epilepsy with ragged red fibers,"Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.",MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,"Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://www.ncbi.nlm.nih.gov/pubmed/21494841",Levetiracetam/Clonazepam/Zonisamide,DB01202/DB01068/DB00909,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Myoclonic epliepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/14981187,,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://www.ncbi.nlm.nih.gov/pubmed/21494841,,,,,,
2075,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,Coenzyme Q10+L-carnitine+ lipoic acid,DB09270+DB00583+ DB00166,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Ankle weakness progression (Disease progression)*,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/17080429,,,,,,,,,,
2076,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,Coenzyme Q10+L-carnitine+ lipoic acid,DB09270+DB00583+ DB00166,,,,,,,,,,High resting plasma lactate concentration,,HP:0003288,https://www.ncbi.nlm.nih.gov/pubmed/17275787,,,,,,,,,,
2077,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,Levetiracetam+ l-carnitine +CoQ10,DB01202+DB00583+DB09270,ECO:0000352,,,,,Symptomatic+Functional interaction+Functional interaction,C+B+B,combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Myoclonus,,HP:0002123,,,,,,,,,,,
2078,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,Levetiracetam+ l-carnitine +CoQ10,DB01202+DB00583+DB09270,,,,,,,,,,Low quality of life (Constitutional symptoms)*,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/28686997,https://www.ncbi.nlm.nih.gov/pubmed/21494841,,,,,,,,,
2079,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,Piracetam,DB09210,ECO:0000352,m.8344A > G,"In a 71yo female with MERRF syndrome due to the mutation m.8344A > G myoclonic, seizures did only respond to piracetam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506757/",,,Symptomatic,C,symptomatic therapeutic procedure,,Myoclonic seizures,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/28717435,,,,,,,,,,
2080,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,Clonazepam,DB01068,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Asterixis-like movement (Abnormality of movement),,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/1490314,,,,,,,,,,
2081,4,# 601776,"EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1",,CHST14,Dermatan-4-sulfotransferase-1,2.8.2.35,,,Magnesium,DB14513,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Constipation,,HP:0002019,https://www.ncbi.nlm.nih.gov/pubmed/21744491,,,,,,,,,,
2082,5,# 300559,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",Most patients do not require any specific treatment.https://rarediseases.info.nih.gov/diseases/3858/muscular-phosphorylase-kinase-deficiency#,PHKA1,alpha subunit of muscle phosphorylase kinase,2.7.11.19,,,Cortisone,DB14681,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Muscular hypotonia,,HP:0001252,https://www.ncbi.nlm.nih.gov/pubmed/15637709,,,,,,,,,,
2083,,# 300559,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,alpha subunit of muscle phosphorylase kinase,2.7.11.19,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Glucose,DB01914,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Exercise intolerance,,HP:0009020,https://www.ncbi.nlm.nih.gov/pubmed/18401027,,,,,,,,,,
2084,6,# 602541,Congenital megaconial myopathy,"Cardiac involvement occurs relatively frequently in the patients with megaconial congenital muscular dystrophy, Heart transplanation is considered a successful therapeutic option in those patients not responding to medical treatment. https://www.ncbi.nlm.nih.gov/pubmed/26855408",CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,,,L-carnitine,DB00583,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction (mitochondrail dysfunction)*,,HP:0003287*,https://www.ncbi.nlm.nih.gov/pubmed/26006750,,,,,,,,,,
2085,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,,,Riboflavin,DB00140,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction (mitochondrail dysfunction)*,,HP:0003287*,,,,,,,,,,,
2086,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,,,Thiamine,DB00152,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction (mitochondrail dysfunction)*,,HP:0003287*,,,,,,,,,,,
2087,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,,,Corticosteroid,D07A,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Nummular eczema (Eczema)*,,HP:0000964*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701/,,,,,,,,,,
2088,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,,,B-Blockers+Angiotensin-converting enzyme inhibitors,C07+C09,ECO:0000352,,,,,Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/26067811,,,,,,,,,,
2089,7,# 253280,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Q8WZA1,,,botulinum toxin,DB00083,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Strabismus,,HP:0000486,https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract,,,,,,,,,,
2090,,# 253280,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Q8WZA1,,,botulinum toxin,DB00083,,,,,,,,,,Esotropia,,HP:0000565,https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract,,,,,,,,,,
2091,,# 253280,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Q8WZA1,,,Ad5-LARGE-eGFP,NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Muscle dystrophy,,HP:0003560,https://www.ncbi.nlm.nih.gov/pubmed/15184894,,,,,,,,,,
2092,8,# 236670,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1",,POMT1,protein O-mannosyltransferase 1,2.4.1.109,,,Ad5-LARGE-eGFP,NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Muscle dystrophy,,HP:0003560,https://www.ncbi.nlm.nih.gov/pubmed/15184894,,,,,,,,,,
2093,9,# 613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,Protein O-mannosyl-transferase 2,2.4.1.109,,,Diuretics,C03,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Congestive cardiac failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/28980384,,,,,,,,,,
2094,,# 613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,Protein O-mannosyl-transferase 2,2.4.1.109,,,Diuretics,C03,,,,,,,,,,Tachypnea,,HP:0002789,https://www.ncbi.nlm.nih.gov/pubmed/28980384,,,,,,,,,,
2095,10,# 253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4",,FKTN,Fukutin,O75072,,,Antisense oligonucleotide,NA,ECO:0001565/ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Abnormal Fukutin function(,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21979053,,,,,,,,,,
2096,11,# 613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,Fukutin-related protein,Q9H9S5,,,Adeno-associated Virus 9 Mediated FKRP Gene Therapy,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Abnormal muscle function,,HP:0011804,https://www.sciencedirect.com/science/article/pii/S152500161632250X,,,,,,,,,,
2097,,# 613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,Fukutin-related protein,Q9H9S5,,,Ad5-LARGE-eGFP,NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Muscle dystrophy,,HP:0003560,https://www.ncbi.nlm.nih.gov/pubmed/15184894,,,,,,,,,,
2098,12,# 613154,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6",,LARGE,LARGE xylosyl- and glucuronyltransferase 1,O95461,,,Ad5-LARGE-eGFP,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Muscle dystrophy,,HP:0003560,https://www.ncbi.nlm.nih.gov/pubmed/15184894,,,,,,,,,,
2099,13,# 614643,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7",,ISPD,D-ribitol-5-phosphate cytidylyltransferase,2.7.7.40,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2100,14,# 614830,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8",,POMGNT2,"Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2",2.4.1.312,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2101,15,# 616538,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9",,DAG1,Dystroglycan,Q14118,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2102,16,# 615041,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10",,RXYLT1,Ribitol-5-phosphate xylosyltransferase 1,Q9Y2B1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2103,17,# 615181,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11",,B3GALNT2,"UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2",2.4.1.313,,,Phenobarbital,DB01174,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/29273094,,,,,,,,,,
2104,18,# 615249,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12",,POMK,Protein O-mannose kinase,2.7.1.183,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2105,19,# 615287,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13",,B4GAT1,"Beta-1,4-glucuronyltransferase 1",O43505,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2106,20,151800,Multiple symmetric lipomatosis,The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/,MT-TK,"Beta-1,4-glucuronyltransferase 1",O43505,,,Salbutamol,DB01001,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,Drug name: A correlated gene mutation has not been discovered. https://www.ncbi.nlm.nih.gov/pubmed/8190288,Rapid progression in body fat mass (Abnormality of adipose tissue* ),,HP:0009124*,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,,,,,,,,,,
2107,,151800,Multiple symmetric lipomatosis,,MT-TK,"Beta-1,4-glucuronyltransferase 1",O43505,,,Salbutamol,DB01001,,,,,,,,,,Disease progression (Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,,,,,,,,,,
2108,,151800,Multiple symmetric lipomatosis,,MT-TK,"Beta-1,4-glucuronyltransferase 1",O43505,,,Salbutamol,DB01001,,,,,,,,,,Increased intraabdominal fat,,HP:0008993,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,,,,,,,,,,
2109,,151800,Multiple symmetric lipomatosis,,MT-TK,"Beta-1,4-glucuronyltransferase 1",O43505,,,Salbutamol,DB01001,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,,,,,,,,,,
2110,21,# 272200,Multiple sulfatase deficiency,,SUMF1,Formylglycine-generating enzyme,1.8.3.7,,,No treatment is available in DDIEM,,,,,,,,,,,Low metabolic rate (Abnormality of fatty acid metabolism)*,,HP:0004359*,,,,,,,,,,,
2111,22,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Dexamethasone,DB01234,ECO:0001565,,,,,Direct interaction,A,procedure to mitigate dominant effects of a genetically abnormal protein,Drug name: The trial was conducted on a cell line that is held to be an in vitro model for medullary carcinoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157381/,Abnormal cellular proliferation,,HP:0031377,https://www.ncbi.nlm.nih.gov/pubmed/10947080,https://www.ncbi.nlm.nih.gov/pubmed/3491070/,,,,,,,,,
2112,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",Vandetanib,DB05294,ECO:0007121,M918T,,,,Direct interaction,A,procedure to mitigate dominant effects of a genetically abnormal protein,"Mutation improved: If data from the ARMS assay are taken into account, patients with sporadic MTC received benefit from vandetanib whether their tumors were M918T positive or negative; however, the response rate was greater in those who had an M918T mutation. https://www.ncbi.nlm.nih.gov/pubmed/22025146/",Low quality of life (Constitutional symptom)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/23766359,,,,,,,,,,
2113,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Pain,,HP:0012531,https://www.ncbi.nlm.nih.gov/pubmed/23766359,,,,,,,,,,
2114,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Objective response rate (ORR),,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,,,,,,,,,,
2115,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Disease progression rate (Rapid disease progression),,HP:0003678,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,,,,,,,,,,
2116,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Short Progression-free survival (Rapidly progressive )*,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/22025146/,https://www.ncbi.nlm.nih.gov/pubmed/20371662/,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2117,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Elevated calcitonin,,HP:0003528,https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2118,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Increased plasma CEA,,HP:0031029,https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2119,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Bone pain,,HP:0002653,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225/,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2120,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Low skeletal muscle mass,,HP:0003199,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2121,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Weight loss,,HP:0001824,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2122,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,Decreased adipose tissue,,HP:0040063,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2123,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Vandetanib,DB05294,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2124,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Bortezomib + Vandetanib,DB00188+DB05294,ECO:0007121,,,,,Direct interaction+Direct interaction,A+A,combination therapeutic procedure+procedure to mitigate dominant effects of a genetically abnormal protein+procedure to mitigate dominant effects of a genetically abnormal protein,Drug name:,Neoplastic growth,,HP:0002664,https://www.ncbi.nlm.nih.gov/pubmed/18381602/,https://www.ncbi.nlm.nih.gov/pubmed/26170630,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/,,,,,,,
2125,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,ECO:0007121,,,,,Direct interaction,A,procedure to mitigate dominant effects of a genetically abnormal protein,,Phosphorylation of RET,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21606412/,https://clinicaltrials.gov/ct2/show/NCT00215605,,,,,,,,,
2126,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,Elevated calcitonin,,HP:0003528,https://www.ncbi.nlm.nih.gov/pubmed/21606412/,https://clinicaltrials.gov/ct2/show/NCT00215605,,,,,,,,,
2127,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,Short Progression-free survival (Rapidly progressive )*,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2128,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,Low tumor response rate,"The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501",NA,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2129,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,Overall survival (premature death)*,"Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/",MP:0002083,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2130,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2131,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2132,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2133,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,Cabozantinib ( XL184),DB08875,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2134,23,# 614080,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,GPI ethanolamine phosphate transferase 1,O95427,,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",Levetiracetam,DB01202,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/,,,,,,,,,,
2135,,# 614080,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,GPI ethanolamine phosphate transferase 1,O95427,,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",Topiramate,DB00273,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
2136,,# 614080,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,GPI ethanolamine phosphate transferase 1,O95427,,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",Oxcarbazepine,DB00776,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,,,,,,,,,,,
2137,24,# 300868,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,2.4.1.198,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2138,25,# 300818,Paroxysmal nocturnal hemoglobinuria,PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,2.4.1.199,,,Eculizumab,DB01257,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Paroxysmal nocturnal hemoglobinuria,,HP:0004818,https://www.ncbi.nlm.nih.gov/pubmed/28516949,,,,,,,,,,
2139,26,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,,Drugs has decreased rhe frequency of the tonic seizuress,Phenobarbital,DB01174,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Tonic seizures (Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
2140,,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,,Drugs has decreased rhe frequency of the tonic seizuress,Clonzepam,DB01068,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Tonic seizures (Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
2141,,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,,Drugs has decreased rhe frequency of the tonic seizuress,Potassium bromide,CHEBI:32030,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Tonic seizures (Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
2142,,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,,,Acetazolamide,DB00819,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,"Epileptic apnea (Apneic episodes precipitated by illness, fatigue, stress)",,HP:0002872*,,,,,,,,,,,
2143,28,# 248510,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",,MANBA,Beta-mannosidase,3.2.1.25,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2144,29,# 248600,Maple syrup urine disease type Ia,"In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.",BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,No phenotypes were mentioned in the study. In vitro Study.,Natural osmolyte trimethylamine N-oxide (TMAO),CHEBI:15724,ECO:0001565,F364C- alpha,Activity of F364C- mutant E1 was increased markedly from 1% of wild type without TMAO to 30% with 0.75 M TMAO. https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,A209D-alpha,"The S289L- beta and A209D- alpha mutants showed 0 and 40% residual activities, respectively, in the absence of TMAO, but these activities re- mained unchanged after incubation with the osmolyte",Direct interaction,A,activity modification of a genetically defective protein,,Abnormal MSUD enzyme activity (Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,,,,,,,,,,
2145,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,Natural osmolyte trimethylamine N-oxide (TMAO),CHEBI:15724,,Y368C- alpha,Y368C- E1 in that residue activity is 3% in the absence of TMAO and 27% in its presence.,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,,,,,,,,,,
2146,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,Natural osmolyte trimethylamine N-oxide (TMAO),CHEBI:15724,,Y393N- alpha,"TMAO also activated Y393N- E1 with activity increased from 0 to 9% of the wild type, in the absence and the presence of TMAO, respectively.",,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,,,,,,,,,,
2147,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,Norleucine,NA,ECO:0000352,,,,,Functional interaction,B,functional complementatin of a genetically defective protein,,Branched-chain amino acid accumulation,Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.,HP:0008344,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,,,,,,,,,,
2148,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,Norleucine,NA,,,,,,,,,,Encephalopathy,"The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.",HP:0001298,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,,,,,,,,,,
2149,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,Norleucine,NA,,,,,,,,,,High α-ketoisocaproate level,,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,,,,,,,,,,
2150,30,# 248600,Maple syrup urine disease type Ib,,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",1.2.4.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,High plasma branched chain keto acids,,NA,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799,,,,,,,,,
2151,,# 248600,Maple syrup urine disease type Ib,,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",1.2.4.4,,,Sodium phenylbutyrate,DB06819,,,,,,,,,,High plasma branched chain amino acids,,HP:0008344,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799,,,,,,,,,
2152,31,# 248600,Maple syrup urine disease type II,,DBT,"Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial",2.3.1.168,,,Thiamine,DB00152,ECO:0000352,,,,,Functional interaction,B,functional complementatin of a genetically defective protein,,High plasma branched chain amino acids,,HP:0008344,https://www.ncbi.nlm.nih.gov/pubmed/?term=Thiamin-responsive+maple-syrup-urine+disease+chuang+2006,,,,,,,,,,
2153,32,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,N-acetylcysteine +deferoxamine,DB06151+ DB00746,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Memory impairment,,HP:0002354,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,,,,,,,,,,
2154,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,N-acetylcysteine +deferoxamine,DB06151+ DB00746,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581,,,,,,,,,
2155,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,N-acetylcysteine +deferoxamine,DB06151+ DB00746,,,,,,,,,,Behavioural abnormalites,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581,,,,,,,,,
2156,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,N-acetylcysteine +deferoxamine,DB06151+ DB00746,,,,,,,,,,cognitive imapirment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581,,,,,,,,,
2157,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,N-acetylcysteine +deferoxamine,DB06151+ DB00746,,,,,,,,,,Learning impairment,,HP:0001328,https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581,,,,,,,,,
2158,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,Riboflavin,DB00140,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Exercise intolerance,,HP:0003546,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,,,,
2159,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,Riboflavin,DB00140,,,,,,,,,,Mitochondrial proliferation in the muscle,,HP:0003200,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,,,,
2160,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,Riboflavin,DB00140,,,,,,,,,,Myopathy,,HP:0003198,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,,,,
2161,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,Riboflavin,DB00140,,,,,,,,,,Lactic acidosis,,HP:0003128,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,,,,
2162,33,# 261600,PHENYLKETONURIA,"Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub",PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,,Tetrahydrobiopterin (sapropterin),DB00360,ECO:0000352,"P407S
A373T
R241C","The serum Phe concentrations of patients have those mutaions never exceeded 20 mg/dL, even when they were not on a Phe-restricted diet, suggesting that mutant PAH molecules with P407S, A373T, and R241C have residual enzymatic activities. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihubhttps://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub","Homozygotes of R252W 
Homozygotes of IVS4-1G→A 
Homozygotes of R413P","Homozygotes of R252W, IVS4-1G→A, and R413P presented with clinical symptoms typical of classical PKU. Therefore these mutations appear to abolish PAH function. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub",Direct interaction,A,activity modification of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/20971365,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://clinicaltrials.gov/ct2/show/results/NCT01977820?cond=sapropterin&rank=1,https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub,,,,,,,
2163,,# 261600,PHENYLKETONURIA,,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,,Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/16319949,https://www.ncbi.nlm.nih.gov/pubmed/18362925,,,,,,,,,
2164,,# 261600,PHENYLKETONURIA,,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,,Phenylalanine ammonia lyase,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/16165390,https://www.ncbi.nlm.nih.gov/pubmed/29941359,https://www.ncbi.nlm.nih.gov/pubmed/25151978,https://www.ncbi.nlm.nih.gov/pubmed/10051643/,https://www.ncbi.nlm.nih.gov/pubmed/10051643/,https://www.ncbi.nlm.nih.gov/pubmed/7071414/,,,,,
2165,,# 261600,PHENYLKETONURIA,,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,,Phenylalanine ammonia lyase,NA,,,,,,,,,,Increased phenylalanine concentration in brain tissue,,HP:0500223,https://www.ncbi.nlm.nih.gov/pubmed/16165390,https://www.ncbi.nlm.nih.gov/pubmed/29941359,https://www.ncbi.nlm.nih.gov/pubmed/25151978,https://www.ncbi.nlm.nih.gov/pubmed/10051643/,https://www.ncbi.nlm.nih.gov/pubmed/10051643/,https://www.ncbi.nlm.nih.gov/pubmed/7071414/,,,,,
2166,,# 261600,PHENYLKETONURIA,,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,Only PEGylated Anabaena variabilis (Av) PAL-treated mice demonstrated sustained low Phe levels with weekly injection and was the only PAL evaluated that maintained full enzymatic activity upon PEGylation.,Pegylated recombinant phenylalanine ammonia lyase,NA,ECO:0000179/ECO:0007121,,,,,Direct interaction,A,direct complementation of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/28282402,https://www.ncbi.nlm.nih.gov/pubmed/21803624,https://www.ncbi.nlm.nih.gov/pubmed/19095795/,https://clinicaltrials.gov/ct2/show/NCT00634660,https://clinicaltrials.gov/ct2/show/NCT00924703,https://clinicaltrials.gov/ct2/show/NCT01212744,,,,,
2167,,# 261600,PHENYLKETONURIA,,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,,Pegylated recombinant phenylalanine ammonia lyase,NA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28282402,https://www.ncbi.nlm.nih.gov/pubmed/21803624,https://www.ncbi.nlm.nih.gov/pubmed/19095795/,https://clinicaltrials.gov/ct2/show/NCT00634660,https://clinicaltrials.gov/ct2/show/NCT00924703,https://clinicaltrials.gov/ct2/show/NCT01212744,,,,,
2168,34,# 261600,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,,Tetrahydrobiopterin,DB00360,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,,,,,,,,,,,
2169,,# 261600,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,,Pegvaliase,DB12839,ECO:0007121+ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal blood Phenylalanine levels,,HP:0004923,https://www.sciencedirect.com/science/article/pii/S1096719218300210,https://www.sciencedirect.com/science/article/pii/S1525001605000845,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short,,,,
2170,35,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Coenzyme Q10,DB09270,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/24746802,,,,,,,,,
2171,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",Vitamin B12+imipramine,DB00115+DB00458,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Diabetic polyneuropathy,,HP:0001271,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
2172,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Prokinetic agents,NA,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Epigastric pain,,HP:0410019,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
2173,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Prokinetic agents,NA,,,,,,,,,,Acid regurgitation,,HP:0002020,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
2174,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Pregabalin,DB00230,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Neuropathic pain (Abnormality of pain sensation)*,,HP:0010832*,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
2175,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Insulin,DB00030,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Diabetes,"Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802",HP:0000819,https://www.ncbi.nlm.nih.gov/pubmed/28756474,,,,,,,,,,
2176,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Clonazepam,DB01068,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Involuntary movement,,HP:0004305,https://www.ncbi.nlm.nih.gov/pubmed/28756475,,,,,,,,,,
2177,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,"The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.",Immunosuppressent +Carbonic anhydrase inhibitors,L04+S01EC,ECO:0000352,,,,,Symptomatic,C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Macular cystoid changes,,HP:0008028,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
2178,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,The drug was administered through intravitreal injection.,Triamcinolone acetonide,DB00620,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Macular cystoid changes,,HP:0011505,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
2179,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Triamcinolone acetonide,DB00620,,,,,,,,,,Abnormal visual acuity,,HP:0030532,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
2180,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Triamcinolone acetonide,DB00620,,,,,,,,,,Intraretinal cystoid spaces (Retinal disease)*,,HP:0000479*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
2181,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Non-steroidal anti-inflammatory agents,M02AA,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Intraretinal cystoid spaces (Retinal disease)*,,HP:0000479*,https://www.ncbi.nlm.nih.gov/pubmed/23806424/,,,,,,,,,,
2182,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Vitamins,A11,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Malnutrition,,HP:0004395,,,,,,,,,,,
2183,,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Coenzyme Q10+Vitamin C+Vitamin B+Vitamin K +Carnitine,DB09270+A11EB+B02BA+ DB01022+DB00583,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic+Symptomatic+Symptomatic,C+C+C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Mitochondrial dysfunction,,HP:0003287,,,,,,,,,,,
2184,36,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS","MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000",MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Coenzyme Q10,DB09270,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/26823911,https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29596118,,,,,,,,
2185,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Coenzyme Q10,DB09270,,,,,,,,,,Reduced electron transport chain activity (Decreased activity of mitochondrial respiratory chain)*,,HP:0008972*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994/,https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29596118,,,,,,,,
2186,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Arginine hydrochloride,DB00125,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Stroke-like episodes,,HP:0002401,https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,,,,,,,,
2187,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Arginine hydrochloride,DB00125,,,,,,,,,,Painful neuropathy (neuropathy)*,,HP:0009830*,https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,,,,,,,,
2188,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Arginine hydrochloride,DB00125,,,,,,,,,,Congestive heart failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,,,,,,,,
2189,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Arginine hydrochloride,DB00125,,,,,,,,,,Pancreatic beta-cell dysfunction,,HP:0006279,https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,,,,,,,,
2190,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Nicotinamide Riboside,DB03227,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Muscle abnormality related to mitochondrial dysfunction,,HP:0003800,https://clinicaltrials.gov/ct2/show/NCT03432871?cond=Chronic+progressive+external+ophthalmoplegia&rank=2,http://ichgcp.net/clinical-trials-registry/NCT03432871,,,,,,,,,
2191,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Sodium Pyruvate,DB00119,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Elevated serum lactate level,,HP:0002151,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
2192,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Sodium Pyruvate,DB00119,,,,,,,,,,High lactate /pyruvate ratio,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
2193,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Sodium Pyruvate,DB00119,,,,,,,,,,Increased lateral ventricular lactate level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
2194,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Sodium Pyruvate,DB00119,,,,,,,,,,High serum GDF15 level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
2195,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Duloxetine,DB00476,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Depression,,HP:0000716,https://www.ncbi.nlm.nih.gov/pubmed/29596118,,,,,,,,,,
2196,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Taurine,DB01956,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,,,,,,,,,,,
2197,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Taurine,DB01956,,,,,,,,,,Mitochondrial dysfunction,,HP:0003287,,,,,,,,,,,
2198,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Idebenone,DB09081,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Decreased activity of mitochondrial ATP synthase complex,,HP:0011925,https://clinicaltrials.gov/ct2/show/NCT00887562,https://www.ncbi.nlm.nih.gov/pubmed/8757046,,,,,,,,,
2199,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Idebenone+Riboflavin,DB09081+DB00140,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/11382201,,,,,,,,,,
2200,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Idebenone+Riboflavin,DB09081+DB00140,,,,,,,,,,Abnormal EEG (focal epileptiform activity),,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/11382201,,,,,,,,,,
2201,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Idebenone+Riboflavin,DB09081+DB00140,,,,,,,,,,Hyperintensity of cerebral white matter on MRI,,HP:0030890,https://www.ncbi.nlm.nih.gov/pubmed/11382201,,,,,,,,,,
2202,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Idebenone+Riboflavin,DB09081+DB00140,,,,,,,,,,Stroke-like attacks,,HP:0002401,https://www.ncbi.nlm.nih.gov/pubmed/11382201,,,,,,,,,,
2203,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,Idebenone+Coenzyme Q10,DB09081+DB09270,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Abnormal EEG,,HP:0002353,https://www.sciencedirect.com/science/article/pii/0022510X89901123,,,,,,,,,,
2204,37,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,ECO:0000352,R229W,,,,Functional interaction,B,functional complementatin of a genetically defective protein,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2205,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,,,,,,,,,,Clonic contractions,There was partial improvement then patients died,MP:0003996,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2206,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,,,,,,,,,,Lip-smacking automatisms (Epilepsy)*,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2207,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2208,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2209,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2210,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2211,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxine,DB00165,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2212,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxal phosphate,DB00114,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/12747882,,,,,,,,,,
2213,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxal phosphate,DB00114,,,,,,,,,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/12747882,,,,,,,,,,
2214,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Pyridoxal phosphate,DB00114,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12747882,,,,,,,,,,
2215,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,Phenobarbitone,DB01174,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2216,38,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Low total RBC folate level,,HP:0040087,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2217,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,,,,,,,,,,Bone marrow megaloblastic changes,,HP:0001980,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2218,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,,,,,,,,,,Low 5-MTHF level,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
2219,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,,,,,,,,,,Abscent 5-MTHF (Abnormal CSF metabolite level)*,,HP:0025454*,https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
2220,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,,,,,,,,,,Abnormal CSF folate level,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
2221,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,,,,,,,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
2222,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
2223,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Folinic acid,DB00650,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
2224,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Hydroxycobalamin+Folic acid,DB00200+DB00158,ECO:0000352,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Abnormal hemoglobin level,,HP:0025546,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2225,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Hydroxycobalamin+Folic acid,DB00200+DB00158,,,,,,,,,,Abnormal MCV level,,HP:0025065,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2226,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,Phenobarbitone+levetiracetam,DB01174+DB01202,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Seizure,Partial improvement in seizures on this regimen,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2227,39,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,PubChem CID: 151722,ECO:0000352/ECO:0007121,G666R,,2757delAG,"We found no evidence for residual copper transport in patients with ATP7A deletions that disrupt the translational reading frame, and the nine infants with Menkes disease who had these mutations did not achieve normal neurodevelopment, despite early treatment. However, these patients had better survival and a lower incidence of clinical seizures (two of nine infants, or 22%) than would be expected among those with untreated Menkes disease,4 perhaps as a result of their access to early diagnosis and treatment. The mechanisms underlying these improvements in patients with complete loss-of-function mutations remain unclear. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/",Functional interaction,B,functional complementation of a genetically defective protein,,Abnormal brain electrical activity,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://clinicaltrials.gov/ct2/show/results/NCT00001262?cond=Menkes&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/16786254,,,,,,,
2228,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,N1304S,,Del ex20–23,,,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/18256395,https://www.ncbi.nlm.nih.gov/pubmed/16786254,,,,,,,
2229,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,"IVS9,DS,+6T→G",,Q1385X,,,,,,Neurological abnormalities.,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2230,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Neurologic burden,,HP:0002344,https://clinicaltrials.gov/ct2/show/results/NCT00001262,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2231,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Rapid disease progression,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2232,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Eplieptic discharge (Interictal EEG abnormality)*,,HP:0025373,https://www.ncbi.nlm.nih.gov/pubmed/8223785,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2233,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Low muscular tone,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/8223785,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2234,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Appendicular hyoptonia,,HP:0012389,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2235,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Socio-cognitive abnormality (Neurodevelopmental abnormality)*,,HP:0012759*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2236,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Poor weight gain,,HP:0001508,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2237,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Woolly hair,,HP:0002224,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2238,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper Histidine,PubChem CID: 151722,,,,,,,,,,Hypopigmented skin,,HP:0001010,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2239,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,"However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",Thiuram + (Copper Dimethyldithiocarbamate (Cu-DMDTC )),DB13245+PubChem CID:472181,ECO:0000179,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Low Brain Copper (Abnormal copper levels)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/22815746,https://www.ncbi.nlm.nih.gov/pubmed/30384011,,,,,,,,,
2240,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Thiuram + (Copper Dimethyldithiocarbamate (Cu-DMDTC )),DB13245+PubChem CID:472181,,,,,,,,,,Copper accumulation in kidney (Abnormal copper levels)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/22815746,https://www.ncbi.nlm.nih.gov/pubmed/30384011,,,,,,,,,
2241,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Copper nitrilotriacetate (Cu-NTA),PubChem CID: 56840862,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Low survival rate (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/?term=Copper+nitrilotriacetate%3A+A+potent+therapeutic+agent+in+the+treatment+of+a+genetic+disorder+of+copper+metabolism,,,,,,,,,,
2242,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,"Due to its strong copper chelation capability, a copper salt should be added simultaneously",Alpha-lipoic acid,DB00166,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Copper storage abnormalities (Copper storage abnormalities)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,,,,,,,,,
2243,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM,NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Low life span (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/30127521,https://www.ncbi.nlm.nih.gov/pubmed/31160463,,,,,,,,,
2244,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,ECO:0000179,,,,,Direct interaction+Functional interaction,A+B,combination therapeutic procedure+direct complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Low brain copper levels (Abnormal copper levels)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2245,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*,,HP:0012535*,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2246,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,Abnormal growth,,HP:0001507,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2247,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,Brain mitochondrial abnormalities (Mitochondrial dysfunction),,HP:0003287*,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2248,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,Behavioral abnormality,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2249,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,Neurological abnormalties,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2250,40,# 249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,,PSAP,Prosaposin,P07602,,,No medical treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2251,41,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Poor appetite,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2252,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Low IQ,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2253,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Behavioural abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2254,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Abnormal Awake EEG,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2255,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Delayed mylination,,HP:0012449,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2256,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2257,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Hyperreflexia,,HP:0001347,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2258,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2259,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Foot clouns,,HP:0011448,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2260,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Poor traction response,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2261,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Poor weight gain,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2262,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Delayed motor milestone,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2263,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Neurodevelopmental abnormalities,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2264,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Brain demylination,,HP:0007266,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2265,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,Valproic acid,DB00313,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Myoclonic epilepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,,
2266,42,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Poor appetite,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2267,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Low IQ,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/27671892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2268,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Behavioural abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27671893,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2269,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Abnormal Awake EEG,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/27671894,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2270,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Delayed development,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/27671895,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2271,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/27671896,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2272,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Hyperreflexia,,HP:0001347,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2273,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2274,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Foot clouns,,HP:0011448,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2275,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Poor traction response (Poor muscle tone)*,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2276,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Poor weight gain,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2277,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Delayed motor milestone,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2278,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Neurodevelopmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2279,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,S-adenosylmethionine,DB00118,,,,,,,,,,Brain demylination,,HP:0007266,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2280,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,Valproic acid,DB00313,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Myoclonic epilepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,,
2281,43,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Haemolysis,,HP:0001878,https://www.ncbi.nlm.nih.gov/pubmed/24210589,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,
2282,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/24210590,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2283,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,High urine methylmalonic acid level,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2284,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Impaired renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2285,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Decreased glomerular filtration rate,,HP:0012213,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2286,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2287,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Anorexia,,HP:0002039,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2288,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Delirium,,HP:0031258,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2289,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2290,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid,DB00200+DB06756+DB00650,,,,,,,,,,Lower limb hyperreflexia,,HP:0002395,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/26369474,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9266389,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2291,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day),Hydroxicobalamin+betaine+Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Psychiatric disturbances,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/30863077,,,,,,,,,,
2292,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,,,,,,,,,,Lower extremity weakness,,HP:0007340,https://www.ncbi.nlm.nih.gov/pubmed/30863077,,,,,,,,,,
2293,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,,,,,,,,,,Gait instability,,HP:0002317,https://www.ncbi.nlm.nih.gov/pubmed/30863077,,,,,,,,,,
2294,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30863077,,,,,,,,,,
2295,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction,B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High urine methylmalonic acid level,,HP:0012120,https://www.google.com/search?client=safari&rls=en&q=Clinical+heterogeneity+and+prognosis+in+combined+methylmalonic+aciduria+and+homocystinuria+(cblC&ie=UTF-8&oe=UTF-8,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2296,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/9266389,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2297,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,High urine methylmalonic acid level,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2298,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Abnormal brain stem auditory evoked potentials,,HP:0006958,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2299,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Abnormal visual evoked potentials,,HP:0000649,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2300,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Mental impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2301,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Emotional lability,,HP:0000712,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2302,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Psychiatric disturbances,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2303,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2304,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,Dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2305,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+carnitine,DB00200+DB06756+DB00583,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2306,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin,DB00200,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,
2307,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin,DB00200,,,,,,,,,,Methylmalonic aciduria,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,
2308,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin,DB00200,,,,,,,,,,Elevated blood homocystine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,
2309,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin,DB00200,,,,,,,,,,Dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/6749192/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2310,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin,DB00200,,,,,,,,,,Myelopathy,,HP:0002196,https://www.ncbi.nlm.nih.gov/pubmed/6749192/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2311,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin,DB00200,,,,,,,,,,Gait instability,,HP:0002317,https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2312,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Coumadin,DB00682,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Deep venous thrombosis,,HP:0002625,https://www.ncbi.nlm.nih.gov/pubmed/11320193/,,,,,,,,,,
2313,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Fluoxetine,DB00472,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Emotional lability,,HP:0000712,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2314,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Fluoxetine,DB00472,,,,,,,,,,Poor eye contact,,HP:0000817,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2315,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Lorazepam,DB00186,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Abnormal mental status,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2316,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120,Zonisamide,DB00909,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Sleep cycle disturbance,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2317,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Methylprednisolone sodium succinate+Immune Globulin,DB14644+DB00028,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Autoimmune encephalopathy(Encephalopathy)*/(Autoimmune disorder)*,"Doctors prescribed these drugs combination""""Methylprednisolone sodium succinate +
Immune Globulin """" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",HP:0001298*/HP:0002960*,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2318,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Risperidone,DB00734,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Psychiatric disturbance,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,,
2319,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid+carnitine,DB00200+DB06756+DB00650+DB00583,ECO:0000352,,,,,Functional interaction+Functional interaction+Functional interaction+Functional interaction,B+B+B+B,combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High urine methylmalonic acid level,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/18848477,,,,,,,,,,
2320,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Hydroxicobalamin+betaine+Folinic acid+carnitine,DB00200+DB06756+DB00650+DB00583,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/18848477,,,,,,,,,,
2321,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Vatiquinone (Epi-743),DB11917,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,,,,,,,,,
2322,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Vatiquinone (Epi-743),DB11917,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,,,,,,,,,
2323,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Vatiquinone (Epi-743),DB11917,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,,,,,,,,,
2324,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Vatiquinone (Epi-743),DB11917,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,,,,,,,,,
2325,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,Vatiquinone (Epi-743),DB11917,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,,,,,,,,,
2326,44,# 277410,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE;",,MMADHC,"Methylmalonic aciduria and homocystinuria type D protein, mitochondrial",Q9H3L0,,,Vatiquinone (Epi-743),,,,,,,,,,,,,,,,,,,,,,,,
2327,45,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Eculizumab,DB01257,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Microhematuria,,HP:0002907,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2328,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Eculizumab,DB01257,,,,,,,,,,Microalbuminura,,HP:0012594,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2329,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Eculizumab,DB01257,,,,,,,,,,Anemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2330,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Eculizumab,DB01257,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2331,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Eculizumab,DB01257,,,,,,,,,,Thrombotic microangiopathy,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2332,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,ECO:0000352,,,,,Direct interaction,A,activity modification of a genetically defective protein,,Elevated plasma homocysteine concentration,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2333,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2334,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2335,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,Granulocytopenia,,HP:0001913,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2336,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,Microhematuria,,HP:0002907,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2337,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2338,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2339,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2340,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,Hydroxicobalamin,DB00200,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2341,46,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,,Hydroxycobalamin+Betaine+Folate,DB00200+DB06756+DB00158,ECO:0000352,,,,,Functional interaction,B+C+C,combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Macrocytic anemia,,HP:0001972,https://www.ncbi.nlm.nih.gov/pubmed/25978498,https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract,,,,,,,,,
2342,,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,,Hydroxycobalamin+Betaine+Folate,DB00200+DB06756+DB00158,,,,,,,,,,Neurological impairment,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/25978498,https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract,,,,,,,,,
2343,,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,,Hydroxycobalamin+Betaine+Folate,DB00200+DB06756+DB00158,,,,,,,,,,Low heamoglobin level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/25978498,https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract,,,,,,,,,
2344,,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,,Hydroxycobalamin+Betaine+Folate,DB00200+DB06756+DB00158,,,,,,,,,,Increased mean corpuscular volume,,HP:0005518,https://www.ncbi.nlm.nih.gov/pubmed/25978498,https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract,,,,,,,,,
2345,,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,,Hydroxycobalamin+Betaine+Folate,DB00200+DB06756+DB00158,,,,,,,,,,Decreased methionine level,,MP:0030642,https://www.ncbi.nlm.nih.gov/pubmed/25978498,https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract,,,,,,,,,
2346,,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,,Hydroxycobalamin+Betaine+Folate,DB00200+DB06756+DB00158,,,,,,,,,,Hyperhomocysteinemia,Slight improvement,NA,https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract,,,,,,,,,
2347,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Levodopa,DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Limb dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2348,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Levodopa,DB01235,,,,,,,,,,Axial dystonia,,HP:0002530,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2349,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Levodopa,DB01235,,,,,,,,,,Gait abnormality,,HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2350,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Levodopa,DB01235,,,,,,,,,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24943079,,,,,,,,,,
2351,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Levodopa,DB01235,,,,,,,,,,Tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2352,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Levodopa,DB01235,,,,,,,,,,Rigidity,,HP:0002063,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2353,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,Levodopa,DB01235,,,,,,,,,,Bradykinesia,,HP:0002067,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2354,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",Phenytoin+oxcarbazepine+levetiracetam,DB00252+DB00776+ DB01202,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic,C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Mitochondrial epilepsy (Epilepsy)*,,HP:0001250*,https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract,,,,,,,,,,
2355,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Phenytoin+oxcarbazepine+levetiracetam,DB00252+DB00776+ DB01202,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract,,,,,,,,,,
2356,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Coenzyme Q10,DB09270,,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Mitochondrial myopathy,,HP:0003737,https://www.ncbi.nlm.nih.gov/pubmed/27442316,,,,,,,,,,
2357,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Coenzyme Q10,DB09270,,,,,,,,,,Low energy level,,HP:0003473,https://www.ncbi.nlm.nih.gov/pubmed/27442316,,,,,,,,,,
2358,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Inflammatory myopathy,,HP:0009071,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2359,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,Dysphagia,,HP:0002015,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2360,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2361,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,Neck muscle weakness,,HP:0000467,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2362,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2363,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,Dysarthria,,HP:0001260,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2364,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2365,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2366,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,Prednisone,DB00635,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2367,,# 258450,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1",,POLG,DNA polymerase subunit gamma-2,2.7.7.7,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/12872260,,,,,,,,,,
2368,,# 609283,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2",,SLC25A4,ADP/ATP translocase 1,P12235,,,Levodopa,,,,,,,,,,,,,,,,,,,,,,,,
2369,,# 616479,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2",,RNASEH1,Ribonuclease H1,3.1.26.4,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2370,,# 609286,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3",,TWNK,"Twinkle protein, mitochondrial",3.6.4.12,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260,,,,,,,,,
2371,,# 617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,"Thymidine kinase 2, mitochondrial",2.7.1.21,,,Levodopa,,,,,,,,,,,,,,,,,,,,,,,,
2372,,# 617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,"Thymidine kinase 2, mitochondrial",2.7.1.21,,,Levodopa,,,,,,,,,,,,,,,,,,,,,,,,
2373,,# 617070,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4",,DGUOK,"Deoxyguanosine kinase, mitochondrial",2.7.1.113,,,Levodopa,,,,,,,,,,,,,,,,,,,,,,,,
2374,,# 613077,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5",,RRM2B,Ribonucleoside-diphosphate reductase subunit M2 B,1.17.4.1,,,Levodopa,,,,,,,,,,,,,,,,,,,,,,,,
2375,,# 618098,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5",,TOP3A,DNA topoisomerase 3-alpha,5.6.2.2,,,Levodopa,,,,,,,,,,,,,,,,,,,,,,,,
2376,,# 615156,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6",,DNA2,DNA replication ATP-dependent helicase/nuclease DNA2,3.6.4.12/3.1.-.-,,,Vitamin E+L-carnitine+Dichloroacetate+Creatine,DB00163+DB00583+DB08809+DB00148,ECO:0000352,,,,,Symptomatic+Symptomatic+Symptomatic+Symptomatic,C+C+C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770/,,,,,,,,,,
2377,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,ECO:0007121/ECO:0000352,,,,,Symptomatic,C,symptomatic therapeutic procedure,,High left ventricular mass index ( Left ventricular hypertrophy)*,,HP:0001712*,https://www.ncbi.nlm.nih.gov/pubmed/11907009,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2378,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Cardiomyopathy progression (Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/18234531,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2379,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Progressive neurologic deterioration,,HP:0002344,https://www.ncbi.nlm.nih.gov/pubmed/18234531,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2380,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Interventricular septal thickning (Ventricular septum abnormality)*,,HP:0010438*,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2381,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Neurological abnormality,Another study has an opposing results https://www.ncbi.nlm.nih.gov/pubmed/20697044,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/17826341,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2382,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Cerebellar dysfunction,,NA,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2383,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Saccadic ocular movement abnormality (Abnormality of saccadic eye movements),,HP:0000570,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2384,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Nystagmus,,HP:0000639,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2385,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2386,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Idebenone,DB09081,,,,,,,,,,Disease progression (Rapid progression)*,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/18234531,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,
2387,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Recombinant human erythropoietin (rhuEPO),DB00016,ECO:0001565/ECO:0007121,,,,,Functional interaction,B,activity modification of a genetically defective protein by transcriptional or translational modification,,Low Frataxin expression level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16269021?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2388,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Recombinant human erythropoietin (rhuEPO),DB00016,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2389,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Recombinant human erythropoietin (rhuEPO),DB00016,,,,,,,,,,High urinary 8-hydroxydeoxyguanosine level (Abnormality of DNA repair)*,,HP:0003254,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2390,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Recombinant human erythropoietin (rhuEPO),DB00016,,,,,,,,,,Neurological impairment,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2391,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Recombinant human erythropoietin (rhuEPO),DB00016,,,,,,,,,,Tiredness,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2392,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Recombinant human erythropoietin (rhuEPO),DB00016,,,,,,,,,,High ferritin level,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2393,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Recombinant human erythropoietin (rhuEPO),DB00016,,,,,,,,,,Low NADH/NAD ratio (Mitochondrial dysfunction),,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2394,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Rosuvastatin,DB01098,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Decreased apolipoprotein AI level HP:0031799,,HP:0031799,https://clinicaltrials.gov/ct2/show/NCT02705547,,,,,,,,,,
2395,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Simvastatin,DB00641,ECO:0001565,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Decreased apolipoprotein AI level HP:0031800,,HP:0031799,https://www.ncbi.nlm.nih.gov/pubmed/29447225,,,,,,,,,,
2396,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Vatiquinone (EPI-743),DB11917,ECO:0007121/ECO:0000352/ECO:0000179,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Balber coordination abnormalities (Bulbar signs )*,,HP:0002483,https://clinicaltrials.gov/ct2/show/NCT01728064,https://clinicaltrials.gov/ct2/show/NCT01962363,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=EPI-743+for+Friedreichs+Ataxia+Patients+with+Point+Mutations+%28P5.388%29&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/30051753,https://www.ncbi.nlm.nih.gov/pubmed/31417369,https://www.ncbi.nlm.nih.gov/pubmed/31640150,,,,,
2397,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Vatiquinone (EPI-743),DB11917,,,,,,,,,,Upper limb coordination (Poor motor coordination)*,,HP:0002275,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=EPI-743+for+Friedreichs+Ataxia+Patients+with+Point+Mutations+%28P5.388%29&btnG=,https://clinicaltrials.gov/ct2/show/NCT01962363,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=EPI-743+for+Friedreichs+Ataxia+Patients+with+Point+Mutations+%28P5.388%29&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/30051753,https://www.ncbi.nlm.nih.gov/pubmed/31417369,https://www.ncbi.nlm.nih.gov/pubmed/31640150,,,,,
2398,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Vatiquinone (EPI-743),DB11917,,,,,,,,,,,,,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Emerging+therapeutics+for+the+treatment+of+Friedreich%E2%80%99s+ataxia&btnG=,https://clinicaltrials.gov/ct2/show/NCT01962363,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=EPI-743+for+Friedreichs+Ataxia+Patients+with+Point+Mutations+%28P5.388%29&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/30051753,https://www.ncbi.nlm.nih.gov/pubmed/31417369,https://www.ncbi.nlm.nih.gov/pubmed/31640150,,,,,
2399,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,α-tocopheryl quinone,DB14094,ECO:0007121,,,,,Symptomatic,C,symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT01035671,https://www.ncbi.nlm.nih.gov/pubmed/22744651,https://www.ncbi.nlm.nih.gov/pubmed/21600768,,,,,,,,
2400,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,low dose regimen is as effective as the high dose.,CoQ10+Vitamin E,DB09270+DB00163,ECO:00007121,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Mitochondrial dysfunction,,HP:0008972,https://www.ncbi.nlm.nih.gov/pubmed/19049556,https://www.ncbi.nlm.nih.gov/pubmed/11357949?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract,,,,,,,,
2401,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,CoQ10+Vitamin E,DB09270+DB00163,,,,,,,,,,Disease progression (Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19049556,https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract,,,,,,,,
2402,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,CoQ10+Vitamin E,DB09270+DB00163,,,,,,,,,,Low cardiac function (Abnormal cardiac ventricular function)*,,HP:0030872,https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19049556,https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract,,,,,,,,
2403,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,"Although some improvemant in pediatric patients in this trial, the study is considered to be an overall negative study.",Methylprednisolone,DB00959,ECO:0007121,,,,,Symptomatic/Functional interaction? (Symptomatic),C/B (C),symptomatic therapeutic procedure,,Fatigue,,HP:0012378,https://www.clinicaltrials.gov/ct2/show/NCT02424435,https://www.ncbi.nlm.nih.gov/pubmed/31206761,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,
2404,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Methylprednisolone,DB00959,,,,,,,,,,Gait disturbance,"Mild imprvement,eventual progresssion",HP:0001288,https://www.clinicaltrials.gov/ct2/show/NCT02424435,https://www.ncbi.nlm.nih.gov/pubmed/31206761,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,
2405,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Methylprednisolone,DB00959,,,,,,,,,,Poor speech,,HP:0002466,https://www.clinicaltrials.gov/ct2/show/NCT02424435,https://www.ncbi.nlm.nih.gov/pubmed/31206761,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,
2406,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide,PubChem CID:56654642,ECO:0001565/ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein by epigenetic manipulation,,Low frataxin level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20098685,https://www.ncbi.nlm.nih.gov/pubmed/25159818,https://www.ncbi.nlm.nih.gov/pubmed/25798128,,,,,,,,
2407,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Prednisone+Medrol,DB00635+DB00959,ECO:0000352,,,,,Symptomatic,C/B (C),combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,One patient,Gait disturbance,"Mild imprvement,eventual progresssion",HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,,
2408,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Prednisone,DB00635,ECO:0000352,,,,,Symptomatic,C/B (C),symptomatic therapeutic procedure,Two patient have used the treatment,Gait disturbance,,HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,,
2409,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Prednisone,DB00635,,,,,,,,,,Postural instability,Eventual progression later on.,HP:0002172,https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,,
2410,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Prednisolone,DB00860,ECO:0000352,,,,,Symptomatic,C/B (C),symptomatic therapeutic procedure,Two patients,Gait disturbance,,HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,,
2411,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Prednisolone,DB00860,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,,
2412,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Prednisolone,DB00860,,,,,,,,,,Falls,,HP:0002527,https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,,
2413,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Solumedrol,DB14644,ECO:0000352,,,,,Symptomatic,C/B (C),symptomatic therapeutic procedure,,Postural instability,Eventual progression later on.,HP:0002172,https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract,,,,,,,,,
2414,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Darbepoetin alfa+ idebenone+riboflavin,DB00012+DB09081+DB00140,ECO:00007121,,,,,Direct interaction+Symptomatic+Symptomatic,A+C+C,combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/23625326/,,,,,,,,,,
2415,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Darbepoetin alfa+ idebenone+riboflavin,DB00012+DB09081+DB00140,,,,,,,,,,Disease progression (Progressive neurologic deterioration)*,,HP:0002344,https://www.ncbi.nlm.nih.gov/pubmed/23625326/,,,,,,,,,,
2416,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,"In one randomized controlled study, Erythropiotin didn't show any effect on frataxin. https://www.ncbi.nlm.nih.gov/pubmed/22411849/",Erythropoietin,DB00016,ECO:0001565/ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/23859343,https://www.ncbi.nlm.nih.gov/pubmed/31105516,https://www.ncbi.nlm.nih.gov/pubmed/17702040/,https://www.ncbi.nlm.nih.gov/pubmed/18759345,https://www.ncbi.nlm.nih.gov/pubmed/21506154,,,,,,
2417,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Omaveloxolone (RTA 408),DB12513,ECO:0001565/ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein by stimulation,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/30065630,https://clinicaltrials.gov/ct2/show/NCT02255435,,,,,,,,,
2418,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Omaveloxolone (RTA 408),DB12513,,,,,,,,,,Decreased activity of mitochondrial complex I,,HP:0011923,https://www.ncbi.nlm.nih.gov/pubmed/30065630,https://clinicaltrials.gov/ct2/show/NCT02255435,,,,,,,,,
2419,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Omaveloxolone (RTA 408),DB12513,,,,,,,,,,Impaired neurological function (Low mFARS score),,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/30656180,https://clinicaltrials.gov/ct2/show/NCT02255435,,,,,,,,,
2420,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Omaveloxolone (RTA 408),DB12513,,,,,,,,,,Poor motor coordination,,HP:0002275,https://www.ncbi.nlm.nih.gov/pubmed/30656180,https://clinicaltrials.gov/ct2/show/NCT02255435,,,,,,,,,
2421,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Sulforaphane,DB12422,ECO:0001565,,,,,Direct interaction,A,functional complementation of a genetically defective protein,,Redox imbalance (Abnormality of redox activity),,HP:0025463,https://www.ncbi.nlm.nih.gov/pubmed/29057804,https://www.ncbi.nlm.nih.gov/pubmed/31640150,https://www.ncbi.nlm.nih.gov/pubmed/31417369,,,,,,,,
2422,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Sulforaphane,DB12422,,,,,,,,,,Lipid peroxidation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/26141703,https://www.ncbi.nlm.nih.gov/pubmed/31640150,https://www.ncbi.nlm.nih.gov/pubmed/31417369,,,,,,,,
2423,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Sulforaphane,DB12422,,,,,,,,,,Mitochondrial imbalance (mitochondrial imbalance)*,,HP:0012103,https://www.ncbi.nlm.nih.gov/pubmed/26141703,https://www.ncbi.nlm.nih.gov/pubmed/31640150,https://www.ncbi.nlm.nih.gov/pubmed/31417369,,,,,,,,
2424,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Sulforaphane,DB12422,,,,,,,,,,Inflammation,,HP:0012649,https://www.ncbi.nlm.nih.gov/pubmed/31640150,https://www.ncbi.nlm.nih.gov/pubmed/31640150,https://www.ncbi.nlm.nih.gov/pubmed/31417369,,,,,,,,
2425,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Resveratrol,DB02709,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Neurological deficit,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/25845763,https://clinicaltrials.gov/ct2/show/NCT01339884,https://clinicaltrials.gov/ct2/show/NCT03933163,,,,,,,,
2426,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Resveratrol,DB02709,,,,,,,,,,Poor speech,,HP:0002465,https://www.ncbi.nlm.nih.gov/pubmed/25845763,https://clinicaltrials.gov/ct2/show/NCT01339884,https://clinicaltrials.gov/ct2/show/NCT03933163,,,,,,,,
2427,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Resveratrol,DB02709,,,,,,,,,,Oxidative stress,"There was also a trend for improvement in the SARA, but little evidence of improvement in components of the Friedreich Ataxia Composite Test",HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/25845763,https://clinicaltrials.gov/ct2/show/NCT01339884,https://clinicaltrials.gov/ct2/show/NCT03933163,,,,,,,,
2428,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Resveratrol,DB02709,,,,,,,,,,Low frataxin level (Abnormal circulating protein level)*,,HP:0010876,https://www.ncbi.nlm.nih.gov/pubmed/23418481,https://clinicaltrials.gov/ct2/show/NCT01339884,https://clinicaltrials.gov/ct2/show/NCT03933163,,,,,,,,
2429,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,"In one case, a life threatening adverse effect was documented upon a large dose of nicotinamide admnistration for treating Friedreich ataxia.https://ejcrim.com/index.php/EJCRIM/article/view/234",Nicotinamide,DB02701,ECO:0007121/ECO:0001565/ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Frataxin deficiency (Abnormal circulating protein level)*,,HP:0010876,https://www.ncbi.nlm.nih.gov/pubmed/24794818,https://www.ncbi.nlm.nih.gov/pubmed/24794816/,https://www.ncbi.nlm.nih.gov/pubmed/23859350/,https://www.ncbi.nlm.nih.gov/pubmed/23474817/,https://clinicaltrials.gov/ct2/show/NCT01589809,,,,,,
2430,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Interferon Gamma-1b,DB00033,ECO:0007121/ECO:0000179,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Low whole blood frataxin level(Abnormal circulating protein level)*,,HP:0010876,https://clinicaltrials.gov/ct2/show/NCT01965327,https://clinicaltrials.gov/ct2/show/NCT03888664?cond=Friedreich+ataxia&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT02797080?cond=Friedreich+ataxia&draw=2&rank=21,https://clinicaltrials.gov/ct2/show/results/NCT02593773?cond=Friedreich+ataxia&draw=2&rank=22,,,,,,,
2431,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Interferon Gamma-1b,DB00033,,,,,,,,,,Disease progression (Progressive neurologic deterioration)*,,HP:0002344,https://www.ncbi.nlm.nih.gov/pubmed/26634868,https://www.ncbi.nlm.nih.gov/pubmed/30911578,https://clinicaltrials.gov/ct2/show/NCT02797080?cond=Friedreich+ataxia&draw=2&rank=21,https://clinicaltrials.gov/ct2/show/results/NCT02593773?cond=Friedreich+ataxia&draw=2&rank=22,,,,,,,
2432,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Interferon Gamma-1b,DB00033,,,,,,,,,,Poor motor coordination,,HP:0002275,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Interferon+gamma+as+a+potential+therapy+for+Friedreich+ataxia&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/30911578,https://clinicaltrials.gov/ct2/show/NCT02797080?cond=Friedreich+ataxia&draw=2&rank=21,https://clinicaltrials.gov/ct2/show/results/NCT02593773?cond=Friedreich+ataxia&draw=2&rank=22,,,,,,,
2433,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Interferon Gamma-1b,DB00033,,,,,,,,,,Low neuronal frataxin levels,,NA,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Interferon+gamma+as+a+potential+therapy+for+Friedreich+ataxia&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/22447512,https://clinicaltrials.gov/ct2/show/NCT02797080?cond=Friedreich+ataxia&draw=2&rank=21,https://clinicaltrials.gov/ct2/show/results/NCT02593773?cond=Friedreich+ataxia&draw=2&rank=22,,,,,,,
2434,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Interferon Gamma-1b,DB00033,,,,,,,,,,Sensorimotor neuropathy,,HP:0007141,https://www.ncbi.nlm.nih.gov/pubmed/22447512,https://www.ncbi.nlm.nih.gov/pubmed/22447512,https://clinicaltrials.gov/ct2/show/NCT02797080?cond=Friedreich+ataxia&draw=2&rank=21,https://clinicaltrials.gov/ct2/show/results/NCT02593773?cond=Friedreich+ataxia&draw=2&rank=22,,,,,,,
2435,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,"Deferiprone ,in low concentration, does not subtract iron fromFe–S clusters and it can stimulate frataxin expression, possibly by an iron-dependent mechanism activated by a shift of iron from mitochondria into the cytosol.However;  when its concentration exceeds about 50 micrM in cultured cells, it starts to induce iron depletion rather than redistribution, with deleterious effects on Fe–S enzyme activitiesand frataxin levels. https://www.ncbi.nlm.nih.gov/pubmed/23859349",Deferiprone,DB08826,ECO:0007121,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Excess iron in the central nervous system (Abnormal serum iron concentration)*,,HP:0040130,https://www.ncbi.nlm.nih.gov/pubmed/23859349,https://clinicaltrials.gov/ct2/show/NCT00897221?cond=Friedreich+ataxia&draw=6&rank=10,https://clinicaltrials.gov/ct2/show/NCT00530127?cond=Friedreich+ataxia&draw=6&rank=13,,,,,,,,
2436,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Deferiprone,DB08826,,,,,,,,,,Disease progression (Progressive neurologic deterioration)*,,HP:0002344,https://www.ncbi.nlm.nih.gov/pubmed/23859349,https://clinicaltrials.gov/ct2/show/NCT00897221?cond=Friedreich+ataxia&draw=6&rank=10,https://clinicaltrials.gov/ct2/show/NCT00530127?cond=Friedreich+ataxia&draw=6&rank=13,,,,,,,,
2437,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Deferiprone,DB08826,,,,,,,,,,Ataxic gait,,HP:0002066,https://www.ncbi.nlm.nih.gov/pubmed/17379741?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00897221?cond=Friedreich+ataxia&draw=6&rank=10,https://clinicaltrials.gov/ct2/show/NCT00530127?cond=Friedreich+ataxia&draw=6&rank=13,,,,,,,,
2438,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Deferiprone,DB08826,,,,,,,,,,Neuropathy,,HP:0009830,https://www.ncbi.nlm.nih.gov/pubmed/17379741?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00897221?cond=Friedreich+ataxia&draw=6&rank=10,https://clinicaltrials.gov/ct2/show/NCT00530127?cond=Friedreich+ataxia&draw=6&rank=13,,,,,,,,
2439,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Deferiprone,DB08826,,,,,,,,,,Low frataxin level (Abnormal circulating protein level)*,,HP:0010876,https://www.ncbi.nlm.nih.gov/pubmed/23418481,https://clinicaltrials.gov/ct2/show/NCT00897221?cond=Friedreich+ataxia&draw=6&rank=10,https://clinicaltrials.gov/ct2/show/NCT00530127?cond=Friedreich+ataxia&draw=6&rank=13,,,,,,,,
2440,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Deferiprone+Idebenone,DB08826+DB09081,ECO:0007121,,,,,Direct interaction+Symptomatic,A+C,combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+symptomatic therapeutic procedure,Trial was conducted on 5 patients,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/27029487,https://clinicaltrials.gov/ct2/show/NCT00224640?cond=Friedreich+ataxia&draw=2&rank=42,,,,,,,,,
2441,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Deferiprone+Idebenone,DB08826+DB09081,,,,,,,,,,Cardiomyocyte hypertrophy,,HP:0031319,https://www.ncbi.nlm.nih.gov/pubmed/27029487,https://clinicaltrials.gov/ct2/show/NCT00224640?cond=Friedreich+ataxia&draw=2&rank=42,,,,,,,,,
2442,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,"RT001(11,11-di-deutero-linoleic acid ethyl ester)",NA,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT02445794?term=NCT02445794&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04102501?cond=Friedreich+ataxia&draw=2&rank=12,https://www.ncbi.nlm.nih.gov/pubmed/29624723,https://clinicaltrials.gov/ct2/show/NCT04102501,,,,,,,
2443,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Acetyl-L-Carnitine,DB08842,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Incoordination,,HP:0002311,https://clinicaltrials.gov/ct2/show/NCT01921868,,,,,,,,,,
2444,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Levocarnitine,DB00583,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Impaired oxidative phosphorylation,Mild improvement,NA,https://www.ncbi.nlm.nih.gov/pubmed/15480852,,,,,,,,,,
2445,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Dimethyl fumarate,DB08908,ECO:0001565,,,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Low frataxin level (Abnormal circulating protein level)*,,HP:0010876,https://www.ncbi.nlm.nih.gov/pubmed/31158268,https://www.ncbi.nlm.nih.gov/pubmed/29057804,,,,,,,,,
2446,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Dimethyl fumarate,DB08908,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31158268,https://www.ncbi.nlm.nih.gov/pubmed/29057804,,,,,,,,,
2447,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Dimethyl fumarate,DB08908,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31158268,https://www.ncbi.nlm.nih.gov/pubmed/29057804,,,,,,,,,
2448,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Dimethyl fumarate,DB08908,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31158268,https://www.ncbi.nlm.nih.gov/pubmed/29057804,,,,,,,,,
2449,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Dimethyl fumarate,DB08908,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31158268,https://www.ncbi.nlm.nih.gov/pubmed/29057804,,,,,,,,,
2450,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,Dimethyl fumarate,DB08908,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31158268,https://www.ncbi.nlm.nih.gov/pubmed/29057804,,,,,,,,,
2451,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,Single treatment with an adeno-associated viral vector expressing a functional copy of the mutated gene can only transiently treat adrenocortical hereditary disorders,AAVrh.10-21OH-HA,NA,ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,Low 21-hydroxylase enzyme activity (Abnormal enzyme/coenzyme activity)*,Transient improvement,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/29316814,,,,,,,,,,
2452,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,AAVrh.10-21OH-HA,NA,,,,,,,,,,Abnormal steroidgenesis profile (Decreased circulating cortisol level),Transient improvement,HP:0008163,https://www.ncbi.nlm.nih.gov/pubmed/29316814,,,,,,,,,,
2453,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,AAVrh.10-21OH-HA,NA,,,,,,,,,,Abnormal steroidgenesis profile (Decreased circulating cortisol level),,HP:0008163,https://www.ncbi.nlm.nih.gov/pubmed/29316814,,,,,,,,,,
2454,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,Extra-adrenal induction of Cyp21a1,adeno-associated viral vector containing Cyp21a1,NA,ECO:0001565/ECO:0000179,,,,,Direct interaction,A,direct complementation of a genetically defective protein by gene therapy,,High progesteron/deoxycorticosterone ratio,,NA,https://www.ncbi.nlm.nih.gov/pubmed/27432820,,,,,,,,,,
2455,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Abiraterone acetate+Prednisolone,DB05812+DB00860,ECO:0007121,,,,,Functional interaction+Functional interaction,B+B,combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+functional complementation of a genetically defective protein,,Increased circulating androgen level,,HP:0030348,https://www.ncbi.nlm.nih.gov/pubmed/24780050,https://clinicaltrials.gov/ct2/show/NCT02574910,https://clinicaltrials.gov/ct2/show/NCT03548246,,,,,,,,
2456,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Abiraterone acetate+Prednisolone,DB05812+DB00860,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24780050,https://clinicaltrials.gov/ct2/show/NCT02574910,https://clinicaltrials.gov/ct2/show/NCT03548246,,,,,,,,
2457,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Abiraterone acetate+Prednisolone,DB05812+DB00860,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24780050,https://clinicaltrials.gov/ct2/show/NCT02574910,https://clinicaltrials.gov/ct2/show/NCT03548246,,,,,,,,
2458,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Abiraterone acetate+Prednisolone,DB05812+DB00860,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24780050,https://clinicaltrials.gov/ct2/show/NCT02574910,https://clinicaltrials.gov/ct2/show/NCT03548246,,,,,,,,
2459,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Abiraterone acetate+Prednisolone,DB05812+DB00860,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24780050,https://clinicaltrials.gov/ct2/show/NCT02574910,https://clinicaltrials.gov/ct2/show/NCT03548246,,,,,,,,
2460,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Carbenoxolone,DB02329,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,Elevated plasma 17-hydroxyprogesterone,,HP:0031213,https://www.ncbi.nlm.nih.gov/pubmed/10469007,,,,,,,,,,
2461,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Carbenoxolone,DB02329,,,,,,,,,,Increased renin activity,,HP:0000841,https://www.ncbi.nlm.nih.gov/pubmed/10469007,,,,,,,,,,
2462,,#201910,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY",,CYP21A2,"Frataxin, mitochondrial",1.16.3.1,,,Carbenoxolone,DB02329,,,,,,,,,,High TRH-stimulated TSH levels,,HP:0002925,https://www.ncbi.nlm.nih.gov/pubmed/10469007,,,,,,,,,,
2463,,# 264300,17-beta hydroxysteroid dehydrogenase 3 deficiency,,HSD17B3,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2464,,#203400,18 Hydroxylase deficiency,,CYP11B2,"Frataxin, mitochondrial",1.16.3.1,,,Fludrocortisone,DB00687,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Hyponatremia,,HP:0002902,https://www.ncbi.nlm.nih.gov/pubmed/29201470,https://www.ncbi.nlm.nih.gov/pubmed/11174838/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550606/,https://www.ncbi.nlm.nih.gov/pubmed/22931312,https://www.ncbi.nlm.nih.gov/pubmed/31302112,https://www.ncbi.nlm.nih.gov/pubmed/26936515,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Aldosterone+synthase+deficiency+due+to+a+novel+mutation+in+CYP11B2&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/11701710,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=,
2465,,#203400,18 Hydroxylase deficiency,,CYP11B2,"Frataxin, mitochondrial",1.16.3.1,,,Fludrocortisone,DB00687,,,,,,,,,,Hyperkalemia,,HP:0002153,https://www.ncbi.nlm.nih.gov/pubmed/29201471,https://www.ncbi.nlm.nih.gov/pubmed/26936515,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/11701710,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/26936515,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Aldosterone+synthase+deficiency+due+to+a+novel+mutation+in+CYP11B2&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/11701710,,
2466,,#203400,18 Hydroxylase deficiency,,CYP11B2,"Frataxin, mitochondrial",1.16.3.1,,,Fludrocortisone,DB00687,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/29201470,https://www.ncbi.nlm.nih.gov/pubmed/24694176,https://www.ncbi.nlm.nih.gov/pubmed/31302112,https://www.ncbi.nlm.nih.gov/pubmed/26936515,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/26936515,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Aldosterone+synthase+deficiency+due+to+a+novel+mutation+in+CYP11B2&btnG=,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/11701710,,
2467,,#203400,18 Hydroxylase deficiency,,CYP11B2,"Frataxin, mitochondrial",1.16.3.1,,,NaCl,DB09153,ECO:0000352,,,,,Functional interaction,B,metabolite replacement,,Hyponatremia,,HP:0002902,https://www.ncbi.nlm.nih.gov/pubmed/29201470,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550606/,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/26936516,https://www.ncbi.nlm.nih.gov/pubmed/11701710,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=,,,,,
2468,,#203400,18 Hydroxylase deficiency,,CYP11B2,"Frataxin, mitochondrial",1.16.3.1,,,NaCl,DB09153,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29201470,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550606/,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/26936516,https://www.ncbi.nlm.nih.gov/pubmed/11701710,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=,,,,,
2469,,#203400,18 Hydroxylase deficiency,,CYP11B2,"Frataxin, mitochondrial",1.16.3.1,,,NaCl,DB09153,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29201470,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550606/,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/26936516,https://www.ncbi.nlm.nih.gov/pubmed/11701710,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=,,,,,
2470,,#203400,18 Hydroxylase deficiency,,CYP11B2,"Frataxin, mitochondrial",1.16.3.1,,,NaCl,DB09153,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29201470,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550606/,https://www.ncbi.nlm.nih.gov/pubmed/30864636,https://www.ncbi.nlm.nih.gov/pubmed/26936516,https://www.ncbi.nlm.nih.gov/pubmed/11701710,https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=,,,,,
2471,,# 607906,ALG2-CDG (CDG-Ii),,ALG2,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2472,,# 601110,ALG3-CDG (CDG-Id),,ALG3,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2473,,# 603147,ALG6-CDG (CDG-Ic),,ALG6,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2474,,# 608104,ALG8-CDG (CDG-Ih),,ALG8,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2475,,# 608776,ALG9-CDG (CDG-IL),,ALG9,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2476,,# 613489,COG4-CDG (CDG-IIj),,COG4,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2477,,# 613612,COG5-CDG (CDG-IIi),,COG5,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2478,,# 608779,COG7-CDG (CDG-IIe),,COG7,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2479,,# 611182,COG8-CDG (CDG-IIh),,COG8,"Frataxin, mitochondrial",1.16.3.1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2480,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Magnesium phosphate,DB13862,ECO:0000179/ECO:0001565,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Ectopic mineralization of connective tissues (Abnormality of connective tissue HP:0003549)*,,HP:0003549,https://www.ncbi.nlm.nih.gov/pubmed/19122649/,https://www.ncbi.nlm.nih.gov/pubmed/21671388,https://www.ncbi.nlm.nih.gov/pubmed/22897576/,https://www.ncbi.nlm.nih.gov/pubmed/24330694/,https://www.ncbi.nlm.nih.gov/pubmed/25383264/,,,,,,
2481,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Magnesium Oxide,DB01377,ECO:0007121/ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Calcium mineralization of connective tissues (Abnormality of connective tissue HP:0003549)*,,HP:0003549,https://clinicaltrials.gov/ct2/show/NCT01525875,https://www.ncbi.nlm.nih.gov/pubmed/30826287,,,,,,,,,
2482,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Magnesium Oxide,DB01377,,,,,,,,,,Vascular calcification,,HP:0004934,https://www.ncbi.nlm.nih.gov/pubmed/20177653/,https://www.ncbi.nlm.nih.gov/pubmed/30826287,,,,,,,,,
2483,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Magnesium carbonate,DB09481,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Ectopic mineralization of connective tissues (Abnormality of connective tissue HP:0003549)*,,HP:0003549,https://www.ncbi.nlm.nih.gov/pubmed/20443931/,https://www.ncbi.nlm.nih.gov/pubmed/22897576/,https://www.ncbi.nlm.nih.gov/pubmed/24330694/,https://www.ncbi.nlm.nih.gov/pubmed/25383264/,,,,,,,
2484,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Aluminium hydroxide,DB06723,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Skin abnormalities (Abnormal cutaneous elastic fiber morphology)*,,HP:0025082,https://www.ncbi.nlm.nih.gov/pubmed/16198780/,,,,,,,,,,
2485,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Aluminium hydroxide,DB06723,,,,,,,,,,Redundant skin folds,,HP:0001582,https://www.ncbi.nlm.nih.gov/pubmed/16198780/,,,,,,,,,,
2486,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Aluminium hydroxide,DB06723,,,,,,,,,,Vascular claudication (Intermittent claudication)*,,HP:0004417,https://www.ncbi.nlm.nih.gov/pubmed/16198780/,,,,,,,,,,
2487,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,Study shows limitations.,Sevelamer hydrochloride,DB00658,ECO:0007121,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21496949/,,,,,,,,,,
2488,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,pLive-LacZ or pLive-Fetuin-A vector,NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Connective tissue mineralisation (Abnormality of connective tissue HP:0003549)*,,HP:0003549,https://www.ncbi.nlm.nih.gov/pubmed/20090764/,,,,,,,,,,
2489,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Sodium 4-phenylbutyrate,DB06819,ECO:0001565/ECO:0000179/ECO:0007764,"R1114P, S1121W, Q1347H, and R1314W",,,,Direct interaction,A,activity modification of a genetically defective protein,,Abnormal substantial transport activity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24352041/,https://www.ncbi.nlm.nih.gov/pubmed/21671388,https://www.ncbi.nlm.nih.gov/pubmed/17890229/,,,,,,,,
2490,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,PTC124,DB05016,ECO:0001565,"p.R1141X,",The drug has the ability to facilitate read-through of nonsense mutations.,,,Direct interaction,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Premature Termination Codon Read-Through of ABCC6,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23702584/,,,,,,,,,,
2491,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Bevacizumab,DB00112,ECO:0000352,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Reduced visual acuity,,HP:0007663,https://www.ncbi.nlm.nih.gov/pubmed/21386758,https://www.ncbi.nlm.nih.gov/pubmed/29279654,https://clinicaltrials.gov/ct2/show/NCT00510965,https://www.ncbi.nlm.nih.gov/pubmed/20703035/,,,,,,,
2492,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Bevacizumab,DB00112,,,,,,,,,,Subfoveal choroidal neovascularization,,HP:0031241,https://www.ncbi.nlm.nih.gov/pubmed/19205505,https://www.ncbi.nlm.nih.gov/pubmed/19996818/,https://www.ncbi.nlm.nih.gov/pubmed/20703035/,https://www.ncbi.nlm.nih.gov/pubmed/20703035/,,,,,,,
2493,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Bevacizumab,DB00112,,,,,,,,,,Subretinal fluid,,HP:0031526,https://www.ncbi.nlm.nih.gov/pubmed/24325973,https://www.ncbi.nlm.nih.gov/pubmed/19996818/,https://www.ncbi.nlm.nih.gov/pubmed/20703035/,https://www.ncbi.nlm.nih.gov/pubmed/20703035/,,,,,,,
2494,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Bevacizumab,DB00112,,,,,,,,,,Hyper-reflective retinal structure (Abnormal retinal vascular morphology)*,,HP:0008046,https://www.ncbi.nlm.nih.gov/pubmed/24325973,https://www.ncbi.nlm.nih.gov/pubmed/19996818/,https://www.ncbi.nlm.nih.gov/pubmed/20703035/,https://www.ncbi.nlm.nih.gov/pubmed/20703035/,,,,,,,
2495,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Bisphosphonates (Etidronic acid),DB01077,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Ectopic mineralisation of skin and aorta,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30414410,https://www.ncbi.nlm.nih.gov/pubmed/28701330,,,,,,,,,
2496,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Bisphosphonates (Etidronic acid),DB01077,,,,,,,,,,Arterial calcification,,HP:0003207,https://www.ncbi.nlm.nih.gov/pubmed/29519353,https://www.ncbi.nlm.nih.gov/pubmed/28701330,,,,,,,,,
2497,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Bisphosphonates (Etidronic acid),DB01077,,,,,,,,,,Subretinal neovascularization (Retinal neovascularization)*,,HP:0030666,https://www.ncbi.nlm.nih.gov/pubmed/29519353,https://www.ncbi.nlm.nih.gov/pubmed/28701330,,,,,,,,,
2498,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,"The role of antioxidant therapy for PXE is unclear, and there is a need for controlled clinical trials. Regression was followed by progression during the additional 6-month period of treatment. Plus, It had no effect on ectopic mineralization process on a trial on mice.",Tocopherol acetate+ascorbic acid,DB14003+DB00126,ECO:0000352,,,,,Symptomatic+Symptomatic,C+C,combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure,,Fragmented elastic fibers in the dermis,,HP:0025167,https://www.ncbi.nlm.nih.gov/pubmed/23675997/,,,,,,,,,,
2499,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Tocopherol acetate+ascorbic acid,DB14003+DB00126,,,,,,,,,,Clumping of elastic fibers in the dermis,,HP:0025165,https://www.ncbi.nlm.nih.gov/pubmed/23675997/,,,,,,,,,,
2500,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Tocopherol acetate+ascorbic acid,DB14003+DB00126,,,,,,,,,,Dermis calcification (Subcutaneous calcification)*,,HP:0007618,https://www.ncbi.nlm.nih.gov/pubmed/23675997/,,,,,,,,,,
2501,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Tocopherol acetate+ascorbic acid,DB14003+DB00126,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/23675997/,https://www.ncbi.nlm.nih.gov/pubmed/18049453/,,,,,,,,,
2502,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425),NA,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein by inhibition,,skin mineralization (Ectopic calcification )*,,HP:0010766,https://www.ncbi.nlm.nih.gov/pubmed/30130617,https://www.ncbi.nlm.nih.gov/pubmed/28592560,https://www.ncbi.nlm.nih.gov/pubmed/29299451,,,,,,,,
2503,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,"Oral administration may represent a simple route to achieve therapeutic levels of the physiological, non‐toxic metabolite PPi in the blood circulation.",Pyrophosphate,DB04160,ECO:0000179,,,,,Functional interaction,B,functional complementation of a genetically defective protein,,Connective tissue calcification (Abnormality in connective tissue)*,,HP:0003549,https://www.ncbi.nlm.nih.gov/pubmed/28701330,,,,,,,,,,
,,# 264800,PSEUDOXANTHOMA ELASTICUM; PXE,,ABCC6,"Frataxin, mitochondrial",1.16.3.1,,,Pyrophosphate,DB04160,,,,,,,,,,Ectopic calcification,,HP:0010766,https://www.ncbi.nlm.nih.gov/pubmed/28701330,,,,,,,,,,
